

No. 31874

---

**Multilateral**

**Marrakesh Agreement establishing the World Trade Organization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994**

*Authentic texts: English, French and Spanish.*

*Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995.*

---

**Multilatéral**

**Accord de Marrakech instituant l'Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu à Marrakech le 15 avril 1994**

*Textes authentiques : anglais, français et espagnol.*

*Enregistré par le Directeur général de l'Organisation mondiale du commerce, agissant au nom des Parties, le 1<sup>er</sup> juin 1995.*

**Table of contents****Table des matières****Indice**

[Volume 1867]

FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND  
OF MULTILATERAL TRADE NEGOTIATIONS  
ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS  
COMMERCIALES MULTILATERALES DU CYCLE D'URUGUAY  
ACTA FINAL EN QUE SE INCORPORAN LOS RESULTADOS  
DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES  
MULTILATERALES

SIGNATURES - SIGNATURES - FIRMAS

MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING  
DECISIONS, DECLARATIONS ET MEMORANDUM  
D'ACCORD MINISTERIELS  
DECISIONES, DECLARACIONES Y ENTENDIMIENTO MINISTERIALES

MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION  
ACCORD DE MARRAKECH INSTTUANT L'ORGANISATION MONDIALE DU  
COMMERCE  
ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACIÓN  
MUNDIAL DEL COMERCIO

ANNEX 1  
ANNEXE 1  
ANEXO 1

ANNEX 1A: MULTILATERAL AGREEMENTS ON TRADE IN GOODS  
ANNEXE 1A: ACCORDS MULTILATERAUX SUR LE COMMERCE DES  
MARCHANDISES  
ANEXO 1A: ACUERDOS MULTILATERALES SOBRE EL COMERCIO DE  
MERCANCÍAS

MARRAKESH PROTOCOL TO THE GENERAL AGREEMENT ON  
TARIFFS AND TRADE 1994  
PROTOCOLE DE MARRAKECH ANNEXE A L'ACCORD GENERAL  
SUR LES TARIFS DOUANIERS ET LE COMMERCE DE 1994  
PROTOCOLO DE MARRAKECH ANEXO AL ACUERDO  
GENERAL SOBRE ARANCELES ADUANEROS Y COMERCIO DE 1994

TRADE IN PHARMACEUTICAL PRODUCTS  
COMMERCE DES PRODUITS PHARMACEUTIQUES  
COMERCIO DE PRODUCTOS FARMACÉUTICOS

## SCHEDULES/LISTES/LISTAS

I	-	AUSTRALIA
III	-	BRAZIL
IV	-	MYANMAR
V	-	CANADA
VI	-	SRI LANKA
VII	-	CHILE
VIII	-	CHINA
IX	-	CUBA
XII	-	INDIA
XIII	-	NEW ZEALAND
XIV	-	NORWAY
XV	-	PAKISTAN
XVIII	-	SOUTH AFRICA
XX	-	UNITED STATES
XXI	-	INDONESIA
XXIII	-	DOMINICAN REPUBLIC
XXIV	-	FINLAND
XXIX	-	NICARAGUA
XXX	-	SWEDEN
XXXI	-	URUGUAY
XXXII	-	AUSTRIA
XXXV	-	PERU
XXXVII	-	TURKEY
XXXVIII	-	JAPAN
XXXIX	-	MALAYSIA
XLII	-	ISRAEL
XLIII	-	NIGERIA
XLVII	-	GABON
XLIX	-	SENEGAL
LI	-	MADAGASCAR
LII	-	CÔTE D'IVOIRE
LIV	-	ZIMBABWE
LIX	-	SWITZERLAND-LIECHTENSTEIN
LX	-	KOREA
LXII	-	ICELAND
LXIII	-	EGYPT
LXIV	-	ARGENTINA

LXV	-	POLAND
LXVI	-	JAMAICA
LXVII	-	TRINIDAD AND TOBAGO
LXIX	-	ROMANIA
LXXI	-	HUNGARY
LXXIII	-	SINGAPORE
LXXIV	-	SURINAME
LXXV	-	PHILIPPINES
LXXVI	-	COLOMBIA
LXXVII	-	MÉXICO
LXXVIII	-	ZAMBIA
LXXIX	-	THAILAND
LXXX	-	EUROPEAN COMMUNITIES
LXXXI	-	MOROCCO
LXXXII	-	HONG KONG
LXXXIII	-	TUNISIA
LXXXIV	-	BOLIVIA
LXXXV	-	COSTA RICA
LXXXVI	-	VENEZUELA
LXXXVII	-	EL SALVADOR
LXXXVIII	-	GUATEMALA
LXXXIX	-	MACAU
XC	-	NAMIBIA
XCI	-	PARAGUAY
XCII	-	CZECH REPUBLIC
XCIII	-	SLOVAK REPUBLIC
XCV	-	HONDURAS
XCVII	-	ANTIGUA AND BARBUDA
XCVIII	-	BAHRAIN
XCIV	-	BARBADOS
C	-	BELIZE
CII	-	BRUNEI DARUSSALAM
CIII	-	CAMEROON
CVII	-	CYPRUS
CVIII	-	DOMINICA
CIX	-	FIJI
CXI	-	GHANA
CXII	-	GUYANA
CXIII	-	KENYA
CXIV	-	KUWAIT
CXVII	-	MALTA
CXVIII	-	MAURITIUS
CXXI	-	ST. LUCIA
CXXII	-	ST. VINCENT AND THE GRENADINES
CXXIII	-	SWAZILAND

XLVIII	-	BENIN
L	-	MAURITANIA
LIII	-	NIGER
LXX	-	BANGLADESH
CVI	-	CONGO
CXXIV	-	TANZANIA
CXXVI	-	UGANDA

MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION  
 ACCORD DE MARRAKECH INSTITUANT L'ORGANISATION MONDIALE  
 DU COMMERCE  
 ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA  
 ORGANIZACIÓN MUNDIAL DEL COMERCIO

ANNEX 1A (cont.)

ANNEXE 1A (suite)

ANEXO 1A (cont.)

AGREEMENT ON AGRICULTURE  
 ACCORD SUR L'AGRICULTURE  
 ACUERDO SOBRE LA AGRICULTURA

AGREEMENT ON THE APPLICATION OF SANITARY AND  
 PHYTOSANITARY MEASURES  
 ACCORD SUR L'APPLICATION DES MESURES SANITAIRES  
 ET PHYTOSANITAIRES  
 ACUERDO SOBRE LA APLICACIÓN DE MEDIDAS SANITARIAS  
 Y FITOSANITARIAS

[Volume 1868]

AGREEMENT ON TEXTILES AND CLOTHING  
 ACCORD SUR LES TEXTILES ET LES VETEMENTS  
 ACUERDO SOBRE LOS TEXTILES Y EL VESTIDO

AGREEMENT ON TECHNICAL BARRIERS TO TRADE  
 ACCORD SUR LES OBSTACLES TECHNIQUES AU COMMERCE  
 ACUERDO SOBRE OBSTÁCULOS TÉCNICOS AL COMERCIO

AGREEMENT ON TRADE-RELATED INVESTMENT MEASURES  
 ACCORD SUR LES MESURES CONCERNANT LES INVESTISSEMENTS  
 ET LIEES AU COMMERCE  
 ACUERDO SOBRE LAS MEDIDAS EN MATERIA DE INVERSIONES  
 RELACIONADAS CON EL COMERCIO

AGREEMENT ON IMPLEMENTATION OF ARTICLE VI OF THE  
 GENERAL AGREEMENT ON TARIFFS AND TRADE 1994  
 ACCORD SUR LA MISE EN OEUVRE DE L'ARTICLE VI  
 DE L'ACCORD GENERAL SUR LES TARIFS DOUANIERS ET LE  
 COMMERCE DE 1994  
 ACUERDO RELATIVO A LA APLICACIÓN DEL ARTÍCULO VI  
 DEL ACUERDO GENERAL SOBRE ARANCELES ADUANEROS  
 Y COMERCIO DE 1994

AGREEMENT ON IMPLEMENTATION OF ARTICLE VII OF  
THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994  
ACCORD SUR LA MISE EN OEUVRE DE L'ARTICLE VII  
DE L'ACCORD GENERAL SUR LES TARIFS DOUANIERS ET  
LE COMMERCE DE 1994

ACUERDO RELATIVO A LA APLICACIÓN DEL  
ARTÍCULO VII DEL ACUERDO GENERAL SOBRE ARANCELES  
ADUANEROS Y COMERCIO DE 1994

AGREEMENT ON PRESHIPMENT INSPECTION  
ACCORD SUR L'INSPECTION AVANT EXPEDITION  
ACUERDO SOBRE INSPECCIÓN PREVIA A LA EXPEDICIÓN

AGREEMENT ON RULES OF ORIGIN  
ACCORD SUR LES REGLES D'ORIGINE  
ACUERDO SOBRE NORMAS DE ORIGEN

AGREEMENT ON IMPORT LICENSING PROCEDURES  
ACCORD SUR LES PROCEDURES DE LICENCES D'IMPORTATION  
ACUERDO SOBRE PROCEDIMIENTOS PARA EL TRÁMITE DE  
LICENCIAS DE IMPORTACIÓN

[Volume 1869]

AGREEMENT ON SUBSIDIES AND COUNTERVAILING MEASURES  
ACCORD SUR LES SUBVENTIONS ET LES MESURES COMPENSATOIRES  
ACUERDO SOBRE SUBVENCIONES Y MEDIDAS COMPENSATORIAS

AGREEMENT ON SAFEGUARDS  
ACCORD SUR LES SAUVEGARDES  
ACUERDO SOBRE SALVAGUARDIAS

MARRAKESH AGREEMENT ESTABLISHING THE  
WORLD TRADE ORGANIZATION  
ACCORD DE MARRAKECH INSTITUANT L'ORGANISATION  
MONDIALE DU COMMERCE  
ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA  
ORGANIZACIÓN MUNDIAL DEL COMERCIO

ANNEX 1 B: GENERAL AGREEMENT ON TRADE IN SERVICES  
ANNEXE 1 B: ACCORD GENERAL SUR LE COMMERCE DES SERVICES  
ANEXO 1 B: ACUERDO GENERAL SOBRE EL COMERCIO DE SERVICIOS

**SCHEDULES/LISTES/LISTAS**

ALGERIE (LISTE)  
ANTIGUA AND BARBUDA (SCHEDULE)  
ARGENTINA (LISTA)  
AUSTRALIA (SCHEDULE)  
(ART.II EXEMPTIONS)  
AUSTRIA (SCHEDULE)  
(ART.II EXEMPTIONS)  
BAHRAIN (SCHEDULE)  
BANGLADESH (SCHEDULE)  
BARBADOS (SCHEDULE)  
BELIZE (SCHEDULE)  
BENIN (LISTE)  
(EXEMPTIONS ART.II)  
BOLIVIA (LISTA)  
(EXENCIONES ART.II)  
BRAZIL (SCHEDULE)  
(ART.II EXEMPTIONS)  
BRUNEI DARUSSALAM (SCHEDULE)  
(ART.II EXEMPTIONS)  
BURKINA FASO (LISTE)  
CAMEROUN (LISTE)  
CANADA (SCHEDULE)  
(ART.II EXEMPTIONS)  
CHILE (LISTA)  
(EXENCIONES ART.II)  
CHINA (SCHEDULE)  
(ART.II EXEMPTIONS)  
COLOMBIA (LISTA)  
(EXENCIONES ART.II)  
CONGO (LISTE)  
(EXEMPTIONS ART.II)  
COSTA RICA (LISTA)  
(EXENCIONES ART.II)  
CÔTE D'IVOIRE (LISTE)  
(EXEMPTIONS ART.II)  
CUBA (LISTA)  
(EXENCIONES ART.II)  
CYPRUS (SCHEDULE)  
(ART.II EXEMPTIONS)  
CZECH REPUBLIC (SCHEDULE)  
(ART.II EXEMPTIONS)  
DOMINICA (SCHEDULE)  
REPÚBLICA DOMINICANA (LISTA)  
(EXENCIONES ART.II)  
EGYPT (SCHEDULE)  
(ART.II EXEMPTIONS)  
EL SALVADOR (LISTA)  
(EXENCIONES ART.II)  
EUROPEAN COMMUNITIES  
AND THEIR MEMBER STATES (SCHEDULE)  
(ART.II EXEMPTIONS)  
FIJI (SCHEDULE)

FINLAND (SCHEDULE)  
(ART. II EXEMPTIONS)  
FRANCE AU TITRE DE  
LA NOUVELLE-CALÉDONIE (LISTE)  
GABON (LISTE)  
(EXEMPTIONS ART. II)  
GHANA (SCHEDULE)  
GRENADA (SCHEDULE)  
GUATEMALA (LISTA)  
(EXENCIONES ART. II)  
GUYANA (SCHEDULE)  
HONDURAS (LISTA)  
(EXENCIONES ART. II)  
HONG KONG (SCHEDULE)  
(ART. II EXEMPTIONS)  
HUNGARY (SCHEDULE)  
(ART. II EXEMPTIONS)  
ICELAND (SCHEDULE)  
(ART. II EXEMPTIONS)  
INDIA (SCHEDULE)  
(ART. II EXEMPTIONS)  
INDONESIA (SCHEDULE)  
(ART. II EXEMPTIONS)  
ISRAEL (SCHEDULE)  
(ART. II EXEMPTIONS)  
JAMAICA (SCHEDULE)  
(ART. II EXEMPTIONS)  
JAPAN (SCHEDULE)  
KENYA (SCHEDULE)  
KOREA, REP. OF (SCHEDULE)  
(ART. II EXEMPTIONS)  
KUWAIT (SCHEDULE)  
(ART. II EXEMPTIONS)  
LIECHTENSTEIN (SCHEDULE)  
(ART. II EXEMPTIONS)  
MACAU (SCHEDULE)  
MADAGASCAR (LISTE)  
MALAYSIA (SCHEDULE)  
(ART. II EXEMPTIONS)  
MALTA (SCHEDULE)  
(ART. II EXEMPTIONS)  
MAROC (LISTE)  
(EXEMPTIONS ART. II)  
MAURITIUS (SCHEDULE)  
MÉXICO (LISTA)  
(EXENCIONES ART. II)  
MOZAMBIQUE (SCHEDULE)  
MYANMAR (SCHEDULE)  
NAMIBIA (SCHEDULE)  
NETHERLANDS WITH RESPECT  
TO ARUBA (SCHEDULE)  
NETHERLANDS WITH RESPECT  
TO NETHERLANDS ANTILLES (SCHEDULE)



NEW ZEALAND (SCHEDULE)  
(ART.II EXEMPTIONS)  
NICARAGUA (LISTA)  
NIGER (LISTE)  
(EXEMPTIONS ART.II)  
NIGERIA (SCHEDULE)  
NORWAY (SCHEDULE)  
(ART.II EXEMPTIONS)  
PAKISTAN (SCHEDULE)  
(ART.II EXEMPTIONS)  
PARAGUAY (LISTA)  
PERÚ (LISTA)  
(EXENCIONES ART.II)  
PHILIPPINES (SCHEDULE)  
(ART.II EXEMPTIONS)  
POLAND (SCHEDULE)  
(ART.II EXEMPTIONS)  
ROMANIA (SCHEDULE)  
(ART.II EXEMPTIONS)  
ST. LUCIA (SCHEDULE)  
ST. VINCENT AND  
THE GRENADINES (SCHEDULE)  
SENEGAL (LISTE)  
(EXEMPTIONS ART.II)  
SINGAPORE (SCHEDULE)  
(ART.II EXEMPTIONS)  
SLOVAK REPUBLIC (SCHEDULE)  
(ART.II EXEMPTIONS)  
SOUTH AFRICA (SCHEDULE)  
(ART.II EXEMPTIONS)  
SRI LANKA (SCHEDULE)  
SURINAME (SCHEDULE)  
SWAZILAND (SCHEDULE)  
(ART.II EXEMPTIONS)  
SWEDEN (SCHEDULE)  
(ART.II EXEMPTIONS)  
SWITZERLAND (SCHEDULE)  
(ART.II EXEMPTIONS)  
TANZANIA (SCHEDULE)  
THAILAND (SCHEDULE)  
(ART.II EXEMPTIONS)  
TRINIDAD AND TOBAGO (SCHEDULE)  
(ART.II EXEMPTIONS)  
TUNISIE (LISTE)  
(EXEMPTIONS ART.II)  
TURKEY (SCHEDULE)  
(ART.II EXEMPTIONS)  
UGANDA (SCHEDULE)  
UNITED STATES (SCHEDULE)  
(ART.II EXEMPTIONS)  
URUGUAY (LISTA)  
(EXENCIONES ART.II)  
VENEZUELA (LISTA)  
(EXENCIONES ART.II)  
ZAMBIA (SCHEDULE)  
ZIMBABWE (SCHEDULE)

MARRAKESH AGREEMENT ESTABLISHING THE  
WORLD TRADE ORGANIZATION  
ACCORD DE MARRAKECH INSTITUANT  
L'ORGANISATION MONDIALE DU COMMERCE  
ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE  
LA ORGANIZACIÓN MUNDIAL DEL COMERCIO

- ANNEX 1C: AGREEMENT ON TRADE-RELATED  
ASPECTS OF INTELLECTUAL PROPERTY  
RIGHTS
- ANNEXE 1C: ACCORD SUR LES ASPECTS DES  
DROITS DE PROPRIETE INTELLECTUELLE  
QUI TOUCHENT AU COMMERCE
- ANEXO 1C: ACUERDO SOBRE LOS ASPECTOS DE  
LOS DERECHOS DE PROPIEDAD INTELLECTUAL  
RELACIONADOS CON EL COMERCIO
- ANNEX 2: UNDERSTANDING ON RULES AND  
PROCEDURES GOVERNING THE  
SETTLEMENT OF DISPUTES
- ANNEXE 2: MEMORANDUM D'ACCORD SUR  
LES REGLES ET PROCEDURES REGISSANT  
LE REGLEMENT DES DIFFERENDS
- ANEXO 2: ENTENDIMIENTO RELATIVO A LAS  
NORMAS Y PROCEDIMIENTOS POR  
LOS QUE SE RIGE LA SOLUCIÓN  
DE DIFERENCIAS
- ANNEX 3: TRADE POLICY REVIEW MECHANISM
- ANNEXE 3: MECANISME D'EXAMEN DES  
POLITIQUES COMMERCIALES
- ANEXO 3: MECANISMO DE EXAMEN DE  
LAS POLÍTICAS COMERCIALES
- ANNEX 4: PLURILATERAL TRADE AGREEMENTS
- AGREEMENT ON TRADE IN CIVIL AIRCRAFT
- AGREEMENT ON GOVERNMENT PROCUREMENT
- INTERNATIONAL DAIRY AGREEMENT
- INTERNATIONAL BOVINE MEAT AGREEMENT

**ANNEXE 4: ACCORDS COMMERCIAUX PLURILATERAUX**

ACCORD SUR LE COMMERCE DES  
AERONEFS CIVILS

ACCORD SUR LES MARCHES PUBLICS

ACCORD INTERNATIONAL SUR LE  
SECTEUR LAITIER

ACCORD INTERNATIONAL SUR LA  
VIANDE BOVINE

**ANEXO 4: ACUERDOS COMERCIALES PLURILATERALES**

ACUERDO SOBRE EL COMERCIO DE  
AERONAVES CIVILES

ACUERDO SOBRE CONTRATACIÓN PÚBLICA

ACUERDO INTERNACIONAL DE LOS  
PRODUCTOS LÁCTEOS

ACUERDO INTERNACIONAL DE LA  
CARNE DE BOVINO

**FINAL ACT EMBODYING THE RESULTS OF THE  
URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS**

1. Having met in order to conclude the Uruguay Round of Multilateral Trade Negotiations, representatives of the governments and of the European Communities, members of the Trade Negotiations Committee, *agree* that the Agreement Establishing the World Trade Organization (referred to in this Final Act as the "WTO Agreement"), the Ministerial Declarations and Decisions, and the Understanding on Commitments in Financial Services, as annexed hereto, embody the results of their negotiations and form an integral part of this Final Act.

2. By signing the present Final Act, the representatives *agree*

- (a) to submit, as appropriate, the WTO Agreement for the consideration of their respective competent authorities with a view to seeking approval of the Agreement in accordance with their procedures; and
- (b) to adopt the Ministerial Declarations and Decisions.

3. The representatives *agree* on the desirability of acceptance of the WTO Agreement by all participants in the Uruguay Round of Multilateral Trade Negotiations (hereinafter referred to as "participants") with a view to its entry into force by 1 January 1995, or as early as possible thereafter. Not later than late 1994, Ministers will meet, in accordance with the final paragraph of the Punta del Este Ministerial Declaration, to decide on the international implementation of the results, including the timing of their entry into force.

4. The representatives *agree* that the WTO Agreement shall be open for acceptance as a whole, by signature or otherwise, by all participants pursuant to Article XIV thereof. The acceptance and entry into force of a Plurilateral Trade Agreement included in Annex 4 of the WTO Agreement shall be governed by the provisions of that Plurilateral Trade Agreement.

5. Before accepting the WTO Agreement, participants which are not contracting parties to the General Agreement on Tariffs and Trade<sup>1</sup> must first have concluded negotiations for their accession to the General Agreement and become contracting parties thereto. For participants which are not contracting parties to the General Agreement as of the date of the Final Act, the Schedules are not definitive and shall be subsequently completed for the purpose of their accession to the General Agreement and acceptance of the WTO Agreement.

6. This Final Act and the texts annexed hereto shall be deposited with the Director-General to the CONTRACTING PARTIES to the General Agreement on Tariffs and Trade who shall promptly furnish to each participant a certified copy thereof.

DONE at Marrakesh this fifteenth day of April one thousand nine hundred and ninety-four, in a single copy, in the English, French and Spanish languages, each text being authentic.

[For the signatures, see page 17 of this volume.]

---

<sup>1</sup>United Nations, *Treaty Series*, vol. 55, p. 187.

For the People's Democratic Republic of Algeria:	Pour la République algérienne démocratique et populaire: Mustapha Mokraoui (Sous réserve de ratification) <sup>1</sup>	Por la República Argentina Democrática y Popular:
For the Republic of Angola:	Pour la République d'Angola: J. Eduardo Pinnock	Por la República de Angola:
For Antigua and Barbuda:	Pour Antigua et Barbuda: J.A.E. Thomas	Por Antigua y Barbuda:
For the Argentine Republic:	Pour la République argentine: Guido Di Tella	Por la República Argentina:
For Australia:	Pour l'Australie: R. Francis McMullan	Por Australia:
For the Republic of Austria:	Pour la République d'Autriche: Wolfgang Schlüssel	Por la República de Austria:

---

<sup>1</sup> Subject to ratification.

For the State of Bahrain:	Pour l'Etat de Bahraïn:	Por el Estado de Bahrein:
	Habib A. Qassim	
	(Subject to ratification) <sup>2</sup>	
For the People's Republic of Bangladesh:	Pour la République populaire du Bangladesh:	Por la República Popular de Bangladesh:
	Shamsul Islam	
For Barbados:	Pour la Barbade:	Por Barbados:
	Warwick O. Franklin	
For the Kingdom of Belgium, the French Community of Belgium, the Flemish Community of Belgium, the German-language Community of Belgium, the Walloon Region of Belgium, the Flemish Region of Belgium, and the Brussels-Capital Region of Belgium:	Pour le Royaume de Belgique, la Communauté française de Belgique, la Communauté flamande de Belgique, la Communauté germanophone de Belgique, la Région wallonne de Belgique, la Région flamande de Belgique et la Région Bruxelles-Capitale de Belgique:	Por el Reino de Bélgica, la Comunidad Francesa de Bélgica, la Comunidad Flamenca de Bélgica, la Comunidad Germanohablante de Bélgica, la Región Valona de Bélgica, la Región Flamenca de Bélgica y la Región de Bruselas Capital de Bélgica:
	R. Urbain (Subject to ratification)	
For Belize:	Pour le Belize:	Por Belice:
	Jean Tamer	

<sup>2</sup> Sous réserve de ratification.

For the Republic of Benin:	Pour la République du Bénin:	Por la República de Benin:
	Yacoubou A. Fassassi	
For the Republic of Bolivia:	Pour la République de Bolivie:	Por la República de Bolivia:
	M. Reyes Chavez	
For the Republic of Botswana:	Pour la République du Botswana:	Por la República de Botswana:
	P.H.K. Kedikilwe	
For the Federative Republic of Brazil:	Pour la République fédérative du Brésil:	Por la República Federativa del Brasil:
	C.L.N. Amorim	
For Brunei Darussalam:	Pour Brunéi Darussalam:	Por Brunei Darussalam:
	P.D. Abdul-Rahman Taib	
For Burkina Faso:	Pour le Burkina Faso:	Por Burkina Faso:

For the Republic of Burundi:	Pour la République du Burundi:	Por la República de Burundi:
	Claudine Matuturu	
For the Republic of Cameroon:	Pour la République du Cameroun:	Por la República del Camerún:
	F.-Xavier Ngoubeyou	
For Canada:	Pour le Canada:	Por el Canadá:
	Roy MacLaren	
For the Central African Republic:	Pour la République centrafricaine:	Por la República Centroafricana:
	L. Odoudou Ignabode	
For the Republic of Chad:	Pour la République du Tchad:	Por la República del Chad:
For the Republic of Chile:	Pour la République du Chili:	Por la República de Chile:
	Carlos Figueroa Serrano	



For the People's Republic  
of China:

Pour la République populaire  
de Chine:

Por la República Popular  
de China:

Gu Jongjiang

For the Republic of Colombia:

Pour la République de Colombie:

Por la República de Colombia:

Juan M. Santos

For the Republic of the Congo:

Pour la République du Congo:

Por la República del Congo:

Maurice Mouabenga

For the Republic of  
Costa Rica:

Pour la République du  
Costa Rica:

Por la República de  
Costa Rica:

Roberto Rojas

For the Republic of  
Côte d'Ivoire:

Pour la République de  
Côte d'Ivoire:

Por la República de  
Côte d'Ivoire:

Amara Essy

For the Republic of Cuba:

Pour la République de Cuba:

Por la República de Cuba:

Cabrisas Ruiz

- For the Republic of Cyprus:      Pour la République de Chypre:      Por la República de Chipre:  
A.P. Michaelides
- For the Czech Republic:      Pour la République tchèque:      Por la República Checa:  
Vladimir Dlouhy
- For the Kingdom of Denmark:      Pour le Royaume du Danemark:      Por el Reino de Dinamarca:  
Niels L. Helveg Petersen
- For the Commonwealth of  
Dominica:      Pour le Commonwealth de la  
Dominique:      Por el Commonwealth de  
Dominica:
- For the Dominican Republic:      Pour la République dominicaine:      Por la República Dominicana:  
Federico A. Cuello
- For the Arab Republic  
of Egypt:      Pour la République arabe  
d'Égypte:      Por la República Árabe  
de Egipto:  
M. Mohamed Mahmoud

For the Republic of El Salvador:	Pour la République d'El Salvador:  M.A. Salaverria	Por la República de El Salvador:
For the European Communities:	Pour les Communautés européennes:  G. Romaïos  L. Brittan	Por las Comunidades Europeas:
For the Republic of Fiji:	Pour la République des Fidji:  Kaliopate Tavola	Por la República de Fiji:
For the Republic of Finland:	Pour la République de Finlande:  Pertti Salolainen	Por la República de Finlandia:
For the French Republic:	Pour la République française:  G. Longuet	Por la República Francesa:
For the Gabonese Republic:	Pour la République gabonaise:  Patrice Nziengui	Por la República Gabonesa:

For the Republic of the  
Gambia:

Pour la République de  
Gambie:

Por la República de  
Gambia:

For the Federal Republic  
of Germany:

Pour la République fédérale  
d'Allemagne:

Por la República Federal  
de Alemania:

G. Rexrodt

(Subject to ratification)

Alois Jelonek

For the Republic of Ghana:

Pour la République du Ghana:

Por la República de Ghana:

Emma Mitchell

For the Hellenic Republic:

Pour la République hellénique:

Por la República Helénica:

Theodoros Pangalos

For Grenada:

Pour la Grenade:

Por Granada:

For the Republic of  
Guatemala:

Pour la République du  
Guatemala:

Por la República de  
Guatemala:

Marithza Ruiz de Vielman

Manuel E. Gonzalez Castillo

For the Republic of  
Guinea-Bissau:

Pour la République du  
Guinée-Bissau:

Por la República de  
Guinea-Bissau:

Ansumane Mane

For the Republic of  
Guyana:

Pour la République de  
Guyana:

Por la República de  
Guyana:

M. Shree Chand

For the Republic of Haiti:

Pour la République d'Haïti:

Por la República de Haití:

For the Republic of  
Honduras:

Pour la République du  
Honduras:

Por la República de  
Honduras:

D. Urbizo Panting

For Hong Kong:

Pour Hong Kong:

Por Hong Kong:

T.H. Chau

For the Republic of Hungary:

Pour la République de Hongrie:

Por la República de Hungría:

Béla Kádár

---

For the Republic of Iceland:	Pour la République d'Islande:	Por la República de Islandia:
	Jon Baldvin Hannibalsson	
For the Republic of India:	Pour la République de l'Inde:	Por la República de la India:
	Pranab Mukherjee	
For the Republic of Indonesia:	Pour la République d'Indonésie:	Por la República de Indonesia:
	S.B. Joedono	
For Ireland:	Pour l'Irlande:	Por Irlanda:
	Charles McCreevy	
For the State of Israel:	Pour l'Etat d'Israël:	Por el Estado de Israel:
	M. Harish	
For the Italian Republic:	Pour la République italienne:	Por la República Italiana:
	Paolo Baratta	

---

For Jamaica:	Pour la Jamaïque: P. Robertson	Por Jamaica:
For Japan:	Pour le Japon: T. Hata	Por el Japón:
For the Republic of Kenya:	Pour la République du Kenya: R. Laibon M'Munkindia	Por la República de Kenya:
For the Republic of Korea:	Pour la République de Corée: Chulsu Kim	Por la República de Corea:
For the State of Kuwait:	Pour l'Etat du Koweït: Walid A. Al Wahib	Por el Estado de Kuwait:
For the Kingdom of Lesotho:	Pour le Royaume du Lesotho:	Por el Reino de Lesotho:

For the Principality of  
Liechtenstein:

Pour la Principauté de  
Liechtenstein:

Por el Principado de  
Liechtenstein:

Andrea Willi

For the Grand Duchy of  
Luxembourg:

Pour le Grand-Duché de  
Luxembourg:

Por el Gran Ducado de  
Luxemburgo:

Georges Wohlfart

For Macau:

Pour Macao

Por Macao:

V. Rodriguez Pessoa

For the Republic of  
Madagascar:

Pour la République de  
Madagascar:

Por la República de  
Madagascar:

Jacques Sylla

For the Republic of Malawi:

Pour la République du Malawi:

Por la República de Malawi:

M.W. Mbekeani

For Malaysia:

Pour la Malaisie:

Por Malasia:

Rafidah Aziz



For the Republic of  
Maldives:

Pour la République des  
Maldives:

Por la República de  
de Maldivas:

For the Republic of Mali:

Pour la République du Mali:  
Ahmad Ag Hamani

Por la República de Malí:

For the Republic of Malta:

Pour la République de Malte:  
Anthony E. Borg

Por la República de Malta:

For the Islamic Republic  
of Mauritania:

Pour la République islamique  
de Mauritanie:  
Ould Cheikh Melainine Chebih

Por la República Islámica  
de Mauritania:

For the Republic of  
Mauritius:

Pour la République de  
Maurice:  
A.K. Bachoo

Por la República de  
Mauricio:

For the United  
Mexican States:

Pour les Etats-Unis  
du Mexique:

Por los Estados Unidos  
Mexicanos:

J. Serra Puche

For the Kingdom of  
Morocco:

Pour le Royaume du  
Maroc:

Por el Reino de  
Marruecos:

Abdellatif Filali

For the Republic of  
Mozambique:

Pour la République du  
Mozambique:

Por la República de  
Mozambique:

D.G. Tembe

For the Union of Myanmar:

Pour l'Union de Myanmar:

Por la Unión de Myanmar:

Brigadier D.O. Abel

For the Republic of Namibia:

Pour la République de Namibie:

Por la República de Namibia:

H. Hamutenya

For the Kingdom of the  
Netherlands:

Pour le Royaume des  
Pays-Bas:

Por el Reino de los  
Países Bajos:

Y. van Rooy

For New Zealand:

Pour la Nouvelle-Zélande:

Por Nueva Zelandia:

P. Burdon

For the Republic of  
Nicaragua:

Pour la République du  
Nicaragua:

Por la República de  
Nicaragua:

E. Belli Pereira

For the Republic of Niger:

Pour la République du Niger:

Por la República del Niger:

Maliki Barhouni

For the Federal Republic of  
Nigeria:

Pour la République fédérale du  
Nigeria:

Por la República Federal de  
Nigeria:

Chief Melford Okilo

For the Kingdom of Norway:

Pour le Royaume de Norvège:

Por el Reino de Noruega:

Grete Knudsen

For the Islamic Republic of  
Pakistan:

Pour la République islamique  
du Pakistan:

Por la República Islámica del  
Pakistán:

Ahmad Mukhtar

For the Republic of Paraguay:

Pour la République du Paraguay:

Por la República del Paraguay:

Luis M. Ramirez-Boettner

For the Republic of Peru:

Pour la République du Pérou:

Por la República del Perú:

Efrain Goldenberg

For the Republic of the  
Philippines:

Pour la République des  
Philippines:

Por la República de  
Filipinas:

Rizalino S. Navarro

For the Republic of Poland:

Pour la République de Pologne:

Por la República de Polonia:

Leslaw Podkanski

For the Portuguese Republic:      Pour la République portugaise:      Por la República Portuguesa:

Jose M. D. Barroso

For the State of Qatar:      Pour l'Etat du Qatar:      Por el Estado de Qatar:

A. Ahmed Al-Suleiti

For Romania:      Pour la Roumanie:      Por Rumania:

M. Berinde

For the Rwandese Republic:      Pour la République rwandaise:      Por la República Rwandesa:

For Saint Kitts and Nevis:      Pour Saint-Kitts-Nevis:      Por Saint Kitts y Nevis:

For Saint Lucia:      Pour Sainte-Lucie:      Por Santa Lucía:

Edwin Laurent

For Saint Vincent and  
the Grenadines:

Pour Saint-Vincent-et-  
Grenadines:

Por San Vicente y las  
Granadinas:

For the Republic of Senegal:

Pour la République du Sénégal: Por la República del Senegal:

Moustapha Niassa

For the Republic of  
Sierra Leone:

Pour la République de  
Sierra Leone:

Por la República de  
Sierra Leona:

For the Republic of  
Singapore:

Pour la République de  
Singapour:

Por la República de  
Singapur:

Yeo Cheow Tong

For the Slovak Republic:

Pour la République slovaque:

Por la República Eslovaca:

Peter Magvasi

For the Republic of  
South Africa:

Pour la République  
sud-africaine:

Por la República de  
Sudáfrica:

D.L. Keys

For the Kingdom of Spain:

Pour le Royaume d'Espagne:

Por el Reino de España:

J. Gomez-Navarro

For the Democratic Socialist  
Republic of Sri Lanka:

Pour la République socialiste  
démocratique de Sri Lanka:

Por la República Socialista  
Democrática de Sri Lanka:

A.R. Munsoor

For the Republic of  
Suriname:

Pour la République de  
Suriname:

Por la República de  
Suriname:

R.B. Kalløe

For the Kingdom of  
Swaziland:

Pour le Royaume du  
Swaziland:

Por el Reino de  
Swazilandia:

---

For the Kingdom of Sweden:	Pour le Royaume de Suède: Ulf Dinkelspiel (Subject to ratification)	Por el Reino de Suecia:
For the Swiss Confederation:	Pour la Confédération suisse: J.-P. Delamuraz	Por la Confederación Suiza:
For the United Republic of Tanzania:	Pour la République Unie de Tanzanie: C.D. Msuya	Por la República Unida de Tanzania:
For the Kingdom of Thailand:	Pour le Royaume de Thaïlande: S. Panitchpakdi	Por el Reino de Tailandia:
For the Togolese Republic:	Pour la République togolaise:	Por la República Togolesa:



For the Republic of Trinidad  
and Tobago:

Pour la République de Trinité-  
et-Tobago:

Por la República de Trinidad  
y Tabago:

Ralph Maraj

For the Republic of Tunisia:

Pour la République tunisienne:

Por la República de Túnez:

Habib B. Yahia

Subject to ratification

For the Republic of Turkey:

Pour la République turque:

Por la República de Turquía:

Yener Dinçmen

For the Republic of  
Uganda:

Pour la République de  
l'Ouganda:

Por la República de  
Uganda:

Richard Kaijuka

For the United Arab  
Emirates:

Pour les Emirats arabes  
unis:

Por los Emiratos Arabes  
Unidos:

S.A. Ghobash

For the United Kingdom of  
Great Britain and  
Northern Ireland:

Pour la Royaume-Uni de  
Grande-Bretagne et  
d'Irlande du Nord:

Por el Reino Unido de  
Gran Bretaña e  
Irlande del Norte:

Timothy Sainsbury

For the United States  
of America:

Pour les Etats-Unis  
d'Amérique:

Por los Estados Unidos  
de América:

Michael Kantor

For the Eastern Republic  
of Uruguay:

Pour la République orientale  
de l'Uruguay:

Por la República Oriental  
del Uruguay:

Sergio A. Bonilla

For the Republic of  
Venezuela:

Pour la République du  
Venezuela:

Por la República de  
Venezuela:

Alberto Poletto

For the Republic of Zaire:

Pour la République du Zaïre:

Por la República del Zaïre:

T.B. Tangale

For the Republic of Zambia:

Pour la République de Zambie:

Por la República de Zambia:

D. Patel

For the Republic of  
Zimbabwe:

Pour la République du  
Zimbabwe:

Por la República de  
Zimbabwe:

H.M. Murerwa

---

MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING

DECISIONS, DECLARATIONS, ET MEMORANDUM D'ACCORD MINISTERIELS

DECISIONES, DECLARACIONES Y ENTENDIMIENTO MINISTERIALES

## DECISION ON MEASURES IN FAVOUR OF LEAST-DEVELOPED COUNTRIES

*Ministers,*

*Recognizing* the plight of the least-developed countries and the need to ensure their effective participation in the world trading system, and to take further measures to improve their trading opportunities;

*Recognizing* the specific needs of the least-developed countries in the area of market access where continued preferential access remains an essential means for improving their trading opportunities;

*Reaffirming* their commitment to implement fully the provisions concerning the least-developed countries contained in paragraphs 2(d), 6 and 8 of the Decision of 28 November 1979 on Differential and More Favourable Treatment, Reciprocity and Fuller Participation of Developing Countries;

*Having regard* to the commitment of the participants as set out in Section B (vii) of Part I of the Punta del Este Ministerial Declaration;

1. *Decide* that, if not already provided for in the instruments negotiated in the course of the Uruguay Round, notwithstanding their acceptance of these instruments, the least-developed countries, and for so long as they remain in that category, while complying with the general rules set out in the aforesaid instruments, will only be required to undertake commitments and concessions to the extent consistent with their individual development, financial and trade needs, or their administrative and institutional capabilities. The least-developed countries shall be given additional time of one year from 15 April 1994 to submit their schedules as required in Article XI of the Agreement Establishing the World Trade Organization.

2. *Agree* that:

- (i) Expeditious implementation of all special and differential measures taken in favour of least-developed countries including those taken within the context of the Uruguay Round shall be ensured through, *inter alia*, regular reviews.
- (ii) To the extent possible, MFN concessions on tariff and non-tariff measures agreed in the Uruguay Round on products of export interest to the least-developed countries may be implemented autonomously, in advance and without staging. Consideration shall be given to further improve GSP and other schemes for products of particular export interest to least-developed countries.
- (iii) The rules set out in the various agreements and instruments and the transitional provisions in the Uruguay Round should be applied in a flexible and supportive manner for the least-developed countries. To this effect, sympathetic consideration shall be given to specific and motivated concerns raised by the least-developed countries in the appropriate Councils and Committees.
- (iv) In the application of import relief measures and other measures referred to in paragraph 3(c) of Article XXXVII of GATT 1947 and the corresponding provision of GATT 1994, special consideration shall be given to the export interests of least-developed countries.
- (v) Least-developed countries shall be accorded substantially increased technical assistance in the development, strengthening and diversification of their production and export bases including those of services, as well as in trade promotion, to enable them to maximize the benefits from liberalized access to markets.

3. *Agree* to keep under review the specific needs of the least-developed countries and to continue to seek the adoption of positive measures which facilitate the expansion of trading opportunities in favour of these countries.

**DECLARATION ON THE CONTRIBUTION OF THE  
WORLD TRADE ORGANIZATION TO ACHIEVING GREATER  
COHERENCE IN GLOBAL ECONOMIC POLICYMAKING**

1. *Ministers recognize* that the globalization of the world economy has led to ever-growing interactions between the economic policies pursued by individual countries, including interactions between the structural, macroeconomic, trade, financial and development aspects of economic policymaking. The task of achieving harmony between these policies falls primarily on governments at the national level, but their coherence internationally is an important and valuable element in increasing the effectiveness of these policies at national level. The Agreements reached in the Uruguay Round show that all the participating governments recognize the contribution that liberal trading policies can make to the healthy growth and development of their own economies and of the world economy as a whole.
2. Successful cooperation in each area of economic policy contributes to progress in other areas. Greater exchange rate stability, based on more orderly underlying economic and financial conditions, should contribute towards the expansion of trade, sustainable growth and development, and the correction of external imbalances. There is also a need for an adequate and timely flow of concessional and non-concessional financial and real investment resources to developing countries and for further efforts to address debt problems, to help ensure economic growth and development. Trade liberalization forms an increasingly important component in the success of the adjustment programmes that many countries are undertaking, often involving significant transitional social costs. In this connection, Ministers note the role of the World Bank and the IMF in supporting adjustment to trade liberalization, including support to net food-importing developing countries facing short-term costs arising from agricultural trade reforms.
3. The positive outcome of the Uruguay Round is a major contribution towards more coherent and complementary international economic policies. The results of the Uruguay Round ensure an expansion of market access to the benefit of all countries, as well as a framework of strengthened multilateral disciplines for trade. They also guarantee that trade policy will be conducted in a more transparent manner and with greater awareness of the benefits for domestic competitiveness of an open trading environment. The strengthened multilateral trading system emerging from the Uruguay Round has the capacity to provide an improved forum for liberalization, to contribute to more effective surveillance, and to ensure strict observance of multilaterally agreed rules and disciplines. These improvements mean that trade policy can in the future play a more substantial role in ensuring the coherence of global economic policymaking.
4. *Ministers recognize*, however, that difficulties the origins of which lie outside the trade field cannot be redressed through measures taken in the trade field alone. This underscores the importance of efforts to improve other elements of global economic policymaking to complement the effective implementation of the results achieved in the Uruguay Round.
5. The interlinkages between the different aspects of economic policy require that the international institutions with responsibilities in each of these areas follow consistent and mutually supportive policies. The World Trade Organization should therefore pursue and develop cooperation with the international organizations responsible for monetary and financial matters, while respecting the mandate, the confidentiality requirements and the necessary autonomy in decision-making procedures of each institution, and avoiding the imposition on governments of cross-conditionality or additional conditions. Ministers further invite the Director-General of the WTO to review with the Managing Director of the International Monetary Fund and the President of the World Bank, the implications of the WTO's responsibilities for its cooperation with the Bretton Woods institutions, as well as the forms such cooperation might take, with a view to achieving greater coherence in global economic policymaking.

## DECISION ON NOTIFICATION PROCEDURES

*Ministers decide* to recommend adoption by the Ministerial Conference of the decision on improvement and review of notification procedures set out below.

*Members,*

*Desiring* to improve the operation of notification procedures under the Agreement Establishing the World Trade Organization (hereinafter referred to as the "WTO Agreement"), and thereby to contribute to the transparency of Members' trade policies and to the effectiveness of surveillance arrangements established to that end;

*Recalling* obligations under the WTO Agreement to publish and notify, including obligations assumed under the terms of specific protocols of accession, waivers, and other agreements entered into by Members;

*Agree* as follows:

### I. *General obligation to notify*

Members affirm their commitment to obligations under the Multilateral Trade Agreements and, where applicable, the Plurilateral Trade Agreements, regarding publication and notification.

Members recall their undertakings set out in the Understanding Regarding Notification, Consultation, Dispute Settlement and Surveillance adopted on 28 November 1979 (BISD 26S/210). With regard to their undertaking therein to notify, to the maximum extent possible, their adoption of trade measures affecting the operation of GATT 1994, such notification itself being without prejudice to views on the consistency of measures with or their relevance to rights and obligations under the Multilateral Trade Agreements and, where applicable, the Plurilateral Trade Agreements, Members agree to be guided, as appropriate, by the annexed list of measures. Members therefore agree that the introduction or modification of such measures is subject to the notification requirements of the 1979 Understanding.

### II. *Central registry of notifications*

A central registry of notifications shall be established under the responsibility of the Secretariat. While Members will continue to follow existing notification procedures, the Secretariat shall ensure that the central registry records such elements of the information provided on the measure by the Member concerned as its purpose, its trade coverage, and the requirement under which it has been notified. The central registry shall cross-reference its records of notifications by Member and obligation.

The central registry shall inform each Member annually of the regular notification obligations to which that Member will be expected to respond in the course of the following year.

The central registry shall draw the attention of individual Members to regular notification requirements which remain unfulfilled.

Information in the central registry regarding individual notifications shall be made available on request to any Member entitled to receive the notification concerned.

### III. *Review of notification obligations and procedures*

The Council for Trade in Goods will undertake a review of notification obligations and procedures under the Agreements in Annex 1A of the WTO Agreement. The review will be carried out by a working group, membership in which will be open to all Members. The group will be established immediately after the date of entry into force of the WTO Agreement.

The terms of reference of the working group will be:

- to undertake a thorough review of all existing notification obligations of Members established under the Agreements in Annex 1A of the WTO Agreement, with a view to simplifying, standardizing and consolidating these obligations to the greatest extent practicable, as well as to improving compliance with these obligations, bearing in mind the overall objective of improving the transparency of the trade policies of Members and the effectiveness of surveillance arrangements established to this end, and also bearing in mind the possible need of some developing country Members for assistance in meeting their notification obligations;
- to make recommendations to the Council for Trade in Goods not later than two years after the entry into force of the WTO Agreement.



## ANNEX

INDICATIVE LIST<sup>1</sup> OF NOTIFIABLE MEASURES

Tariffs (including range and scope of bindings, GSP provisions, rates applied to members of free-trade areas/customs unions, other preferences)

Tariff quotas and surcharges

Quantitative restrictions, including voluntary export restraints and orderly marketing arrangements affecting imports

Other non-tariff measures such as licensing and mixing requirements; variable levies

Customs valuation

Rules of origin

Government procurement

Technical barriers

Safeguard actions

Anti-dumping actions

Countervailing actions

Export taxes

Export subsidies, tax exemptions and concessionary export financing

Free-trade zones, including in-bond manufacturing

Export restrictions, including voluntary export restraints and orderly marketing arrangements

Other government assistance, including subsidies, tax exemptions

Role of state-trading enterprises

Foreign exchange controls related to imports and exports

Government-mandated countertrade

Any other measure covered by the Multilateral Trade Agreements in Annex 1A to the WTO Agreement

---

<sup>1</sup>This list does not alter existing notification requirements in the Multilateral Trade Agreements in Annex 1A to the WTO Agreement or, where applicable, the Plurilateral Trade Agreements in Annex 4 of the WTO Agreement.

**DECLARATION ON THE RELATIONSHIP OF THE  
WORLD TRADE ORGANIZATION WITH THE  
INTERNATIONAL MONETARY FUND**

*Ministers,*

*Noting* the close relationship between the CONTRACTING PARTIES to the GATT 1947 and the International Monetary Fund, and the provisions of the GATT 1947 governing that relationship, in particular Article XV of the GATT 1947;

*Recognizing* the desire of participants to base the relationship of the World Trade Organization with the International Monetary Fund, with regard to the areas covered by the Multilateral Trade Agreements in Annex 1A of the WTO Agreement, on the provisions that have governed the relationship of the CONTRACTING PARTIES to the GATT 1947 with the International Monetary Fund;

Hereby *reaffirm* that, unless otherwise provided for in the Final Act, the relationship of the WTO with the International Monetary Fund, with regard to the areas covered by the Multilateral Trade Agreements in Annex 1A of the WTO Agreement, will be based on the provisions that have governed the relationship of the CONTRACTING PARTIES to the GATT 1947 with the International Monetary Fund.

**DECISION ON MEASURES CONCERNING  
THE POSSIBLE NEGATIVE EFFECTS OF THE  
REFORM PROGRAMME ON LEAST-DEVELOPED AND  
NET FOOD-IMPORTING DEVELOPING COUNTRIES**

1. *Ministers recognize* that the progressive implementation of the results of the Uruguay Round as a whole will generate increasing opportunities for trade expansion and economic growth to the benefit of all participants.
2. *Ministers recognize* that during the reform programme leading to greater liberalization of trade in agriculture least-developed and net food-importing developing countries may experience negative effects in terms of the availability of adequate supplies of basic foodstuffs from external sources on reasonable terms and conditions, including short-term difficulties in financing normal levels of commercial imports of basic foodstuffs.
3. *Ministers accordingly agree* to establish appropriate mechanisms to ensure that the implementation of the results of the Uruguay Round on trade in agriculture does not adversely affect the availability of food aid at a level which is sufficient to continue to provide assistance in meeting the food needs of developing countries, especially least-developed and net food-importing developing countries. To this end *Ministers agree*:
  - (i) to review the level of food aid established periodically by the Committee on Food Aid under the Food Aid Convention 1986 and to initiate negotiations in the appropriate forum to establish a level of food aid commitments sufficient to meet the legitimate needs of developing countries during the reform programme;
  - (ii) to adopt guidelines to ensure that an increasing proportion of basic foodstuffs is provided to least-developed and net food-importing developing countries in fully grant form and/or on appropriate concessional terms in line with Article IV of the Food Aid Convention 1986;
  - (iii) to give full consideration in the context of their aid programmes to requests for the provision of technical and financial assistance to least-developed and net food-importing developing countries to improve their agricultural productivity and infrastructure.
4. *Ministers further agree* to ensure that any agreement relating to agricultural export credits makes appropriate provision for differential treatment in favour of least-developed and net food-importing developing countries.
5. *Ministers recognize* that as a result of the Uruguay Round certain developing countries may experience short-term difficulties in financing normal levels of commercial imports and that these countries may be eligible to draw on the resources of international financial institutions under existing facilities, or such facilities as may be established, in the context of adjustment programmes, in order to address such financing difficulties. In this regard Ministers take note of paragraph 37 of the report of the Director-General to the CONTRACTING PARTIES to GATT 1947 on his consultations with the Managing Director of the International Monetary Fund and the President of the World Bank (MTN.GNG/NG14/W/35).
6. The provisions of this Decision will be subject to regular review by the Ministerial Conference, and the follow-up to this Decision shall be monitored, as appropriate, by the Committee on Agriculture.

**DECISION ON NOTIFICATION OF FIRST INTEGRATION UNDER  
ARTICLE 2.6 OF THE AGREEMENT ON TEXTILES AND CLOTHING**

*Ministers agree* that the participants maintaining restrictions falling under paragraph 1 of Article 2 of the Agreement on Textiles and Clothing shall notify full details of the actions to be taken pursuant to paragraph 6 of Article 2 of that Agreement to the GATT Secretariat not later than 1 October 1994. The GATT Secretariat shall promptly circulate these notifications to the other participants for information. These notifications will be made available to the Textiles Monitoring Body, when established, for the purposes of paragraph 21 of Article 2 of the Agreement on Textiles and Clothing.

**DECISION ON PROPOSED UNDERSTANDING  
ON WTO-ISO STANDARDS INFORMATION SYSTEM**

*Ministers decide* to recommend that the Secretariat of the World Trade Organization reach an understanding with the International Organization for Standardization ("ISO") to establish an information system under which:

1. ISONET members shall transmit to the ISO/IEC Information Centre in Geneva the notifications referred to in paragraphs C and J of the Code of Good Practice for the Preparation, Adoption and Application of Standards in Annex 3 to the Agreement on Technical Barriers to Trade, in the manner indicated there;

2. the following (alpha)numeric classification systems shall be used in the work programmes referred to in paragraph J:

( a )  
*a standards classification system* which would allow standardizing bodies to give for each standard mentioned in the work programme an (alpha)numeric indication of the subject matter;

( b )  
*a stage code system* which would allow standardizing bodies to give for each standard mentioned in the work programme an (alpha)numeric indication of the stage of development of the standard; for this purpose, at least five stages of development should be distinguished: (1) the stage at which the decision to develop a standard has been taken, but technical work has not yet begun; (2) the stage at which technical work has begun, but the period for the submission of comments has not yet started; (3) the stage at which the period for the submission of comments has started, but has not yet been completed; (4) the stage at which the period for the submission of comments has been completed, but the standard has not yet been adopted; and (5) the stage at which the standard has been adopted;

( c )  
*an identification system* covering all international standards which would allow standardizing bodies to give for each standard mentioned in the work programme an (alpha)numeric indication of the international standard(s) used as a basis;

3. the ISO/IEC Information Centre shall promptly convey to the Secretariat copies of any notifications referred to in paragraph C of the Code of Good Practice;

4. the ISO/IEC Information Centre shall regularly publish the information received in the notifications made to it under paragraphs C and J of the Code of Good Practice; this publication, for which a reasonable fee may be charged, shall be available to ISONET members and through the Secretariat to the Members of the WTO.

DECISION ON REVIEW OF THE ISO/IEC  
INFORMATION CENTRE PUBLICATION

*Ministers decide* that in conformity with paragraph 1 of Article 13 of the Agreement on Technical Barriers to Trade in Annex 1A of the Agreement Establishing the World Trade Organization, the Committee on Technical Barriers to Trade established thereunder shall, without prejudice to provisions on consultation and dispute settlement, at least once a year review the publication provided by the ISO/IEC Information Centre on information received according to the Code of Good Practice for the Preparation, Adoption and Application of Standards in Annex 3 of the Agreement, for the purpose of affording Members opportunity of discussing any matters relating to the operation of that Code.

In order to facilitate this discussion, the Secretariat shall provide a list by Member of all standardizing bodies that have accepted the Code, as well as a list of those standardizing bodies that have accepted or withdrawn from the Code since the previous review.

The Secretariat shall also distribute promptly to the Members copies of the notifications it receives from the ISO/IEC Information Centre.

## DECISION ON ANTI-CIRCUMVENTION

*Ministers,*

*Noting* that while the problem of circumvention of anti-dumping duty measures formed part of the negotiations which preceded the Agreement on Implementation of Article VI of GATT 1994, negotiators were unable to agree on specific text,

*Mindful* of the desirability of the applicability of uniform rules in this area as soon as possible,

*Decide* to refer this matter to the Committee on Anti-Dumping Practices established under that Agreement for resolution.

**DECISION ON REVIEW OF ARTICLE 17.6 OF THE  
AGREEMENT ON IMPLEMENTATION OF ARTICLE VI OF THE  
GENERAL AGREEMENT ON TARIFFS AND TRADE 1994**

*Ministers decide* as follows:

The standard of review in paragraph 6 of Article 17 of the Agreement on Implementation of Article VI of GATT 1994 shall be reviewed after a period of three years with a view to considering the question of whether it is capable of general application.



**DECLARATION ON DISPUTE SETTLEMENT PURSUANT TO THE AGREEMENT  
ON IMPLEMENTATION OF ARTICLE VI OF THE GENERAL AGREEMENT ON  
TARIFFS AND TRADE 1994 OR PART V OF THE AGREEMENT  
ON SUBSIDIES AND COUNTERVAILING MEASURES**

*Ministers recognize*, with respect to dispute settlement pursuant to the Agreement on Implementation of Article VI of GATT 1994 or Part V of the Agreement on Subsidies and Countervailing Measures, the need for the consistent resolution of disputes arising from anti-dumping and countervailing duty measures.

**DECISION REGARDING CASES WHERE CUSTOMS  
ADMINISTRATIONS HAVE REASONS TO DOUBT THE TRUTH  
OR ACCURACY OF THE DECLARED VALUE**

*Ministers invite* the Committee on Customs Valuation established under the Agreement on Implementation of Article VII of GATT 1994 to take the following decision:

*The Committee on Customs Valuation,*

*Reaffirming* that the transaction value is the primary basis of valuation under the Agreement on Implementation of Article VII of GATT 1994 (hereinafter referred to as the "Agreement");

*Recognizing* that the customs administration may have to address cases where it has reason to doubt the truth or accuracy of the particulars or of documents produced by traders in support of a declared value;

*Emphasizing* that in so doing the customs administration should not prejudice the legitimate commercial interests of traders;

*Taking into account* Article 17 of the Agreement, paragraph 6 of Annex III to the Agreement, and the relevant decisions of the Technical Committee on Customs Valuation;

*Decides* as follows:

1. When a declaration has been presented and where the customs administration has reason to doubt the truth or accuracy of the particulars or of documents produced in support of this declaration, the customs administration may ask the importer to provide further explanation, including documents or other evidence, that the declared value represents the total amount actually paid or payable for the imported goods, adjusted in accordance with the provisions of Article 8. If, after receiving further information, or in the absence of a response, the customs administration still has reasonable doubts about the truth or accuracy of the declared value, it may, bearing in mind the provisions of Article 11, be deemed that the customs value of the imported goods cannot be determined under the provisions of Article 1. Before taking a final decision, the customs administration shall communicate to the importer, in writing if requested, its grounds for doubting the truth or accuracy of the particulars or documents produced and the importer shall be given a reasonable opportunity to respond. When a final decision is made, the customs administration shall communicate to the importer in writing its decision and the grounds therefor.
2. It is entirely appropriate in applying the Agreement for one Member to assist another Member on mutually agreed terms.

DECISION ON TEXTS RELATING TO MINIMUM VALUES AND IMPORTS  
BY SOLE AGENTS, SOLE DISTRIBUTORS AND SOLE CONCESSIONAIRES

*Ministers decide* to refer the following texts to the Committee on Customs Valuation established under the Agreement on Implementation of Article VII of GATT 1994, for adoption.

I

Where a developing country makes a reservation to retain officially established minimum values within the terms of paragraph 2 of Annex III and shows good cause, the Committee shall give the request for the reservation sympathetic consideration.

Where a reservation is consented to, the terms and conditions referred to in paragraph 2 of Annex III shall take full account of the development, financial and trade needs of the developing country concerned.

II

1. A number of developing countries have a concern that problems may exist in the valuation of imports by sole agents, sole distributors and sole concessionaires. Under paragraph 1 of Article 20, developing country Members have a period of delay of up to five years prior to the application of the Agreement. In this context, developing country Members availing themselves of this provision could use the period to conduct appropriate studies and to take such other actions as are necessary to facilitate application.

2. In consideration of this, the Committee recommends that the Customs Co-operation Council assist developing country Members, in accordance with the provisions of Annex II, to formulate and conduct studies in areas identified as being of potential concern, including those relating to importations by sole agents, sole distributors and sole concessionaires.

**DECISION ON INSTITUTIONAL ARRANGEMENTS  
FOR THE GENERAL AGREEMENT ON TRADE IN SERVICES**

*Ministers decide* to recommend that the Council for Trade in Services at its first meeting adopt the decision on subsidiary bodies set out below.

*The Council for Trade in Services,*

*Acting pursuant to Article XXIV with a view to facilitating the operation and furthering the objectives of the General Agreement on Trade in Services,*

*Decides as follows:*

1. Any subsidiary bodies that the Council may establish shall report to the Council annually or more often as necessary. Each such body shall establish its own rules of procedure, and may set up its own subsidiary bodies as appropriate.
2. Any sectoral committee shall carry out responsibilities as assigned to it by the Council, and shall afford Members the opportunity to consult on any matters relating to trade in services in the sector concerned and the operation of the sectoral annex to which it may pertain. Such responsibilities shall include:
  - (a) to keep under continuous review and surveillance the application of the Agreement with respect to the sector concerned;
  - (b) to formulate proposals or recommendations for consideration by the Council in connection with any matter relating to trade in the sector concerned;
  - (c) if there is an annex pertaining to the sector, to consider proposals for amendment of that sectoral annex, and to make appropriate recommendations to the Council;
  - (d) to provide a forum for technical discussions, to conduct studies on measures of Members and to conduct examinations of any other technical matters affecting trade in services in the sector concerned;
  - (e) to provide technical assistance to developing country Members and developing countries negotiating accession to the Agreement Establishing the World Trade Organization in respect of the application of obligations or other matters affecting trade in services in the sector concerned; and
  - (f) to cooperate with any other subsidiary bodies established under the General Agreement on Trade in Services or any international organizations active in any sector concerned.
3. There is hereby established a Committee on Trade in Financial Services which will have the responsibilities listed in paragraph 2.

**DECISION ON CERTAIN DISPUTE SETTLEMENT PROCEDURES  
FOR THE GENERAL AGREEMENT ON TRADE IN SERVICES**

*Ministers decide* to recommend that the Council for Trade in Services at its first meeting adopt the decision set out below.

*The Council for Trade in Services,*

*Taking into account* the specific nature of the obligations and specific commitments of the Agreement, and of trade in services, with respect to dispute settlement under Articles XXII and XXIII,

*Decides* as follows:

1. A roster of panelists shall be established to assist in the selection of panelists.
2. To this end, Members may suggest names of individuals possessing the qualifications referred to in paragraph 3 for inclusion on the roster, and shall provide a curriculum vitae of their qualifications including, if applicable, indication of sector-specific expertise.
3. Panels shall be composed of well-qualified governmental and/or non-governmental individuals who have experience in issues related to the General Agreement on Trade in Services and/or trade in services, including associated regulatory matters. Panelists shall serve in their individual capacities and not as representatives of any government or organisation.
4. Panels for disputes regarding sectoral matters shall have the necessary expertise relevant to the specific services sectors which the dispute concerns.
5. The Secretariat shall maintain the roster and shall develop procedures for its administration in consultation with the Chairman of the Council.

## DECISION ON TRADE IN SERVICES AND THE ENVIRONMENT

*Ministers decide* to recommend that the Council for Trade in Services at its first meeting adopt the decision set out below.

*The Council for Trade in Services,*

*Acknowledging* that measures necessary to protect the environment may conflict with the provisions of the Agreement; and

*Noting* that since measures necessary to protect the environment typically have as their objective the protection of human, animal or plant life or health, it is not clear that there is a need to provide for more than is contained in paragraph (b) of Article XIV;

*Decides* as follows:

1. In order to determine whether any modification of Article XIV of the Agreement is required to take account of such measures, to request the Committee on Trade and Environment to examine and report, with recommendations if any, on the relationship between services trade and the environment including the issue of sustainable development. The Committee shall also examine the relevance of inter-governmental agreements on the environment and their relationship to the Agreement.
2. The Committee shall report the results of its work to the first biennial meeting of the Ministerial Conference after the entry into force of the Agreement Establishing the World Trade Organization.

## DECISION ON NEGOTIATIONS ON MOVEMENT OF NATURAL PERSONS

*Ministers,*

*Noting* the commitments resulting from the Uruguay Round negotiations on the movement of natural persons for the purpose of supplying services;

*Mindful* of the objectives of the General Agreement on Trade in Services, including the increasing participation of developing countries in trade in services and the expansion of their service exports;

*Recognizing* the importance of achieving higher levels of commitments on the movement of natural persons, in order to provide for a balance of benefits under the General Agreement on Trade in Services;

*Decide* as follows:

1. Negotiations on further liberalization of movement of natural persons for the purpose of supplying services shall continue beyond the conclusion of the Uruguay Round, with a view to allowing the achievement of higher levels of commitments by participants under the General Agreement on Trade in Services.
2. A Negotiating Group on Movement of Natural Persons is established to carry out the negotiations. The group shall establish its own procedures and shall report periodically to the Council on Trade in Services.
3. The negotiating group shall hold its first negotiating session no later than 16 May 1994. It shall conclude these negotiations and produce a final report no later than six months after the entry into force of the Agreement Establishing the World Trade Organization.
4. Commitments resulting from these negotiations shall be inscribed in Members' Schedules of specific commitments.

## DECISION ON FINANCIAL SERVICES

*Ministers,*

*Noting* that commitments scheduled by participants on financial services at the conclusion of the Uruguay Round shall enter into force on an MFN basis at the same time as the Agreement Establishing the World Trade Organization (hereinafter referred to as the "WTO Agreement"),

*Decide* as follows:

1. At the conclusion of a period ending no later than six months after the date of entry into force of the WTO Agreement, Members shall be free to improve, modify or withdraw all or part of their commitments in this sector without offering compensation, notwithstanding the provisions of Article XXI of the General Agreement on Trade in Services. At the same time Members shall finalize their positions relating to MFN exemptions in this sector, notwithstanding the provisions of the Annex on Article II Exemptions. From the date of entry into force of the WTO Agreement and until the end of the period referred to above, exemptions listed in the Annex on Article II Exemptions which are conditional upon the level of commitments undertaken by other participants or upon exemptions by other participants will not be applied.
2. The Committee on Trade in Financial Services shall monitor the progress of any negotiations undertaken under the terms of this Decision and shall report thereon to the Council for Trade in Services no later than four months after the date of entry into force of the WTO Agreement.



## DECISION ON NEGOTIATIONS ON MARITIME TRANSPORT SERVICES

*Ministers,*

*Noting that* commitments scheduled by participants on maritime transport services at the conclusion of the Uruguay Round shall enter into force on an MFN basis at the same time as the Agreement Establishing the World Trade Organization (hereinafter referred to as the "WTO Agreement"),

*Decide as follows:*

1. Negotiations shall be entered into on a voluntary basis in the sector of maritime transport services within the framework of the General Agreement on Trade in Services. The negotiations shall be comprehensive in scope, aiming at commitments in international shipping, auxiliary services and access to and use of port facilities, leading to the elimination of restrictions within a fixed time scale.
2. A Negotiating Group on Maritime Transport Services (hereinafter referred to as the "NGMTS") is established to carry out this mandate. The NGMTS shall report periodically on the progress of these negotiations.
3. The negotiations in the NGMTS shall be open to all governments and the European Communities which announce their intention to participate. To date, the following have announced their intention to take part in the negotiations:  
  
Argentina, Canada, European Communities and their member States, Finland, Hong Kong, Iceland, Indonesia, Korea, Malaysia, Mexico, New Zealand, Norway, Philippines, Poland, Romania, Singapore, Sweden, Switzerland, Thailand, Turkey, United States.

Further notifications of intention to participate shall be addressed to the depositary of the WTO Agreement.

4. The NGMTS shall hold its first negotiating session no later than 16 May 1994. It shall conclude these negotiations and make a final report no later than June 1996. The final report of the NGMTS shall include a date for the implementation of results of these negotiations.
5. Until the conclusion of the negotiations Article II and paragraphs 1 and 2 of the Annex on Article II Exemptions are suspended in their application to this sector, and it is not necessary to list MFN exemptions. At the conclusion of the negotiations, Members shall be free to improve, modify or withdraw any commitments made in this sector during the Uruguay Round without offering compensation, notwithstanding the provisions of Article XXI of the Agreement. At the same time Members shall finalize their positions relating to MFN exemptions in this sector, notwithstanding the provisions of the Annex on Article II Exemptions. Should negotiations not succeed, the Council for Trade in Services shall decide whether to continue the negotiations in accordance with this mandate.
6. Any commitments resulting from the negotiations, including the date of their entry into force, shall be inscribed in the Schedules annexed to the General Agreement on Trade in Services and be subject to all the provisions of the Agreement.
7. Commencing immediately and continuing until the implementation date to be determined under paragraph 4, it is understood that participants shall not apply any measure affecting trade in maritime transport services except in response to measures applied by other countries and with a view to maintaining or improving the freedom of provision of maritime transport services, nor in such a manner as would improve their negotiating position and leverage.
8. The implementation of paragraph 7 shall be subject to surveillance in the NGMTS. Any participant may bring to the attention of the NGMTS any action or omission which it believes to be relevant to the fulfilment of paragraph 7. Such notifications shall be deemed to have been submitted to the NGMTS upon their receipt by the Secretariat.

## DECISION ON NEGOTIATIONS ON BASIC TELECOMMUNICATIONS

*Ministers decide as follows:*

1. Negotiations shall be entered into on a voluntary basis with a view to the progressive liberalization of trade in telecommunications transport networks and services (hereinafter referred to as "basic telecommunications") within the framework of the General Agreement on Trade in Services.

2. Without prejudice to their outcome, the negotiations shall be comprehensive in scope, with no basic telecommunications excluded *a priori*.

3. A Negotiating Group on Basic Telecommunications (hereinafter referred to as the "NGBT") is established to carry out this mandate. The NGBT shall report periodically on the progress of these negotiations.

4. The negotiations in the NGBT shall be open to all governments and the European Communities which announce their intention to participate. To date, the following have announced their intention to take part in the negotiations:

Australia, Austria, Canada, Chile, Cyprus, European Communities and their member States, Finland, Hong Kong, Hungary, Japan, Korea, Mexico, New Zealand, Norway, Slovak Republic, Sweden, Switzerland, Turkey, United States.

Further notifications of intention to participate shall be addressed to the depositary of the Agreement Establishing the World Trade Organization.

5. The NGBT shall hold its first negotiating session no later than 16 May 1994. It shall conclude these negotiations and make a final report no later than 30 April 1996. The final report of the NGBT shall include a date for the implementation of results of these negotiations.

6. Any commitments resulting from the negotiations, including the date of their entry into force, shall be inscribed in the Schedules annexed to the General Agreement on Trade in Services and shall be subject to all the provisions of the Agreement.

7. Commencing immediately and continuing until the implementation date to be determined under paragraph 5, it is understood that no participant shall apply any measure affecting trade in basic telecommunications in such a manner as would improve its negotiating position and leverage. It is understood that this provision shall not prevent the pursuit of commercial and governmental arrangements regarding the provision of basic telecommunications services.

8. The implementation of paragraph 7 shall be subject to surveillance in the NGBT. Any participant may bring to the attention of the NGBT any action or omission which it believes to be relevant to the fulfilment of paragraph 7. Such notifications shall be deemed to have been submitted to the NGBT upon their receipt by the Secretariat.

## DECISION ON PROFESSIONAL SERVICES

*Ministers decide* to recommend that the Council for Trade in Services at its first meeting adopt the decision set out below.

*The Council for Trade in Services,*

*Recognizing* the impact of regulatory measures relating to professional qualifications, technical standards and licensing on the expansion of trade in professional services;

*Desiring* to establish multilateral disciplines with a view to ensuring that, when specific commitments are undertaken, such regulatory measures do not constitute unnecessary barriers to the supply of professional services;

*Decides* as follows:

1. The work programme foreseen in paragraph 4 of Article VI on Domestic Regulation should be put into effect immediately. To this end, a Working Party on Professional Services shall be established to examine and report, with recommendations, on the disciplines necessary to ensure that measures relating to qualification requirements and procedures, technical standards and licensing requirements in the field of professional services do not constitute unnecessary barriers to trade.

2. As a matter of priority, the Working Party shall make recommendations for the elaboration of multilateral disciplines in the accountancy sector, so as to give operational effect to specific commitments. In making these recommendations, the Working Party shall concentrate on:

- (a) developing multilateral disciplines relating to market access so as to ensure that domestic regulatory requirements are: (i) based on objective and transparent criteria, such as competence and the ability to supply the service; (ii) not more burdensome than necessary to ensure the quality of the service, thereby facilitating the effective liberalization of accountancy services;
- (b) the use of international standards and, in doing so, it shall encourage the cooperation with the relevant international organizations as defined under paragraph 5(b) of Article VI, so as to give full effect to paragraph 5 of Article VII;
- (c) facilitating the effective application of paragraph 6 of Article VI of the Agreement by establishing guidelines for the recognition of qualifications.

In elaborating these disciplines, the Working Party shall take account of the importance of the governmental and non-governmental bodies regulating professional services.

**DECISION ON ACCESSION TO THE  
AGREEMENT ON GOVERNMENT PROCUREMENT**

1. *Ministers invite* the Committee on Government Procurement established under the Agreement on Government Procurement in Annex 4(b) of the Agreement Establishing the World Trade Organization to clarify that:

- (a) a Member interested in accession according to paragraph 2 of Article XXIV of the Agreement on Government Procurement would communicate its interest to the Director-General of the WTO, submitting relevant information, including a coverage offer for incorporation in Appendix I having regard to the relevant provisions of the Agreement, in particular Article I and, where appropriate, Article V;
- (b) the communication would be circulated to Parties to the Agreement;
- (c) the Member interested in accession would hold consultations with the Parties on the terms for its accession to the Agreement;
- (d) with a view to facilitating accession, the Committee would establish a working party if the Member in question, or any of the Parties to the Agreement, so requests. The working party should examine:  
(i) the coverage offer made by the applicant Member; and (ii) relevant information pertaining to export opportunities in the markets of the Parties, taking into account the existing and potential export capabilities of the applicant Member and export opportunities for the Parties in the market of the applicant Member;
- (e) upon a decision by the Committee agreeing to the terms of accession including the coverage lists of the acceding Member, the acceding Member would deposit with the Director-General of the WTO an instrument of accession which states the terms so agreed. The acceding Member's coverage lists in English, French and Spanish would be appended to the Agreement;
- (f) prior to the date of entry into force of the WTO Agreement, the above procedures would apply *mutatis mutandis* to contracting parties to the GATT 1947 interested in accession, and the tasks assigned to the Director-General of the WTO would be carried out by the Director-General to the CONTRACTING PARTIES to the GATT 1947.

2. It is noted that Committee decisions are arrived at on the basis of consensus. It is also noted that the non-application clause of paragraph 11 of Article XXIV is available to any Party.

**DECISION ON THE APPLICATION AND REVIEW OF THE UNDERSTANDING  
ON RULES AND PROCEDURES GOVERNING THE SETTLEMENT OF DISPUTES**

*Ministers,*

*Recalling* the Decision of 22 February 1994 that existing rules and procedures of GATT 1947 in the field of dispute settlement shall remain in effect until the date of entry into force of the Agreement Establishing the World Trade Organization,

*Invite* the relevant Councils and Committees to decide that they shall remain in operation for the purpose of dealing with any dispute for which the request for consultation was made before that date;

*Invite* the Ministerial Conference to complete a full review of dispute settlement rules and procedures under the World Trade Organization within four years after the entry into force of the Agreement Establishing the World Trade Organization, and to take a decision on the occasion of its first meeting after the completion of the review, whether to continue, modify or terminate such dispute settlement rules and procedures.

## UNDERSTANDING ON COMMITMENTS IN FINANCIAL SERVICES

Participants in the Uruguay Round have been enabled to take on specific commitments with respect to financial services under the General Agreement on Trade in Services (hereinafter referred to as the "Agreement") on the basis of an alternative approach to that covered by the provisions of Part III of the Agreement. It was agreed that this approach could be applied subject to the following understanding:

- (i) it does not conflict with the provisions of the Agreement;
- (ii) it does not prejudice the right of any Member to schedule its specific commitments in accordance with the approach under Part III of the Agreement;
- (iii) resulting specific commitments shall apply on a most-favoured-nation basis;
- (iv) no presumption has been created as to the degree of liberalization to which a Member is committing itself under the Agreement.

Interested Members, on the basis of negotiations, and subject to conditions and qualifications where specified, have inscribed in their schedule specific commitments conforming to the approach set out below.

### A. *Standstill*

Any conditions, limitations and qualifications to the commitments noted below shall be limited to existing non-conforming measures.

### B. *Market Access*

#### *Monopoly Rights*

1. In addition to Article VIII of the Agreement, the following shall apply:

Each Member shall list in its schedule pertaining to financial services existing monopoly rights and shall endeavour to eliminate them or reduce their scope. Notwithstanding subparagraph 1(b) of the Annex on Financial Services, this paragraph applies to the activities referred to in subparagraph 1(b)(iii) of the Annex.

#### *Financial Services purchased by Public Entities*

2. Notwithstanding Article XIII of the Agreement, each Member shall ensure that financial service suppliers of any other Member established in its territory are accorded most-favoured-nation treatment and national treatment as regards the purchase or acquisition of financial services by public entities of the Member in its territory.

#### *Cross-border Trade*

3. Each Member shall permit non-resident suppliers of financial services to supply, as a principal, through an intermediary or as an intermediary, and under terms and conditions that accord national treatment, the following services:

- (a) insurance of risks relating to:
  - (i) maritime shipping and commercial aviation and space launching and freight (including satellites), with such insurance to cover any or all of the following: the goods being transported, the vehicle transporting the goods and any liability arising therefrom; and
  - (ii) goods in international transit;
- (b) reinsurance and retrocession and the services auxiliary to insurance as referred to in subparagraph 5(a)(iv) of the Annex;
- (c) provision and transfer of financial information and financial data processing as referred to in subparagraph 5(a)(xv) of the Annex and advisory and other auxiliary services, excluding intermediation, relating to banking and other financial services as referred to in subparagraph 5(a)(xvi) of the Annex.

4. Each Member shall permit its residents to purchase in the territory of any other Member the financial services indicated in:

- (a) subparagraph 3(a);
- (b) subparagraph 3(b); and
- (c) subparagraphs 5(a)(v) to (xvi) of the Annex.

*Commercial Presence*

5. Each Member shall grant financial service suppliers of any other Member the right to establish or expand within its territory, including through the acquisition of existing enterprises, a commercial presence.

6. A Member may impose terms, conditions and procedures for authorization of the establishment and expansion of a commercial presence in so far as they do not circumvent the Member's obligation under paragraph 5 and they are consistent with the other obligations of the Agreement.

*New Financial Services*

7. A Member shall permit financial service suppliers of any other Member established in its territory to offer in its territory any new financial service.

*Transfers of Information and Processing of Information*

8. No Member shall take measures that prevent transfers of information or the processing of financial information, including transfers of data by electronic means, or that, subject to importation rules consistent with international agreements, prevent transfers of equipment, where such transfers of information, processing of financial information or transfers of equipment are necessary for the conduct of the ordinary business of a financial service supplier. Nothing in this paragraph restricts the right of a Member to protect personal data, personal privacy and the confidentiality of individual records and accounts so long as such right is not used to circumvent the provisions of the Agreement.

*Temporary Entry of Personnel*

9. (a) Each Member shall permit temporary entry into its territory of the following personnel of a financial service supplier of any other Member that is establishing or has established a commercial presence in the territory of the Member:

- (i) senior managerial personnel possessing proprietary information essential to the establishment, control and operation of the services of the financial service supplier; and
- (ii) specialists in the operation of the financial service supplier.

(b) Each Member shall permit, subject to the availability of qualified personnel in its territory, temporary entry into its territory of the following personnel associated with a commercial presence of a financial service supplier of any other Member:

- (i) specialists in computer services, telecommunication services and accounts of the financial service supplier; and
- (ii) actuarial and legal specialists.

*Non-discriminatory Measures*

10. Each Member shall endeavour to remove or to limit any significant adverse effects on financial service suppliers of any other Member of:

- (a) non-discriminatory measures that prevent financial service suppliers from offering in the Member's territory, in the form determined by the Member, all the financial services permitted by the Member;
- (b) non-discriminatory measures that limit the expansion of the activities of financial service suppliers into the entire territory of the Member;

- (c) measures of a Member, when such a Member applies the same measures to the supply of both banking and securities services, and a financial service supplier of any other Member concentrates its activities in the provision of securities services; and
- (d) other measures that, although respecting the provisions of the Agreement, affect adversely the ability of financial service suppliers of any other Member to operate, compete or enter the Member's market;

provided that any action taken under this paragraph would not unfairly discriminate against financial service suppliers of the Member taking such action.

11. With respect to the non-discriminatory measures referred to in subparagraphs 10(a) and (b), a Member shall endeavour not to limit or restrict the present degree of market opportunities nor the benefits already enjoyed by financial service suppliers of all other Members as a class in the territory of the Member, provided that this commitment does not result in unfair discrimination against financial service suppliers of the Member applying such measures.

#### C. *National Treatment*

1. Under terms and conditions that accord national treatment, each Member shall grant to financial service suppliers of any other Member established in its territory access to payment and clearing systems operated by public entities, and to official funding and refinancing facilities available in the normal course of ordinary business. This paragraph is not intended to confer access to the Member's lender of last resort facilities.

2. When membership or participation in, or access to, any self-regulatory body, securities or futures exchange or market, clearing agency, or any other organization or association, is required by a Member in order for financial service suppliers of any other Member to supply financial services on an equal basis with financial service suppliers of the Member, or when the Member provides directly or indirectly such entities, privileges or advantages in supplying financial services, the Member shall ensure that such entities accord national treatment to financial service suppliers of any other Member resident in the territory of the Member.

#### D. *Definitions*

For the purposes of this approach:

1. A non-resident supplier of financial services is a financial service supplier of a Member which supplies a financial service into the territory of another Member from an establishment located in the territory of another Member, regardless of whether such a financial service supplier has or has not a commercial presence in the territory of the Member in which the financial service is supplied.

2. "Commercial presence" means an enterprise within a Member's territory for the supply of financial services and includes wholly- or partly-owned subsidiaries, joint ventures, partnerships, sole proprietorships, franchising operations, branches, agencies, representative offices or other organizations.

3. A new financial service is a service of a financial nature, including services related to existing and new products or the manner in which a product is delivered, that is not supplied by any financial service supplier in the territory of a particular Member but which is supplied in the territory of another Member.



ADDITIONAL DECISIONS AND DECLARATIONS ADOPTED  
AT THE MINISTERIAL MEETING AT MARRAKESH

DECISIONS ET DECLARATIONS ADDITIONNELLES ADOPTÉES  
A LA REUNIÓN MINISTERIELLE DE MARRAKECH

DECISIONES Y DECLARACIONES ADICIONALES ADOPTADAS  
EN LA REUNIÓN MINISTERIAL DE MARRAKECH

**Acceptance of and Accession to the Agreement  
Establishing the World Trade Organization**

Decision of 14 April 1994

*Ministers,*

*Noting* that Articles XI and XIV of the Agreement Establishing the World Trade Organization (hereinafter referred to as "WTO Agreement") provide that only contracting parties to the GATT 1947 as of the entry into force of the WTO Agreement for which schedules of concessions and commitments are annexed to GATT 1994 and for which schedules of specific commitments are annexed to the General Agreement on Trade in Services (hereinafter referred to as "GATS") may accept the WTO Agreement;

*Noting* further that paragraph 5 of the Final Act Embodying the Results of the Uruguay Round of Multilateral Trade Negotiations (hereinafter referred to as "Final Act" and "Uruguay Round" respectively) provides that the schedules of participants which are not contracting parties to GATT 1947 as of the date of the Final Act are not definitive and shall be subsequently completed for the purpose of their accession to GATT 1947 and their acceptance of the WTO Agreement;

*Having regard to* paragraph 1 of the Decision on Measures in Favour of Least-Developed Countries which provides that the least-developed countries shall be given an additional time of one year from 15 April 1994 to submit their schedules as required in Article XI of the WTO Agreement;

*Recognizing* that certain participants in the Uruguay Round which had applied GATT 1947 on a *de facto* basis and became contracting parties under Article XXVI:5(c) of the GATT 1947 were not in a position to submit schedules to GATT 1994 and the GATS;

*Recognizing* further that some States or separate customs territories which were not participants in the Uruguay Round may become contracting parties to GATT 1947 before the entry into force of the WTO Agreement and that States or customs territories should be given the opportunity to negotiate schedules to GATT 1994 and the GATS so as to enable them to accept the WTO Agreement;

*Taking into account* that some States or separate customs territories which cannot complete the process of accession to GATT 1947 before the entry into force of the WTO Agreement or which do not intend to become contracting parties to GATT 1947 may wish to initiate the process of their accession to the WTO before the entry into force of the WTO Agreement;

*Recognizing* that the WTO Agreement does not distinguish in any way between WTO Members which accepted that Agreement in accordance with its Articles XI and XIV and WTO Members which acceded to it in accordance with its Article XII and wishing to ensure that the procedures for accession of the States and separate customs territories which have not become contracting parties to the GATT 1947 as of the date of entry into force of the WTO Agreement are such as to avoid any unnecessary disadvantage or delay for these States and separate customs territories;

*Decide* that:

1. (a) Any Signatory of the Final Act

-to which paragraph 5 of the Final Act applies, or

to which paragraph 1 of the Decision on Measures in Favour of Least-Developed Countries applies, or

which became a contracting party under Article XXVI:5(c) of the GATT 1947 before 15 April 1994 and was not in a position to establish a schedule to GATT 1994 and the GATS for inclusion in the Final Act, and

any State or separate customs territory

which becomes a contracting party to the GATT 1947 between 15 April 1994 and the date of entry into force of the WTO Agreement

may submit to the Preparatory Committee for its examination and approval a schedule of concessions and commitments to GATT 1994 and a schedule of specific commitments to the GATS.

(b) The WTO Agreement shall be open for acceptance in accordance with Article XIV of that Agreement by contracting parties to GATT 1947 the schedules of which have been so submitted and approved before the entry into force of the WTO Agreement.

(c) The provisions of subparagraphs (a) and (b) of this paragraph shall be without prejudice to the right of the least-developed countries to submit their schedules within one year from 15 April 1994.

2. (a) Any State or separate customs territory may request the Preparatory Committee to propose for approval by the Ministerial Conference of the WTO the terms of its accession to the WTO Agreement in accordance with Article XII of that Agreement. If such a request is made by a State or separate customs territory which is in the process of acceding to GATT 1947, the Preparatory Committee shall, to the extent practicable, examine the request jointly with the Working Party established by the CONTRACTING PARTIES to GATT 1947 to examine the accession of that State or separate customs territory.

(b) The Preparatory Committee shall submit to the Ministerial Conference a report on its examination of the request. The report may include a protocol of accession, including a schedule of concessions and commitments to GATT 1994 and a schedule of specific commitments for the GATS, for approval by the Ministerial Conference. The report of the Preparatory Committee shall be taken into account by the Ministerial Conference in its consideration of any application by the State or separate customs territory concerned to accede to the WTO Agreement.

## Trade and Environment

Decision of 14 April 1994

*Ministers*, meeting on the occasion of signing the Final Act embodying the results of the Uruguay Round of Multilateral Trade Negotiations at Marrakesh on 15 April 1994,

*Recalling* the preamble of the Agreement establishing the World Trade Organization (WTO), which states that members' "relations in the field of trade and economic endeavour should be conducted with a view to raising standards of living, ensuring full employment and a large and steadily growing volume of real income and effective demand, and expanding the production of and trade in goods and services, while allowing for the optimal use of the world's resources in accordance with the objective of sustainable development, seeking both to protect and preserve the environment and to enhance the means for doing so in a manner consistent with their respective needs and concerns at different levels of economic development,"

*Noting:*

- the Rio Declaration on Environment and Development, Agenda 21, and its follow-up in GATT, as reflected in the statement of the Chairman of the Council of Representatives to the CONTRACTING PARTIES at their 48th Session in December 1992, as well as the work of the Group on Environmental Measures and International Trade, the Committee on Trade and Development, and the Council of Representatives;
- the work programme envisaged in the Decision on Trade in Services and the Environment; and
- the relevant provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights,

*Considering* that there should not be, nor need be, any policy contradiction between upholding and safeguarding an open, non-discriminatory and equitable multilateral trading system on the one hand, and acting for the protection of the environment, and the promotion of sustainable development on the other,

*Desiring* to coordinate the policies in the field of trade and environment, and this without exceeding the competence of the multilateral trading system, which is limited to trade policies and those trade-related aspects of environmental policies which may result in significant trade effects for its members,

*Decide:*

- to direct the first meeting of the General Council of the WTO to establish a Committee on Trade and Environment open to all members of the WTO to report to the first biennial meeting of the Ministerial Conference after the entry into force of the WTO when the work and terms of reference of the Committee will be reviewed, in the light of recommendations of the Committee,
- that the TNC Decision of 15 December 1993 which reads, in part, as follows:
  - "(a) to identify the relationship between trade measures and environmental measures, in order to promote sustainable development;
  - (b) to make appropriate recommendations on whether any modifications of the provisions of the multilateral trading system are required, compatible with the open, equitable and non-discriminatory nature of the system, as regards, in particular:
- the need for rules to enhance positive interaction between trade and environmental measures, for the promotion of sustainable development, with special consideration to the needs of developing countries, in particular those of the least developed among them; and

- the avoidance of protectionist trade measures, and the adherence to effective multilateral disciplines to ensure responsiveness of the multilateral trading system to environmental objectives set forth in Agenda 21 and the Rio Declaration, in particular Principle 12; and
- surveillance of trade measures used for environmental purposes, of trade-related aspects of environmental measures which have significant trade effects, and of effective implementation of the multilateral disciplines governing those measures;\*

constitutes, along with the preambular language above, the terms of reference of the Committee on Trade and Environment,

— that, within these terms of reference, and with the aim of making international trade and environmental policies mutually supportive, the Committee will initially address the following matters, in relation to which any relevant issue may be raised:

- the relationship between the provisions of the multilateral trading system and trade measures for environmental purposes, including those pursuant to multilateral environmental agreements;
- the relationship between environmental policies relevant to trade and environmental measures with significant trade effects and the provisions of the multilateral trading system;
- the relationship between the provisions of the multilateral trading system and:
  - (a) charges and taxes for environmental purposes
  - (b) requirements for environmental purposes relating to products, including standards and technical regulations, packaging, labelling and recycling;
- the provisions of the multilateral trading system with respect to the transparency of trade measures used for environmental purposes and environmental measures and requirements which have significant trade effects;
- the relationship between the dispute settlement mechanisms in the multilateral trading system and those found in multilateral environmental agreements;
- the effect of environmental measures on market access, especially in relation to developing countries, in particular to the least developed among them, and environmental benefits of removing trade restrictions and distortions;
- the issue of exports of domestically prohibited goods,

— that the Committee on Trade and Environment will consider the work programme envisaged in the Decision on Trade in Services and the Environment and the relevant provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights as an integral part of its work, within the above terms of reference,

— that, pending the first meeting of the General Council of the WTO, the work of the Committee on Trade and Environment should be carried out by a Sub-Committee of the Preparatory Committee of the World Trade Organization (PCWTO), open to all members of the PCWTO,

— to invite the Sub-Committee of the Preparatory Committee, and the Committee on Trade and Environment when it is established, to provide input to the relevant bodies in respect of appropriate arrangements for relations with inter-governmental and non-governmental organizations referred to in Article V of the WTO.

**Organizational and Financial Consequences flowing from  
Implementation of the Agreement Establishing  
the World Trade Organization**

Decision of 14 April 1994

*Ministers,*

*Recognizing* the importance of the rôle and contribution to international trade of the World Trade Organization (hereinafter referred to as the WTO),

*Desiring* to ensure the efficient functioning of the WTO Secretariat,

*Recognizing* that implementation of the results of the Uruguay Round will expand the scope and complexity of the duties of the Secretariat and that the resource implications thereof need to be studied,

*Recalling* the statements made by previous Chairmen of the GATT CONTRACTING PARTIES and the GATT Council drawing attention to the need to improve the terms and conditions of service, including salaries and pensions, for the professional staff of the Secretariat,

*Mindful* of the need for the WTO to be competitive in the conditions of service it will offer to its professional staff so as to attract the required expertise,

*Noting* the proposal of the Director-General that, in setting WTO staff conditions of services, including salaries and pensions, due account be taken of those of the International Monetary Fund and the World Bank,

*Noting* Article VI of the Agreement establishing the WTO, in particular paragraph 3 thereof empowering the Director-General to appoint the staff of the Secretariat to determine their duties and conditions of service in accordance with regulations adopted by the Ministerial Conference,

*Recalling* that the mandate of the Preparatory Committee requires it to perform such functions as may be necessary to ensure the efficient operation of the WTO immediately as of the date of its establishment, including the preparation of recommendations for the consideration of the competent body of the WTO, or to the extent necessary, the taking of decisions or, as appropriate, provisional decisions with respect to administrative, budgetary and financial matters assisted by proposals from the Secretariat,

Hereby *agree* that the Preparatory Committee shall consider the organizational changes, resource requirements and staff conditions of service proposed in connection with the establishment of the WTO and the implementation of the Uruguay Round agreements and prepare recommendations and take decisions, to the extent necessary, on the adjustments required.

Decision on the Establishment of the Preparatory Committee  
for the World Trade Organization

Decision of 14 April 1994

Ministers,

*Having regard to* the Agreement Establishing the World Trade Organization (hereinafter referred to as "WTO Agreement" and "WTO"), and

*Mindful* of the desirability of ensuring an orderly transition to the WTO and the efficient operation of the WTO as of the date of entry into force,

hereby *agree* as follows:

1. A Preparatory Committee for the WTO (hereinafter referred to as "Committee") is hereby established. Mr. P.D. Sutherland in his personal capacity is appointed Chairman of the Committee.
2. The Committee shall be open for membership to all Signatories of the Final Act of the Uruguay Round of Multilateral Trade Negotiations and to any contracting party eligible to become an original member of the WTO in accordance with Article XI of the WTO Agreement.
3. A Sub-Committee on Budget, Finance and Administration, to be chaired by the Chairman of the GATT CONTRACTING PARTIES, and a Sub-Committee on Services responsible for preparatory work on GATS matters are also established. The Committee may establish additional sub-committees as appropriate. Membership of the Sub-Committees shall be open to all members of the Committee. The Committee shall establish its own procedures and those of its sub-committees.
4. The Committee will make all its decisions by consensus.
5. Only those members of the Committee that are GATT contracting parties eligible to become original Members of the WTO in accordance with Articles XI and XIV of the WTO Agreement may participate in the decision-making of the Committee.
6. The Committee and its sub-committees shall be serviced by the GATT Secretariat.
7. The Committee shall cease to exist upon the entry into force of the WTO Agreement, at which time it will forward its records and recommendations to the WTO.
8. The Committee shall perform such functions as may be necessary to ensure the efficient operation of the WTO immediately as of the date of its establishment, including the functions set out below:
  - (a) Administrative, budgetary and financial matters:

To prepare recommendations for the consideration of the competent body of the WTO, or, to the extent necessary, take decisions or, as appropriate, provisional decisions in advance of the establishment of the WTO, with respect to the recommendations submitted to it by the Chairman of the Sub-Committee on Budget, Finance and Administration referred to in paragraph 3 above, in cooperation with the Chairman of the GATT Committee on Budget, Finance and Administration, assisted by proposals from the Secretariat on:

    - (i) the headquarters agreement provided for in Article VIII:5 of the WTO Agreement;
    - (ii) financial regulations, including guidelines for the assessment of WTO members' budget contributions, in accordance with the criteria set out in Article VII of the WTO Agreement;
    - (iii) the budget estimates for the first year of operation of the WTO;

- (iv) the transfer of the property, including financial assets, of the ICITO/GATT to the WTO;
- (v) the transfer and the terms and conditions of the transfer of the GATT staff to the WTO Secretariat; and
- (vi) the relationship between the International Trade Centre and the WTO.
- (b) Institutional, procedural and legal matters:
  - (i) To carry out the examination of and approve the schedules submitted to it in accordance with the "Decision on Acceptance of and Accession to the Agreement Establishing the World Trade Organization" and to propose terms of accession in accordance with paragraph 2 of that Decision;
  - (ii) To make proposals concerning terms of reference for the bodies of the WTO, in particular those established in Article IV of the WTO Agreement, and the rules of procedure which they are called upon to establish for themselves, bearing in mind paragraph 1 of Article XVI;
  - (iii) To make recommendations to the General Council of the WTO concerning the appropriate arrangements with respect to relations with other organizations referred to in Article V of the WTO Agreement; and
  - (iv) To prepare and submit a report on its activities to the WTO.
- (c) Matters related to the entry into force of the WTO Agreement and to the activities of the WTO within its scope and functions:
  - (i) To convene and prepare the Implementation Conference;
  - (ii) To initiate the work programme arising from the Uruguay Round results as set out in the Final Act, such as overseeing, in the Sub-Committee on Services referred to in paragraph 3 above, negotiations in specific services sectors, and also to undertake work resulting from Decisions of the Marrakesh meeting;
  - (iii) To discuss suggestions for the inclusion of additional items on the agenda of the WTO's work programme;
  - (iv) To make proposals concerning the composition of the Textiles Monitoring Body in accordance with the criteria set out in Article 8 of the Agreement on Textiles and Clothing; and
  - (v) To convene the first meeting of the Ministerial Conference or the General Council of the WTO, whichever meets first, and to prepare the provisional agenda thereof.



## Marrakesh Declaration of 15 April 1994

*Ministers,*

*Representing* the 124 Governments and the European Communities participating in the Uruguay Round of Multilateral Trade Negotiations, on the occasion of the final session of the Trade Negotiations Committee at Ministerial level held at Marrakesh, Morocco from 12 to 15 April 1994,

*Recalling* the Ministerial Declaration adopted at Punta del Este, Uruguay on 20 September 1986 to launch the Uruguay Round of Multilateral Trade Negotiations,

*Recalling* the progress achieved at the Ministerial meetings held at Montreal, Canada and Brussels, Belgium in December of 1988 and 1990 respectively,

*Noting* that the negotiations were substantially concluded on 15 December 1993,

*Determined* to build upon the success of the Uruguay Round through the participation of their economies in the world trading system, based upon open, market-oriented policies and the commitments set out in the Uruguay Round Agreements and Decisions,

Have today adopted the following:

**DECLARATION:**

16. Ministers salute the historic achievement represented by the conclusion of the Round, which they believe will strengthen the world economy and lead to more trade, investment, employment and income growth throughout the world. In particular, they welcome:
  - the stronger and clearer legal framework they have adopted for the conduct of international trade, including a more effective and reliable dispute settlement mechanism,
  - the global reduction by 40 per cent of tariffs and wider market-opening agreements on goods, and the increased predictability and security represented by a major expansion in the scope of tariff commitments, and
  - the establishment of a multilateral framework of disciplines for trade in services and for the protection of trade-related intellectual property rights, as well as the reinforced multilateral trade provisions in agriculture and in textiles and clothing.
17. Ministers affirm that the establishment of the World Trade Organization (WTO) ushers in a new era of global economic cooperation, reflecting the widespread desire to operate in a fairer and more open multilateral trading system for the benefit and welfare of their peoples. Ministers express their determination to resist protectionist pressures of all kinds. They believe that the trade liberalization and strengthened rules achieved in the Uruguay Round will lead to a progressively more open world trading environment. Ministers undertake, with immediate effect and until the entry into force of the WTO, not to take any trade measures that would undermine or adversely affect the results of the Uruguay Round negotiations or their implementation.
18. Ministers confirm their resolution to strive for greater global coherence of policies in the fields of trade, money and finance, including cooperation between the WTO, the IMF and the World Bank for that purpose.
19. Ministers welcome the fact that participation in the Uruguay Round was considerably wider than in any previous multilateral trade negotiation and, in particular, that developing countries played a notably active rôle in it. This has marked a historic step towards a more balanced and integrated global trade partnership. Ministers note that during the period these negotiations were underway significant measures of economic reform and autonomous trade liberalization were implemented in many developing countries and formerly centrally planned economies.

20. Ministers recall that the results of the negotiations embody provisions conferring differential and more favourable treatment for developing economies, including special attention to the particular situation of least-developed countries. Ministers recognize the importance of the implementation of these provisions for the least-developed countries and declare their intention to continue to assist and facilitate the expansion of their trade and investment opportunities. They agree to keep under regular review by the Ministerial Conference and the appropriate organs of the WTO the impact of the results of the Round on the least-developed countries as well as on the net-food importing developing countries, with a view to fostering positive measures to enable them to achieve their development objectives. Ministers recognize the need for strengthening the capability of the GATT and the WTO to provide increased technical assistance in their areas of competence, and in particular to substantially expand its provision to the least-developed countries.
21. Ministers declare that their signature of the "Final Act Embodying the Results of the Uruguay Round of Multilateral Trade Negotiations" and their adoption of associated Ministerial Decisions initiates the transition from the GATT to the WTO. They have in particular established a Preparatory Committee to lay the ground for the entry into force of the WTO Agreement and commit themselves to seek to complete all steps necessary to ratify the WTO Agreement so that it can enter into force by 1 January 1995 or as early as possible thereafter. Ministers have furthermore adopted a Decision on Trade and Environment.
22. Ministers express their sincere gratitude to His Majesty King Hassan II for his personal contribution to the success of this Ministerial Meeting, and to his Government and the people of Morocco for their warm hospitality and the excellent organization they have provided. The fact that this final Ministerial Meeting of the Uruguay Round has been held at Marrakesh is an additional manifestation of Morocco's commitment to an open world trading system and to its fullest integration to the global economy.
23. With the adoption and signature of the Final Act and the opening for acceptance of the WTO Agreement, Ministers declare the work of the Trade Negotiations Committee to be complete and the Uruguay Round formally concluded.

## MARRAKESH AGREEMENT<sup>1</sup> ESTABLISHING THE WORLD TRADE ORGANIZATION

### The Parties to this Agreement,

*Recognizing* that their relations in the field of trade and economic endeavour should be conducted with a view to raising standards of living, ensuring full employment and a large and steadily growing volume of real income and effective demand, and expanding the production of and trade in goods and services, while allowing for the optimal use of the world's resources in accordance with the objective of sustainable development, seeking both to protect and preserve the environment and to enhance the means for doing so in a manner consistent with their respective needs and concerns at different levels of economic development,

*Recognizing* further that there is need for positive efforts designed to ensure that developing countries, and especially the least developed among them, secure a share in the growth in international trade commensurate with the needs of their economic development,

*Being desirous* of contributing to these objectives by entering into reciprocal and mutually advantageous arrangements directed to the substantial reduction of tariffs and other barriers to trade and to the elimination of discriminatory treatment in international trade relations,

<sup>1</sup> The above Agreement and the Multilateral Trade Agreements annexed hereto came into force in respect of the following Contracting Parties to the General Agreement on Tariffs and Trade of 1947 and the European Communities, which were eligible to become original Members of the World Trade Organization, on 1 January 1995, i.e., the date determined by the Ministers of all participants in the Uruguay Round of Multilateral Trade Negotiations, in accordance with article XIV (1):

<i>Participant</i>	<i>Date of deposit of the instrument of ratification, accession (a), acceptance (A), approval (AA) or date of definitive signature (s)</i>	<i>Participant</i>	<i>Date of deposit of the instrument of ratification, accession (a), acceptance (A), approval (AA) or date of definitive signature (s)</i>
Antigua and Barbuda .....	15 April 1994s	Guyana .....	15 April 1994s
Argentina .....	29 December 1994	Honduras* .....	16 December 1994
Australia* .....	21 December 1994A	Hong Kong .....	3 October 1994A
Austria* .....	6 December 1994	Hungary .....	28 December 1994
Bahrain .....	27 July 1994	Iceland .....	30 December 1994
Bangladesh* .....	15 April 1994s	India .....	30 December 1994
Barbados .....	15 April 1994s	Indonesia* .....	2 December 1994
Belgium .....	30 December 1994	Ireland .....	30 December 1994
Belize .....	15 April 1994s	Italy .....	30 December 1994
Brazil* .....	21 December 1994	Japan .....	27 December 1994A
Brunei Darussalam .....	16 November 1994	Kenya* .....	23 December 1994
Canada* .....	30 December 1994	Kuwait .....	15 April 1994s
Chile* .....	28 December 1994A	Luxembourg .....	30 December 1994
Costa Rica* .....	26 December 1994A	Macau .....	23 December 1994A
Côte d'Ivoire* .....	29 December 1994	Malaysia* .....	6 September 1994A
Czech Republic .....	23 December 1994AA	Malta* .....	22 December 1994
Denmark .....	30 December 1994	Mauritius* .....	15 April 1994s
Dominica .....	22 December 1994s	Mexico .....	31 August 1994
European Community .....	30 December 1994AA	Morocco .....	15 April 1994s
Finland .....	30 December 1994	Myanmar* .....	29 November 1994A
France .....	30 December 1994	Namibia .....	15 April 1994s
Gabon* .....	15 April 1994s	Netherlands .....	30 December 1994A
Germany .....	30 December 1994	(For the Kingdom in Europe and the Netherlands Antilles.)	
Ghana* .....	23 December 1994	New Zealand* .....	7 December 1994
Greece .....	30 December 1994A		

(Continued on page 155)

*Resolved*, therefore, to develop an integrated, more viable and durable multilateral trading system encompassing the General Agreement on Tariffs and Trade, the results of past trade liberalization efforts, and all of the results of the Uruguay Round of Multilateral Trade Negotiations,

*Determined* to preserve the basic principles and to further the objectives underlying this multilateral trading system,

Agree as follows:

### Article I

#### *Establishment of the Organization*

The World Trade Organization (hereinafter referred to as "the WTO") is hereby established.

### Article II

#### *Scope of the WTO*

1. The WTO shall provide the common institutional framework for the conduct of trade relations among its Members in matters related to the agreements and associated legal instruments included in the Annexes to this Agreement.
2. The agreements and associated legal instruments included in Annexes 1, 2 and 3 (hereinafter referred to as "Multilateral Trade Agreements") are integral parts of this Agreement, binding on all Members.
3. The agreements and associated legal instruments included in Annex 4 (hereinafter referred to as "Plurilateral Trade Agreements") are also part of this Agreement for those Members that have

(Footnote / continued from page 154)

<i>Participant</i>	<i>Date of deposit of the instrument of ratification, accession (a), acceptance (A), approval (AA) or date of definitive signature (s)</i>	<i>Participant</i>	<i>Date of deposit of the instrument of ratification, accession (a), acceptance (A), approval (AA) or date of definitive signature (s)</i>
Nigeria .....	6 December 1994A	Spain .....	30 December 1994
Norway .....	7 December 1994	Sri Lanka* .....	6 July 1994A
Pakistan* .....	30 December 1994	Suriname .....	15 April 1994s
Paraguay* .....	30 November 1994	Swaziland .....	28 December 1994
Peru .....	21 December 1994	Sweden .....	22 December 1994
Philippines* .....	19 December 1994	Thailand* .....	28 December 1994
Portugal .....	30 December 1994	Uganda .....	15 April 1994s
Republic of Korea .....	30 December 1994A	United Kingdom of Great Britain and Northern Ireland .....	30 December 1994
Romania .....	23 December 1994	United Republic of Tanzania ..	6 September 1994A
Saint Lucia .....	30 December 1994	United States of America* .....	30 December 1994A
Saint Vincent and the Grenadines	28 December 1994A	Uruguay* .....	29 December 1994
Senegal* .....	29 December 1994	Venezuela* .....	30 December 1994
Singapore* .....	17 October 1994	Zambia .....	15 April 1994s
Slovakia .....	23 December 1994A		
South Africa .....	2 December 1994A		

\* For the texts of the statements, communications, reservations and declarations made upon ratification, acceptance, or definitive signature, see page 511 of volume 1869.

accepted them, and are binding on those Members. The Plurilateral Trade Agreements do not create either obligations or rights for Members that have not accepted them.

4. The General Agreement on Tariffs and Trade 1994 as specified in Annex 1A (hereinafter referred to as "GATT 1994") is legally distinct from the General Agreement on Tariffs and Trade, dated 30 October 1947, annexed to the Final Act Adopted at the Conclusion of the Second Session of the Preparatory Committee of the United Nations Conference on Trade and Employment, as subsequently rectified, amended or modified (hereinafter referred to as "GATT 1947").

### *Article III*

#### *Functions of the WTO*

1. The WTO shall facilitate the implementation, administration and operation, and further the objectives, of this Agreement and of the Multilateral Trade Agreements, and shall also provide the framework for the implementation, administration and operation of the Plurilateral Trade Agreements.

2. The WTO shall provide the forum for negotiations among its Members concerning their multilateral trade relations in matters dealt with under the agreements in the Annexes to this Agreement. The WTO may also provide a forum for further negotiations among its Members concerning their multilateral trade relations, and a framework for the implementation of the results of such negotiations, as may be decided by the Ministerial Conference.

3. The WTO shall administer the Understanding on Rules and Procedures Governing the Settlement of Disputes (hereinafter referred to as the "Dispute Settlement Understanding" or "DSU") in Annex 2 to this Agreement.

4. The WTO shall administer the Trade Policy Review Mechanism (hereinafter referred to as the "TPRM") provided for in Annex 3 to this Agreement.

5. With a view to achieving greater coherence in global economic policy-making, the WTO shall cooperate, as appropriate, with the International Monetary Fund and with the International Bank for Reconstruction and Development and its affiliated agencies.

### *Article IV*

#### *Structure of the WTO*

1. There shall be a Ministerial Conference composed of representatives of all the Members, which shall meet at least once every two years. The Ministerial Conference shall carry out the functions of the WTO and take actions necessary to this effect. The Ministerial Conference shall have the authority to take decisions on all matters under any of the Multilateral Trade Agreements, if so requested by a Member, in accordance with the specific requirements for decision-making in this Agreement and in the relevant Multilateral Trade Agreement.

2. There shall be a General Council composed of representatives of all the Members, which shall meet as appropriate. In the intervals between meetings of the Ministerial Conference, its functions shall be conducted by the General Council. The General Council shall also carry out the functions assigned to it by this Agreement. The General Council shall establish its rules of procedure and approve the rules of procedure for the Committees provided for in paragraph 7.

3. The General Council shall convene as appropriate to discharge the responsibilities of the Dispute Settlement Body provided for in the Dispute Settlement Understanding. The Dispute Settlement Body may have its own chairman and shall establish such rules of procedure as it deems necessary for the fulfilment of those responsibilities.
4. The General Council shall convene as appropriate to discharge the responsibilities of the Trade Policy Review Body provided for in the TPRM. The Trade Policy Review Body may have its own chairman and shall establish such rules of procedure as it deems necessary for the fulfilment of those responsibilities.
5. There shall be a Council for Trade in Goods, a Council for Trade in Services and a Council for Trade-Related Aspects of Intellectual Property Rights (hereinafter referred to as the "Council for TRIPS"), which shall operate under the general guidance of the General Council. The Council for Trade in Goods shall oversee the functioning of the Multilateral Trade Agreements in Annex 1A. The Council for Trade in Services shall oversee the functioning of the General Agreement on Trade in Services (hereinafter referred to as "GATS"). The Council for TRIPS shall oversee the functioning of the Agreement on Trade-Related Aspects of Intellectual Property Rights (hereinafter referred to as the "Agreement on TRIPS"). These Councils shall carry out the functions assigned to them by their respective agreements and by the General Council. They shall establish their respective rules of procedure subject to the approval of the General Council. Membership in these Councils shall be open to representatives of all Members. These Councils shall meet as necessary to carry out their functions.
6. The Council for Trade in Goods, the Council for Trade in Services and the Council for TRIPS shall establish subsidiary bodies as required. These subsidiary bodies shall establish their respective rules of procedure subject to the approval of their respective Councils.
7. The Ministerial Conference shall establish a Committee on Trade and Development, a Committee on Balance-of-Payments Restrictions and a Committee on Budget, Finance and Administration, which shall carry out the functions assigned to them by this Agreement and by the Multilateral Trade Agreements, and any additional functions assigned to them by the General Council, and may establish such additional Committees with such functions as it may deem appropriate. As part of its functions, the Committee on Trade and Development shall periodically review the special provisions in the Multilateral Trade Agreements in favour of the least-developed country Members and report to the General Council for appropriate action. Membership in these Committees shall be open to representatives of all Members.
8. The bodies provided for under the Plurilateral Trade Agreements shall carry out the functions assigned to them under those Agreements and shall operate within the institutional framework of the WTO. These bodies shall keep the General Council informed of their activities on a regular basis.

#### *Article V*

##### *Relations with Other Organizations*

1. The General Council shall make appropriate arrangements for effective cooperation with other intergovernmental organizations that have responsibilities related to those of the WTO.
2. The General Council may make appropriate arrangements for consultation and cooperation with non-governmental organizations concerned with matters related to those of the WTO.

*Article VI**The Secretariat*

1. There shall be a Secretariat of the WTO (hereinafter referred to as “the Secretariat”) headed by a Director-General.
2. The Ministerial Conference shall appoint the Director-General and adopt regulations setting out the powers, duties, conditions of service and term of office of the Director-General.
3. The Director-General shall appoint the members of the staff of the Secretariat and determine their duties and conditions of service in accordance with regulations adopted by the Ministerial Conference.
4. The responsibilities of the Director-General and of the staff of the Secretariat shall be exclusively international in character. In the discharge of their duties, the Director-General and the staff of the Secretariat shall not seek or accept instructions from any government or any other authority external to the WTO. They shall refrain from any action which might adversely reflect on their position as international officials. The Members of the WTO shall respect the international character of the responsibilities of the Director-General and of the staff of the Secretariat and shall not seek to influence them in the discharge of their duties.

*Article VII**Budget and Contributions*

1. The Director-General shall present to the Committee on Budget, Finance and Administration the annual budget estimate and financial statement of the WTO. The Committee on Budget, Finance and Administration shall review the annual budget estimate and the financial statement presented by the Director-General and make recommendations thereon to the General Council. The annual budget estimate shall be subject to approval by the General Council.
2. The Committee on Budget, Finance and Administration shall propose to the General Council financial regulations which shall include provisions setting out:
  - (a) the scale of contributions apportioning the expenses of the WTO among its Members; and
  - (b) the measures to be taken in respect of Members in arrears.

The financial regulations shall be based, as far as practicable, on the regulations and practices of GATT 1947.

3. The General Council shall adopt the financial regulations and the annual budget estimate by a two-thirds majority comprising more than half of the Members of the WTO.
4. Each Member shall promptly contribute to the WTO its share in the expenses of the WTO in accordance with the financial regulations adopted by the General Council.

### Article VIII

#### *Status of the WTO*

1. The WTO shall have legal personality, and shall be accorded by each of its Members such legal capacity as may be necessary for the exercise of its functions.
2. The WTO shall be accorded by each of its Members such privileges and immunities as are necessary for the exercise of its functions.
3. The officials of the WTO and the representatives of the Members shall similarly be accorded by each of its Members such privileges and immunities as are necessary for the independent exercise of their functions in connection with the WTO.
4. The privileges and immunities to be accorded by a Member to the WTO, its officials, and the representatives of its Members shall be similar to the privileges and immunities stipulated in the Convention on the Privileges and Immunities of the Specialized Agencies, approved by the General Assembly of the United Nations on 21 November 1947.\*
5. The WTO may conclude a headquarters agreement.

### Article IX

#### *Decision-Making*

1. The WTO shall continue the practice of decision-making by consensus followed under GATT 1947.<sup>1</sup> Except as otherwise provided, where a decision cannot be arrived at by consensus, the matter at issue shall be decided by voting. At meetings of the Ministerial Conference and the General Council, each Member of the WTO shall have one vote. Where the European Communities exercise their right to vote, they shall have a number of votes equal to the number of their member States<sup>2</sup> which are Members of the WTO. Decisions of the Ministerial Conference and the General Council shall be taken by a majority of the votes cast, unless otherwise provided in this Agreement or in the relevant Multilateral Trade Agreement.<sup>3</sup>
2. The Ministerial Conference and the General Council shall have the exclusive authority to adopt interpretations of this Agreement and of the Multilateral Trade Agreements. In the case of an interpretation of a Multilateral Trade Agreement in Annex 1, they shall exercise their authority on the basis of a recommendation by the Council overseeing the functioning of that Agreement. The decision to adopt an interpretation shall be taken by a three-fourths majority of the Members. This paragraph shall not be used in a manner that would undermine the amendment provisions in Article X.
3. In exceptional circumstances, the Ministerial Conference may decide to waive an obligation imposed on a Member by this Agreement or any of the Multilateral Trade Agreements, provided that

<sup>1</sup> The body concerned shall be deemed to have decided by consensus on a matter submitted for its consideration, if no Member, present at the meeting when the decision is taken, formally objects to the proposed decision.

<sup>2</sup> The number of votes of the European Communities and their member States shall in no case exceed the number of the member States of the European Communities.

<sup>3</sup> Decisions by the General Council when convened as the Dispute Settlement Body shall be taken only in accordance with the provisions of paragraph 4 of Article 2 of the Dispute Settlement Understanding.

\* United Nations, *Treaty Series*, vol. 33, p. 261. For the final and revised texts of annexes published subsequently, see vol. 71, p. 318; vol. 79, p. 326; vol. 117, p. 386; vol. 275, p. 298; vol. 314, p. 308; vol. 323, p. 364; vol. 327, p. 326; vol. 371, p. 266; vol. 423, p. 284; vol. 559, p. 348; vol. 645, p. 340; vol. 1057, p. 320 and vol. 1060, p. 337.



any such decision shall be taken by three fourths<sup>4</sup> of the Members unless otherwise provided for in this paragraph.

- (a) A request for a waiver concerning this Agreement shall be submitted to the Ministerial Conference for consideration pursuant to the practice of decision-making by consensus. The Ministerial Conference shall establish a time-period, which shall not exceed 90 days, to consider the request. If consensus is not reached during the time-period, any decision to grant a waiver shall be taken by three fourths<sup>4</sup> of the Members.
- (b) A request for a waiver concerning the Multilateral Trade Agreements in Annexes 1A or 1B or 1C and their annexes shall be submitted initially to the Council for Trade in Goods, the Council for Trade in Services or the Council for TRIPS, respectively, for consideration during a time-period which shall not exceed 90 days. At the end of the time-period, the relevant Council shall submit a report to the Ministerial Conference.

4. A decision by the Ministerial Conference granting a waiver shall state the exceptional circumstances justifying the decision, the terms and conditions governing the application of the waiver, and the date on which the waiver shall terminate. Any waiver granted for a period of more than one year shall be reviewed by the Ministerial Conference not later than one year after it is granted, and thereafter annually until the waiver terminates. In each review, the Ministerial Conference shall examine whether the exceptional circumstances justifying the waiver still exist and whether the terms and conditions attached to the waiver have been met. The Ministerial Conference, on the basis of the annual review, may extend, modify or terminate the waiver.

5. Decisions under a Plurilateral Trade Agreement, including any decisions on interpretations and waivers, shall be governed by the provisions of that Agreement.

#### *Article X*

#### *Amendments*

1. Any Member of the WTO may initiate a proposal to amend the provisions of this Agreement or the Multilateral Trade Agreements in Annex 1 by submitting such proposal to the Ministerial Conference. The Councils listed in paragraph 5 of Article IV may also submit to the Ministerial Conference proposals to amend the provisions of the corresponding Multilateral Trade Agreements in Annex 1 the functioning of which they oversee. Unless the Ministerial Conference decides on a longer period, for a period of 90 days after the proposal has been tabled formally at the Ministerial Conference any decision by the Ministerial Conference to submit the proposed amendment to the Members for acceptance shall be taken by consensus. Unless the provisions of paragraphs 2, 5 or 6 apply, that decision shall specify whether the provisions of paragraphs 3 or 4 shall apply. If consensus is reached, the Ministerial Conference shall forthwith submit the proposed amendment to the Members for acceptance. If consensus is not reached at a meeting of the Ministerial Conference within the established period, the Ministerial Conference shall decide by a two-thirds majority of the Members whether to submit the proposed amendment to the Members for acceptance. Except as provided in paragraphs 2, 5 and 6, the provisions of paragraph 3 shall apply to the proposed amendment, unless the Ministerial Conference decides by a three-fourths majority of the Members that the provisions of paragraph 4 shall apply.

---

<sup>4</sup> A decision to grant a waiver in respect of any obligation subject to a transition period or a period for staged implementation that the requesting Member has not performed by the end of the relevant period shall be taken only by consensus.

2. Amendments to the provisions of this Article and to the provisions of the following Articles shall take effect only upon acceptance by all Members:

Article IX of this Agreement;  
Articles I and II of GATT 1994;  
Article II:1 of GATS;  
Article 4 of the Agreement on TRIPS.

3. Amendments to provisions of this Agreement, or of the Multilateral Trade Agreements in Annexes 1A and 1C, other than those listed in paragraphs 2 and 6, of a nature that would alter the rights and obligations of the Members, shall take effect for the Members that have accepted them upon acceptance by two thirds of the Members and thereafter for each other Member upon acceptance by it. The Ministerial Conference may decide by a three-fourths majority of the Members that any amendment made effective under this paragraph is of such a nature that any Member which has not accepted it within a period specified by the Ministerial Conference in each case shall be free to withdraw from the WTO or to remain a Member with the consent of the Ministerial Conference.

4. Amendments to provisions of this Agreement or of the Multilateral Trade Agreements in Annexes 1A and 1C, other than those listed in paragraphs 2 and 6, of a nature that would not alter the rights and obligations of the Members, shall take effect for all Members upon acceptance by two thirds of the Members.

5. Except as provided in paragraph 2 above, amendments to Parts I, II and III of GATS and the respective annexes shall take effect for the Members that have accepted them upon acceptance by two thirds of the Members and thereafter for each Member upon acceptance by it. The Ministerial Conference may decide by a three-fourths majority of the Members that any amendment made effective under the preceding provision is of such a nature that any Member which has not accepted it within a period specified by the Ministerial Conference in each case shall be free to withdraw from the WTO or to remain a Member with the consent of the Ministerial Conference. Amendments to Parts IV, V and VI of GATS and the respective annexes shall take effect for all Members upon acceptance by two thirds of the Members.

6. Notwithstanding the other provisions of this Article, amendments to the Agreement on TRIPS meeting the requirements of paragraph 2 of Article 71 thereof may be adopted by the Ministerial Conference without further formal acceptance process.

7. Any Member accepting an amendment to this Agreement or to a Multilateral Trade Agreement in Annex 1 shall deposit an instrument of acceptance with the Director-General of the WTO within the period of acceptance specified by the Ministerial Conference.

8. Any Member of the WTO may initiate a proposal to amend the provisions of the Multilateral Trade Agreements in Annexes 2 and 3 by submitting such proposal to the Ministerial Conference. The decision to approve amendments to the Multilateral Trade Agreement in Annex 2 shall be made by consensus and these amendments shall take effect for all Members upon approval by the Ministerial Conference. Decisions to approve amendments to the Multilateral Trade Agreement in Annex 3 shall take effect for all Members upon approval by the Ministerial Conference.

9. The Ministerial Conference, upon the request of the Members parties to a trade agreement, may decide exclusively by consensus to add that agreement to Annex 4. The Ministerial Conference, upon the request of the Members parties to a Plurilateral Trade Agreement, may decide to delete that Agreement from Annex 4.

10. Amendments to a Plurilateral Trade Agreement shall be governed by the provisions of that Agreement.

*Article XI**Original Membership*

1. The contracting parties to GATT 1947 as of the date of entry into force of this Agreement, and the European Communities, which accept this Agreement and the Multilateral Trade Agreements and for which Schedules of Concessions and Commitments are annexed to GATT 1994 and for which Schedules of Specific Commitments are annexed to GATS shall become original Members of the WTO.
2. The least-developed countries recognized as such by the United Nations will only be required to undertake commitments and concessions to the extent consistent with their individual development, financial and trade needs or their administrative and institutional capabilities.

*Article XII**Accession*

1. Any State or separate customs territory possessing full autonomy in the conduct of its external commercial relations and of the other matters provided for in this Agreement and the Multilateral Trade Agreements may accede to this Agreement, on terms to be agreed between it and the WTO. Such accession shall apply to this Agreement and the Multilateral Trade Agreements annexed thereto.
2. Decisions on accession shall be taken by the Ministerial Conference. The Ministerial Conference shall approve the agreement on the terms of accession by a two-thirds majority of the Members of the WTO.
3. Accession to a Plurilateral Trade Agreement shall be governed by the provisions of that Agreement.

*Article XIII**Non-Application of Multilateral Trade Agreements  
between Particular Members*

1. This Agreement and the Multilateral Trade Agreements in Annexes 1 and 2 shall not apply as between any Member and any other Member if either of the Members, at the time either becomes a Member, does not consent to such application.
2. Paragraph 1 may be invoked between original Members of the WTO which were contracting parties to GATT 1947 only where Article XXXV of that Agreement had been invoked earlier and was effective as between those contracting parties at the time of entry into force for them of this Agreement.
3. Paragraph 1 shall apply between a Member and another Member which has acceded under Article XII only if the Member not consenting to the application has so notified the Ministerial Conference before the approval of the agreement on the terms of accession by the Ministerial Conference.
4. The Ministerial Conference may review the operation of this Article in particular cases at the request of any Member and make appropriate recommendations.
5. Non-application of a Plurilateral Trade Agreement between parties to that Agreement shall be governed by the provisions of that Agreement.

*Article XIV**Acceptance, Entry into Force and Deposit*

1. This Agreement shall be open for acceptance, by signature or otherwise, by contracting parties to GATT 1947, and the European Communities, which are eligible to become original Members of the WTO in accordance with Article XI of this Agreement. Such acceptance shall apply to this Agreement and the Multilateral Trade Agreements annexed hereto. This Agreement and the Multilateral Trade Agreements annexed hereto shall enter into force on the date determined by Ministers in accordance with paragraph 3 of the Final Act Embodying the Results of the Uruguay Round of Multilateral Trade Negotiations and shall remain open for acceptance for a period of two years following that date unless the Ministers decide otherwise. An acceptance following the entry into force of this Agreement shall enter into force on the 30th day following the date of such acceptance.
2. A Member which accepts this Agreement after its entry into force shall implement those concessions and obligations in the Multilateral Trade Agreements that are to be implemented over a period of time starting with the entry into force of this Agreement as if it had accepted this Agreement on the date of its entry into force.
3. Until the entry into force of this Agreement, the text of this Agreement and the Multilateral Trade Agreements shall be deposited with the Director-General to the CONTRACTING PARTIES to GATT 1947. The Director-General shall promptly furnish a certified true copy of this Agreement and the Multilateral Trade Agreements, and a notification of each acceptance thereof, to each government and the European Communities having accepted this Agreement. This Agreement and the Multilateral Trade Agreements, and any amendments thereto, shall, upon the entry into force of this Agreement, be deposited with the Director-General of the WTO.
4. The acceptance and entry into force of a Plurilateral Trade Agreement shall be governed by the provisions of that Agreement. Such Agreements shall be deposited with the Director-General to the CONTRACTING PARTIES to GATT 1947. Upon the entry into force of this Agreement, such Agreements shall be deposited with the Director-General of the WTO.

*Article XV**Withdrawal*

1. Any Member may withdraw from this Agreement. Such withdrawal shall apply both to this Agreement and the Multilateral Trade Agreements and shall take effect upon the expiration of six months from the date on which written notice of withdrawal is received by the Director-General of the WTO.
2. Withdrawal from a Plurilateral Trade Agreement shall be governed by the provisions of that Agreement.

*Article XVI**Miscellaneous Provisions*

1. Except as otherwise provided under this Agreement or the Multilateral Trade Agreements, the WTO shall be guided by the decisions, procedures and customary practices followed by the CONTRACTING PARTIES to GATT 1947 and the bodies established in the framework of GATT 1947.

2. To the extent practicable, the Secretariat of GATT 1947 shall become the Secretariat of the WTO, and the Director-General to the CONTRACTING PARTIES to GATT 1947, until such time as the Ministerial Conference has appointed a Director-General in accordance with paragraph 2 of Article VI of this Agreement, shall serve as Director-General of the WTO.
3. In the event of a conflict between a provision of this Agreement and a provision of any of the Multilateral Trade Agreements, the provision of this Agreement shall prevail to the extent of the conflict.
4. Each Member shall ensure the conformity of its laws, regulations and administrative procedures with its obligations as provided in the annexed Agreements.
5. No reservations may be made in respect of any provision of this Agreement. Reservations in respect of any of the provisions of the Multilateral Trade Agreements may only be made to the extent provided for in those Agreements. Reservations in respect of a provision of a Plurilateral Trade Agreement shall be governed by the provisions of that Agreement.
6. This Agreement shall be registered in accordance with the provisions of Article 102 of the Charter of the United Nations.

DONE at Marrakesh this fifteenth day of April one thousand nine hundred and ninety-four, in a single copy, in the English, French and Spanish languages, each text being authentic.

[*For the signatures, see page 489 of volume 1869.* ]

#### Explanatory Notes:

The terms "country" or "countries" as used in this Agreement and the Multilateral Trade Agreements are to be understood to include any separate customs territory Member of the WTO.

In the case of a separate customs territory Member of the WTO, where an expression in this Agreement and the Multilateral Trade Agreements is qualified by the term "national", such expression shall be read as pertaining to that customs territory, unless otherwise specified.

**ANNEX 1****ANNEX 1A****MULTILATERAL AGREEMENTS ON TRADE IN GOODS***General interpretative note to Annex 1A:*

In the event of conflict between a provision of the General Agreement on Tariffs and Trade 1994 and a provision of another agreement in Annex 1A to the Agreement Establishing the World Trade Organization (referred to in the agreements in Annex 1A as the "WTO Agreement"), the provision of the other agreement shall prevail to the extent of the conflict.

**GENERAL AGREEMENT ON TARIFFS AND TRADE 1994**

1. The General Agreement on Tariffs and Trade 1994 ("GATT 1994") shall consist of:

(a) the provisions in the General Agreement on Tariffs and Trade, dated 30 October 1947, annexed to the Final Act Adopted at the Conclusion of the Second Session of the Preparatory Committee of the United Nations Conference on Trade and Employment (excluding the Protocol of Provisional Application), as rectified, amended or modified by the terms of legal instruments which have entered into force before the date of entry into force of the WTO Agreement;

(b) the provisions of the legal instruments set forth below that have entered into force under the GATT 1947 before the date of entry into force of the WTO Agreement:

- (i) protocols and certifications relating to tariff concessions;
- (ii) protocols of accession (excluding the provisions (a) concerning provisional application and withdrawal of provisional application and (b) providing that Part II of GATT 1947 shall be applied provisionally to the fullest extent not inconsistent with legislation existing on the date of the Protocol);
- (iii) decisions on waivers granted under Article XXV of GATT 1947 and still in force on the date of entry into force of the WTO Agreement<sup>1</sup>;
- (iv) other decisions of the CONTRACTING PARTIES to GATT 1947;

(c) the Understandings set forth below:

- (i) Understanding on the Interpretation of Article II:1(b) of the General Agreement on Tariffs and Trade 1994;
- (ii) Understanding on the Interpretation of Article XVII of the General Agreement on Tariffs and Trade 1994;
- (iii) Understanding on Balance-of-Payments Provisions of the General Agreement on Tariffs and Trade 1994;
- (iv) Understanding on the Interpretation of Article XXIV of the General Agreement on Tariffs and Trade 1994;
- (v) Understanding in Respect of Waivers of Obligations under the General Agreement on Tariffs and Trade 1994;
- (vi) Understanding on the Interpretation of Article XXVIII of the General Agreement on Tariffs and Trade 1994; and

(d) the Marrakesh Protocol to GATT 1994.

---

<sup>1</sup>The waivers covered by this provision are listed in footnote 7 on pages 11 and 12 in Part II of document MTN/FA of 15 December 1993 and in MTN/FA/Corr.6 of 21 March 1994. The Ministerial Conference shall establish at its first session a revised list of waivers covered by this provision that adds any waivers granted under GATT 1947 after 15 December 1993 and before the date of entry into force of the WTO Agreement, and deletes the waivers which will have expired by that time.

## 2. *Explanatory Notes*

(a) The references to "contracting party" in the provisions of GATT 1994 shall be deemed to read "Member". The references to "less-developed contracting party" and "developed contracting party" shall be deemed to read "developing country Member" and "developed country Member". The references to "Executive Secretary" shall be deemed to read "Director-General of the WTO".

(b) The references to the CONTRACTING PARTIES acting jointly in Articles XV:1, XV:2, XV:8, XXXVIII and the Notes *Ad* Article XII and XVIII; and in the provisions on special exchange agreements in Articles XV:2, XV:3, XV:6, XV:7 and XV:9 of GATT 1994 shall be deemed to be references to the WTO. The other functions that the provisions of GATT 1994 assign to the CONTRACTING PARTIES acting jointly shall be allocated by the Ministerial Conference.

- (c) (i) The text of GATT 1994 shall be authentic in English, French and Spanish.
- (ii) The text of GATT 1994 in the French language shall be subject to the rectifications of terms indicated in Annex A to document MTN.TNC/41.
- (iii) The authentic text of GATT 1994 in the Spanish language shall be the text in Volume IV of the Basic Instruments and Selected Documents series, subject to the rectifications of terms indicated in Annex B to document MTN.TNC/41.

3. (a) The provisions of Part II of GATT 1994 shall not apply to measures taken by a Member under specific mandatory legislation, enacted by that Member before it became a contracting party to GATT 1947, that prohibits the use, sale or lease of foreign-built or foreign-reconstructed vessels in commercial applications between points in national waters or the waters of an exclusive economic zone. This exemption applies to: (a) the continuation or prompt renewal of a non-conforming provision of such legislation; and (b) the amendment to a non-conforming provision of such legislation to the extent that the amendment does not decrease the conformity of the provision with Part II of GATT 1947. This exemption is limited to measures taken under legislation described above that is notified and specified prior to the date of entry into force of the WTO Agreement. If such legislation is subsequently modified to decrease its conformity with Part II of GATT 1994, it will no longer qualify for coverage under this paragraph.

(b) The Ministerial Conference shall review this exemption not later than five years after the date of entry into force of the WTO Agreement and thereafter every two years for as long as the exemption is in force for the purpose of examining whether the conditions which created the need for the exemption still prevail.

(c) A Member whose measures are covered by this exemption shall annually submit a detailed statistical notification consisting of a five-year moving average of actual and expected deliveries of relevant vessels as well as additional information on the use, sale, lease or repair of relevant vessels covered by this exemption.

(d) A Member that considers that this exemption operates in such a manner as to justify a reciprocal and proportionate limitation on the use, sale, lease or repair of vessels constructed in the territory of the Member invoking the exemption shall be free to introduce such a limitation subject to prior notification to the Ministerial Conference.

(e) This exemption is without prejudice to solutions concerning specific aspects of the legislation covered by this exemption negotiated in sectoral agreements or in other fora.



**UNDERSTANDING ON THE INTERPRETATION OF ARTICLE II:1(b)  
OF THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994**

*Members hereby agree as follows:*

1. In order to ensure transparency of the legal rights and obligations deriving from paragraph 1(b) of Article II, the nature and level of any "other duties or charges" levied on bound tariff items, as referred to in that provision, shall be recorded in the Schedules of concessions annexed to GATT 1994 against the tariff item to which they apply. It is understood that such recording does not change the legal character of "other duties or charges".
2. The date as of which "other duties or charges" are bound, for the purposes of Article II, shall be 15 April 1994. "Other duties or charges" shall therefore be recorded in the Schedules at the levels applying on this date. At each subsequent renegotiation of a concession or negotiation of a new concession the applicable date for the tariff item in question shall become the date of the incorporation of the new concession in the appropriate Schedule. However, the date of the instrument by which a concession on any particular tariff item was first incorporated into GATT 1947 or GATT 1994 shall also continue to be recorded in column 6 of the Loose-Leaf Schedules.
3. "Other duties or charges" shall be recorded in respect of all tariff bindings.
4. Where a tariff item has previously been the subject of a concession, the level of "other duties or charges" recorded in the appropriate Schedule shall not be higher than the level obtaining at the time of the first incorporation of the concession in that Schedule. It will be open to any Member to challenge the existence of an "other duty or charge", on the ground that no such "other duty or charge" existed at the time of the original binding of the item in question, as well as the consistency of the recorded level of any "other duty or charge" with the previously bound level, for a period of three years after the date of entry into force of the WTO Agreement or three years after the date of deposit with the Director-General of the WTO of the instrument incorporating the Schedule in question into GATT 1994, if that is a later date.
5. The recording of "other duties or charges" in the Schedules is without prejudice to their consistency with rights and obligations under GATT 1994 other than those affected by paragraph 4. All Members retain the right to challenge, at any time, the consistency of any "other duty or charge" with such obligations.
6. For the purposes of this Understanding, the provisions of Articles XXII and XXIII of GATT 1994 as elaborated and applied by the Dispute Settlement Understanding shall apply.
7. "Other duties or charges" omitted from a Schedule at the time of deposit of the instrument incorporating the Schedule in question into GATT 1994 with, until the date of entry into force of the WTO Agreement, the Director-General to the CONTRACTING PARTIES to GATT 1947 or, thereafter, with the Director-General of the WTO, shall not subsequently be added to it and any "other duty or charge" recorded at a level lower than that prevailing on the applicable date shall not be restored to that level unless such additions or changes are made within six months of the date of deposit of the instrument.
8. The decision in paragraph 2 regarding the date applicable to each concession for the purposes of paragraph 1(b) of Article II of GATT 1994 supersedes the decision regarding the applicable date taken on 26 March 1980 (BISD 27S/24).

## UNDERSTANDING ON THE INTERPRETATION OF ARTICLE XVII OF THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994

### *Members,*

*Noting* that Article XVII provides for obligations on Members in respect of the activities of the state trading enterprises referred to in paragraph 1 of Article XVII, which are required to be consistent with the general principles of non-discriminatory treatment prescribed in GATT 1994 for governmental measures affecting imports or exports by private traders;

*Noting* further that Members are subject to their GATT 1994 obligations in respect of those governmental measures affecting state trading enterprises;

*Recognizing* that this Understanding is without prejudice to the substantive disciplines prescribed in Article XVII;

Hereby *agree* as follows:

1. In order to ensure the transparency of the activities of state trading enterprises, Members shall notify such enterprises to the Council for Trade in Goods, for review by the working party to be set up under paragraph 5, in accordance with the following working definition:

"Governmental and non-governmental enterprises, including marketing boards, which have been granted exclusive or special rights or privileges, including statutory or constitutional powers, in the exercise of which they influence through their purchases or sales the level or direction of imports or exports."

This notification requirement does not apply to imports of products for immediate or ultimate consumption in governmental use or in use by an enterprise as specified above and not otherwise for resale or use in the production of goods for sale.

2. Each Member shall conduct a review of its policy with regard to the submission of notifications on state trading enterprises to the Council for Trade in Goods, taking account of the provisions of this Understanding. In carrying out such a review, each Member should have regard to the need to ensure the maximum transparency possible in its notifications so as to permit a clear appreciation of the manner of operation of the enterprises notified and the effect of their operations on international trade.

3. Notifications shall be made in accordance with the questionnaire on state trading adopted on 24 May 1960 (BISD 9S/184-185), it being understood that Members shall notify the enterprises referred to in paragraph 1 whether or not imports or exports have in fact taken place.

4. Any Member which has reason to believe that another Member has not adequately met its notification obligation may raise the matter with the Member concerned. If the matter is not satisfactorily resolved it may make a counter-notification to the Council for Trade in Goods, for consideration by the working party set up under paragraph 5, simultaneously informing the Member concerned.

5. A working party shall be set up, on behalf of the Council for Trade in Goods, to review notifications and counter-notifications. In the light of this review and without prejudice to paragraph 4(c) of Article XVII, the Council for Trade in Goods may make recommendations with regard to the adequacy of notifications and the need for further information. The working party shall also review, in the light of the notifications received, the adequacy of the above-mentioned questionnaire on state trading and the coverage of state trading enterprises notified under paragraph 1. It shall also develop an illustrative list showing the kinds of relationships between governments and enterprises, and the kinds of activities,

engaged in by these enterprises, which may be relevant for the purposes of Article XVII. It is understood that the Secretariat will provide a general background paper for the working party on the operations of state trading enterprises as they relate to international trade. Membership of the working party shall be open to all Members indicating their wish to serve on it. It shall meet within a year of the date of entry into force of the WTO Agreement and thereafter at least once a year. It shall report annually to the Council for Trade in Goods.<sup>1</sup>

---

<sup>1</sup>The activities of this working party shall be coordinated with those of the working group provided for in Section III of the Ministerial Decision on Notification Procedures adopted on 15 April 1994.

## UNDERSTANDING ON THE BALANCE-OF-PAYMENTS PROVISIONS OF THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994

### *Members,*

Recognizing the provisions of Articles XII and XVIII:B of GATT 1994 and of the Declaration on Trade Measures Taken for Balance-of-Payments Purposes adopted on 28 November 1979 (BISD 26S/205-209, referred to in this Understanding as the "1979 Declaration") and in order to clarify such provisions<sup>1</sup>;

Hereby *agree* as follows:

### *Application of Measures*

1. Members confirm their commitment to announce publicly, as soon as possible, time-schedules for the removal of restrictive import measures taken for balance-of-payments purposes. It is understood that such time-schedules may be modified as appropriate to take into account changes in the balance-of-payments situation. Whenever a time-schedule is not publicly announced by a Member, that Member shall provide justification as to the reasons therefor.
2. Members confirm their commitment to give preference to those measures which have the least disruptive effect on trade. Such measures (referred to in this Understanding as "price-based measures") shall be understood to include import surcharges, import deposit requirements or other equivalent trade measures with an impact on the price of imported goods. It is understood that, notwithstanding the provisions of Article II, price-based measures taken for balance-of-payments purposes may be applied by a Member in excess of the duties inscribed in the Schedule of that Member. Furthermore, that Member shall indicate the amount by which the price-based measure exceeds the bound duty clearly and separately under the notification procedures of this Understanding.
3. Members shall seek to avoid the imposition of new quantitative restrictions for balance-of-payments purposes unless, because of a critical balance-of-payments situation, price-based measures cannot arrest a sharp deterioration in the external payments position. In those cases in which a Member applies quantitative restrictions, it shall provide justification as to the reasons why price-based measures are not an adequate instrument to deal with the balance-of-payments situation. A Member maintaining quantitative restrictions shall indicate in successive consultations the progress made in significantly reducing the incidence and restrictive effect of such measures. It is understood that not more than one type of restrictive import measure taken for balance-of-payments purposes may be applied on the same product.
4. Members confirm that restrictive import measures taken for balance-of-payments purposes may only be applied to control the general level of imports and may not exceed what is necessary to address the balance-of-payments situation. In order to minimize any incidental protective effects, a Member shall administer restrictions in a transparent manner. The authorities of the importing Member shall provide adequate justification as to the criteria used to determine which products are subject to restriction. As provided in paragraph 3 of Article XII and paragraph 10 of Article XVIII, Members may, in the

---

<sup>1</sup>Nothing in this Understanding is intended to modify the rights and obligations of Members under Articles XII or XVIII:B of GATT 1994. The provisions of Articles XXII and XXIII of GATT 1994 as elaborated and applied by the Dispute Settlement Understanding may be invoked with respect to any matters arising from the application of restrictive import measures taken for balance-of-payments purposes.

case of certain essential products, exclude or limit the application of surcharges applied across the board or other measures applied for balance-of-payments purposes. The term "essential products" shall be understood to mean products which meet basic consumption needs or which contribute to the Member's effort to improve its balance-of-payments situation, such as capital goods or inputs needed for production. In the administration of quantitative restrictions, a Member shall use discretionary licensing only when unavoidable and shall phase it out progressively. Appropriate justification shall be provided as to the criteria used to determine allowable import quantities or values.

#### *Procedures for Balance-of-Payments Consultations*

5. The Committee on Balance-of-Payments Restrictions (referred to in this Understanding as the "Committee") shall carry out consultations in order to review all restrictive import measures taken for balance-of-payments purposes. The membership of the Committee is open to all Members indicating their wish to serve on it. The Committee shall follow the procedures for consultations on balance-of-payments restrictions approved on 28 April 1970 (BISD 18S/48-53, referred to in this Understanding as "full consultation procedures"), subject to the provisions set out below.

6. A Member applying new restrictions or raising the general level of its existing restrictions by a substantial intensification of the measures shall enter into consultations with the Committee within four months of the adoption of such measures. The Member adopting such measures may request that a consultation be held under paragraph 4(a) of Article XII or paragraph 12(a) of Article XVIII as appropriate. If no such request has been made, the Chairman of the Committee shall invite the Member to hold such a consultation. Factors that may be examined in the consultation would include, *inter alia*, the introduction of new types of restrictive measures for balance-of-payments purposes, or an increase in the level or product coverage of restrictions.

7. All restrictions applied for balance-of-payments purposes shall be subject to periodic review in the Committee under paragraph 4(b) of Article XII or under paragraph 12(b) of Article XVIII, subject to the possibility of altering the periodicity of consultations in agreement with the consulting Member or pursuant to any specific review procedure that may be recommended by the General Council.

8. Consultations may be held under the simplified procedures approved on 19 December 1972 (BISD 20S/47-49, referred to in this Understanding as "simplified consultation procedures") in the case of least-developed country Members or in the case of developing country Members which are pursuing liberalization efforts in conformity with the schedule presented to the Committee in previous consultations. Simplified consultation procedures may also be used when the Trade Policy Review of a developing country Member is scheduled for the same calendar year as the date fixed for the consultations. In such cases the decision as to whether full consultation procedures should be used will be made on the basis of the factors enumerated in paragraph 8 of the 1979 Declaration. Except in the case of least-developed country Members, no more than two successive consultations may be held under simplified consultation procedures.

#### *Notification and Documentation*

9. A Member shall notify to the General Council the introduction of or any changes in the application of restrictive import measures taken for balance-of-payments purposes, as well as any modifications in time-schedules for the removal of such measures as announced under paragraph 1. Significant changes shall be notified to the General Council prior to or not later than 30 days after their announcement. On a yearly basis, each Member shall make available to the Secretariat a consolidated notification, including all changes in laws, regulations, policy statements or public notices, for examination by Members. Notifications shall include full information, as far as possible, at the tariff-line level, on the type of measures applied, the criteria used for their administration, product coverage and trade flows affected.

10. At the request of any Member, notifications may be reviewed by the Committee. Such reviews would be limited to the clarification of specific issues raised by a notification or examination of whether a consultation under paragraph 4(a) of Article XII or paragraph 12(a) of Article XVIII is required. Members which have reasons to believe that a restrictive import measure applied by another Member was taken for balance-of-payments purposes may bring the matter to the attention of the Committee. The Chairman of the Committee shall request information on the measure and make it available to all Members. Without prejudice to the right of any member of the Committee to seek appropriate clarifications in the course of consultations, questions may be submitted in advance for consideration by the consulting Member.

11. The consulting Member shall prepare a Basic Document for the consultations which, in addition to any other information considered to be relevant, should include: (a) an overview of the balance-of-payments situation and prospects, including a consideration of the internal and external factors having a bearing on the balance-of-payments situation and the domestic policy measures taken in order to restore equilibrium on a sound and lasting basis; (b) a full description of the restrictions applied for balance-of-payments purposes, their legal basis and steps taken to reduce incidental protective effects; (c) measures taken since the last consultation to liberalize import restrictions, in the light of the conclusions of the Committee; (d) a plan for the elimination and progressive relaxation of remaining restrictions. References may be made, when relevant, to the information provided in other notifications or reports made to the WTO. Under simplified consultation procedures, the consulting Member shall submit a written statement containing essential information on the elements covered by the Basic Document.

12. The Secretariat shall, with a view to facilitating the consultations in the Committee, prepare a factual background paper dealing with the different aspects of the plan for consultations. In the case of developing country Members, the Secretariat document shall include relevant background and analytical material on the incidence of the external trading environment on the balance-of-payments situation and prospects of the consulting Member. The technical assistance services of the Secretariat shall, at the request of a developing country Member, assist in preparing the documentation for the consultations.

#### *Conclusions of Balance-of-Payments Consultations*

13. The Committee shall report on its consultations to the General Council. When full consultation procedures have been used, the report should indicate the Committee's conclusions on the different elements of the plan for consultations, as well as the facts and reasons on which they are based. The Committee shall endeavour to include in its conclusions proposals for recommendations aimed at promoting the implementation of Articles XII and XVIII:B, the 1979 Declaration and this Understanding. In those cases in which a time-schedule has been presented for the removal of restrictive measures taken for balance-of-payments purposes, the General Council may recommend that, in adhering to such a time-schedule, a Member shall be deemed to be in compliance with its GATT 1994 obligations. Whenever the General Council has made specific recommendations, the rights and obligations of Members shall be assessed in the light of such recommendations. In the absence of specific proposals for recommendations by the General Council, the Committee's conclusions should record the different views expressed in the Committee. When simplified consultation procedures have been used, the report shall include a summary of the main elements discussed in the Committee and a decision on whether full consultation procedures are required.

**UNDERSTANDING ON THE INTERPRETATION OF ARTICLE XXIV  
OF THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994**

*Members,*

*Having regard* to the provisions of Article XXIV of GATT 1994;

*Recognizing* that customs unions and free trade areas have greatly increased in number and importance since the establishment of GATT 1947 and today cover a significant proportion of world trade;

*Recognizing* the contribution to the expansion of world trade that may be made by closer integration between the economies of the parties to such agreements;

*Recognizing* also that such contribution is increased if the elimination between the constituent territories of duties and other restrictive regulations of commerce extends to all trade, and diminished if any major sector of trade is excluded;

*Reaffirming* that the purpose of such agreements should be to facilitate trade between the constituent territories and not to raise barriers to the trade of other Members with such territories; and that in their formation or enlargement the parties to them should to the greatest possible extent avoid creating adverse effects on the trade of other Members;

*Convinced* also of the need to reinforce the effectiveness of the role of the Council for Trade in Goods in reviewing agreements notified under Article XXIV, by clarifying the criteria and procedures for the assessment of new or enlarged agreements, and improving the transparency of all Article XXIV agreements;

*Recognizing* the need for a common understanding of the obligations of Members under paragraph 12 of Article XXIV;

Hereby *agree* as follows:

1. Customs unions, free-trade areas, and interim agreements leading to the formation of a customs union or free-trade area, to be consistent with Article XXIV, must satisfy, *inter alia*, the provisions of paragraphs 5, 6, 7 and 8 of that Article.

*Article XXIV:5*

2. The evaluation under paragraph 5(a) of Article XXIV of the general incidence of the duties and other regulations of commerce applicable before and after the formation of a customs union shall in respect of duties and charges be based upon an overall assessment of weighted average tariff rates and of customs duties collected. This assessment shall be based on import statistics for a previous representative period to be supplied by the customs union, on a tariff-line basis and in values and quantities, broken down by WTO country of origin. The Secretariat shall compute the weighted average tariff rates and customs duties collected in accordance with the methodology used in the assessment of tariff offers in the Uruguay Round of Multilateral Trade Negotiations. For this purpose, the duties and charges to be taken into consideration shall be the applied rates of duty. It is recognized that for the purpose of the overall assessment of the incidence of other regulations of commerce for which quantification and aggregation are difficult, the examination of individual measures, regulations, products covered and trade flows affected may be required.

3. The "reasonable length of time" referred to in paragraph 5(c) of Article XXIV should exceed 10 years only in exceptional cases. In cases where Members parties to an interim agreement believe that 10 years would be insufficient they shall provide a full explanation to the Council for Trade in Goods of the need for a longer period.

*Article XXIV:6*

4. Paragraph 6 of Article XXIV establishes the procedure to be followed when a Member forming a customs union proposes to increase a bound rate of duty. In this regard Members reaffirm that the procedure set forth in Article XXVIII, as elaborated in the guidelines adopted on 10 November 1980 (BISD 27S/26-28) and in the Understanding on the Interpretation of Article XXVIII of GATT 1994, must be commenced before tariff concessions are modified or withdrawn upon the formation of a customs union or an interim agreement leading to the formation of a customs union.

5. These negotiations will be entered into in good faith with a view to achieving mutually satisfactory compensatory adjustment. In such negotiations, as required by paragraph 6 of Article XXIV, due account shall be taken of reductions of duties on the same tariff line made by other constituents of the customs union upon its formation. Should such reductions not be sufficient to provide the necessary compensatory adjustment, the customs union would offer compensation, which may take the form of reductions of duties on other tariff lines. Such an offer shall be taken into consideration by the Members having negotiating rights in the binding being modified or withdrawn. Should the compensatory adjustment remain unacceptable, negotiations should be continued. Where, despite such efforts, agreement in negotiations on compensatory adjustment under Article XXVIII as elaborated by the Understanding on the Interpretation of Article XXVIII of GATT 1994 cannot be reached within a reasonable period from the initiation of negotiations, the customs union shall, nevertheless, be free to modify or withdraw the concessions; affected Members shall then be free to withdraw substantially equivalent concessions in accordance with Article XXVIII.

6. GATT 1994 imposes no obligation on Members benefiting from a reduction of duties consequent upon the formation of a customs union, or an interim agreement leading to the formation of a customs union, to provide compensatory adjustment to its constituents.

*Review of Customs Unions and Free-Trade Areas*

7. All notifications made under paragraph 7(a) of Article XXIV shall be examined by a working party in the light of the relevant provisions of GATT 1994 and of paragraph 1 of this Understanding. The working party shall submit a report to the Council for Trade in Goods on its findings in this regard. The Council for Trade in Goods may make such recommendations to Members as it deems appropriate.

8. In regard to interim agreements, the working party may in its report make appropriate recommendations on the proposed time-frame and on measures required to complete the formation of the customs union or free-trade area. It may if necessary provide for further review of the agreement.

9. Members parties to an interim agreement shall notify substantial changes in the plan and schedule included in that agreement to the Council for Trade in Goods and, if so requested, the Council shall examine the changes.

10. Should an interim agreement notified under paragraph 7(a) of Article XXIV not include a plan and schedule, contrary to paragraph 5(c) of Article XXIV, the working party shall in its report recommend such a plan and schedule. The parties shall not maintain or put into force, as the case may be, such agreement if they are not prepared to modify it in accordance with these recommendations. Provision shall be made for subsequent review of the implementation of the recommendations.



11. Customs unions and constituents of free-trade areas shall report periodically to the Council for Trade in Goods, as envisaged by the CONTRACTING PARTIES to GATT 1947 in their instruction to the GATT 1947 Council concerning reports on regional agreements (BISD 18S/38), on the operation of the relevant agreement. Any significant changes and/or developments in the agreements should be reported as they occur.

*Dispute Settlement*

12. The provisions of Articles XXII and XXIII of GATT 1994 as elaborated and applied by the Dispute Settlement Understanding may be invoked with respect to any matters arising from the application of those provisions of Article XXIV relating to customs unions, free-trade areas or interim agreements leading to the formation of a customs union or free-trade area.

*Article XXIV:12*

13. Each Member is fully responsible under GATT 1994 for the observance of all provisions of GATT 1994, and shall take such reasonable measures as may be available to it to ensure such observance by regional and local governments and authorities within its territory.

14. The provisions of Articles XXII and XXIII of GATT 1994 as elaborated and applied by the Dispute Settlement Understanding may be invoked in respect of measures affecting its observance taken by regional or local governments or authorities within the territory of a Member. When the Dispute Settlement Body has ruled that a provision of GATT 1994 has not been observed, the responsible Member shall take such reasonable measures as may be available to it to ensure its observance. The provisions relating to compensation and suspension of concessions or other obligations apply in cases where it has not been possible to secure such observance.

15. Each Member undertakes to accord sympathetic consideration to and afford adequate opportunity for consultation regarding any representations made by another Member concerning measures affecting the operation of GATT 1994 taken within the territory of the former.

**UNDERSTANDING IN RESPECT OF WAIVERS OF OBLIGATIONS  
UNDER THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994**

*Members hereby agree as follows:*

1. A request for a waiver or for an extension of an existing waiver shall describe the measures which the Member proposes to take, the specific policy objectives which the Member seeks to pursue and the reasons which prevent the Member from achieving its policy objectives by measures consistent with its obligations under GATT 1994.

2. Any waiver in effect on the date of entry into force of the WTO Agreement shall terminate, unless extended in accordance with the procedures above and those of Article IX of the WTO Agreement, on the date of its expiry or two years from the date of entry into force of the WTO Agreement, whichever is earlier.

3. Any Member considering that a benefit accruing to it under GATT 1994 is being nullified or impaired as a result of:

- (a) the failure of the Member to whom a waiver was granted to observe the terms or conditions of the waiver, or
- (b) the application of a measure consistent with the terms and conditions of the waiver

may invoke the provisions of Article XXIII of GATT 1994 as elaborated and applied by the Dispute Settlement Understanding.

## UNDERSTANDING ON THE INTERPRETATION OF ARTICLE XXVIII OF THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994

*Members hereby agree as follows:*

1. For the purposes of modification or withdrawal of a concession, the Member which has the highest ratio of exports affected by the concession (i.e. exports of the product to the market of the Member modifying or withdrawing the concession) to its total exports shall be deemed to have a principal supplying interest if it does not already have an initial negotiating right or a principal supplying interest as provided for in paragraph 1 of Article XXVIII. It is however agreed that this paragraph will be reviewed by the Council for Trade in Goods five years from the date of entry into force of the WTO Agreement with a view to deciding whether this criterion has worked satisfactorily in securing a redistribution of negotiating rights in favour of small and medium-sized exporting Members. If this is not the case, consideration will be given to possible improvements, including, in the light of the availability of adequate data, the adoption of a criterion based on the ratio of exports affected by the concession to exports to all markets of the product in question.
2. Where a Member considers that it has a principal supplying interest in terms of paragraph 1, it should communicate its claim in writing, with supporting evidence, to the Member proposing to modify or withdraw a concession, and at the same time inform the Secretariat. Paragraph 4 of the "Procedures for Negotiations under Article XXVIII" adopted on 10 November 1980 (BISD 27S/26-28) shall apply in these cases.
3. In the determination of which Members have a principal supplying interest (whether as provided for in paragraph 1 above or in paragraph 1 of Article XXVIII) or substantial interest, only trade in the affected product which has taken place on an MFN basis shall be taken into consideration. However, trade in the affected product which has taken place under non-contractual preferences shall also be taken into account if the trade in question has ceased to benefit from such preferential treatment, thus becoming MFN trade, at the time of the negotiation for the modification or withdrawal of the concession, or will do so by the conclusion of that negotiation.
4. When a tariff concession is modified or withdrawn on a new product (i.e. a product for which three years' trade statistics are not available) the Member possessing initial negotiating rights on the tariff line where the product is or was formerly classified shall be deemed to have an initial negotiating right in the concession in question. The determination of principal supplying and substantial interests and the calculation of compensation shall take into account, *inter alia*, production capacity and investment in the affected product in the exporting Member and estimates of export growth, as well as forecasts of demand for the product in the importing Member. For the purposes of this paragraph, "new product" is understood to include a tariff item created by means of a breakout from an existing tariff line.
5. Where a Member considers that it has a principal supplying or a substantial interest in terms of paragraph 4, it should communicate its claim in writing, with supporting evidence, to the Member proposing to modify or withdraw a concession, and at the same time inform the Secretariat. Paragraph 4 of the above-mentioned "Procedures for Negotiations under Article XXVIII" shall apply in these cases.
6. When an unlimited tariff concession is replaced by a tariff rate quota, the amount of compensation provided should exceed the amount of the trade actually affected by the modification of the concession. The basis for the calculation of compensation should be the amount by which future trade prospects exceed the level of the quota. It is understood that the calculation of future trade prospects should be based on the greater of:

- (a) the average annual trade in the most recent representative three-year period, increased by the average annual growth rate of imports in that same period, or by 10 per cent, whichever is the greater; or
- (b) trade in the most recent year increased by 10 per cent.

In no case shall a Member's liability for compensation exceed that which would be entailed by complete withdrawal of the concession.

7. Any Member having a principal supplying interest, whether as provided for in paragraph 1 above or in paragraph 1 of Article XXVIII, in a concession which is modified or withdrawn shall be accorded an initial negotiating right in the compensatory concessions, unless another form of compensation is agreed by the Members concerned.

**MARRAKESH PROTOCOL TO THE  
GENERAL AGREEMENT ON TARIFFS AND TRADE 1994**

*Members,*

*Having* carried out negotiations within the framework of GATT 1947, pursuant to the Ministerial Declaration on the Uruguay Round,

Hereby *agree* as follows:

1. The schedule annexed to this Protocol relating to a Member shall become a Schedule to GATT 1994 relating to that Member on the day on which the WTO Agreement enters into force for that Member. Any schedule submitted in accordance with the Ministerial Decision on measures in favour of least-developed countries shall be deemed to be annexed to this Protocol.
2. The tariff reductions agreed upon by each Member shall be implemented in five equal rate reductions, except as may be otherwise specified in a Member's Schedule. The first such reduction shall be made effective on the date of entry into force of the WTO Agreement, each successive reduction shall be made effective on 1 January of each of the following years, and the final rate shall become effective no later than the date four years after the date of entry into force of the WTO Agreement, except as may be otherwise specified in that Member's Schedule. Unless otherwise specified in its Schedule, a Member that accepts the WTO Agreement after its entry into force shall, on the date that Agreement enters into force for it, make effective all rate reductions that have already taken place together with the reductions which it would under the preceding sentence have been obligated to make effective on 1 January of the year following, and shall make effective all remaining rate reductions on the schedule specified in the previous sentence. The reduced rate should in each stage be rounded off to the first decimal. For agricultural products, as defined in Article 2 of the Agreement on Agriculture, the staging of reductions shall be implemented as specified in the relevant parts of the schedules.
3. The implementation of the concessions and commitments contained in the schedules annexed to this Protocol shall, upon request, be subject to multilateral examination by the Members. This would be without prejudice to the rights and obligations of Members under Agreements in Annex 1A of the WTO Agreement.
4. After the schedule annexed to this Protocol relating to a Member has become a Schedule to GATT 1994 pursuant to the provisions of paragraph 1, such Member shall be free at any time to withhold or to withdraw in whole or in part the concession in such Schedule with respect to any product for which the principal supplier is any other Uruguay Round participant the schedule of which has not yet become a Schedule to GATT 1994. Such action can, however, only be taken after written notice of any such withholding or withdrawal of a concession has been given to the Council for Trade in Goods and after consultations have been held, upon request, with any Member, the relevant schedule relating to which has become a Schedule to GATT 1994 and which has a substantial interest in the product involved. Any concessions so withheld or withdrawn shall be applied on and after the day on which the schedule of the Member which has the principal supplying interest becomes a Schedule to GATT 1994.
5. (a) Without prejudice to the provisions of paragraph 2 of Article 4 of the Agreement on Agriculture, for the purpose of the reference in paragraphs 1:(b) and 1(c) of Article II of GATT 1994 to the date of that Agreement, the applicable date in respect of each product which is the subject of a concession provided for in a schedule of concessions annexed to this Protocol shall be the date of this Protocol.

- (b) For the purpose of the reference in paragraph 6(a) of Article II of GATT 1994 to the date of that Agreement, the applicable date in respect of a schedule of concessions annexed to this Protocol shall be the date of this Protocol.
6. In cases of modification or withdrawal of concessions relating to non-tariff measures as contained in Part III of the schedules, the provisions of Article XXVIII of GATT 1994 and the "Procedures for Negotiations under Article XXVIII" adopted on 10 November 1980 (BISD 27S/26-28) shall apply. This would be without prejudice to the rights and obligations of Members under GATT 1994.
7. In each case in which a schedule annexed to this Protocol results for any product in treatment less favourable than was provided for such product in the Schedules of GATT 1947 prior to the entry into force of the WTO Agreement, the Member to whom the schedule relates shall be deemed to have taken appropriate action as would have been otherwise necessary under the relevant provisions of Article XXVIII of GATT 1947 or 1994. The provisions of this paragraph shall apply only to Egypt, Peru, South Africa and Uruguay.
8. The Schedules annexed hereto are authentic in the English, French or Spanish language as specified in each Schedule.
9. The date of this Protocol is 15 April 1994.

MARRAKESH PROTOCOL TO THE GENERAL AGREEMENT  
ON TARIFFS AND TRADE 1994

SCHEDULES

PROTOCOLE DE MARRAKECH ANNEXE A L'ACCORD GENERAL  
SUR LES TARIFS DOUANIERS ET LE COMMERCE DE 1994

LISTES

PROTOCOLO DE MARRAKECH ANEXO AL ACUERDO GENERAL  
SOBRE ARANCELES ADUANEROS Y COMERCIO DE 1994

LISTAS

SCHEDULES/LISTES/LISTAS<sup>1</sup>

Vol. 2	I	-	AUSTRALIA
	III	-	BRAZIL
	IV	-	MYANMAR
Vol. 3 (a + b)	V	-	CANADA
Vol. 4	VI	-	SRI LANKA
	VII	-	CHILE
	VIII	-	CHINA
Vol. 5	IX	-	CUBA
	XII	-	INDIA
	XIII	-	NEW ZEALAND
Vol. 6	XIV	-	NORWAY
	XV	-	PAKISTAN
Vol. 7	XVIII	-	SOUTH AFRICA
Vol. 8 (a + b)	XX	-	UNITED STATES
Vol. 9	XXI	-	INDONESIA
	XXIII	-	DOMINICAN REPUBLIC
	XXIV	-	FINLAND
	XXIX	-	NICARAGUA
	XXX	-	SWEDEN
Vol. 10	XXXI	-	URUGUAY
	XXXII	-	AUSTRIA
	XXXV	-	PERU
	XXXVII	-	TURKEY
Vol. 11	XXXVIII	-	JAPAN
Vol. 12	XXXIX	-	MALAYSIA
	XLII	-	ISRAEL
Vol. 13	XLIII	-	NIGERIA
	XLVII	-	GABON
	XLIX	-	SENEGAL
	LI	-	MADAGASCAR
	LII	-	CÔTE D'IVOIRE
	LIV	-	ZIMBABWE
	LIX	-	SWITZERLAND-LIECHTENSTEIN

<sup>1</sup> For the schedules, see World Trade Organization publication VI-1994-600, volumes 2 to 26 — Pour les listes, voir la publication de l'Organisation mondiale du commerce VI-1994-600, volumes 2 à 26.



Vol. 14	LX	-	KOREA
Vol. 15	LXII	-	ICELAND
	LXIII	-	EGYPT
	LXIV	-	ARGENTINA
Vol. 16	LXV	-	POLAND
	LXVI	-	JAMAICA
	LXVII	-	TRINIDAD AND TOBAGO
	LXIX	-	ROMANIA
Vol. 17	LXXI	-	HUNGARY
	LXXIII	-	SINGAPORE
	LXXIV	-	SURINAME
	LXXV	-	PHILIPPINES <sup>2</sup>
Vol. 18	LXXVI	-	COLOMBIA
	LXXVII	-	MÉXICO
	LXXVIII	-	ZAMBIA
	LXXIX	-	THAILAND
Vol. 19	LXXX	-	EUROPEAN COMMUNITIES
Vol. 20	LXXXI	-	MOROCCO
	LXXXII	-	HONG KONG
	LXXXIII	-	TUNISIA
	LXXXIV	-	BOLIVIA
	LXXXV	-	COSTA RICA
	LXXXVI	-	VENEZUELA
	LXXXVII	-	EL SALVADOR
	LXXXVIII	-	GUATEMALA
	LXXXIX	-	MACAU
Vol. 21	XC	-	NAMIBIA
Vol. 22	XCI	-	PARAGUAY
	XCII	-	CZECH REPUBLIC
Vol. 23	XCIII	-	SLOVAK REPUBLIC
	XCIV	-	HONDURAS
	XCVII	-	ANTIGUA AND BARBUDA
	XCVIII	-	BAHRAIN
	XCIV	-	BARBADOS
	C	-	BELIZE

<sup>2</sup> With procès-verbal of rectification of 30 November 1994 (GLI/303) — Avec procès-verbal de rectification du 30 novembre 1994 (GLI/303).

Vol. 24	CII	-	BRUNEI DARUSSALAM
	CIII	-	CAMEROON
	CVII	-	CYPRUS
	CVIII	-	DOMINICA
	CIX	-	FIJI
	CXI	-	GHANA
	CXII	-	GUYANA
	CXIII	-	KENYA
	CXIV	-	KUWAIT
	CXVII	-	MALTA
	CXVIII	-	MAURITIUS
	CXXI	-	ST. LUCIA
	CXXII	-	ST. VINCENT AND THE GRENADINES
Vol. 25	CXXIII	-	SWAZILAND
Vol. 26	XLVIII	-	BENIN
	L	-	MAURITANIA
	LIII	-	NIGER
	LXX	-	BANGLADESH
	CVI	-	CONGO
	CXXIV	-	TANZANIA
	CXXVI	-	UGANDA

## TRADE IN PHARMACEUTICAL PRODUCTS

The following communication concerning trade in pharmaceutical products has been received from the delegations listed below:

---

### RECORD OF DISCUSSION

In the course of the Uruguay Round negotiations, representatives of the following governments discussed the treatment of pharmaceutical products and came to the following conclusions:

Australia  
Austria  
Canada  
Czech Republic  
European Communities  
Finland  
Japan  
Norway  
Slovak Republic  
Sweden  
Switzerland  
United States

Each government will eliminate customs duties on pharmaceutical products, as defined below, recognizing the objective of tariff elimination should not be frustrated by trade restrictive or trade distorting measures. Other governments are encouraged to do the same.

1. With respect to pharmaceutical products (as defined below), they will eliminate customs duties and all other duties and charges, as defined within the meaning of Article II.1 (b) of the General Agreement on Tariffs and Trade (1994), on ALL items in the following categories:

- (i) items classified (or classifiable) in Harmonized System Chapter 30;
- (ii) items classified (or classifiable) in HS headings 2936, 2937, 2939, and 2941, with the exception of dihydrostreptomycin and salts, esters, and hydrates thereof;
- (iii)\* pharmaceutical active ingredients as designated in Annex I and that bear an "international non-proprietary name," (INN) from the World Health Organization;
- (iv) salts, esters, and hydrates of pharmaceutical products which are described by the combination of an INN active ingredient contained in Annex I with a prefix or suffix as designated in Annex II to this record, as long as such salt, ester, or hydrate is classified in the same HS 6-digit heading as the INN active ingredient;

- (v) salts, esters, and hydrates of INN active ingredients that are separately contained in Annex III to this record and that are not classified in the same HS 6-digit heading as the INN active ingredient;
- (vi) additional products used for the production and manufacture of finished pharmaceuticals as designated in Annex IV to this record.

In addition, to ensure transparency, each government will incorporate these measures into that government's schedule to the General Agreement on Tariffs and Trade (1994), and, in addition, at either its national tariff line level or the Harmonized System 6-digit level in either its national tariff or any other published versions of the tariff schedule, whichever is ordinarily used by importers and exporters.

Each government will fully implement the duty elimination on the date of entry into force of the World Trade Organization (WTO) agreement, for that government.

In incorporating the results described above, duty elimination can be achieved either by creating sub-headings at the national tariff line level, or attaching an Annex to the national tariff listing all products concerned or by a combination of the above methods, whereby duty-free treatment is provided for at national tariff line level for certain products.

In cases where it is not possible to designate an entire national tariff line for duty-free treatment, EACH GOVERNMENT will list the pharmaceutical products covered in an Annex to its national tariff, with a full concordance to the products listed in Annexes I, III, and IV at either the national tariff line level or the Harmonized System 6-digit level. Where some or all of the products are incorporated in such an Annex, each government will include appropriate footnotes (or other means of cross-referencing at the national tariff line level or the Harmonized System 6-digit level) either in the national tariff or in any other published version of the national tariff to indicate that bound duty-free treatment is provided for the products listed in the Annex.

2. In implementing these measures, each government's national customs authorities may require importers to provide one or more of the following types of information to certify that the imported chemical is included in this record:

- (i) Harmonized System 6-digit heading of the chemical;
- (ii) Chemical Description;
- (iii) International Non-proprietary Name (INN);
- (iv) Chemical Abstracts Service (CAS) Registry Number (RN);
- (v) Prefix or suffix of the salt/ester/hydrate (if applicable).

3. Representatives of the governments listed above will meet under the auspices of the Council for Trade in Goods of the WTO -- normally at least once every three years -- to review the product coverage with a view to including, by consensus, additional pharmaceutical products for tariff elimination. They agreed to encourage autonomous elimination of duties prior to agreement to eliminate duties on a permanent and reciprocal basis, in accordance with their national procedures.

4. The positive list of products covered by these annexes has been deposited with the GATT Secretariat.

**Paracetamol, ibuprofen, dihydrostreptomycin, monosodium glutamate, and levomenthol have been excluded from the coverage of this record of discussion.**

## ANNEX I - DESIGNATED PHARMACEUTICAL ACTIVE INGREDIENTS (INN).

HS 6	CAS #	Description	Alternative Classification
281830	1330-44-5	algedrate (INN)	
283322	61115-28-4	alusulf (INN)	
284110	41342-54-5	carbaldrate (INN)	
284210	71205-22-6	almasilate (INN)	
284210	12408-47-8	simaldrate (INN)	
284290	60239-66-9	almadrate sulfate (INN)	
284290	66827-12-1	almagate (INN)	
284290	12304-65-3	hydrotalcite (INN)	
284290	74978-16-8	magaldrate (INN)	
284330	34031-32-8	auranofin (INN)	
284330	16925-51-2	aurothioglycanide (INN)	
284330	12244-57-4	sodium aurothiomalate (INN)	
284330	10210-36-3	sodium aurotiosulfate (INN)	
284390	41575-94-4	carboplatin (INN)	
284390	15663-27-1	cisplatin (INN)	
284390	96392-96-0	dexormaplatin (INN)	
284390	111523-41-2	enloplatin (INN)	
284390	62928-11-4	iproplatin (INN)	
284390	135558-11-1	lobaplatin (INN)	
284390	103775-75-3	miboplatin (INN)	
284390	95734-82-0	nedaplatin (INN)	
284390	62816-98-2	ormaplatin (INN)	
284390	61825-94-3	oxaliplatin (INN)	
284390	110172-45-7	sebriplatin (INN)	
284390	74790-08-2	spiroplatin (INN)	
284390	111490-36-9	zeniplitin (INN)	
284440	0-00-0	altumomab (INN)	3002
284440	15690-63-8	cesium (131 Cs) chloride (INN)	
284440	10375-56-1	chlomerodrin (197 Hg) (INN)	
284440	13115-03-2	cyanocobalamin (57 Co) (INN)	
284440	18195-32-9	cyanocobalamin (58 Co) (INN)	
284440	13422-53-2	cyanocobalamin (60 Co) (INN)	
284440	8016-07-7	ethiodized oil (131 I) (INN)	
284440	54063-42-2	ferric (59 Fe) citrate injection (INN)	
284440	-00-0	fibrinogen (125 I) (INN)	
284440	105851-17-0	fludeoxyglucose (18 F) (INN)	

HS 6	CAS #	Description	Alternative Classification
284440	92812-82-3	fluorodopa 18F (INN)	
284440	41183-64-6	gallium (67 Ga) citrate (INN)	
284440	10043-49-9	gold (198 Au), colloidal (INN)	
284440	77679-27-7	iobenguane (131 I) (INN)	
284440	9048-49-1	iodinated (125 I) human serum albumin (INN)	
284440	9048-49-1	iodinated (131 I) human serum albumin (INN)	
284440	54510-20-2	iodocetiliic acid (123 I) (INN)	
284440	42220-21-3	iodocholesterol (131 I) (INN)	
284440	75917-92-9	iofetamine (123 I) (INN)	
284440	127396-36-5	iomazenil (123 I) (INN)	
284440	17033-82-8	iometin (125 I) (INN)	
284440	17033-83-9	iometin (131 I) (INN)	
284440	54182-63-7	macrosalb (131 I) (INN)	
284440	54277-47-3	macrosalb (99m Tc) (INN)	
284440	5579-94-2	merisoprol (197 Hg) (INN)	
284440	15251-14-6	rose bengal (131 I) sodium (INN)	
284440	144058-40-2	satumomab (INN)	3002
284440	1187-56-0	selenomethionine (75 Se) (INN)	
284440	10039-53-9	sodium chromate (51 Cr) (INN)	
284440	24359-64-6	sodium iodide (125 I) (INN)	
284440	7790-26-3	sodium iodide (131 I) (INN)	
284440	881-17-4	sodium iodohippurate (131 I) (INN)	
284440	17692-74-9	sodium iotalamate (125 I) (INN)	
284440	15845-98-4	sodium iotalamate (131 I) (INN)	
284440	8027-28-9	sodium phosphate (32 P) (INN)	
284440	121281-41-2	technetium (99m Tc) bicsate (INN)	
284440	109581-73-9	technetium (99m Tc) sestamibi (INN)	
284440	106417-28-1	technetium (99m Tc) siboroxime (INN)	
284440	104716-22-5	technetium (99m Tc) teboroxime (INN)	
284440	54182-60-4	tolpovidone (131 I) (INN)	
284440	14932-42-4	xenon (133 Xe) (INN)	
284590	35523-45-6	fludalanine (INN)	
284590	103831-41-0	sodium borocaptate (10 B) (INN)	
284590	122431-96-3	zilascorb (2 H) (INN)	
284690	113662-23-0	gadobenic acid (INN)	
284690	138071-82-6	gadobutrol (INN)	
284690	122795-43-1	gadodiamide (INN)	
284690	117827-80-2	gadopenamide (INN)	
284690	80529-93-7	gadopentetic acid (INN)	

HS 6	CAS #	Description	Alternative Classification
284690	72573-82-1	gadoteric acid (INN)	
284690	120066-54-8	gadoteridol (INN)	
290219	75-19-4	cyclopropane (INN)	
290290	75078-91-0	temarotene (INN)	
290322	79-01-6	trichloroethylene (INN)	
290330	811-97-2	norflurane (INN)	
290340	76-14-2	cryofluorane (INN)	
290340	151-67-7	halothane (INN)	
290340	423-55-2	perflubron (INN)	
290340	124-72-1	teflurane (INN)	
290351	58-89-9	lindane (ISO) (INN)	
290359	1715-40-8	bromocyclen (ISO) (INN)	
290359	306-94-5	perflunafene (INN)	
290362	50-29-3	clofenotane (INN)	
290369	479-68-5	broparestrol (INN)	
290369	34106-48-4	feniodium chloride (INN)	
290369	56917-29-4	fluretofen (INN)	
290369	53-19-0	mitotane (INN)	
290410	99287-30-6	egualen (INN)	
290410	5560-69-0	ethyl dibunate (INN)	
290410	14992-59-7	sodium dibunate (INN)	
290410	6223-35-4	sodium gualenate (INN)	
290490	124-88-9	dimethiodal sodium (INN)	
290490	126-31-8	methiodal sodium (INN)	
290529	77-75-8	methylpentynol (INN)	
290539	35449-36-6	gemcadiol (INN)	
290539	64218-02-6	plaunotol (INN)	
290549	7518-35-6	mannosulfan (INN)	
290550	52-51-7	bronopol (INN)	
290550	55-98-1	busulfan (INN)	
290550	57-15-8	chlorobutanol (INN)	
290550	24403-04-1	debropol (INN)	
290550	113-18-8	ethchlorvynol (INN)	
290550	2209-86-1	loprodiol (INN)	
290550	488-41-5	mitobronitol (INN)	
290550	10318-26-0	mitolactol (INN)	
290550	299-75-2	treosulfan (INN)	
290611	15356-70-4	racementhol (INN)	
290619	19793-20-5	bolandiol (INN)	



HS 6	CAS #	Description	Alternative Classification
290619	112828-00-9	calcipotriol (INN)	
290619	29474-12-2	cimepanol (INN)	
290619	67-96-9	dihydrotachysterol (INN)	
290619	23089-26-1	levomenol (INN)	
290621	100-51-6	benzyl alcohol (INN)	
290629	104561-36-6	doretinel (INN)	
290629	583-03-9	fenipentol (INN)	
290629	15687-18-0	fenpentadiol (INN)	
290629	56430-99-0	flumecinol (INN)	
290629	13980-94-4	metaglycodol (INN)	
290629	79-93-6	phenaglycodol (INN)	
290629	14088-71-2	proclonol (INN)	
290719	1300-94-3	amylmetacresol (INN)	
290719	5591-47-9	cyclomenol (INN)	
290719	2078-54-8	propofol (INN)	
290719	13741-18-9	xibomol (INN)	
290729	85-95-0	benzestrol (INN)	
290729	84-17-3	dienestrol (INN)	
290729	56-53-1	diethylstilbestrol (INN)	
290729	10457-66-6	geroquinol (INN)	
290729	5635-50-7	hexestrol (INN)	
290729	27686-84-6	masoprocol (INN)	
290729	130-73-4	methestrol (INN)	
290810	6915-57-7	bibrocathol (INN)	
290810	15686-33-6	biclotymol (INN)	
290810	34633-34-6	bifluranol (INN)	
290810	59-50-7	chlorocresol (INN)	
290810	88-04-0	chloroxylenol (INN)	
290810	10572-34-6	cicliomenol (INN)	
290810	37693-01-9	clofoctol (INN)	
290810	145-94-8	clorindanol (INN)	
290810	120-32-1	clorofene (INN)	
290810	97-23-4	dichlorophen (ISO) (INN)	
290810	133-53-9	dichloroxylenol (INN)	
290810	127035-60-3	enofelast (INN)	
290810	70-30-4	hexachlorophene (INN)	
290810	65634-39-1	pentafuranol (INN)	
290810	64396-09-4	terfluranol (INN)	
290820	20123-80-2	calcium dobesilate (INN)	

HS 6	CAS #	Description	Alternative Classification
290820	78480-14-5	dicresulene (INN)	
290820	4444-23-9	persilic acid (INN)	
290820	57775-26-5	sultosilic acid (INN)	
290890	10331-57-4	niclofolan (INN)	
290890	39224-48-1	nitroclofene (INN)	
290919	57041-67-5	desflurane (INN)	
290919	13838-16-9	enflurane (INN)	
290919	333-36-8	flurotyl (INN)	
290919	406-90-6	fluroxene (INN)	
290919	26675-46-7	isoflurane (INN)	
290919	76-38-0	methoxyflurane (INN)	
290919	679-90-3	roflurane (INN)	
290919	28523-86-6	sevoflurane (INN)	
290920	56689-41-9	aliflurane (INN)	
290930	569-57-3	chlorotrianisene (INN)	
290930	55837-16-6	entsufon (INN)	
290930	80844-07-1	etofenprox (INN)	
290930	777-11-7	haloprogin (INN)	
290930	39219-28-8	promestriene (INN)	
290949	544-62-7	batilol (INN)	
290949	3563-58-4	chloralodol (INN)	
290949	104-29-0	chlorphenesin (INN)	
290949	2216-77-5	dibuprol (INN)	
290949	3102-00-9	febuprol (INN)	
290949	3671-05-4	fenocinol (INN)	
290949	27318-86-1	floverine (INN)	
290949	63834-83-3	guaietolin (INN)	
290949	93-14-1	guaifenesin (INN)	
290949	59-47-2	mephenesin (INN)	
290949	26159-36-4	naproxol (INN)	
290949	39791-20-3	nilestriol (INN)	
290949	78-12-6	petrichloral (INN)	
290949	13021-53-9	terbuprol (INN)	
290949	6055-48-7	toloxychlorinol (INN)	
290950	2174-64-3	flamenol (INN)	
290950	150-76-5	mequinol (INN)	
290950	103-16-2	monobenzone (INN)	
290950	1321-14-8	sulfogaiacol (INN)	
290950	3380-34-5	triclosan (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
291090	60-57-1	dieldrin (ISO) (INN)	
291090	1954-28-5	etoglucid (INN)	
291219	111-30-8	glutaral (INN)	
291419	6809-52-5	teprenone (INN)	
291429	2226-11-1	bornelone (INN)	
291429	63014-96-0	delanterone (INN)	
291429	77016-85-4	plomestane (INN)	
291430	58298-92-3	colimecycline (INN)	
291430	82-66-6	diphacinone (ISO) diphenadione (INN)	
291430	6723-40-6	fluindarol (INN)	
291430	83-12-5	phenindione (INN)	
291430	55845-78-8	xenipentone (INN)	
291449	14107-37-0	alfadolone (INN)	
291449	23930-19-0	alfaxalone (INN)	
291449	30781-27-2	amadinone (INN)	
291449	3570-10-3	benorterone (INN)	
291449	85969-07-9	budotitane (INN)	
291449	5251-34-3	cioprednol (INN)	
291449	50673-97-7	colestolone (INN)	
291449	152-58-9	cortodoxone (INN)	
291449	465-53-2	cyclopregnol (INN)	
291449	21208-26-4	dimepregnen (INN)	
291449	128-20-1	eltanolone (INN)	
291449	35100-44-8	endrisone (INN)	
291449	566-48-3	formestane (INN)	
291449	14340-01-3	gestadienol (INN)	
291449	17332-61-5	isoprednidene (INN)	
291449	58691-88-6	nomegestrol (INN)	
291449	33765-68-3	oxendolone (INN)	
291449	18118-80-4	oxisopred (INN)	
291449	565-99-1	renanolone (INN)	
291449	77287-05-9	noprostil (INN)	
291449	10161-33-8	trenbolone (INN)	
291449	2673-23-6	xenygloxal (INN)	
291450	117-37-3	anisindione (INN)	
291450	70356-09-1	avobenzone (INN)	
291450	75464-11-8	butantrone (INN)	
291450	89672-11-7	cioteronel (INN)	
291450	3030-53-3	clofenoxycide (INN)	

HS 6	CAS #	Description	Alternative Classification
291450	579-23-7	cyclovalone (INN)	
291450	131-53-3	dioxybenzone (INN)	
291450	480-22-8	dithranol (INN)	
291450	52479-85-3	exifone (INN)	
291450	2295-58-1	flopropione (INN)	
291450	27762-78-3	ketoxal (INN)	
291450	18493-30-6	metochalcone (INN)	
291450	1641-17-4	mexenone (INN)	
291450	42924-53-8	nabumetone (INN)	
291450	7114-11-6	naphthonone (INN)	
291450	1843-05-6	octabenzone (INN)	
291450	69648-40-4	oxoprostol (INN)	
291450	131-57-7	oxybenzone (INN)	
291450	70-70-2	paroxypropione (INN)	
291450	2487-63-0	quinbolone (INN)	
291450	112018-00-5	tebufelone (INN)	
291469	88426-33-9	buparvaquone (INN)	
291469	117-10-2	dantron (INN)	
291469	114-43-2	desaspidin (INN)	
291469	80809-81-0	docebenone (INN)	
291469	58186-27-9	idebenone (INN)	
291469	863-61-6	menatetrenone (INN)	
291469	14561-42-3	menoctone (INN)	
291469	4042-30-2	parvaquone (INN)	
291469	319-89-1	tetroquinone (INN)	
291469	303-98-0	ubidecarenone (INN)	
291470	56219-57-9	arildone (INN)	
291470	95233-18-4	atovaquone (INN)	
291470	1146-98-1	bromindione (INN)	
291470	1146-99-2	ciorindione (INN)	
291470	1879-77-2	doxibetasol (INN)	
291470	957-56-2	fluidione (INN)	
291470	15687-21-5	flumedroxone (INN)	
291470	24320-27-2	halocortolone (INN)	
291470	16469-74-2	hydromadinone (INN)	
291470	1470-35-5	isobromindione (INN)	
291470	130-37-0	menadione sodium bisulfite (INN)	
291470	116313-94-1	nitecapone (INN)	
291470	49561-92-4	nivimedone (INN)	

HS 6	CAS #	Description	Alternative Classification
291470	4065-45-6	sulisobenzone (INN)	
291470	134308-13-7	tolcapone (INN)	
291529	82279-57-0	zinc acetate, basic (INN)	
291539	514-50-1	acebrochol (INN)	
291539	80595-73-9	acefiuranol (INN)	
291539	99107-52-5	bunaprolast (INN)	
291539	2624-43-3	cyclofenil (INN)	
291539	5984-83-8	fenabutene (INN)	
291539	91431-42-4	lonapalene (INN)	
291539	102-76-1	triacetin (INN)	
291550	13885-31-9	orestrate (INN)	
291570	555-44-2	tripalmitin (INN)	
291570	555-44-2	tripalmitin (INN)	
291590	7008-02-8	iodetryl (INN)	
291590	124-07-2	octanoic acid (INN)	
291590	77372-61-3	valproate pivoxil (INN)	
291590	76584-70-8	valproate semisodium (INN)	
291590	99-66-1	valproic acid (INN)	
291615	26266-58-0	sorbitan trioleate (INN)	
291619	6217-54-5	doconexent (INN)	
291619	506-26-3	gamolenic acid (INN)	
291619	51-77-4	gefamate (INN)	
291619	10417-94-4	icosapent (INN)	
291619	83689-23-0	molfamate (INN)	
291620	25229-42-9	cicrotoic acid (INN)	
291620	75867-00-4	fenfluthnn (INN)	
291620	69915-62-4	loxanast (INN)	
291620	52645-53-1	permethrin (ISO) (INN)	
291620	26002-80-2	phenothrin (INN)	
291639	55837-18-8	butibufen (INN)	
291639	36950-96-6	cicloprofen (INN)	
291639	34148-01-1	clidanac (INN)	
291639	33159-27-2	ecabet (INN)	
291639	51543-39-6	esflurbiprofen (INN)	
291639	5728-52-9	felbinac (INN)	
291639	36616-52-1	fenclorac (INN)	
291639	15301-67-4	feneritrol (INN)	
291639	7698-97-7	fenestrel (INN)	
291639	17692-38-5	fluprofen (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
291639	5104-49-4	flurbiprofen (INN)	
291639	24645-20-3	hexaprofen (INN)	
291639	1553-60-2	ibufenac (INN)	
291639	99-79-6	iofendylate (INN)	
291639	57144-56-6	isoprofen (INN)	
291639	37529-08-1	mexoprofen (INN)	
291639	1085-91-2	naftcaproic acid (INN)	
291639	91587-01-8	pelretin (INN)	
291639	28168-10-7	tetripofen (INN)	
291639	84392-17-6	xenalipin (INN)	
291639	959-10-4	xenbucin (INN)	
291639	964-82-9	xenyhexenic acid (INN)	
291713	123-99-9	azelaic acid (INN)	
291719	577-11-7	docusate sodium (INN)	
291719	53-10-1	hydroxydione sodium succinate (INN)	
291720	5634-42-4	tocamphyl (INN)	
291734	131-67-9	ftalofyne (INN)	
291811	15145-14-9	ciclactate (INN)	
291816	1317-30-2	potassium glucoaldrate (INN)	
291817	456-59-7	cyclandelate (INN)	
291819	26976-72-7	aceburic acid (INN)	
291819	74176-31-1	alfaprostol (INN)	
291819	83997-19-7	ataprost (INN)	
291819	17140-60-2	calcium glucoheptonate (INN)	
291819	5793-88-4	calcium saccharate (INN)	
291819	34150-62-4	calcium sodium ferriclate (INN)	
291819	35700-23-3	carboprost (INN)	
291819	474-25-9	chenodeoxycholic acid (INN)	
291819	57808-63-6	cicloxilic acid (INN)	
291819	81845-44-5	ciprostene (INN)	
291819	88931-51-5	clinprost (INN)	
291819	17692-20-5	cyclobutoic acid (INN)	
291819	512-16-3	cyclobutyrol (INN)	
291819	68635-50-7	deloxolone (INN)	
291819	551-11-1	dinoprost (INN)	
291819	5977-10-6	fencibutirol (INN)	
291819	31221-85-9	ibuverine (INN)	
291819	73873-87-7	iloprost (INN)	
291819	130209-82-4	latanoprost (INN)	

HS 6	CAS #	Description	Alternative Classification
291819	93105-81-8	lodolaben (INN)	
291819	503-49-1	meglutol (INN)	
291819	61263-35-2	meteneprost (INN)	
291819	87269-59-8	naxaprostene (INN)	
291819	79360-43-3	nocloprost (INN)	
291819	125-65-5	pleuromulin (INN)	
291819	81093-37-0	pravastatin (INN)	
291819	54120-61-5	prostalene (INN)	
291819	56695-65-9	rosaprostol (INN)	
291819	7009-49-6	sodium hexacyclonate (INN)	
291819	7007-81-0	trethocanic acid (INN)	
291819	128-13-2	ursodeoxycholic acid (INN)	
291822	55482-89-8	guacetisal (INN)	
291822	64496-66-8	salafibrate (INN)	
291823	118-56-9	homosalate (INN)	
291823	552-94-3	salsalate (INN)	
291823	58703-77-8	sulprosal (INN)	
291829	153-43-5	clorindanic acid (INN)	
291829	1884-24-8	cynarine (INN)	
291829	22494-42-4	diflunisal (INN)	
291829	486-79-3	dipyrocetyl (INN)	
291829	22494-27-5	flufenisal (INN)	
291829	490-79-9	gentisic acid (INN)	
291829	83-40-9	hydroxytoluic acid (INN)	
291829	96-84-4	iophenoic acid (INN)	
291829	7009-60-1	phenidol sodium (INN)	
291829	4955-90-2	sodium gentisate (INN)	
291829	15534-92-6	terbuficin (INN)	
291829	322-79-2	triflusal (INN)	
291830	32808-51-8	bucloxic acid (INN)	
291830	81-23-2	dehydrocholic acid (INN)	
291830	36330-85-5	fenbufen (INN)	
291830	519-95-9	florantyrone (INN)	
291830	892-01-3	hexacyprone (INN)	
291830	58182-63-1	itanoxone (INN)	
291830	22071-15-4	ketoprofen (INN)	
291830	41387-02-4	lexofenac (INN)	
291830	68767-14-6	loxoprofen (INN)	
291830	3562-99-0	menbutone (INN)	

HS 6	CAS #	Description	Alternative Classification
291830	63472-04-8	metbufen (INN)	
291830	2522-81-8	pibecarb (INN)	
291830	145-41-5	sodium dehydrocholate (INN)	
291890	2260-08-4	acetiromate (INN)	
291890	55079-83-9	acitretin (INN)	
291890	106685-40-9	adapalene (INN)	
291890	22131-79-9	alclofenac (INN)	
291890	745-65-3	alprostadiil (INN)	
291890	24818-79-9	aluminium clofibrate (INN)	
291890	5129-14-6	anisacril (INN)	
291890	55028-70-1	arbaprostil (INN)	
291890	117819-25-7	bakeprofen (INN)	
291890	84386-11-8	baxitozine (INN)	
291890	55937-99-0	beclobrate (INN)	
291890	5711-40-0	bromebric acid (INN)	
291890	69648-38-0	butaprost (INN)	
291890	39087-48-4	calcium clofibrate (INN)	
291890	4138-96-9	canrenoic acid (INN)	
291890	5697-56-3	carbenoxolone (INN)	
291890	95722-07-9	cicaprost (INN)	
291890	52247-86-6	cicloxolone (INN)	
291890	35703-32-3	cinametic acid (INN)	
291890	66984-59-6	cinfenoac (INN)	
291890	104-28-9	cinoxate (INN)	
291890	31581-02-9	cinoxolone (INN)	
291890	52214-84-3	ciprofibrate (INN)	
291890	30299-08-2	clinofibrate (INN)	
291890	22494-47-9	clobuzarit (INN)	
291890	637-07-0	clofibrate (INN)	
291890	882-09-7	clofbric acid (INN)	
291890	88431-47-4	clomoxir (INN)	
291890	40665-92-7	cloprostamol (INN)	
291890	62524-99-6	delprostenate (INN)	
291890	33813-84-2	deprostil (INN)	
291890	13739-02-1	diacerein (INN)	
291890	7706-67-4	dimecrotic acid (INN)	
291890	90243-98-4	dimoxaprost (INN)	
291890	363-24-6	dinoprostone (INN)	
291890	51953-95-8	doxaprost (INN)	



<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
291890	61887-16-9	dulofibrate (INN)	
291890	81026-63-3	enisoprost (INN)	
291890	471-53-4	enoxolone (INN)	
291890	73121-56-9	enprostil (INN)	
291890	90693-76-8	eptaloprost (INN)	
291890	58-54-8	etacrylic acid (INN)	
291890	124083-20-1	etomoxir (INN)	
291890	54350-48-0	etretinate (INN)	
291890	26281-69-6	exiproben (INN)	
291890	34645-84-6	fenclofenac (INN)	
291890	54419-31-7	fenirofibrate (INN)	
291890	49562-28-9	fenofibrate (INN)	
291890	31879-05-7	fenoprofen (INN)	
291890	69381-94-8	fenprostalene (INN)	
291890	17243-33-3	fepentolic acid (INN)	
291890	86348-98-3	flunoprost (INN)	
291890	33124-50-4	fluocortin (INN)	
291890	40666-16-8	fluprostenol (INN)	
291890	62559-74-4	froxiprost (INN)	
291890	64318-79-2	gemeprost (INN)	
291890	25812-30-0	gemfibrozil (INN)	
291890	57296-63-6	indacrinone (INN)	
291890	2217-44-9	iodophthalein sodium (INN)	
291890	96609-16-4	lifibrol (INN)	
291890	88852-12-4	limaprost (INN)	
291890	41791-49-5	lonaprofen (INN)	
291890	74168-08-4	losmiprofen (INN)	
291890	14613-30-0	magnesium clofibrate (INN)	
291890	579-94-2	menglytate (INN)	
291890	517-18-0	methallenestriol (INN)	
291890	40596-69-8	methoprene (INN)	
291890	88980-20-5	mexiprostil (INN)	
291890	59122-46-2	misoprostol (INN)	
291890	3771-19-5	nafenopin (INN)	
291890	22204-53-1	naproxen (INN)	
291890	70667-26-4	ornoprostil (INN)	
291890	68548-99-2	oxindanac (INN)	
291890	76676-34-1	oxprenolate potassium (INN)	
291890	68170-97-8	palmoixic acid (INN)	

HS 6	CAS #	Description	Alternative Classification
291890	61557-12-8	penprostene (INN)	
291890	554-24-5	phenobutiodil (INN)	
291890	2181-04-6	potassium canrenoate (INN)	
291890	110845-89-1	remiprostol (INN)	
291890	14929-11-4	simfibrate (INN)	
291890	55902-94-8	sitofibrate (INN)	
291890	12214-50-5	sodium glucaspaldrate (INN)	
291890	64506-49-6	sofalcone (INN)	
291890	56488-59-6	terbufibrol (INN)	
291890	51-26-3	thyropropic acid (INN)	
291890	51-24-1	tiratricol (INN)	
291890	41826-92-0	trepibutone (INN)	
291890	69900-72-7	trimoprostil (INN)	
291890	84290-27-7	tucaresol (INN)	
291890	120373-36-6	unoprostone (INN)	
291890	77858-21-0	velaresol (INN)	
291890	73647-73-1	viprostol (INN)	
291900	28841-62-5	atrinositol (INN)	
291900	21466-07-9	bromofenofos (INN)	
291900	470-90-6	chlorfenvinphos (ISO) clofenvinfos (INN)	
291900	62-73-7	dichlorvos (ISO) (INN)	
291900	65708-37-4	flufosal (INN)	
291900	522-40-7	fosfestrol (INN)	
291900	6064-83-1	fosfosal (INN)	
291900	83-86-3	fytic acid (INN)	
291900	306-52-5	triclofos (INN)	
291900	17196-88-2	vincofos (INN)	
292010	2104-96-3	bromophos (ISO) bromofos (INN)	
292010	299-84-3	fenchlorphos (ISO) fenclofos (INN)	
292090	2612-33-1	clonitrate (INN)	
292090	5634-37-7	cloretate (INN)	
292090	7297-25-8	eritrityl tetranitrate (INN)	
292090	15825-70-4	mannitol hexanitrate (INN)	
292090	1612-30-2	menadiol sodium sulfate (INN)	
292090	78-11-5	pentaerithrityl tetranitrate (INN)	
292090	1607-17-6	pentritinol (INN)	
292090	2921-92-8	propatyl nitrate (INN)	
292090	126-92-1	sodium etasulfate (INN)	
292090	139-88-8	sodium tetradecyl sulfate (INN)	

HS 6	CAS #	Description	Alternative Classification
292090	88426-32-8	ursulcholic acid (INN)	
292112	2624-44-4	etamsylate (INN)	
292119	3735-65-7	butynamine (INN)	
292119	51-75-2	chlormethine (INN)	
292119	36505-83-6	dectaflur (INN)	
292119	124-28-7	dimantine (INN)	
292119	61822-36-4	diprobutine (INN)	
292119	3151-59-5	hetaflur (INN)	
292119	13946-02-6	iproheptine (INN)	
292119	503-01-5	isomethheptene (INN)	
292119	502-59-0	octamylamine (INN)	
292119	543-82-8	octodrine (INN)	
292119	338-83-0	perfluamine (INN)	
292119	107-35-7	taurine (INN)	
292119	123-82-0	tuaminoheptane (INN)	
292129	9011-04-5	hexadimethrine bromide (INN)	
292129	555-77-1	trichlormethine (INN)	
292129	112-24-3	trientine (INN)	
292130	768-94-5	amantadine (INN)	
292130	102-45-4	cyclopentamine (INN)	
292130	3570-07-8	dimecamine (INN)	
292130	6192-97-8	levopropylhexedrine (INN)	
292130	60-40-2	mecamylamine (INN)	
292130	19982-08-2	memantine (INN)	
292130	3595-11-7	propylhexedrine (INN)	
292130	13392-28-4	rimantadine (INN)	
292130	79594-24-4	somantadine (INN)	
292145	494-03-1	chlomaphazine (INN)	
292145	79617-96-2	sertraline (INN)	
292145	52795-02-5	tametraline (INN)	
292149	4255-23-6	alfetamine (INN)	
292149	150-59-4	alverine (INN)	
292149	15686-27-8	amfepentorex (INN)	
292149	300-62-9	amfetamine (INN)	
292149	50-48-6	amitriptyline (INN)	
292149	156-08-1	benzfetamine (INN)	
292149	17243-39-9	benzocetamine (INN)	
292149	101828-21-1	butenafine (INN)	
292149	19992-80-4	butixirate (INN)	

HS 6	CAS #	Description	Alternative Classification
292149	35941-65-2	butriptyline (INN)	
292149	461-78-9	chlorphentermine (INN)	
292149	13364-32-4	clobenzorex (INN)	
292149	10389-73-8	clortermine (INN)	
292149	303-53-7	cyclobenzaprine (INN)	
292149	15301-54-9	cypenamine (INN)	
292149	13977-33-8	demelverine (INN)	
292149	51-64-9	dexamphetamine (INN)	
292149	3239-44-9	dexfenfluramine (INN)	
292149	102-05-6	dibemethine (INN)	
292149	5966-41-6	diisopromine (INN)	
292149	5581-40-8	dimefadane (INN)	
292149	17279-39-9	dimetamfetamine (INN)	
292149	57653-27-7	droprenilamine (INN)	
292149	2201-15-2	eticyclidine (INN)	
292149	341-00-4	etifelmine (INN)	
292149	457-87-4	etilamfetamine (INN)	
292149	1209-98-9	fencamfamin (INN)	
292149	13042-18-7	fendiline (INN)	
292149	458-24-2	fenfluramine (INN)	
292149	35764-73-9	fluotracen (INN)	
292149	7273-99-6	gamfexine (INN)	
292149	54063-48-8	heptaverine (INN)	
292149	140850-73-3	igmesine (INN)	
292149	86939-10-8	indatraline (INN)	
292149	7395-90-6	indriine (INN)	
292149	27466-27-9	intriptyline (INN)	
292149	7262-75-1	lefetamine (INN)	
292149	156-34-3	levamfetamine (INN)	
292149	37577-24-5	levofenfluramine (INN)	
292149	5118-30-9	litracen (INN)	
292149	10262-69-8	maprotiline (INN)	
292149	17243-57-1	mefenorex (INN)	
292149	5118-29-6	melitracen (INN)	
292149	100-92-5	mephentermine (INN)	
292149	119386-96-8	mofegiline (INN)	
292149	65472-88-0	naftifine (INN)	
292149	72-69-5	nortriptyline (INN)	
292149	47166-67-6	octriptyline (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
292149	5580-32-5	ortetamine (INN)	
292149	555-57-7	pargyline (INN)	
292149	434-43-5	pentorex (INN)	
292149	93-88-9	phenpromethamine (INN)	
292149	122-09-8	phentermine (INN)	
292149	14334-40-8	pramiverine (INN)	
292149	390-64-7	prenylamine (INN)	
292149	438-60-8	protriptyline (INN)	
292149	14611-51-9	selegiline (INN)	
292149	106650-56-0	sibutramine (INN)	
292149	78628-80-5	terbinafine (INN)	
292149	15793-40-5	terodiline (INN)	
292149	5632-44-0	tolpropamine (INN)	
292149	155-09-9	tranylcypromine (INN)	
292149	58757-61-2	trimexiline (INN)	
292159	77518-07-1	amiflamine (INN)	
292159	37640-71-4	aprimidine (INN)	
292159	3572-43-8	bromhexine (INN)	
292159	3590-16-7	feclemine (INN)	
292211	2272-11-9	monoethanolamine oleate (INN)	
292219	509-74-0	acetylmethadol (INN)	
292219	82168-26-1	adafenoxate (INN)	
292219	64-95-9	adiphenine (INN)	
292219	52742-40-2	alimadol (INN)	
292219	17199-58-5	alphacetylmethadol (INN)	
292219	17199-54-1	alphamethadol (INN)	
292219	18683-91-5	ambroxol (INN)	
292219	54063-24-0	amifloverine (INN)	
292219	54063-25-1	amiterol (INN)	
292219	3563-01-7	apofene (INN)	
292219	87129-71-3	amolol (INN)	
292219	35607-20-6	avidine (INN)	
292219	313-05-3	azacosterol (INN)	
292219	302-40-9	benactyzine (INN)	
292219	22487-42-9	benaprizine (INN)	
292219	2179-37-5	bencyclane (INN)	
292219	23602-78-0	benfluorex (INN)	
292219	17199-59-6	betacetylmethadol (INN)	
292219	17199-55-2	betamethadol (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
292219	90293-01-9	bifemelane (INN)	
292219	20448-86-6	bomaprine (INN)	
292219	118-23-0	bromazine (INN)	
292219	604-74-0	bufenadrine (INN)	
292219	14007-64-8	butetamate (INN)	
292219	7433-10-5	butidrine (INN)	
292219	55769-65-8	butobendine (INN)	
292219	77-22-5	caramiphen (INN)	
292219	112922-55-1	cericlamine (INN)	
292219	77-38-3	chlorphenoxamine (INN)	
292219	69429-84-1	cilobamine (INN)	
292219	54141-87-6	cinfenine (INN)	
292219	1679-75-0	cinnamaverine (INN)	
292219	90-86-8	cinnamedrine (INN)	
292219	71827-56-0	clemeprol (INN)	
292219	37148-27-9	clenbuterol (INN)	
292219	14860-49-2	clobutinol (INN)	
292219	791-35-5	clofedanol (INN)	
292219	5632-52-0	clofenciclan (INN)	
292219	511-46-6	clofenetamine (INN)	
292219	911-45-5	clomifene (INN)	
292219	17780-72-2	clorgiline (INN)	
292219	3811-25-4	clorprenaline (INN)	
292219	96389-68-3	crisnatol (INN)	
292219	15585-86-1	cyprodenate (INN)	
292219	119356-77-3	dapoxetine (INN)	
292219	120444-71-5	deramciclane (INN)	
292219	47419-52-3	dexproxibutene (INN)	
292219	15687-08-8	dextrofemine (INN)	
292219	469-62-5	dextropropoxyphene (INN)	
292219	77-19-0	dicycloverne (INN)	
292219	545-90-4	dimepheptanol (INN)	
292219	53657-16-2	dimepranol (INN)	
292219	58-73-1	diphenhydramine (INN)	
292219	58473-73-7	drobuline (INN)	
292219	1679-76-1	drofenine (INN)	
292219	102-60-3	edetol (INN)	
292219	25314-87-8	elucaine (INN)	
292219	3565-72-8	embramine (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
292219	15690-57-0	enclomifene (INN)	
292219	74-55-5	ethambutol (INN)	
292219	54063-36-4	etolorex (INN)	
292219	1157-87-5	etoloxamine (INN)	
292219	63075-47-8	fepradinol (INN)	
292219	82101-10-8	fierobuterol (INN)	
292219	15221-81-5	fludorex (INN)	
292219	50366-32-0	flunamine (INN)	
292219	54910-89-3	fluoxetine (INN)	
292219	69756-53-2	halofantrine (INN)	
292219	50583-06-7	halonamine (INN)	
292219	372-66-7	heptaminol (INN)	
292219	15599-37-8	hexapradol (INN)	
292219	532-77-4	hexylcaine (INN)	
292219	13425-98-4	improspan (INN)	
292219	16112-96-2	indanorex (INN)	
292219	13445-63-1	itramin tosilate (INN)	
292219	7617-74-5	laurixamine (INN)	
292219	34433-66-4	levacetylmethadol (INN)	
292219	2338-37-6	levopropoxyphene (INN)	
292219	76496-68-9	levoprotiline (INN)	
292219	56341-08-3	mabuterol (INN)	
292219	576-68-1	mannomustine (INN)	
292219	51-68-3	meclofenoxate (INN)	
292219	5668-06-4	meclozamine (INN)	
292219	6284-40-8	meglumine (INN)	
292219	495-70-5	meprylcaine (INN)	
292219	31828-71-4	mexiletine (INN)	
292219	53076-26-9	moxapridine (INN)	
292219	3572-74-5	moxastine (INN)	
292219	15518-87-3	myralact (INN)	
292219	7712-50-7	myrtecaine (INN)	
292219	1234-71-5	namoxyrate (INN)	
292219	53716-48-6	nexeridine (INN)	
292219	7413-36-7	nifenalol (INN)	
292219	53179-07-0	nisoxetine (INN)	
292219	1477-39-0	noracymethadol (INN)	
292219	6818-37-7	olafur (INN)	
292219	83-98-7	orphenadrine (INN)	

HS 6	CAS #	Description	Alternative Classification
292219	56433-44-4	oxaprotiline (INN)	
292219	59-96-1	phenoxybenzamine (INN)	
292219	92-12-6	phenyltoloxamine (INN)	
292219	65236-29-5	preoverine (INN)	
292219	302-33-0	proadifen (INN)	
292219	54-80-8	pronetalol (INN)	
292219	493-76-5	propanocaine (INN)	
292219	14089-84-0	proxibutene (INN)	
292219	22232-57-1	racefemine (INN)	
292219	96743-96-3	ramciclane (INN)	
292219	4148-16-7	nitrosulfan (INN)	
292219	15639-50-6	safingol (INN)	
292219	126924-38-7	seproxetine (INN)	
292219	56481-43-7	setazindol (INN)	
292219	6535-03-1	stevaladil (INN)	
292219	10540-29-1	tamoxifen (INN)	
292219	15301-93-6	tofenacin (INN)	
292219	83015-26-3	tomoxetine (INN)	
292219	89778-26-7	toemifene (INN)	
292219	90845-56-0	trecadrine (INN)	
292219	58313-74-9	treptilamine (INN)	
292219	7077-34-1	trolnitrate (INN)	
292219	53783-83-8	tromantadine (INN)	
292219	77-86-1	trometamol (INN)	
292219	41570-61-0	tulobuterol (INN)	
292219	83480-29-9	voglibose (INN)	
292219	15690-55-8	zuclofemifene (INN)	
292229	112891-97-1	alentemol (INN)	
292229	5585-64-8	aminoxityriphene (INN)	
292229	493-75-4	bialamicol (INN)	
292229	64638-07-9	broramfetamine (INN)	
292229	53648-55-8	dezocine (INN)	
292229	34368-04-2	dobutamine (INN)	
292229	51-61-6	dopamine (INN)	
292229	86197-47-9	dopexamine (INN)	
292229	18840-47-6	gepefrine (INN)	
292229	1518-86-1	hydroxyamphetamine (INN)	
292229	66195-31-1	ibopamine (INN)	
292229	61661-06-1	levdobutamine (INN)	



<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
292229	39951-65-0	lomotriline (INN)	
292229	93-30-1	methoxyphenamine (INN)	
292229	17692-54-5	mitocloimine (INN)	
292229	1199-18-4	oxidopamine (INN)	
292229	370-14-9	pholedrine (INN)	
292229	15599-45-8	symetine (INN)	
292229	124937-51-5	tolterodine (INN)	
292229	15686-23-4	trimoxamine (INN)	
292229	3735-45-3	vetrabutine (INN)	
292230	34911-55-2	amfebutamone (INN)	
292230	90-84-6	amfepramone (INN)	
292230	71031-15-7	cathinone (INN)	
292230	34662-67-4	cotriptyline (INN)	
292230	92629-87-3	dexnafenedone (INN)	
292230	53394-92-6	drinidene (INN)	
292230	466-40-0	isomethadone (INN)	
292230	6740-88-1	ketamine (INN)	
292230	125-58-6	levomethadone (INN)	
292230	15351-09-4	metamfepramone (INN)	
292230	76-99-3	methadone (INN)	
292230	92615-20-8	nafenedone (INN)	
292230	467-85-6	normethadone (INN)	
292241	56-87-1	lysine (INN)	
292242	56-86-0	glutamic acid (INN) excluding monosodium gluta	
292249	89796-99-6	aceclofenac (INN)	
292249	56-41-7	alanine (INN)	
292249	60719-82-6	alaproclate (INN)	
292249	39718-89-3	alminoprofen (INN)	
292249	57574-09-1	amineptine (INN)	
292249	60-32-2	aminocaproic acid (INN)	
292249	553-65-1	amoxecaine (INN)	
292249	15250-13-2	araprofen (INN)	
292249	56-84-8	aspartic acid (INN)	
292249	1134-47-0	baclofen (INN)	
292249	94-09-7	benzocaine (INN)	
292249	104-31-4	benzonatate (INN)	
292249	3818-62-0	betoxycaine (INN)	
292249	149-16-6	butacaine (INN)	
292249	12111-24-9	calcium trisodium pentetate (INN)	

HS 6	CAS #	Description	Alternative Classification
292249	54-30-8	camylofin (INN)	
292249	55986-43-1	cetaben (INN)	
292249	34675-84-8	cetaxate (INN)	
292249	305-03-3	chlorambucil (INN)	
292249	133-16-4	chlorprocaine (INN)	
292249	4295-55-0	clofenamic acid (INN)	
292249	13930-34-2	clormecaine (INN)	
292249	32447-90-8	dextilidine (INN)	
292249	15307-86-5	diclofenac (INN)	
292249	36499-65-7	dicobalt edetate (INN)	
292249	60-00-4	edetic acid (INN)	
292249	67037-37-0	eflornithine (INN)	
292249	23049-93-6	enfenamic acid (INN)	
292249	7424-00-2	fenclonine (INN)	
292249	530-78-9	flufenamic acid (INN)	
292249	60142-96-3	gabapentin (INN)	
292249	56-40-6	glycine (INN)	
292249	96-83-3	iopanoic acid (INN)	
292249	94-14-4	isobutamben (INN)	
292249	73-32-5	isoleucine (INN)	
292249	61-90-5	leucine (INN)	
292249	92-23-9	leucinocaine (INN)	
292249	63329-53-3	lobenzarit (INN)	
292249	644-62-2	meclofenamic acid (INN)	
292249	61-68-7	mefenamic acid (INN)	
292249	148-82-3	melphalan (INN)	
292249	1088-80-8	metamelfalan (INN)	
292249	70-26-8	ornithine (INN)	
292249	21245-01-2	padimate (INN)	
292249	67-43-6	pentetic acid (INN)	
292249	63-91-2	phenylalanine (INN)	
292249	57775-28-7	prefenamate (INN)	
292249	59-46-1	procaine (INN)	
292249	94-12-2	risocaine (INN)	
292249	531-76-0	sarcocysin (INN)	
292249	62-33-9	sodium calcium edetate (INN)	
292249	15708-41-5	sodium feredetate (INN)	
292249	94-24-6	tetracaine (INN)	
292249	20380-58-9	tilidine (INN)	

HS 6	CAS #	Description	Alternative Classification
292249	13710-19-5	tolfenamic acid (INN)	
292249	1197-18-8	tranexamic acid (INN)	
292249	67330-25-0	ufenamate (INN)	
292249	72-18-4	valine (INN)	
292249	60643-86-9	vigabatrin (INN)	
292249	59209-97-1	zafuleptine (INN)	
292250	101479-70-3	adaprolol (INN)	
292250	99-45-6	adrenalone (INN)	
292250	78756-61-3	alifedrine (INN)	
292250	124316-02-5	alprafenone (INN)	
292250	13655-52-2	aiprenolol (INN)	
292250	50588-47-1	amafolone (INN)	
292250	119-29-9	ambucaine (INN)	
292250	64862-96-0	ametrantrone (INN)	
292250	51579-82-9	amfenac (INN)	
292250	646-02-6	aminoethyl nitrate (INN)	
292250	4317-14-0	amitriptylinoxide (INN)	
292250	15350-99-9	amoxydramine camsilate (INN)	
292250	128470-16-6	arbutamine (INN)	
292250	75219-46-4	atrimustine (INN)	
292250	3703-79-5	bamethan (INN)	
292250	18965-97-4	berlafenone (INN)	
292250	63659-18-7	betaxolol (INN)	
292250	59170-23-9	bevantolol (INN)	
292250	66722-44-9	bisoprolol (INN)	
292250	30392-40-6	bitolterol (INN)	
292250	66451-06-7	bornaprolool (INN)	
292250	91714-94-2	bromfenac (INN)	
292250	22103-14-6	bufeniode (INN)	
292250	27591-01-1	bunolol (INN)	
292250	447-41-6	buphenine (INN)	
292250	14556-46-8	bupranolol (INN)	
292250	18109-80-3	butamirate (INN)	
292250	2922-20-5	butaxamine (INN)	
292250	64552-17-6	butofilolol (INN)	
292250	66734-12-1	butopamine (INN)	
292250	63659-12-1	cicloprolol (INN)	
292250	39099-98-4	cinamolol (INN)	
292250	63269-31-8	ciramadol (INN)	

HS 6	CAS #	Description	Alternative Classification
292250	109525-44-2	cliopramine (INN)	
292250	97642-74-5	clomifenoxyde (INN)	
292250	39563-28-5	cloranolol (INN)	
292250	18866-78-9	colterol (INN)	
292250	829-74-3	corbadrine (INN)	
292250	512-15-2	cyclopentolate (INN)	
292250	60812-35-3	decominol (INN)	
292250	83200-09-3	dembrexine (INN)	
292250	3579-62-2	denaverine (INN)	
292250	71771-90-9	denopamine (INN)	
292250	23573-66-2	detanosal (INN)	
292250	3506-31-8	deterenol (INN)	
292250	5714-08-9	detrothyronine (INN)	
292250	407-41-0	dexfosfoferine (INN)	
292250	407-41-0	dexfosfoferine (INN)	
292250	5051-22-9	dexpropranolol (INN)	
292250	90237-04-0	dexsecoverine (INN)	
292250	137-53-1	dextrothyroxine sodium (INN)	
292250	3686-78-0	dietifen (INN)	
292250	80387-96-8	difemerine (INN)	
292250	14587-50-9	difeterol (INN)	
292250	509-78-4	dimenoxadol (INN)	
292250	22950-29-4	dimetofrine (INN)	
292250	497-75-6	dioxethedrin (INN)	
292250	10329-60-9	dioxifedrine (INN)	
292250	52365-63-6	dipivefrine (INN)	
292250	81447-80-5	diprafenone (INN)	
292250	54592-27-7	divabuterol (INN)	
292250	82413-20-5	droloxifene (INN)	
292250	23651-95-8	droxidopa (INN)	
292250	64552-16-5	ecipramidil (INN)	
292250	67-42-5	egtazic acid (INN)	
292250	85320-67-8	encolol (INN)	
292250	103598-03-4	esmolol (INN)	
292250	90-54-0	etafenone (INN)	
292250	93047-39-3	etanterol (INN)	
292250	709-55-7	etilefrine (INN)	
292250	85750-39-6	etilefrine privalate (INN)	
292250	17365-01-4	etiroxate (INN)	

HS 6	CAS #	Description	Alternative Classification
292250	30544-47-9	etofenamate (INN)	
292250	55837-19-9	exaprolol (INN)	
292250	123618-00-8	fedotozine (INN)	
292250	34616-39-2	fenalcomine (INN)	
292250	133-11-9	fenamisal (INN)	
292250	13392-18-2	fenoterol (INN)	
292250	84057-96-5	flusoxolol (INN)	
292250	72973-11-6	forfenimex (INN)	
292250	103878-96-2	fosopamine (INN)	
292250	299-61-6	ganglefene (INN)	
292250	36199-78-7	guafecainol (INN)	
292250	15687-23-7	guaiactamine (INN)	
292250	54-03-5	hexobendine (INN)	
292250	3215-70-1	hexoprenaline (INN)	
292250	487-53-6	hydroxyprocaine (INN)	
292250	490-98-2	hydroxytetracaine (INN)	
292250	53034-85-8	ibuterol (INN)	
292250	27581-02-8	idropranolol (INN)	
292250	60607-68-3	indenolol (INN)	
292250	52403-19-7	iproxamine (INN)	
292250	530-08-5	isoetanne (INN)	
292250	7683-59-2	isoprenaline (INN)	
292250	395-28-8	isoxsuprine (INN)	
292250	1092-46-2	ketocaine (INN)	
292250	7488-92-8	ketocainol (INN)	
292250	51-31-0	levisoprenaline (INN)	
292250	93221-48-8	levobetaxolol (INN)	
292250	47141-42-4	levobunolol (INN)	
292250	59-92-7	levodopa (INN)	
292250	77164-20-6	levomoprolol (INN)	
292250	97747-88-1	lilopristone (INN)	
292250	136-44-7	lisadimate (INN)	
292250	3625-06-7	mebeverine (INN)	
292250	32359-34-5	medifoxamine (INN)	
292250	524-99-2	medrylamine (INN)	
292250	23891-60-3	mepramidil (INN)	
292250	89-57-6	mesalazine (INN)	
292250	3571-71-9	metaterol (INN)	
292250	390-28-3	methoxamine (INN)	

HS 6	CAS #	Description	Alternative Classification
292250	555-30-6	methyldopa (INN)	
292250	22664-55-7	metipranolol (INN)	
292250	1212-03-9	metiprenaline (INN)	
292250	672-87-7	metirosine (INN)	
292250	37350-58-6	metoprolol (INN)	
292250	62571-87-3	minaxolone (INN)	
292250	13877-99-1	minepentate (INN)	
292250	65271-80-9	mitoxantrone (INN)	
292250	5741-22-0	moprolol (INN)	
292250	54-32-0	moxisylyte (INN)	
292250	42200-33-9	nadolol (INN)	
292250	42050-23-7	nafetolol (INN)	
292250	93047-40-6	naminterol (INN)	
292250	60734-87-4	nisbuterol (INN)	
292250	15686-81-4	norbudrine (INN)	
292250	536-21-0	norfenefrine (INN)	
292250	96346-61-1	onapristone (INN)	
292250	96346-61-1	onapristone (INN)	293799
292250	586-06-1	orciprenaline (INN)	
292250	65415-42-1	oxabrexine (INN)	
292250	468-61-1	oxeladin (INN)	
292250	32462-30-9	oxfenicine (INN)	
292250	4075-88-1	oxifentorex (INN)	
292250	365-26-4	oxilofrine (INN)	
292250	6452-71-7	oxprenolol (INN)	
292250	99-43-4	oxybuprocaine (INN)	
292250	5633-20-5	oxybutynin (INN)	
292250	15687-41-9	oxyfedrine (INN)	
292250	65655-59-6	pacrinolol (INN)	
292250	77599-17-8	panomifene (INN)	
292250	94-23-5	parethoxycaïne (INN)	
292250	13479-13-5	pargeverine (INN)	
292250	47082-97-3	pargolol (INN)	
292250	38363-40-5	penbutolol (INN)	
292250	77-23-6	pentoxyverine (INN)	
292250	59-42-7	phenylephrine (INN)	
292250	67577-23-5	pivenfrine (INN)	
292250	57526-81-5	prenalterol (INN)	
292250	27325-36-6	procinolol (INN)	

HS 6	CAS #	Description	Alternative Classification
292250	54063-53-5	propafenone (INN)	
292250	86-43-1	propoxycaïne (INN)	
292250	525-66-6	propranolol (INN)	
292250	499-67-2	proxymetacaine (INN)	
292250	620-30-4	racemetirosine (INN)	
292250	97825-25-7	ractopamine (INN)	
292250	26652-09-5	ritodrine (INN)	
292250	53716-44-2	rociverine (INN)	
292250	92071-51-7	rotraxate (INN)	
292250	58882-17-0	roxadimate (INN)	
292250	18559-94-9	salbutamol (INN)	
292250	18910-65-1	salmefamol (INN)	
292250	89365-50-4	salmeterol (INN)	
292250	125926-17-2	sarpogrelate (INN)	
292250	57558-44-8	secoverine (INN)	
292250	56-45-1	serine (INN)	
292250	68567-30-6	solipécainol (INN)	
292250	65429-87-0	spirendolol (INN)	
292250	23031-25-6	terbutaline (INN)	
292250	29098-15-5	terofenamate (INN)	
292250	72-19-5	threonine (INN)	
292250	27591-97-5	tilorone (INN)	
292250	75626-99-2	tobuteroI (INN)	
292250	2933-94-0	toliprolol (INN)	
292250	27203-92-5	tramadol (INN)	
292250	39133-31-8	trimebutine (INN)	
292250	78-41-1	triparanol (INN)	
292250	15301-96-9	tyromedan (INN)	
292250	60-18-4	tyrosine (INN)	
292250	93413-69-5	venlafaxine (INN)	
292250	1174-11-4	xenazoic acid (INN)	
292250	3572-52-9	xenysalate (INN)	
292250	81584-06-7	xibenolol (INN)	
292250	19179-78-3	xipranolol (INN)	
292250	1600-19-7	xyloxemine (INN)	
292250	68876-74-4	zocainone (INN)	
292310	28319-77-9	choline alfoscerate (INN)	
292310	67-48-1	choline chloride (INN)	
292310	507-30-2	choline gluconate (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
292310	2016-36-6	choline salicylate (INN)	
292310	1336-80-7	ferrocholate (INN)	
292310	28038-04-2	salcolex (INN)	
292320	63-89-8	colfosceril palmitate (INN)	
292390	60-31-1	acetylcholine chloride (INN)	
292390	55077-30-0	acetonium napadisilate (INN)	
292390	58158-77-3	amantanium bromide (INN)	
292390	306-53-6	azamethonium bromide (INN)	
292390	121-54-0	benzethonium chloride (INN)	
292390	139-07-1	benzododecinium chloride (INN)	
292390	19379-90-9	benzoxonium chloride (INN)	
292390	3818-50-6	bephenium hydroxynaphthoate (INN)	
292390	15585-70-3	bibenzonium bromide (INN)	
292390	61-75-6	bretylum tosilate (INN)	
292390	51-83-2	carbachol (INN)	
292390	461-06-3	caritine (INN)	
292390	13254-33-6	carpronium chloride (INN)	
292390	122-18-9	catalkonium chloride (INN)	
292390	58703-78-9	cethexonium chloride (INN)	
292390	57-09-0	cetrimonium bromide (INN)	
292390	7168-18-5	chlorphenoctium amsonate (INN)	
292390	29546-59-6	ciclonium bromide (INN)	
292390	68379-03-3	clofilium phosphate (INN)	
292390	2218-68-0	cloral betaine (INN)	
292390	541-22-0	decamethonium bromide (INN)	
292390	2401-56-1	deditionium bromide (INN)	
292390	2001-81-2	diponium bromide (INN)	
292390	15687-13-5	dodeclonium bromide (INN)	
292390	538-71-6	domiphen bromide (INN)	
292390	70641-51-9	edelfosine (INN)	
292390	116-38-1	edrophonium chloride (INN)	
292390	3614-30-0	emepronium bromide (INN)	
292390	30716-01-9	emilium tosilate (INN)	
292390	65-29-2	gallamine trinitrodide (INN)	
292390	7008-13-1	halopenium chloride (INN)	
292390	317-52-2	hexafluronium bromide (INN)	
292390	55-97-0	hexamethonium bromide (INN)	
292390	19486-61-4	lauralkonium chloride (INN)	
292390	541-15-1	levocamitine (INN)	



HS 6	CAS #	Description	Alternative Classification
292390	7681-78-9	mebezonium iodide (INN)	
292390	3006-10-8	mecetronium etilsulfate (INN)	
292390	4858-60-0	mefenidramium metilsulfate (INN)	
292390	62-51-1	methacholine chloride (INN)	
292390	3166-62-9	methylbenactyzium bromide (INN)	
292390	25155-18-4	methylbenzethonium chloride (INN)	
292390	2424-71-7	metocinium iodide (INN)	
292390	58066-85-6	miltefosine (INN)	
292390	139-08-2	ministalkonium chloride (INN)	
292390	7009-91-8	nitricholine perchlorate (INN)	
292390	15687-40-8	octafonium chloride (INN)	
292390	7002-65-5	oxibetaine (INN)	
292390	7174-23-4	oxydipentonium chloride (INN)	
292390	50-10-2	oxyphenonium bromide (INN)	
292390	17088-72-1	penoctionium bromide (INN)	
292390	541-20-8	pentamethonium bromide (INN)	
292390	42879-47-0	pranolium chloride (INN)	
292390	3690-61-7	prodeconium bromide (INN)	
292390	123-47-7	prolonium iodide (INN)	
292390	77257-42-2	stilonium iodide (INN)	
292390	71-27-2	suxamethonium chloride (INN)	
292390	54063-57-9	suxethonium chloride (INN)	
292390	1119-97-7	tetradonium bromide (INN)	
292390	71-91-0	tetrylammonium bromide (INN)	
292390	552-92-1	toloconium metilsulfate (INN)	
292390	79-90-3	trnclobisonium chloride (INN)	
292390	125-99-5	tridihexethyl iodide (INN)	
292390	391-70-8	troxonium tosilate (INN)	
292390	4304-01-2	truxicurium iodide (INN)	
292410	77337-76-9	acamprosate (INN)	
292410	77-66-7	acecarbromal (INN)	
292410	2490-97-3	aceglutamide (INN)	
292410	131-48-6	aceneuramic acid (INN)	
292410	99-15-0	acetylleucine (INN)	
292410	57-08-9	acexamic acid (INN)	
292410	39825-23-5	bisorcic (INN)	
292410	4213-51-8	bromacrylide (INN)	
292410	496-67-3	bromisoval (INN)	
292410	32838-26-9	butoctamide (INN)	

HS 6	CAS #	Description	Alternative Classification
292410	128326-81-8	caldiamide (INN)	
292410	5579-13-5	capuride (INN)	
292410	541-79-7	carbocloral (INN)	
292410	77-65-6	carbromal (INN)	
292410	78-44-4	carisoprodol (INN)	
292410	154-93-8	carmustine (INN)	
292410	35301-24-7	cedefingol (INN)	
292410	633-47-6	cropropamide (INN)	
292410	6168-76-9	crotetamide (INN)	
292410	3342-61-8	deanol aceglumate (INN)	
292410	116-52-9	dicloralurea (INN)	
292410	95-04-5	ectylurea (INN)	
292410	60784-46-5	elmustine (INN)	
292410	78-28-4	emylcamate (INN)	
292410	56488-60-9	glutaurine (INN)	
292410	306-41-2	hexcarbacholine bromide (INN)	
292410	18679-90-8	hopantenic acid (INN)	
292410	466-14-8	ibrotamide (INN)	
292410	3106-85-2	isospaglumic acid (INN)	
292410	56-85-9	levoglutamide (INN)	
292410	64-55-1	mebutamate (INN)	
292410	1954-79-6	mecloralurea (INN)	
292410	57-53-4	meprobamate (INN)	
292410	76990-56-2	milacemide (INN)	
292410	73105-03-0	neptamustine (INN)	
292410	25269-04-9	nisobamate (INN)	
292410	544-31-0	palmidrol (INN)	
292410	32954-43-1	pendecamaine (INN)	
292410	5667-70-9	pentabamate (INN)	
292410	26305-03-3	pepstatin (INN)	
292410	78512-63-7	pimelautide (INN)	
292410	69542-93-4	pivagabine (INN)	
292410	4910-46-7	spaglumic acid (INN)	
292410	78088-46-7	tabilautide (INN)	
292410	4268-36-4	tybamate (INN)	
292410	51-79-6	urethane (INN)	
292410	512-48-1	valdetamide (INN)	
292410	52061-73-1	valdipromide (INN)	
292410	4171-13-5	valnoctamide (INN)	

HS 6	CAS #	Description	Alternative Classification
292410	2430-27-5	valpromide (INN)	
292421	34866-47-2	carbutoleol (INN)	
292421	56980-93-9	celiprolol (INN)	
292421	51213-99-1	clanfenurol (INN)	
292421	87721-62-8	fiestolol (INN)	
292421	369-77-7	halocarban (INN)	
292421	13010-47-4	lomustine (INN)	
292421	71475-35-9	lozilurea (INN)	
292421	103055-07-8	lufenuron (INN)	
292421	74738-24-2	recaïnám (INN)	
292421	13909-09-6	semustine (INN)	
292421	57460-41-0	talinolol (INN)	
292421	101-20-2	triclocarban (INN)	
292429	37517-30-9	acebutolol (INN)	
292429	32795-44-1	acecainide (INN)	
292429	556-08-1	acedoben (INN)	
292429	118-57-0	acetaminosalol (INN)	
292429	18699-02-0	actarit (INN)	
292429	54785-02-3	adamexine (INN)	
292429	606-17-7	adipiodone (INN)	
292429	2901-75-9	afalanine (INN)	
292429	3011-89-0	aklómide (INN)	
292429	139402-18-9	alestramustine (INN)	
292429	26750-81-2	alibendol (INN)	
292429	5486-77-1	alloclámide (INN)	
292429	88321-09-9	aloxistatin (INN)	
292429	115-79-7	ambenonium chlorure (INN)	
292429	519-88-0	ambucetamide (INN)	
292429	787-93-9	ameltolide (INN)	
292429	5591-49-1	anilamate (INN)	
292429	87071-16-7	arcofenin (INN)	
292429	22839-47-0	aspartame (INN)	
292429	29122-68-7	atenolol (INN)	
292429	16231-75-7	atolide (INN)	
292429	65617-86-9	avizafone (INN)	
292429	81732-65-2	bambuterol (INN)	
292429	102670-46-2	batanopride (INN)	
292429	501-68-8	beclámide (INN)	
292429	5003-48-5	benorilate (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
292429	15686-76-7	bensalan (INN)	
292429	37106-97-1	bentiromide (INN)	
292429	148-07-2	benzmalecene (INN)	
292429	3440-28-6	betamipron (INN)	
292429	41859-67-0	bezafibrate (INN)	
292429	70976-76-0	bifepamide (INN)	
292429	67579-24-2	bromadoline (INN)	
292429	332-69-4	bromamide (INN)	
292429	4093-35-0	bromopride (INN)	
292429	41113-86-4	bromoxanide (INN)	
292429	40912-73-0	brosotamide (INN)	
292429	54340-61-3	brovanexine (INN)	
292429	86216-41-3	broxitalamic acid (INN)	
292429	1083-57-4	bucetin (INN)	
292429	575-74-6	buclosamide (INN)	
292429	32421-46-8	bunaftine (INN)	
292429	1233-53-0	bunamiodyl (INN)	
292429	4663-83-6	buramate (INN)	
292429	3785-21-5	butanilicaine (INN)	
292429	66292-52-2	butilfenin (INN)	
292429	528-96-1	calcium benzamidosalicylate (INN)	
292429	123122-55-4	candoxatriol (INN)	
292429	123122-54-3	candoxatriolat (INN)	
292429	21434-91-3	capobenic acid (INN)	
292429	63-25-2	carbaryl (ISO) carbaril (INN)	
292429	5749-67-7	carbasalate calcium (INN)	
292429	15687-16-8	carbifene (INN)	
292429	1042-42-8	carcainium chloride (INN)	
292429	3567-38-2	carfimate (INN)	
292429	98815-38-4	casokefamide (INN)	
292429	34919-98-7	cetamolol (INN)	
292429	735-52-4	cetofenicol (INN)	
292429	97-27-8	chlorbetamide (INN)	
292429	64379-93-7	cinflumide (INN)	
292429	58473-74-8	cinromide (INN)	
292429	5588-21-6	cintramide (INN)	
292429	75616-03-4	ciprazafone (INN)	
292429	10423-37-7	citenamide (INN)	
292429	6170-69-0	clamidoxic acid (INN)	

HS 6	CAS #	Description	Alternative Classification
292429	30544-61-7	clanobutin (INN)	
292429	3576-64-5	clefamide (INN)	
292429	3207-50-9	clinolamide (INN)	
292429	14437-41-3	clioxanide (INN)	
292429	18966-32-0	clocanfamide (INN)	
292429	5626-25-5	clodacaine (INN)	
292429	1223-36-5	clofexamide (INN)	
292429	26717-47-5	clofibride (INN)	
292429	14261-75-7	clofores (INN)	
292429	15301-50-5	cloponone (INN)	
292429	15687-05-5	cloracetadol (INN)	
292429	65569-29-1	cloxacepride (INN)	
292429	30531-86-3	colfenamate (INN)	
292429	14008-60-7	cresotamide (INN)	
292429	483-63-6	crotamiton (INN)	
292429	5779-54-4	cyclarbamate (INN)	
292429	7199-29-3	cyheptamide (INN)	
292429	14817-09-5	decimemide (INN)	
292429	83435-66-9	delapril (INN)	
292429	56-94-0	demecarium bromide (INN)	
292429	3734-33-6	denatonium benzoate (INN)	
292429	119817-90-2	dexloxiglumide (INN)	
292429	2623-33-8	diacetamate (INN)	
292429	28197-69-5	diacetolol (INN)	
292429	36141-82-9	diamfenetide (INN)	
292429	552-25-0	diampromide (INN)	
292429	87-12-7	dibromsalan (INN)	
292429	24353-45-5	dibusadol (INN)	
292429	15585-88-3	dicarfen (INN)	
292429	17243-49-1	diclometide (INN)	
292429	134-62-3	diethyltoluamide (INN)	
292429	75659-07-3	dilevalol (INN)	
292429	579-38-4	diloxanide (INN)	
292429	60-46-8	dimevamide (INN)	
292429	58338-59-3	dinalin (INN)	
292429	71119-12-5	dinazafone (INN)	
292429	148-01-6	dinitolmide (INN)	
292429	101-71-3	diphenan (INN)	
292429	65717-97-7	disofenin (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
292429	54063-35-3	dofamium chloride (INN)	
292429	39907-68-1	dopamantine (INN)	
292429	75616-02-3	dulozafone (INN)	
292429	104775-36-2	ecabapide (INN)	
292429	71027-13-9	eclanamine (INN)	
292429	15687-14-6	embutramide (INN)	
292429	2521-01-9	encyprate (INN)	
292429	4582-18-7	endomide (INN)	
292429	10087-89-5	enpromate (INN)	
292429	2998-57-4	estramustine (INN)	
292429	304-84-7	etamivan (INN)	
292429	62992-61-4	etersalate (INN)	
292429	938-73-8	ethenzamide (INN)	
292429	126-52-3	ethinamate (INN)	
292429	5714-09-0	ethyl cartrizoate (INN)	
292429	36637-18-0	etidocaine (INN)	
292429	63245-28-3	etifenin (INN)	
292429	25287-60-9	etofamide (INN)	
292429	15302-15-5	etosalamide (INN)	
292429	53370-90-4	exalamide (INN)	
292429	25451-15-4	felbamate (INN)	
292429	4665-04-7	fenacetinol (INN)	
292429	306-20-7	fenaclon (INN)	
292429	27736-80-7	fenafic acid (INN)	
292429	4551-59-1	fenalamide (INN)	
292429	54063-40-0	fenoxedil (INN)	
292429	65646-68-6	fenretinide (INN)	
292429	5107-49-3	flualamide (INN)	
292429	847-20-1	flubanilate (INN)	
292429	40256-99-3	flucetorex (INN)	
292429	30533-89-2	flurantel (INN)	
292429	4776-06-1	flusalan (INN)	
292429	13311-84-7	flutamide (INN)	
292429	15302-18-8	formetorex (INN)	
292429	73573-87-2	formoterol (INN)	
292429	19368-18-4	ftaxilide (INN)	
292429	106719-74-8	galtifenin (INN)	
292429	26718-25-2	halofenate (INN)	
292429	358-52-1	hexapropymate (INN)	

HS 6	CAS #	Description	Alternative Classification
292429	6961-46-2	idrocilamide (INN)	
292429	74517-78-5	indecaimide (INN)	
292429	3115-05-7	iobenzamic acid (INN)	
292429	136949-58-1	iobitridol (INN)	
292429	10397-75-8	iocarmic acid (INN)	
292429	16034-77-8	iocetamic acid (INN)	
292429	440-58-4	iodamide (INN)	
292429	81045-33-2	iodecimol (INN)	
292429	92339-11-2	iodixanol (INN)	
292429	31127-82-9	iodoxamic acid (INN)	
292429	141660-63-1	iofratol (INN)	
292429	49755-67-1	ioglicic acid (INN)	
292429	63941-73-1	ioglucol (INN)	
292429	63941-74-2	ioglucomide (INN)	
292429	56562-79-9	ioglundide (INN)	
292429	2618-25-9	ioglycamic acid (INN)	
292429	66108-95-0	iohexol (INN)	
292429	22730-86-5	iolixanic acid (INN)	
292429	25827-76-3	iomeglamic acid (INN)	
292429	78649-41-9	iomeprol (INN)	
292429	62883-00-5	iopamidol (INN)	
292429	89797-00-2	iopentol (INN)	
292429	1456-52-6	ioprocemic acid (INN)	
292429	73334-07-3	iopromide (INN)	
292429	37723-78-7	iopronic acid (INN)	
292429	97702-82-4	iosarcol (INN)	
292429	5591-33-3	iosefamic acid (INN)	
292429	51876-99-4	ioseric acid (INN)	
292429	79211-10-2	iosimide (INN)	
292429	37863-70-0	iosumetic acid (INN)	
292429	2276-90-6	otalamic acid (INN)	
292429	60019-19-4	iotetric acid (INN)	
292429	26887-04-7	iotranic acid (INN)	
292429	79211-34-0	iotriside (INN)	
292429	16024-67-2	iotrizoic acid (INN)	
292429	79770-24-4	iotrolan (INN)	
292429	51022-74-3	iotroxic acid (INN)	
292429	87771-40-2	ioversol (INN)	
292429	-00-0	ioxabrolic acid (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
292429	59017-64-0	ioxaglic acid (INN)	
292429	107793-72-6	ioxilan (INN)	
292429	28179-44-4	ioxitalamic acid (INN)	
292429	19863-06-0	ioxotrizoic acid (INN)	
292429	31598-07-9	iozomic acid (INN)	
292429	71-81-8	isopropamide iodide (INN)	
292429	122898-67-3	itopride (INN)	
292429	36894-69-6	labetalol (INN)	
292429	137-58-6	lidocaine (INN)	
292429	59160-29-1	lidofenin (INN)	
292429	24353-88-6	lorbamate (INN)	
292429	97964-56-2	lorglumide (INN)	
292429	59179-95-2	lorzafone (INN)	
292429	107097-80-3	loxiglumide (INN)	
292429	82821-47-4	mabuprofen (INN)	
292429	78266-06-5	mebrofenin (INN)	
292429	1227-61-8	mefexamide (INN)	
292429	54870-28-9	meglitinide (INN)	
292429	14417-88-0	melinamide (INN)	
292429	2577-72-2	metabromsalan (INN)	
292429	621-42-1	metacetamol (INN)	
292429	100-95-8	metalkonium chloride (INN)	
292429	532-03-6	methocarbamol (INN)	
292429	364-62-5	metoclopramide (INN)	
292429	42794-76-3	midodrine (INN)	
292429	92623-85-3	milnacipran (INN)	
292429	29619-86-1	moctamide (INN)	
292429	56281-36-8	motretinide (INN)	
292429	1505-95-9	naftypramide (INN)	
292429	114-80-7	neostigmine bromide (INN)	
292429	50-65-7	niclosamide (ISO) (INN)	
292429	2444-46-4	nonivamide (INN)	
292429	13912-77-1	octacaine (INN)	
292429	58493-49-5	olvanil (INN)	
292429	526-18-1	osalmid (INN)	
292429	26095-59-0	otilonium bromide (INN)	
292429	70009-66-4	oxalinast (INN)	
292429	126-93-2	oxanamide (INN)	
292429	70541-17-2	oxazafone (INN)	



HS 6	CAS #	Description	Alternative Classification
292429	126-27-2	oxetacaine (INN)	
292429	29541-85-3	oxitriptyline (INN)	
292429	2277-92-1	oxyclozanide (INN)	
292429	50-19-1	oxyfenamate (INN)	
292429	75949-61-0	pafenolol (INN)	
292429	59110-35-9	pamatolol (INN)	
292429	1693-37-4	parapropamol (INN)	
292429	30653-83-9	parsalmide (INN)	
292429	5579-05-5	paxamate (INN)	
292429	5579-06-6	pentalamide (INN)	
292429	63-98-9	phenacemide (INN)	
292429	62-44-2	phenacetin (INN)	
292429	90-49-3	pheneturide (INN)	
292429	673-31-4	phenprobamate (INN)	
292429	6673-35-4	practolol (INN)	
292429	721-50-6	prilocaine (INN)	
292429	51-06-9	procainamide (INN)	
292429	13931-64-1	procymate (INN)	
292429	62666-20-0	progabide (INN)	
292429	6620-60-6	proglumide (INN)	
292429	66532-85-2	propacetamol (INN)	
292429	1421-14-3	propanidid (INN)	
292429	730-07-4	propetamide (INN)	
292429	5579-08-8	propyl docetrizoate (INN)	
292429	17692-45-4	quatacaine (INN)	
292429	22662-39-1	rafoxanide (INN)	
292429	128298-28-2	remacemide (INN)	
292429	20788-07-2	resorantel (INN)	
292429	90895-85-5	ronactolol (INN)	
292429	487-48-9	salacetamide (INN)	
292429	36093-47-7	salantel (INN)	
292429	46803-81-0	saletamide (INN)	
292429	587-49-5	salfluverine (INN)	
292429	65-45-2	salicylamide (INN)	
292429	6376-26-7	salverine (INN)	
292429	57227-17-5	sevopramide (INN)	
292429	129-63-5	sodium acetrizoate (INN)	
292429	737-31-5	sodium amidotrizoate (INN)	
292429	129-57-7	sodium diprotizoate (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
292429	7225-61-8	sodium metrizoate (INN)	
292429	7246-21-1	sodium tyropanoate (INN)	
292429	94-35-9	styramate (INN)	
292429	129-46-4	suramin sodium (INN)	
292429	5560-78-1	teclozan (INN)	
292429	51012-32-9	tiapride (INN)	
292429	55837-29-1	tiopramide (INN)	
292429	41708-72-9	tocainide (INN)	
292429	38103-61-6	tolamolol (INN)	
292429	3686-58-6	tolycaine (INN)	
292429	97964-54-0	tomoglumide (INN)	
292429	53902-12-8	tranilast (INN)	
292429	87-10-5	tribromsalan (INN)	
292429	6340-87-0	triacetamol (INN)	
292429	76812-98-1	trigevolol (INN)	
292429	616-68-2	trimecaine (INN)	
292429	138-56-7	trimethobenzamide (INN)	
292429	58970-76-6	ubenimex (INN)	
292429	38647-79-9	urefibrate (INN)	
292519	2897-83-8	alonimid (INN)	
292519	51411-04-2	alrestatin (INN)	
292519	125-84-8	aminoglutethimide (INN)	
292519	69408-81-7	amonafide (INN)	
292519	1673-06-9	amphotalide (INN)	
292519	64-65-3	bemegride (INN)	
292519	22855-57-8	brosuximide (INN)	
292519	15518-76-0	ciproximide (INN)	
292519	77-67-8	ethosuximide (INN)	
292519	60-45-7	fenimide (INN)	
292519	77-21-4	glutethimide (INN)	
292519	77-41-8	mesuximide (INN)	
292519	10403-51-7	mitindomide (INN)	
292519	54824-17-8	mitonafide (INN)	
292519	6319-06-8	noreximide (INN)	
292519	1156-05-4	phenglutanamide (INN)	
292519	86-34-0	phensuximide (INN)	
292519	14166-26-8	taglutimide (INN)	
292519	21925-88-2	tesicam (INN)	
292519	35423-09-7	tesimide (INN)	

HS 6	CAS #	Description	Alternative Classification
292519	7696-12-0	tetramethrin (ISO) (INN)	
292519	50-35-1	thalidomide (INN)	
292520	22573-93-9	alexidine (INN)	
292520	5581-35-1	amfecloral (INN)	
292520	3459-96-9	amicarbalide (INN)	
292520	49745-00-8	amidantel (INN)	
292520	33089-61-1	amitraz (ISO) (INN)	
292520	74-79-3	arginine (INN)	
292520	4320-30-3	arginine L-glutamate (INN)	
292520	81907-78-0	batebulast (INN)	
292520	78718-52-2	benexate (INN)	
292520	55-73-2	betanidine (INN)	
292520	85125-49-1	biclodil (INN)	
292520	692-13-7	buformin (INN)	
292520	3748-77-4	bunamidine (INN)	
292520	59721-28-7	camostat (INN)	
292520	22790-84-7	carbantel (INN)	
292520	55-56-1	chlorhexidine (INN)	
292520	537-21-3	chlorproguanil (INN)	
292520	6903-79-3	creatinolfosfate (INN)	
292520	496-00-4	dibrompropamide (INN)	
292520	45086-03-1	etofornin (INN)	
292520	80018-06-0	fengabine (INN)	
292520	39492-01-8	gabexate (INN)	
292520	55926-23-3	guanclofine (INN)	
292520	29110-47-2	guanfacine (INN)	
292520	3658-25-1	guanoxine (INN)	
292520	13050-83-4	guanoxyfen (INN)	
292520	104317-84-2	gusperimus (INN)	
292520	3811-75-4	hexamidine (INN)	
292520	495-99-8	hydroxystilbamidine (INN)	
292520	135-43-3	lauroguadine (INN)	
292520	66871-56-5	lidamidine (INN)	
292520	46464-11-3	meobentine (INN)	
292520	657-24-9	metformin (INN)	
292520	459-86-9	mitoguazone (INN)	
292520	81525-10-2	nafamostat (INN)	
292520	76631-45-3	napactadine (INN)	
292520	886-08-8	nortetamol (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
292520	5879-67-4	oletimol (INN)	
292520	7232-51-1	pararosaniline embonate (INN)	
292520	100-33-4	pentamidine (INN)	
292520	101-93-9	phenacaine (INN)	
292520	114-86-3	phenformin (INN)	
292520	500-92-5	proguanil (INN)	
292520	104-32-5	propamidine (INN)	
292520	1729-61-9	renytoiline (INN)	
292520	1221-56-3	sodium iopodate (INN)	
292520	140-59-0	stilbamidine isetionate (INN)	
292520	85465-82-3	thymotrnan (INN)	
292520	4210-97-3	tiformin (INN)	
292520	86914-11-6	tolgabide (INN)	
292520	6443-40-9	xylamidine tosilate (INN)	
292690	65899-72-1	alozafone (INN)	
292690	17590-01-1	amfetaminil (INN)	
292690	83200-10-6	anipamil (INN)	
292690	1069-55-2	bucrilate (INN)	
292690	34915-68-9	bunitrolol (INN)	
292690	54239-37-1	cimaterol (INN)	
292690	21702-93-2	cloguanamil (INN)	
292690	57808-65-8	closante! (INN)	
292690	85247-76-3	dagapamil (INN)	
292690	92302-55-1	devapamil (INN)	
292690	38321-02-7	dexverapamil (INN)	
292690	78370-13-5	emopamil (INN)	
292690	6606-65-1	enbucrilate (INN)	
292690	130929-57-6	entacapone (INN)	
292690	86880-51-5	epanolol (INN)	
292690	80471-63-2	epostane (INN)	
292690	15599-27-6	etaminile (INN)	
292690	5232-99-5	etocrilene (INN)	
292690	15686-61-0	fenproporex (INN)	
292690	23023-91-8	flucrilate (INN)	
292690	16662-47-8	gallopamil (INN)	
292690	1113-10-6	guancidine (INN)	
292690	77-51-0	isoaminile (INN)	
292690	101238-51-1	levemopamil (INN)	
292690	53882-12-5	lodoxamide (INN)	

HS 6	CAS #	Description	Alternative Classification
292690	137-05-3	mecrilate (INN)	
292690	136033-49-3	nexopamil (INN)	
292690	1689-89-0	nitroxinil (INN)	
292690	6701-17-3	ocrilate (INN)	
292690	6197-30-4	octocriene (INN)	
292690	58503-83-6	penirolol (INN)	
292690	85247-77-4	ronipamil (INN)	
292690	111753-73-2	satigrel (INN)	
292690	52-53-9	verapamil (INN)	
292700	80573-04-2	balsalazide (INN)	
292700	502-98-7	chlorazodin (INN)	
292700	536-71-0	diminazene (INN)	
292700	94-10-0	etoxazene (INN)	
292700	80573-03-1	ipsalazide (INN)	
292800	546-88-3	acethydroxamic acid (INN)	
292800	5854-93-3	alanosine (INN)	
292800	34297-34-2	anidoxime (INN)	
292800	15256-58-3	beloxamide (INN)	
292800	7654-03-7	benmoxin (INN)	
292800	322-35-0	benserazide (INN)	
292800	38274-54-3	benurestat (INN)	
292800	4267-81-6	bolazine (INN)	
292800	555-65-7	brocresine (INN)	
292800	2438-72-4	bufexamac (INN)	
292800	3583-64-0	bumadizone (INN)	
292800	53078-44-7	caproxamine (INN)	
292800	81424-67-1	caracemide (INN)	
292800	3240-20-8	carbenzide (INN)	
292800	28860-95-9	carbidopa (INN)	
292800	25394-78-9	cetoxime (INN)	
292800	3788-16-7	cimemoxin (INN)	
292800	54739-19-4	clovoxamine (INN)	
292800	58832-68-1	cloximate (INN)	
292800	140-87-4	cyacetacide (INN)	
292800	70-51-9	deferoxamine (INN)	
292800	24701-51-7	demexiptiline (INN)	
292800	511-41-1	diphoxazide (INN)	
292800	85750-38-5	erocainide (INN)	
292800	105613-48-7	exametazime (INN)	

HS 6	CAS #	Description	Alternative Classification
292800	90581-63-8	falintolol (INN)	
292800	3818-37-9	fenoxypropazine (INN)	
292800	54739-18-3	fluvoxamine (INN)	
292800	5051-62-7	guanabenz (INN)	
292800	5001-32-1	guanoclor (INN)	
292800	7473-70-3	guanoxabenz (INN)	
292800	127-07-1	hydroxycarbamide (INN)	
292800	53648-05-8	ibuproxam (INN)	
292800	127420-24-0	idrapril (INN)	
292800	3544-35-2	iprocliozide (INN)	
292800	60070-14-6	maniptiline (INN)	
292800	65-64-5	mebanazine (INN)	
292800	54063-51-3	nadoxolol (INN)	
292800	46263-35-8	nafomine (INN)	
292800	15687-37-3	naftazone (INN)	
292800	57925-64-1	naproxodime (INN)	
292800	51354-32-6	nisterime (INN)	
292800	3362-45-6	noxiptiline (INN)	
292800	4684-87-1	octamoxin (INN)	
292800	51-71-8	phenelzine (INN)	
292800	103-03-7	phenicarbazide (INN)	
292800	55-52-7	pheniprazine (INN)	
292800	14816-18-3	phoxim (ISO) (INN)	
292800	79-17-4	pimaged/ine/ (INN)	
292800	671-16-9	procarbazine (INN)	
292800	25875-51-8	robenidine (INN)	
292800	20228-27-7	ruvazone (INN)	
292800	5579-27-1	simtrazene (INN)	
292800	78372-27-7	stirocainide (INN)	
292800	56187-89-4	ximoprofen (INN)	
292990	52658-53-4	benfosformin (INN)	
292990	52758-02-8	benzaprinnoxide (INN)	
292990	299-86-5	crufomate (ISO) (INN)	
292990	3733-81-1	defosfamide (INN)	
292990	15339-50-1	ferrotrenine (INN)	
292990	70788-28-2	flurofamide (INN)	
292990	1491-41-4	naftalofos (INN)	
292990	139-05-9	sodium cyclamate (INN)	
292990	70788-29-3	tofamide (INN)	

HS 6	CAS #	Description	Alternative Classification
293020	148-18-5	ditiocarb sodium (INN)	
293020	3735-90-8	fencarbamide (INN)	
293030	97-77-8	disulfiram (INN)	
293030	95-05-6	sulfiram (INN)	
293030	137-26-8	thiram (ISO) (INN)	
293040	63-68-3	methionine (INN)	
293090	77-46-3	acedapsone (INN)	
293090	127-60-6	acediasulfone sodium (INN)	
293090	616-91-1	acetylcysteine (INN)	
293090	63547-13-7	adrafinil (INN)	
293090	5667-98-1	aldesulfone sodium (INN)	
293090	144-75-2	aldesulfone sodium (INN)	
293090	5965-40-2	allocupeide sodium (INN)	
293090	109-57-9	allylthiourea (INN)	
293090	123955-10-2	almokalant (INN)	
293090	85754-59-2	ambamustine (INN)	
293090	539-21-9	ambazone (INN)	
293090	3569-77-5	amidapsone (INN)	
293090	20537-88-6	amifostine (INN)	
293090	26328-53-0	amoscanate (INN)	
293090	305-97-5	anthiolimine (INN)	
293090	106854-46-0	argimesna (INN)	
293090	42293-72-1	bencisteine (INN)	
293090	103725-47-9	betiatide (INN)	
293090	79467-22-4	bipenamol (INN)	
293090	97-18-7	bithionol (INN)	
293090	844-26-8	bithionoloxide (INN)	
293090	4044-65-9	bitoscanate (INN)	
293090	23233-88-7	brotianide (INN)	
293090	65002-17-7	bucillamine (INN)	
293090	108-02-1	captamine (INN)	
293090	486-17-9	captodiame (INN)	
293090	638-23-3	carbocisteine (INN)	
293090	786-19-6	carbophenothion (ISO) carbofenotion (INN)	
293090	473-32-5	chaulmosulfone (INN)	
293090	82009-34-5	cilastatin (INN)	
293090	1166-34-3	cinansenn (INN)	
293090	89163-44-0	cinaproxen (INN)	
293090	86042-50-4	cistinexine (INN)	

HS 6	CAS #	Description	Alternative Classification
293090	87556-66-9	cloticasone (INN)	
293090	52-90-4	cysteine (INN)	
293090	18725-37-6	dacisteine (INN)	
293090	4938-00-5	danosteine (INN)	
293090	80-08-0	dapsone (INN)	
293090	5964-62-5	diathymosulfone (INN)	
293090	59-52-9	dimercaprol (INN)	
293090	16208-51-8	dimesna (INN)	
293090	67-68-5	dimethyl sulfoxide (INN)	
293090	5835-72-3	diprofene (INN)	
293090	82599-22-2	ditiomustine (INN)	
293090	584-69-0	ditophal (INN)	
293090	502-55-6	dixanthogen (INN)	
293090	74639-40-0	docarpamine (INN)	
293090	112573-73-6	ecadotril (INN)	
293090	513-10-0	ecothiopate iodide (INN)	
293090	87719-32-2	etarotene (INN)	
293090	1234-30-6	etocarlide (INN)	
293090	58306-30-2	febantel (INN)	
293090	97-24-5	fenticlor (INN)	
293090	76639-94-6	florfenicol (INN)	294140
293090	113593-34-3	flosatidil (INN)	
293090	2924-67-6	fluoresone (INN)	
293090	90566-53-3	fluticasone (INN)	
293090	2507-91-7	gloxazone (INN)	
293090	554-18-7	glucosulfone (INN)	
293090	3569-59-3	hexasonium iodide (INN)	
293090	83519-04-4	ilmofosine (INN)	
293090	66608-32-0	imcarbofos (INN)	
293090	23205-04-1	iosulamide (INN)	
293090	71767-13-0	iotasul (INN)	
293090	88041-40-1	lemidosul (INN)	
293090	127304-28-3	linarotene (INN)	
293090	790-69-2	loflucarban (INN)	
293090	67110-79-6	luprostiol (INN)	
293090	2485-62-3	mecysteine (INN)	
293090	60-23-1	mercaptamine (INN)	
293090	66516-09-4	mertiatile (INN)	
293090	19767-45-4	mesna (INN)	



HS 6	CAS #	Description	Alternative Classification
293090	926-93-2	metallibure (INN)	
293090	66960-34-7	metkefamide (INN)	
293090	68693-11-8	modafinil (INN)	
293090	122575-28-4	naglivan (INN)	
293090	88255-01-0	netobirmin (INN)	
293090	19881-18-6	nitroscanate (INN)	
293090	15599-39-0	noxytiolin (INN)	
293090	35727-72-1	ontianil (INN)	
293090	27450-21-1	osmadizone (INN)	
293090	27025-41-8	oxiglutatione (INN)	
293090	3569-58-2	oxysonium iodide (INN)	
293090	114568-26-2	patamostat (INN)	
293090	52-67-5	penicillamine (INN)	
293090	81045-50-3	pivopril (INN)	
293090	5287-46-7	prenisteine (INN)	
293090	23288-49-5	probucof (INN)	
293090	34914-39-1	ritiometan (INN)	
293090	89767-59-9	salmisteine (INN)	
293090	54657-98-6	serfibrate (INN)	
293090	6385-58-6	sodium bitionolate (INN)	
293090	133-65-3	solasulfone (INN)	
293090	121-55-1	subathizone (INN)	
293090	304-55-2	succimer (INN)	
293090	5934-14-5	succisulfone (INN)	
293090	66264-77-5	sulfinalol (INN)	
293090	42461-79-0	sulfonferol (INN)	
293090	38194-50-2	sulindac (INN)	
293090	54063-56-8	sulocetidil (INN)	
293090	25827-12-7	suloxifen (INN)	
293090	69217-67-0	sumacetamol (INN)	
293090	105687-93-2	sumarotene (INN)	
293090	94055-76-2	suplatast tosilate (INN)	
293090	85053-46-9	suricainide (INN)	
293090	3383-96-8	temephos (ISO) temefos (INN)	
293090	500-89-0	thiambutosine (INN)	
293090	104-06-3	thioacetazone (INN)	
293090	111-48-8	thiodiglycol (INN)	
293090	6964-20-1	tiadenol (INN)	
293090	55837-28-0	tiafibrate (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
293090	10433-71-3	tiametonium iodide (INN)	
293090	129731-11-9	tibeglisene (INN)	
293090	13402-51-2	tibenzate (INN)	
293090	82-99-5	tifenamil (INN)	
293090	53993-67-2	tiflorex (INN)	
293090	89987-06-4	tiludronic acid (INN)	
293090	910-86-1	tiocarlide (INN)	
293090	10489-23-3	tiocitlate (INN)	
293090	1953-02-2	tiopronin (INN)	
293090	39516-21-7	tiopropamine (INN)	
293090	15686-78-9	tiosalan (INN)	
293090	26481-51-6	tiprenoiol (INN)	
293090	70895-45-3	tipropidil (INN)	
293090	67040-53-3	tiprostanide (INN)	
293090	50838-36-3	toxiclate (INN)	
293090	27877-51-6	tolindate (INN)	
293090	38452-29-8	tolmesoxide (INN)	
293090	2398-96-1	tolnaftate (INN)	
293090	82964-04-3	tolrestat (INN)	
293090	7009-79-2	xenthiorate (INN)	
293090	22012-72-2	zilantel (INN)	
293100	97-44-9	acetarsol (INN)	
293100	60668-24-8	alafosfalin (INN)	
293100	66376-36-1	alendronic acid (INN)	
293100	98-50-0	arsanilic acid (INN)	
293100	103486-79-9	belfosdil (INN)	
293100	17316-67-5	butafosfan (INN)	
293100	51395-42-7	butedronic acid (INN)	
293100	126-22-7	butonate (ISO) (INN)	
293100	121-59-5	carbarsone (INN)	
293100	62-37-3	chlormerodrin (INN)	
293100	10596-23-3	clodronic acid (INN)	
293100	455-83-4	dichlorophenarsine (INN)	
293100	65606-61-3	diciferron (INN)	
293100	3639-19-8	difetarsone (INN)	
293100	68959-20-6	disiquonium chloride (INN)	
293100	2809-21-4	etidronic acid (INN)	
293100	73514-87-1	fosarilate (INN)	
293100	63585-09-1	foscarnet sodium (INN)	

HS 6	CAS #	Description	Alternative Classification
293100	2398-95-0	foscolic acid (INN)	
293100	16543-10-5	fosenazide (INN)	
293100	54870-27-8	fosfonet sodium (INN)	
293100	13237-70-2	fosmenic acid (INN)	
293100	92118-27-9	fotemustine (INN)	
293100	116-49-4	glycobiarsol (INN)	
293100	14235-86-0	hydrargaphen (INN)	
293100	1984-15-2	medronic acid (INN)	
293100	20223-84-1	mercaptomerin (INN)	
293100	525-30-4	mercuderamide (INN)	
293100	498-73-7	mercurobutol (INN)	
293100	492-18-2	mersalyl (INN)	
293100	76541-72-5	mifobate (INN)	
293100	457-60-3	neoarsphenamine (INN)	
293100	79778-41-9	neridronic acid (INN)	
293100	98-72-6	nitarsone (INN)	
293100	15468-10-7	oxidronic acid (INN)	
293100	306-12-7	oxophenarsine (INN)	
293100	40391-99-9	pamidronic acid (INN)	
293100	535-51-3	phenarsone sulfoxylate (INN)	
293100	8017-88-7	phenylmercuric borate (INN)	
293100	33204-76-1	quadrosilan (INN)	
293100	121-19-7	roxarsone (INN)	
293100	5964-24-9	sodium timerfonate (INN)	
293100	51321-79-0	sparfosic acid (INN)	
293100	1344-34-9	stibamine glucoside (INN)	
293100	5959-10-4	stibosamine (INN)	
293100	618-82-6	sulfarsphenamine (INN)	
293100	75018-71-2	tauroselcholic acid (INN)	
293100	127502-06-1	tetrofosmin (INN)	
293100	14433-82-0	thiacetarsamide sodium (INN)	
293100	54-64-8	thiomersal (INN)	
293100	2430-46-8	tolboxane (INN)	
293100	57808-64-7	toldimfos (INN)	
293100	19028-28-5	toliodium chloride (INN)	
293100	52-68-6	trichlorfon (ISO) metrifonate (INN)	
293100	554-72-3	tryparsamide (INN)	
293219	72420-38-3	acifran (INN)	
293219	75748-50-4	ancarolol (INN)	

HS 6	CAS #	Description	Alternative Classification
293219	28434-01-7	bioresmethrin (ISO) (INN)	
293219	53684-49-4	bufetolol (INN)	
293219	29899-95-4	clobenoside (INN)	
293219	64743-08-4	diclofurime (INN)	
293219	735-64-8	fenamifuril (INN)	
293219	3690-58-2	fubrogonium iodide (INN)	
293219	3776-93-0	furfenorex (INN)	
293219	4662-17-3	furidarone (INN)	
293219	549-40-6	furostilbestrol (INN)	
293219	15686-77-8	fursalan (INN)	
293219	541-64-0	furtrethonium iodide (INN)	
293219	55902-93-7	mebenoside (INN)	
293219	31329-57-4	naftidrofuryl (INN)	
293219	405-22-1	nidroxyzone (INN)	
293219	3270-71-1	nifuraldezone (INN)	
293219	19561-70-7	nifuratrone (INN)	
293219	5580-25-6	nifurethazone (INN)	
293219	5579-95-3	nifurmerone (INN)	
293219	965-52-6	nifuroxazide (INN)	
293219	6236-05-1	nifuroxime (INN)	
293219	5579-89-5	nifursemizone (INN)	
293219	16915-70-1	nifursol (INN)	
293219	67-28-7	nihydrazone (INN)	
293219	84845-75-0	niperotidine (INN)	
293219	64743-09-5	nitrafudam (INN)	
293219	59-87-0	nitrofuril (INN)	
293219	60653-25-0	orpanoxin (INN)	
293219	66357-35-5	ranitidine (INN)	
293219	33779-37-2	salprotoside (INN)	
293219	6673-97-8	spiroxasone (INN)	
293219	10310-32-4	tnbenoside (INN)	
293219	93064-63-2	venritidine (INN)	
293219	3563-92-6	zylofuramine (INN)	
293229	642-83-1	aceglatone (INN)	
293229	152-72-7	acenocoumarol (INN)	
293229	67696-82-6	acnheliin (INN)	
293229	65776-67-2	afurolol (INN)	
293229	76-65-3	amoianone (INN)	
293229	3447-95-8	benfurodil hemisuccinate (INN)	

HS 6	CAS #	Description	Alternative Classification
293229	58409-59-9	bucumolol (INN)	
293229	465-39-4	bufogenin (INN)	
293229	976-71-6	canrenone (INN)	
293229	804-10-4	carbocromen (INN)	
293229	35838-63-2	ciocoumarol (INN)	
293229	60986-89-2	clofurac (INN)	
293229	68206-94-0	cloricromen (INN)	
293229	56-72-4	coumaphos (ISO) coumafos (INN)	
293229	4366-18-1	coumetarol (INN)	
293229	132100-55-1	dalvastatin (INN)	
293229	1233-70-1	diarbarone (INN)	
293229	66-76-2	dicoumarol (INN)	
293229	67392-87-4	drosiprenone (INN)	
293229	476-66-4	ellagic acid (INN)	
293229	2908-75-0	esculamine (INN)	
293229	91406-11-0	esuprone (INN)	
293229	548-00-5	ethyl biscoumacetate (INN)	
293229	480-49-9	filipin (INN)	
293229	87810-56-8	fostriecin (INN)	
293229	67268-43-3	giparmen (INN)	
293229	32449-92-6	glucuro lactone (INN)	
293229	321-55-1	haloxon (INN)	
293229	90-33-5	hymecromone (INN)	
293229	81478-25-3	lomevactone (INN)	
293229	112856-44-7	losigamone (INN)	
293229	75330-75-5	lovastatin (INN)	
293229	87952-98-5	mespirenone (INN)	
293229	52814-39-8	metesculetol (INN)	
293229	73573-88-3	mevastatin (INN)	
293229	75992-53-9	moxadolen (INN)	
293229	96829-58-2	orlistat (INN)	
293229	15301-80-1	oxamann (INN)	
293229	77-09-8	phenolphthalein (INN)	
293229	435-97-2	phenprocoumon (INN)	
293229	57-57-8	propiolactone (INN)	
293229	33156-28-4	ramnodigin (INN)	
293229	79902-63-9	simvastatin (INN)	
293229	52-01-7	spironolactone (INN)	
293229	74220-07-8	spirorenone (INN)	

HS 6	CAS #	Description	Alternative Classification
293229	29334-07-4	sulmann (INN)	
293229	42422-68-4	taleranol (INN)	
293229	66898-60-0	talosalate (INN)	
293229	75139-06-9	tetronasin (INN)	
293229	3902-71-4	trioxysalen (INN)	
293229	3258-51-3	valofane (INN)	
293229	477-32-7	visnadine (INN)	
293229	81-81-2	warfarin (ISO) (INN)	
293229	15301-97-0	xylocoumarol (INN)	
293229	26538-44-3	zeranol (INN)	
293290	96566-25-5	ablukast (INN)	
293290	56180-94-0	acarbose (INN)	
293290	25161-41-5	acevaltrate (INN)	
293290	2455-84-7	ambenoxan (INN)	
293290	58805-38-2	ambicromil (INN)	
293290	4439-67-2	amikhelline (INN)	
293290	1951-25-3	amiodarone (INN)	
293290	79130-64-6	ansoxetine (INN)	
293290	123072-45-7	aprosulate sodium (INN)	
293290	71963-77-4	artemether (INN)	
293290	63968-64-9	artemisinin (INN)	
293290	88495-63-0	artesunate (INN)	
293290	39552-01-7	befunolol (INN)	
293290	27661-27-4	benaxibine (INN)	
293290	85443-48-7	bencianol (INN)	
293290	81703-42-6	bendacalol (INN)	
293290	1477-19-6	benzarone (INN)	
293290	3562-84-3	benzbromarone (INN)	
293290	68-90-6	benziodarone (INN)	
293290	13157-90-9	benzquercin (INN)	
293290	88430-50-6	beraprost (INN)	
293290	72619-34-2	bermoprofen (INN)	
293290	58546-54-6	besigomsin (INN)	
293290	55102-44-8	bofumustine (INN)	
293290	78371-66-1	bucromarone (INN)	
293290	54340-62-4	bufuralol (INN)	
293290	4442-60-8	butamoxane (INN)	
293290	59733-86-7	butikacin (INN)	
293290	55165-22-5	butocrolol (INN)	

HS 6	CAS #	Description	Alternative Classification
293290	12569-38-9	calcium glubionate (INN)	
293290	56689-43-1	canbisol (INN)	
293290	521-35-7	cannabinol (INN)	
293290	15879-93-3	chloralose (INN)	
293290	4940-39-0	chromocarb (INN)	
293290	154-23-4	cianidanol (INN)	
293290	19705-61-4	cicortonide (INN)	
293290	3607-18-9	cidoxepin (INN)	
293290	34753-46-3	ciheptolane (INN)	
293290	59729-33-8	citalopram (INN)	
293290	3611-72-1	clonidarol (INN)	
293290	66575-29-9	colforsin (INN)	
293290	16110-51-3	cromogliic acid (INN)	
293290	66211-92-5	detorubicin (INN)	
293290	18296-45-2	didrovaltrate (INN)	
293290	1165-48-6	dimefine (INN)	
293290	6538-22-3	dimeprozan (INN)	
293290	80743-08-4	dioxadilol (INN)	
293290	3567-40-6	dioxamate (INN)	
293290	78-34-2	dioxathion (ISO) dioxation (INN)	
293290	18467-77-1	diprogulic acid (INN)	
293290	114977-28-5	docetaxel (INN)	
293290	61869-07-6	domiodol (INN)	
293290	61-74-5	domoxin (INN)	
293290	122312-55-4	dosmalfate (INN)	
293290	55286-56-1	doxaminol (INN)	
293290	1668-19-5	doxepin (INN)	
293290	1972-08-3	dronabinol (INN)	
293290	98383-18-7	ecomustine (INN)	
293290	90733-40-7	edifolone (INN)	
293290	119-41-5	efloxate (INN)	
293290	35121-78-9	epoprostenol (INN)	
293290	15686-63-2	etabenzarone (INN)	
293290	16509-23-2	ethomoxane (INN)	
293290	59619-81-7	etiproston (INN)	
293290	77416-65-0	exepanol (INN)	
293290	34887-52-0	fenisorex (INN)	
293290	29041-71-2	fernc fructose (INN)	
293290	15686-60-9	flavamine (INN)	

HS 6	CAS #	Description	Alternative Classification
293290	37470-13-6	flavodic acid (INN)	
293290	79619-31-1	flavodilol (INN)	
293290	71316-84-2	fluradoline (INN)	
293290	23580-33-8	furacrinic acid (INN)	
293290	67700-30-5	furaprofen (INN)	
293290	58012-63-8	furcloprofen (INN)	
293290	38873-55-1	furobufen (INN)	
293290	56983-13-2	furofenac (INN)	
293290	105618-02-8	galamustine (INN)	
293290	3416-24-8	glucosamine (INN)	
293290	61914-43-0	glucuronamide (INN)	
293290	19889-45-3	guabexan (INN)	
293290	81674-79-5	guaimesal (INN)	
293290	40580-59-4	guanadrel (INN)	
293290	2165-19-7	guanoxan (INN)	
293290	451-77-4	homarylamine (INN)	
293290	35212-22-7	ipriflavone (INN)	
293290	37855-80-4	iprocroiol (INN)	
293290	116818-99-6	isalsteine (INN)	
293290	57009-15-1	isocromil (INN)	
293290	652-67-5	isosorbide (INN)	
293290	87-33-2	isosorbide dinitrate (INN)	
293290	16051-77-7	isosorbide mononitrate (INN)	
293290	55453-87-7	isoxepac (INN)	
293290	82-02-0	khellin (INN)	
293290	585-86-4	lactitol (INN)	
293290	480-17-1	leucocianidol (INN)	
293290	65350-86-9	mecladanol (INN)	
293290	26225-59-2	mecinarone (INN)	
293290	56290-94-9	medroxalol (INN)	
293290	4386-35-0	meralein sodium (INN)	
293290	129-16-8	merbromin (INN)	
293290	53-46-3	methanthelium bromide (INN)	
293290	85-90-5	methylchromone (INN)	
293290	31112-62-6	metrizamide (INN)	
293290	87626-55-9	mitoflaxone (INN)	
293290	1508-45-8	mitopodozide (INN)	
293290	74817-61-1	murabutide (INN)	
293290	51022-71-0	nabilone (INN)	



<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
293290	74912-19-9	naboctate (INN)	
293290	52934-83-5	nanafrocin (INN)	
293290	99200-09-6	nebivolol (INN)	
293290	53983-00-9	nibroxane (INN)	
293290	71097-83-1	nileprost (INN)	
293290	81486-22-8	nipradilol (INN)	
293290	22693-65-8	olmidine (INN)	
293290	541-66-2	oxapropanium iodide (INN)	
293290	55689-65-1	oxepinac (INN)	
293290	26020-55-3	oxetorone (INN)	
293290	33069-62-4	paclitaxel (INN)	
293290	87549-36-8	parcetasal (INN)	
293290	4730-07-8	pentamoxane (INN)	
293290	5684-90-2	penthrichloral (INN)	
293290	67102-87-8	pentomone (INN)	
293290	42408-79-7	pirandamine (INN)	
293290	68298-00-0	pimabin (INN)	
293290	53341-49-4	ponfibrate (INN)	
293290	23873-85-0	proligestone (INN)	
293290	470-43-9	promoxolane (INN)	
293290	50-34-0	propantheline bromide (INN)	
293290	136-70-9	protokylol (INN)	
293290	60400-92-2	proxicromil (INN)	
293290	58994-96-0	ranimustine (INN)	
293290	128232-14-4	raxofelast (INN)	
293290	78113-36-7	romurtide (INN)	
293290	22888-70-6	silibinin (INN)	
293290	33889-69-9	silicristin (INN)	
293290	29782-68-1	silidianin (INN)	
293290	474-58-8	sitogluside (INN)	
293290	47254-05-7	spiroxepin (INN)	
293290	72492-12-7	spizofurone (INN)	
293290	49763-96-4	stinpentol (INN)	
293290	18883-66-4	streptozocin (INN)	
293290	58761-87-8	sudexanox (INN)	
293290	7182-51-6	talopram (INN)	
293290	108945-35-3	taprostene (INN)	
293290	66112-59-2	temurtide (INN)	
293290	51497-09-7	tenamfetamine (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
293290	37456-21-6	terbucromil (INN)	
293290	77005-28-8	texacromil (INN)	
293290	602-41-5	thiocolchicoside (INN)	
293290	97483-17-5	tifurac (INN)	
293290	76301-19-4	timefurone (INN)	
293290	40691-50-7	tixanox (INN)	
293290	50465-39-9	tocofibrate (INN)	
293290	97240-79-4	topiramate (INN)	
293290	23915-73-3	trebenzomine (INN)	
293290	30910-27-1	treloxinate (INN)	
293290	18296-44-1	valtrate (INN)	
293290	33459-27-7	xanoxic acid (INN)	
293311	58-15-1	aminophenazone (INN)	
293311	747-30-8	aminophenazone cyclamate (INN)	
293311	55837-24-6	bisfenazone (INN)	
293311	7077-30-7	butopyrammonium iodide (INN)	
293311	1046-17-9	dibupyrone (INN)	
293311	22881-35-2	famprofazone (INN)	
293311	68-89-3	metamizole sodium (INN)	
293311	2139-47-1	nifenazone (INN)	
293311	60-80-0	phenazone (INN)	
293311	479-92-5	propyphenazone (INN)	
293311	3615-24-5	ramifenazone (INN)	
293319	105-20-4	betazole (INN)	
293319	50270-32-1	bufezolac (INN)	
293319	60104-29-2	clofezone (INN)	
293319	81528-80-5	dalbraminol (INN)	
293319	70181-03-2	dazopride (INN)	
293319	20170-20-1	difenamizole (INN)	
293319	23111-34-4	feclobuzone (INN)	
293319	30748-29-9	feprazone (INN)	
293319	80410-36-2	fezolamine (INN)	
293319	7554-65-6	fomepizole (INN)	
293319	115436-73-2	ipazilide (INN)	
293319	50270-33-2	isofezolac (INN)	
293319	853-34-9	kebuzone (INN)	
293319	53808-88-1	lonazolac (INN)	
293319	119322-27-9	menbendan (INN)	
293319	7125-67-9	metoquizine (INN)	

HS 6	CAS #	Description	Alternative Classification
293319	2210-63-1	mofebutazone (INN)	
293319	55294-15-0	muzolimine (INN)	
293319	59040-30-1	nafazatrom (INN)	
293319	129-20-4	oxyphenbutazone (INN)	
293319	50-33-9	phenylbutazone (INN)	
293319	71002-09-0	pirazolac (INN)	
293319	4023-00-1	praxadine (INN)	
293319	34427-79-7	proxifezone (INN)	
293319	57-96-5	sulfinpyrazone (INN)	
293319	27470-51-5	suxibuzone (INN)	
293319	103475-41-8	tepoxalin (INN)	
293319	13221-27-7	tribuzone (INN)	
293319	32710-91-1	trifezolac (INN)	
293321	40828-44-2	clazolimine (INN)	
293321	5588-20-5	clodantoin (INN)	
293321	86-35-1	ethotoin (INN)	
293321	93390-81-9	fosphenytoin (INN)	
293321	89391-50-4	imirestat (INN)	
293321	50-12-4	mephenytoin (INN)	
293321	63612-50-0	nilutamide (INN)	
293321	57-41-0	phenytoin (INN)	
293321	122946-42-3	spinprostil (INN)	
293321	56605-16-4	spiromustine (INN)	
293329	91017-58-2	abunidazole (INN)	
293329	830-89-7	albutoin (INN)	
293329	1317-25-5	alcloxa (INN)	
293329	5579-81-7	aldioxa (INN)	
293329	63824-12-4	aliconazole (INN)	
293329	33178-86-8	alinidine (INN)	
293329	4474-91-3	angiotensin II (INN)	
293329	53-73-6	angiotensinamide (INN)	
293329	91-75-8	antazoline (INN)	
293329	66711-21-5	apraclonidine (INN)	
293329	60173-73-1	arfalasin (INN)	
293329	104054-27-5	atipamezole (INN)	
293329	40828-45-3	azolimine (INN)	
293329	31478-45-2	barnidazole (INN)	
293329	57647-79-7	benclonidine (INN)	
293329	63927-95-7	bentemazole (INN)	

HS 6	CAS #	Description	Alternative Classification
293329	22994-85-0	benznidazole (INN)	
293329	60628-96-8	bifonazole (INN)	
293329	78186-34-2	bisantrene (INN)	
293329	96153-56-9	bisfentidine (INN)	
293329	59803-98-4	brimonidine (INN)	
293329	108894-40-2	broloconazole (INN)	
293329	64872-76-0	butoconazole (INN)	
293329	105920-77-2	camonagrel (INN)	
293329	22232-54-8	carbimazole (INN)	
293329	42116-76-7	camidazole (INN)	
293329	53267-01-9	cibenzoline (INN)	
293329	120635-74-7	cilansetron (INN)	
293329	104902-08-1	cilutazoline (INN)	
293329	51481-61-9	cimetidine (INN)	
293329	59939-16-1	cirazoline (INN)	
293329	38083-17-9	climbazole (INN)	
293329	17692-28-3	clonazoline (INN)	
293329	4205-90-7	clonidine (INN)	
293329	23593-75-1	clotrimazole (INN)	
293329	77175-51-0	croconazole (INN)	
293329	4342-03-4	dacarbazine (INN)	
293329	76894-77-4	dazmegrel (INN)	
293329	78218-09-4	dazoxiben (INN)	
293329	70161-09-0	democonazole (INN)	
293329	73931-96-1	denzimol (INN)	
293329	122830-14-2	denglidole (INN)	
293329	76631-46-4	detomidine (INN)	
293329	81447-79-2	dexlofexidine (INN)	
293329	113775-47-6	dexmedetomidine (INN)	
293329	551-92-8	dimetridazole (INN)	
293329	6043-01-2	domazoline (INN)	
293329	3254-93-1	doxenitoin (INN)	
293329	128326-82-9	eberconazole (INN)	
293329	27220-47-9	econazole (INN)	
293329	99500-54-6	efetozole (INN)	
293329	113082-98-7	enalkiren (INN)	
293329	73790-28-0	enilconazole (INN)	
293329	77671-31-9	enoximone (INN)	
293329	22668-01-5	etanidazole (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
293329	69539-53-3	etintidine (INN)	
293329	33125-97-2	etomidate (INN)	
293329	15037-44-2	etonam (INN)	
293329	73445-46-2	fenflumizol (INN)	
293329	41473-09-0	fenmetozole (INN)	
293329	57653-26-6	fenobam (INN)	
293329	4846-91-7	fenoxazoline (INN)	
293329	72479-26-6	fenticonazole (INN)	
293329	38234-21-8	fertirelin (INN)	
293329	59729-37-2	fexinidazole (INN)	
293329	53597-28-7	fludazonium chloride (INN)	
293329	36740-73-5	flumizole (INN)	
293329	4548-15-6	flunidazole (INN)	
293329	84962-75-4	flutomidate (INN)	
293329	28125-87-3	flutonidine (INN)	
293329	119006-77-8	flutrimazole (INN)	
293329	5786-71-0	fosfocreatinine (INN)	
293329	110883-46-0	giracodazole (INN)	
293329	25859-76-1	glibutimine (INN)	
293329	33515-09-2	gonadorelin (INN)	
293329	71-00-1	histidine (INN)	
293329	57653-28-8	ibazocine (INN)	
293329	95668-38-5	idralfidine (INN)	
293329	84243-58-3	imazodan (INN)	
293329	89371-37-9	imidapril (INN)	
293329	36364-49-5	imidazole salicylate (INN)	
293329	27885-92-3	imidocarb (INN)	
293329	7303-78-8	imidoline (INN)	
293329	55273-05-7	impromidine (INN)	
293329	40507-78-6	indanazoline (INN)	
293329	85392-79-6	indanidine (INN)	
293329	14885-29-1	ipronidazole (INN)	
293329	115574-30-6	itemazole (INN)	
293329	110605-64-6	isaglidole (INN)	
293329	27523-40-6	isoconazole (INN)	
293329	116795-97-2	ledazerol (INN)	
293329	81447-78-1	levlofexidine (INN)	
293329	115575-11-6	liarozole (INN)	
293329	107429-63-0	lintopride (INN)	

HS 6	CAS #	Description	Alternative Classification
293329	65571-68-8	lofemizole (INN)	
293329	31036-80-3	lofexidine (INN)	
293329	60628-98-0	lombazole (INN)	
293329	114798-26-4	losartan (INN)	
293329	86347-14-0	medetomidine (INN)	
293329	58261-91-9	mefenidil (INN)	
293329	14058-90-3	metazamide (INN)	
293329	5696-06-0	metetoin (INN)	
293329	34839-70-8	metiamide (INN)	
293329	5377-20-8	metomidate (INN)	
293329	38349-38-1	metrafazoline (INN)	
293329	443-48-1	metronidazole (INN)	
293329	22916-47-8	miconazole (INN)	
293329	23757-42-8	midafllur (INN)	
293329	80614-27-3	midazolgel (INN)	
293329	83184-43-4	mifentidine (INN)	
293329	20406-60-4	mipimazole (INN)	
293329	13551-87-6	misonidazole (INN)	
293329	125472-02-8	mivazerol (INN)	
293329	97901-21-8	nafagrel (INN)	
293329	64212-22-2	nafimidone (INN)	
293329	91524-14-0	napamezole (INN)	
293329	835-31-4	naphazoline (INN)	
293329	130759-56-7	nemazoline (INN)	
293329	130726-68-0	neticonazole (INN)	
293329	17230-89-6	nimazone (INN)	
293329	21721-92-6	nitrefazole (INN)	
293329	54533-85-6	nizofenone (INN)	
293329	89838-96-0	octmibate (INN)	
293329	137460-88-9	odalprofen (INN)	
293329	74512-12-2	omoconazole (INN)	
293329	116002-70-1	ondansetron (INN)	
293329	66778-37-8	orconazole (INN)	
293329	16773-42-5	omidazole (INN)	
293329	64211-45-6	oxiconazole (INN)	
293329	1491-59-4	oxymetazoline (INN)	
293329	82571-53-7	ozagrel (INN)	
293329	501-62-2	phenamazoline (INN)	
293329	50-60-2	phentolamine (INN)	

HS 6	CAS #	Description	Alternative Classification
293329	130120-57-9	prezatide copper acetate (INN)	
293329	76448-31-2	propenidazole (INN)	
293329	7036-58-0	propoxate (INN)	
293329	126222-34-2	remikiren (INN)	
293329	89781-55-5	rolafagrel (INN)	
293329	65896-16-4	romifidine (INN)	
293329	7681-76-7	ronidazole (INN)	
293329	34273-10-4	saralasin (INN)	
293329	3366-95-8	secnidazole (INN)	
293329	54143-54-3	sepazonium chionde (INN)	
293329	103926-64-3	sepimostat (INN)	
293329	79313-75-0	sopromidine (INN)	
293329	30529-16-9	stirimazole (INN)	
293329	61318-90-9	sulconazole (INN)	
293329	51022-76-5	sulnidazole (INN)	
293329	1082-56-0	tefazoline (INN)	
293329	52232-67-4	tenparatide (INN)	
293329	1077-93-6	temidazole (INN)	
293329	84-22-0	tetryzoline (INN)	
293329	60-56-0	thiamazole (INN)	
293329	62894-89-7	tiflamizole (INN)	
293329	62882-99-9	tinazoline (INN)	
293329	19387-91-8	tinidazole (INN)	
293329	59-98-3	tolazoline (INN)	
293329	4201-22-3	tolonidine (INN)	
293329	1082-57-1	tramazoline (INN)	
293329	56-28-0	triclodazol (INN)	
293329	84203-09-8	trifenagrel (INN)	
293329	62087-96-1	triletide (INN)	
293329	56097-80-4	valconazole (INN)	
293329	526-36-3	xylometazoline (INN)	
293329	51940-78-4	zetidoline (INN)	
293329	90697-56-6	zimidoben (INN)	
293329	71097-23-9	zoficonazole (INN)	
293339	827-61-2	aceclidine (INN)	
293339	807-31-8	aceperone (INN)	
293339	13410-86-1	aconiazide (INN)	
293339	87848-99-5	acrvastine (INN)	
293339	66564-15-6	alepride (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
293339	71195-58-9	alfentanil (INN)	
293339	25384-17-2	allylprodine (INN)	
293339	468-51-9	alphameprodine (INN)	
293339	77-20-3	alphaprodine (INN)	
293339	93277-96-4	altapizone (INN)	
293339	83991-25-7	ambasilide (INN)	
293339	1580-71-8	amiperone (INN)	
293339	88150-42-9	amlodipine (INN)	
293339	15378-99-1	anazocine (INN)	
293339	144-14-9	anilendine (INN)	
293339	98330-05-3	anpirtoline (INN)	
293339	86780-90-7	aranidipine (INN)	
293339	106669-71-0	arpromidine (INN)	
293339	68844-77-9	astemizole (INN)	
293339	115-46-8	azacyclonol (INN)	
293339	3964-81-6	azatadine (INN)	
293339	123524-52-7	azelnidipine (INN)	
293339	4945-47-5	bamipine (INN)	
293339	104713-75-9	barnidipine (INN)	
293339	105979-17-7	benidipine (INN)	
293339	2062-84-2	benperidol (INN)	
293339	2156-27-6	benproperine (INN)	
293339	24671-26-9	benrixate (INN)	
293339	3691-78-9	benzethidine (INN)	
293339	119391-55-8	benzetimide (INN)	
293339	16571-59-8	benzindopyrine (INN)	
293339	16852-81-6	benzoclidine (INN)	
293339	53-89-4	benzpiperylone (INN)	
293339	587-46-2	benzpyrinium bromide (INN)	
293339	126825-36-3	bertosamil (INN)	
293339	5638-76-6	betahistine (INN)	
293339	468-50-8	betameprodine (INN)	
293339	468-59-7	betaprodine (INN)	
293339	5205-82-3	bevonium metilsulfate (INN)	
293339	15301-48-1	bezitramide (INN)	
293339	71195-57-8	bicifadine (INN)	
293339	116078-65-0	bidisomide (INN)	
293339	479-81-2	bietamiverine (INN)	
293339	69047-39-8	binifibrate (INN)	



HS 6	CAS #	Description	Alternative Classification
293339	514-65-8	bipenden (INN)	
293339	603-50-9	bisacodyl (INN)	
293339	89194-77-4	bisaramil (INN)	
293339	13456-08-1	bitipazone (INN)	
293339	71990-00-6	bremazocine (INN)	
293339	101345-71-5	brifentanil (INN)	
293339	71195-56-7	brocicpride (INN)	
293339	1812-30-2	bromazepam (INN)	
293339	10457-90-6	bromperidol (INN)	
293339	86-22-6	brompheniramine (INN)	
293339	33144-79-5	broperamole (INN)	
293339	57982-78-2	budipine (INN)	
293339	22632-06-0	bupicomide (INN)	
293339	2180-92-9	bupivacaine (INN)	
293339	55285-35-3	butanixin (INN)	
293339	55837-14-4	butaverine (INN)	
293339	93821-75-1	butinazocine (INN)	
293339	55837-15-5	butopiprine (INN)	
293339	15302-05-3	butoxylate (INN)	
293339	79449-98-2	cabastine (INN)	
293339	4876-45-3	camphotamide (INN)	
293339	70724-25-3	carbazeran (INN)	
293339	486-16-8	carbinoxamine (INN)	
293339	90729-42-3	carebastine (INN)	
293339	59708-52-0	carfentanil (INN)	
293339	98323-83-2	carboxirole (INN)	
293339	7528-13-4	carperidine (INN)	
293339	20977-50-8	carperone (INN)	
293339	5942-95-0	carpipramine (INN)	
293339	107266-08-0	carvotroline (INN)	
293339	123-03-5	cetylpyridinium chloride (INN)	
293339	59-32-5	chloropyramine (INN)	
293339	132-22-9	chlorphenamine (INN)	
293339	75985-31-8	ciamexon (INN)	
293339	53449-58-4	ciclonicate (INN)	
293339	85166-20-7	ciclotropium bromide (INN)	
293339	132203-70-4	cilnidipine (INN)	
293339	66564-14-5	cinitapride (INN)	
293339	14796-24-8	cinperene (INN)	

HS 6	CAS #	Description	Alternative Classification
293339	81098-60-4	cisapride (INN)	
293339	55905-53-8	clebopride (INN)	
293339	15302-10-0	clibucaïne (INN)	
293339	3485-62-9	clidinium bromide (INN)	
293339	47739-98-0	clocapramine (INN)	
293339	10457-91-7	clofluperol (INN)	
293339	21829-22-1	clonixeril (INN)	
293339	17737-65-4	clonixin (INN)	
293339	3703-76-2	cloperastine (INN)	
293339	2971-90-6	clopidol (INN)	
293339	53179-12-7	clopimozide (INN)	
293339	61764-61-2	cloroperone (INN)	
293339	57653-29-9	cogazocine (INN)	
293339	7007-96-7	crotoniazide (INN)	
293339	3572-80-3	cyclazocine (INN)	
293339	47128-12-1	cycliramine (INN)	
293339	139-62-8	cyclomethycaïne (INN)	
293339	77-39-4	cycrimine (INN)	
293339	129-03-3	cyproheptadine (INN)	
293339	4904-00-1	cyprolidol (INN)	
293339	27115-86-2	dacuronium bromide (INN)	
293339	31232-26-5	danitracen (INN)	
293339	47029-84-5	dazadrol (INN)	
293339	63388-37-4	declenperone (INN)	
293339	30652-11-0	deferiprone (INN)	
293339	99518-29-3	derpanicate (INN)	
293339	132-21-8	dexbrompheniramine (INN)	
293339	25523-97-1	dexchlorpheniramine (INN)	
293339	21888-98-2	dexetimide (INN)	
293339	24358-84-7	dexivacaine (INN)	
293339	120054-86-6	dexniguldipine (INN)	
293339	27112-37-4	diamocaine (INN)	
293339	17737-68-7	diclonixin (INN)	
293339	382-82-1	dicolinium iodide (INN)	
293339	13862-07-2	difemetorex (INN)	
293339	972-02-1	difenidol (INN)	
293339	47806-92-8	difenoximide (INN)	
293339	28782-42-5	difenoxin (INN)	
293339	561-77-3	dihexyverine (INN)	

HS 6	CAS #	Description	Alternative Classification
293339	37398-31-5	dilmefone (INN)	
293339	3425-97-6	dimecolonium iodide (INN)	
293339	5636-83-9	dimetindene (INN)	
293339	300-37-8	diodone (INN)	
293339	101-08-6	diperodon (INN)	
293339	62-97-5	diphepanil metilsulfate (INN)	
293339	915-30-0	diphenoxylate (INN)	
293339	147-20-6	diphenylpyraline (INN)	
293339	467-83-4	dipipanone (INN)	
293339	117-30-6	dipiproverine (INN)	
293339	3696-28-4	dipyrrithione (INN)	
293339	68284-69-5	disobutamide (INN)	
293339	3737-09-5	disopyramide (INN)	
293339	15876-67-2	distigmine bromide (INN)	
293339	99499-40-8	disuprazole (INN)	
293339	103336-05-6	ditekiren (INN)	
293339	74517-42-3	ditercalinium chloride (INN)	
293339	115956-12-2	dolasetron (INN)	
293339	57808-66-9	domperidone (INN)	
293339	21228-13-7	dorastine (INN)	
293339	469-21-6	doxylamine (INN)	
293339	29125-56-2	droclidinium bromide (INN)	
293339	34703-49-6	dropempine (INN)	
293339	548-73-2	droperidol (INN)	
293339	78421-12-2	droxicainide (INN)	
293339	15599-26-5	droxypropine (INN)	
293339	586-60-7	dyclonine (INN)	
293339	90729-43-4	ebastine (INN)	
293339	119431-25-3	eliprodil (INN)	
293339	80879-63-6	emiglitate (INN)	
293339	37612-13-8	encainide (INN)	
293339	93181-85-2	endixaprine (INN)	
293339	67765-04-2	enefexine (INN)	
293339	60662-18-2	eniclobrate (INN)	
293339	66364-73-6	erpiroline (INN)	
293339	64840-90-0	epensone (INN)	
293339	132829-83-5	espatropate (INN)	
293339	4140-20-9	estrapronicate (INN)	
293339	536-33-4	ethionamide (INN)	

HS 6	CAS #	Description	Alternative Classification
293339	31637-97-5	etofibrate (INN)	
293339	469-82-9	etoxeridine (INN)	
293339	100-91-4	eucatropine (INN)	
293339	86189-69-7	felodipine (INN)	
293339	59859-58-4	femoxetine (INN)	
293339	30817-43-7	fenclexonium metilsulfate (INN)	
293339	69365-65-7	fenoctimine (INN)	
293339	55837-26-8	fenperate (INN)	
293339	77-01-0	fenpipramide (INN)	
293339	3540-95-2	fenpiprane (INN)	
293339	125-60-0	fenpiverinium bromide (INN)	
293339	437-38-7	fentanyl (INN)	
293339	553-69-5	fenyramidol (INN)	
293339	53415-46-6	fepitrizol (INN)	
293339	138708-32-4	ferpifosate sodium (INN)	
293339	54063-45-5	fetoxilate (INN)	
293339	21221-18-1	flazalone (INN)	
293339	54143-55-4	flecainide (INN)	
293339	86811-58-7	fluazuron (INN)	
293339	75444-64-3	flumendone (INN)	
293339	38677-85-9	flunixin (INN)	
293339	53179-10-5	fluperamide (INN)	
293339	56995-20-1	flupirtine (INN)	
293339	21686-10-2	flupranone (INN)	
293339	54965-22-9	fluspiperone (INN)	
293339	5598-52-7	fospirate (INN)	
293339	149-17-7	flivazide (INN)	
293339	1539-39-5	gapicomine (INN)	
293339	106686-40-2	gapromidine (INN)	
293339	54063-47-7	gemazocine (INN)	
293339	107266-06-8	gevotroline (INN)	
293339	132553-86-7	glemansern (INN)	
293339	109889-09-0	granisetron (INN)	
293339	852-42-6	guaiapate (INN)	
293339	1463-28-1	guanacine (INN)	
293339	59831-65-1	halopemide (INN)	
293339	52-86-8	haloperidol (INN)	
293339	7237-81-2	hepronicate (INN)	
293339	1096-72-6	hepzidine (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
293339	3626-67-3	hexadiline (INN)	
293339	468-56-4	hydroxypethidine (INN)	
293339	7008-17-5	hydroxypyridine tartrate (INN)	
293339	100927-13-7	idaverine (INN)	
293339	23210-56-2	ifenprodil (INN)	
293339	66208-11-5	ifoxetine (INN)	
293339	63758-79-2	indalpine (INN)	
293339	3569-26-4	indopine (INN)	
293339	26844-12-2	indoramin (INN)	
293339	6556-11-2	inositol nicotinate (INN)	
293339	5579-92-0	iopydol (INN)	
293339	5579-93-1	iopydone (INN)	
293339	22150-28-3	ipragratine (INN)	
293339	54-92-2	iproniazid (INN)	
293339	89667-40-3	isbogrel (INN)	
293339	54-85-3	isoniazid (INN)	
293339	57021-61-1	isonixin (INN)	
293339	36292-69-0	ketazocine (INN)	
293339	469-79-4	ketobemidone (INN)	
293339	103890-78-4	lacidipine (INN)	
293339	73278-54-3	lamtidine (INN)	
293339	103577-45-3	lansoprazole (INN)	
293339	6272-74-8	lapirium chloride (INN)	
293339	76956-02-0	lavoltidine (INN)	
293339	103878-84-8	lazabemide (INN)	
293339	125729-29-5	lemildipine (INN)	
293339	24678-13-5	lenperone (INN)	
293339	5005-72-1	leptacline (INN)	
293339	100427-26-7	lercanidipine (INN)	
293339	79516-68-0	levocabastine (INN)	
293339	634-08-2	levofacetoperane (INN)	
293339	22204-91-7	lifibrate (INN)	
293339	88678-31-3	liranaftate (INN)	
293339	86811-09-8	litoxetine (INN)	
293339	93181-81-8	lodaxaprine (INN)	
293339	61380-40-3	lofentanil (INN)	
293339	53179-11-6	loperamide (INN)	
293339	106900-12-3	loperamide oxide (INN)	
293339	79794-75-5	loratadine (INN)	

HS 6	CAS #	Description	Alternative Classification
293339	59729-31-6	lorcainide (INN)	
293339	128075-79-6	lufironil (INN)	
293339	14745-50-7	meletimide (INN)	
293339	3575-80-2	melperone (INN)	
293339	76-90-4	mepenzolate bromide (INN)	
293339	6968-72-5	mepiroxol (INN)	
293339	22801-44-1	mepivacaine (INN)	
293339	91-84-9	mepyramine (INN)	
293339	62658-88-2	mesudipine (INN)	
293339	4394-04-1	metanixin (INN)	
293339	1707-15-9	metazide (INN)	
293339	3734-52-9	metazocine (INN)	
293339	13447-95-5	methaniazide (INN)	
293339	113-45-1	methylphenidate (INN)	
293339	29342-02-7	metipirox (INN)	
293339	54-36-4	metryrapone (INN)	
293339	114-91-0	metryndine (INN)	
293339	89613-77-4	mezacopride (INN)	
293339	39537-99-0	micinicate (INN)	
293339	66529-17-7	midaglizole (INN)	
293339	72432-03-2	miglitol (INN)	
293339	59831-64-0	milenperone (INN)	
293339	78415-72-2	milnnone (INN)	
293339	75437-14-8	milverine (INN)	
293339	70260-53-6	mindodiol (INN)	
293339	52157-83-2	mindoperone (INN)	
293339	2748-88-1	minipirium chloride (INN)	
293339	2856-74-8	modaline (INN)	
293339	81329-71-7	modECAINIDE (INN)	
293339	122957-06-6	modipafant (INN)	
293339	1050-79-9	moperone (INN)	
293339	89419-40-9	mosapramine (INN)	
293339	58239-89-7	moxazocine (INN)	
293339	4575-34-2	myfadol (INN)	
293339	124858-35-1	nadifloxacin (INN)	
293339	504-03-0	nanofin (INN)	
293339	22443-11-4	nepinalone (INN)	
293339	51-12-7	nialamide (INN)	
293339	3099-52-3	nicametate (INN)	

HS 6	CAS #	Description	Alternative Classification
293339	79455-30-4	nicaraven (INN)	
293339	55985-32-5	nicardipine (INN)	
293339	5868-05-3	niceritrol (INN)	
293339	13912-80-6	nicoboxil (INN)	
293339	10571-59-2	nicoclonate (INN)	
293339	31980-29-7	nicofibrate (INN)	
293339	80614-21-7	nicogrelate (INN)	
293339	27959-26-8	nicomol (INN)	
293339	65141-46-0	nicorandil (INN)	
293339	555-90-8	nicothiazone (INN)	
293339	5657-61-4	nicoxamat (INN)	
293339	36504-64-0	nictindole (INN)	
293339	21829-25-4	nifedipine (INN)	
293339	4394-00-7	niflumic acid (INN)	
293339	113165-32-5	niguldipine (INN)	
293339	59-26-7	nikethamide (INN)	
293339	22609-73-0	niludipine (INN)	
293339	75530-68-6	nilvadipine (INN)	
293339	66085-59-4	nimodipine (INN)	
293339	16426-83-8	niometacin (INN)	
293339	15387-10-7	niprofazone (INN)	
293339	63675-72-9	nisoldipine (INN)	
293339	39562-70-4	nitrendipine (INN)	
293339	4394-05-2	nixylic acid (INN)	
293339	60324-59-6	nomelidine (INN)	
293339	561-48-8	norpipanone (INN)	
293339	96487-37-5	nuvenzepine (INN)	
293339	114-90-9	obidoxime chloride (INN)	
293339	101343-69-5	ocfentanil (INN)	
293339	71138-71-1	octapinol (INN)	
293339	71251-02-0	octenidine (INN)	
293339	87784-12-1	ofornine (INN)	
293339	73590-58-6	omeprazole (INN)	
293339	2779-55-7	opiniazide (INN)	
293339	100158-38-1	otenzepad (INN)	
293339	2398-81-4	oximiacic acid (INN)	
293339	5322-53-2	oxiperomide (INN)	
293339	13958-40-2	oxiramide (INN)	
293339	27302-90-5	oxisuran (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
293339	546-32-7	oxpheneridine (INN)	
293339	4354-45-4	oxycipine (INN)	
293339	96515-73-0	palonidipine (INN)	
293339	121650-80-4	pancopride (INN)	
293339	15500-66-0	pancuronium bromide (INN)	
293339	13752-33-5	panidazole (INN)	
293339	96922-80-4	pantenate (INN)	
293339	102625-70-7	pantoprazole (INN)	
293339	80349-58-2	panuramine (INN)	
293339	5634-41-3	parapenzolate bromide (INN)	
293339	7162-37-0	paridocaine (INN)	
293339	2066-89-9	pasiniazid (INN)	
293339	50432-78-5	pemerid (INN)	
293339	79-55-0	pempidine (INN)	
293339	26864-56-2	penflundol (INN)	
293339	7009-54-3	pentapiperide (INN)	
293339	7681-80-3	pentapiperium metilsulfate (INN)	
293339	359-83-1	pentazocine (INN)	
293339	96513-83-6	pentisomide (INN)	
293339	4960-10-5	perastine (INN)	
293339	92268-40-1	performedil (INN)	
293339	6621-47-2	perhexiline (INN)	
293339	57-42-1	pethidine (INN)	
293339	129-83-9	phenampromide (INN)	
293339	127-35-5	phenazocine (INN)	
293339	94-78-0	phenazopyrdine (INN)	
293339	77-10-1	phencyclidine (INN)	
293339	469-80-7	phenendine (INN)	
293339	86-21-5	pheniramine (INN)	
293339	562-26-5	phenoperdine (INN)	
293339	82227-39-2	pibaxizine (INN)	
293339	57548-79-5	picalifibrate (INN)	
293339	79201-85-7	picenadol (INN)	
293339	51832-87-2	picobenzide (INN)	
293339	17692-43-2	picodralazine (INN)	
293339	3731-52-0	picolamine (INN)	
293339	586-98-1	piconol (INN)	
293339	21755-66-8	picoperne (INN)	
293339	78090-11-6	picoprazole (INN)	



HS 6	CAS #	Description	Alternative Classification
293339	64063-57-6	picotrin (INN)	
293339	130641-36-0	picumeterol (INN)	
293339	15686-87-0	pifenate (INN)	
293339	31224-92-7	pifoxime (INN)	
293339	60576-13-8	piketoprofen (INN)	
293339	534-84-9	pimeclone (INN)	
293339	79992-71-5	pimetacin (INN)	
293339	3565-03-5	pimetine (INN)	
293339	578-89-2	pimetremide (INN)	
293339	13495-09-5	piminodine (INN)	
293339	70132-50-2	pimonidazole (INN)	
293339	2062-78-4	pimozide (INN)	
293339	60560-33-0	pinacidil (INN)	
293339	28240-18-8	pinolcaine (INN)	
293339	1893-33-0	pipamperone (INN)	
293339	125-51-9	pipenzolate bromide (INN)	
293339	82-98-4	piperidolate (INN)	
293339	136-82-3	piperocaine (INN)	
293339	2531-04-6	piperylone (INN)	
293339	4546-39-8	pipethanate (INN)	
293339	18841-58-2	pipoctanone (INN)	
293339	55837-21-3	pipoxizine (INN)	
293339	68797-29-5	pipradimadol (INN)	
293339	467-60-7	pipradrol (INN)	
293339	55313-67-2	pipramadol (INN)	
293339	3562-55-8	piprocuranium iodide (INN)	
293339	38677-81-5	pirbuterol (INN)	
293339	35620-67-8	pirdonium bromide (INN)	
293339	87-21-8	pindocaine (INN)	
293339	24340-35-0	pindoxilate (INN)	
293339	75755-07-6	pidronic acid (INN)	
293339	55285-45-5	pirifibrate (INN)	
293339	55432-15-0	pirinidazole (INN)	
293339	33605-94-6	pirisudanol (INN)	
293339	302-41-0	pirtramide (INN)	
293339	68252-19-7	pirmenol (INN)	
293339	124436-59-5	pirodavir (INN)	
293339	84490-12-0	piroximone (INN)	
293339	54110-25-7	pirozadil (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
293339	103923-27-9	pirtenidine (INN)	
293339	54063-52-4	pitofenone (INN)	
293339	39123-11-0	pituxate (INN)	
293339	94-63-3	pralidoxime iodide (INN)	
293339	99522-79-9	pranidipine (INN)	
293339	85966-89-8	preclamol (INN)	
293339	55837-22-4	pribecaine (INN)	
293339	95374-52-0	prideperone (INN)	
293339	511-45-5	pridinol (INN)	
293339	1219-35-8	primaperone (INN)	
293339	78997-40-7	prisotinol (INN)	
293339	31314-38-2	prodipine (INN)	
293339	561-76-2	properidine (INN)	
293339	3811-53-8	propinetidine (INN)	
293339	3670-68-6	propipocaine (INN)	
293339	15686-91-6	propiram (INN)	
293339	60569-19-9	propiverine (INN)	
293339	587-61-1	propyliodone (INN)	
293339	3781-28-0	propyperone (INN)	
293339	14222-60-7	protionamide (INN)	
293339	1882-26-4	pyncarbate (INN)	
293339	101-26-8	pyndostigmine bromide (INN)	
293339	1740-22-3	pyrinoline (INN)	
293339	13463-41-7	pyrithione zinc (INN)	
293339	1098-97-1	pyritinol (INN)	
293339	15301-88-9	pytamine (INN)	
293339	71276-43-2	quadazocine (INN)	
293339	10447-39-9	quifenadine (INN)	
293339	64755-06-2	quinuclium bromide (INN)	
293339	31721-17-2	quinupramine (INN)	
293339	117976-89-3	rabeprazole (INN)	
293339	132875-61-7	remifentanil (INN)	
293339	112727-80-7	renzapride (INN)	
293339	135062-02-1	repaglinide (INN)	
293339	110140-89-1	ridogrel (INN)	
293339	104153-37-9	riopirox (INN)	
293339	32953-89-2	rimiterol (INN)	
293339	71653-63-9	rodipine (INN)	
293339	105462-24-6	risedronic acid (INN)	

HS 6	CAS #	Description	Alternative Classification
293339	96449-05-7	rispenzepine (INN)	
293339	78092-65-6	ristianol (INN)	
293339	121840-95-7	rogletimide (INN)	
293339	42597-57-9	ronifibrate (INN)	
293339	56079-81-3	ropitoin (INN)	
293339	84057-95-4	ropivacaine (INN)	
293339	5560-77-0	rotoxamine (INN)	
293339	78273-80-0	roxatidine (INN)	
293339	112192-04-8	roxindole (INN)	
293339	2804-00-4	roxoperone (INN)	
293339	134377-69-8	safronil (INN)	
293339	495-84-1	salinazid (INN)	
293339	143257-97-0	sameridine (INN)	
293339	115911-28-9	sampirtine (INN)	
293339	110347-85-8	selfotel (INN)	
293339	57734-69-7	sequifenadine (INN)	
293339	106516-24-9	sertindole (INN)	
293339	122955-18-4	sibopirdine (INN)	
293339	36175-05-0	sodium picofosfate (INN)	
293339	10040-45-6	sodium picosulfate (INN)	
293339	6184-06-1	sorbinate (INN)	
293339	749-02-0	spiperone (INN)	
293339	510-74-7	spiramide (INN)	
293339	144-45-6	spirgetine (INN)	
293339	357-66-4	spirilene (INN)	
293339	3784-99-4	stilbazium iodide (INN)	
293339	80343-63-1	sufotidine (INN)	
293339	47662-15-7	suxemerid (INN)	
293339	59429-50-4	tamitinol (INN)	
293339	90961-53-8	tedisamil (INN)	
293339	77342-26-8	tefenperate (INN)	
293339	108687-08-7	teludipine (INN)	
293339	72808-81-2	tepirindole (INN)	
293339	50679-08-8	terfenadine (INN)	
293339	37087-94-8	tibric acid (INN)	
293339	31932-09-9	ticarbodine (INN)	
293339	57648-21-2	timiperone (INN)	
293339	57237-97-5	timoprazole (INN)	
293339	77502-27-3	tolpadol (INN)	

HS 6	CAS #	Description	Alternative Classification
293339	728-88-1	tolperisone (INN)	
293339	97-57-4	tolpronine (INN)	
293339	71461-18-2	tonazocine (INN)	
293339	88296-62-2	transcainide (INN)	
293339	86365-92-6	trazolopride (INN)	
293339	120656-74-8	trefentanil (INN)	
293339	13422-16-7	triflocin (INN)	
293339	749-13-3	trifluoperidol (INN)	
293339	144-11-6	trihexyphenidyl (INN)	
293339	56-97-3	trimedoxime bromide (INN)	
293339	64-39-1	trimeperidine (INN)	
293339	5789-72-0	trimetamide (INN)	
293339	7009-82-7	trimethidinium methosulfate (INN)	
293339	91-81-6	tripelennamine (INN)	
293339	486-12-4	triprolidine (INN)	
293339	1508-75-4	tropicamide (INN)	
293339	30751-05-4	troxipide (INN)	
293339	35515-77-6	truxipicuriurium iodide (INN)	
293339	73590-85-9	ufiprazole (INN)	
293339	72005-58-4	vadocaine (INN)	
293339	132373-81-0	vamicamide (INN)	
293339	85505-64-2	vapiprost (INN)	
293339	50700-72-6	vecuronium bromide (INN)	
293339	93-47-0	verazide (INN)	
293339	15686-68-7	volazocine (INN)	
293339	83059-56-7	zabicipril (INN)	
293339	90103-92-7	zabiciprilat (INN)	
293339	90182-92-6	zacopride (INN)	
293339	56775-88-3	zimeldine (INN)	
293339	56383-05-2	zindotrine (INN)	
293340	90402-40-7	abanoquil (INN)	
293340	42465-20-3	acequinoline (INN)	
293340	15301-40-3	actinoquinol (INN)	
293340	10023-54-8	aminoquinol (INN)	
293340	3811-56-1	aminoquinuride (INN)	
293340	13425-92-8	amiquinsin (INN)	
293340	86-42-0	amodiaquine (INN)	
293340	550-81-2	amopyroquine (INN)	
293340	17230-85-2	amquinatate (INN)	

HS 6	CAS #	Description	Alternative Classification
293340	64228-81-5	atracurium besilate (INN)	
293340	86-75-9	benzoxiquine (INN)	
293340	108437-28-1	bifloxacin (INN)	
293340	22407-74-5	bisobrin (INN)	
293340	96187-53-0	brequinar (INN)	
293340	15599-52-7	broquinaldol (INN)	
293340	3684-46-6	broxaldine (INN)	
293340	521-74-4	broxyquinoline (INN)	
293340	5486-03-3	buquinolate (INN)	
293340	42408-82-2	butorphanol (INN)	
293340	15686-38-1	carbazocine (INN)	
293340	141725-88-4	cefefloxacin (INN)	
293340	54-05-7	chloroquine (INN)	
293340	72-80-0	chlorquinaldol (INN)	
293340	54063-29-5	cicarperone (INN)	
293340	85-79-0	cinchocaine (INN)	
293340	132-60-5	cinchophen (INN)	
293340	59889-36-0	ciprefadol (INN)	
293340	19485-08-6	ciproquinatate (INN)	
293340	2545-39-3	clamoxyquine (INN)	
293340	4298-15-1	cletoquine (INN)	
293340	55150-67-9	climiqualine (INN)	
293340	105956-97-6	clinafloxacin (INN)	
293340	130-26-7	clioquinol (INN)	
293340	54340-63-5	clofeverine (INN)	
293340	7270-12-4	cloquinatate (INN)	
293340	130-16-5	cloxiquine (INN)	
293340	13007-93-7	cuproxoline (INN)	
293340	1131-64-2	debnsoquine (INN)	
293340	18507-89-6	decoquinatate (INN)	
293340	522-51-0	dequalinium chloride (INN)	
293340	125-71-3	dextromethorphan (INN)	
293340	125-73-5	dextrorphan (INN)	
293340	67165-56-4	diclofensine (INN)	
293340	83-73-8	diiodohydroxyquinoline (INN)	
293340	147-27-3	dimoxyline (INN)	
293340	77086-21-6	dizocipine (INN)	
293340	106819-53-8	doxacurium chloride (INN)	
293340	14009-24-6	drotaverine (INN)	

HS 6	CAS #	Description	Alternative Classification
293340	3176-03-2	drotebanol (INN)	
293340	37517-33-2	esproquine (INN)	
293340	486-47-5	ethaverine (INN)	
293340	18429-78-2	famotine (INN)	
293340	23779-99-9	floctafenine (INN)	
293340	83863-79-0	florifenine (INN)	
293340	76568-02-0	flosequinan (INN)	
293340	3820-67-5	glafenine (INN)	
293340	154-73-4	guanisoquine (INN)	
293340	4310-89-8	hedaquinium chloride (INN)	
293340	118-42-3	hydroxychloroquine (INN)	
293340	55299-11-1	iquindamine (INN)	
293340	91524-15-1	irifloxacin (INN)	
293340	56717-18-1	isotiquimide (INN)	
293340	90828-99-2	itrocainide (INN)	
293340	72714-75-1	ivoqualine (INN)	
293340	79798-39-3	ketorfanol (INN)	
293340	3253-60-9	laudexium metilsulfate (INN)	
293340	146-37-2	laurolinium acetate (INN)	
293340	10351-50-5	leniquinsin (INN)	
293340	152-02-3	levallorphan (INN)	
293340	125-70-2	levomethorphan (INN)	
293340	10061-32-2	levophenacymorphan (INN)	
293340	77-07-6	levorphanol (INN)	
293340	23910-07-8	mebiquine (INN)	
293340	53230-10-7	mefloquine (INN)	
293340	18429-69-1	memotine (INN)	
293340	110013-21-3	merafloxacin (INN)	
293340	2154-02-1	metofoline (INN)	
293340	106861-44-3	mivacurium chloride (INN)	
293340	103775-10-6	moexipril (INN)	
293340	103775-14-0	moexipriat (INN)	
293340	10539-19-2	moxaverne (INN)	
293340	485-34-7	neocinchophen (INN)	
293340	13997-19-8	nequinat (INN)	
293340	64039-88-9	nicafenine (INN)	
293340	76252-06-7	nicainoprol (INN)	
293340	2545-24-6	nicevenne (INN)	
293340	4008-48-4	nitroxoline (INN)	

HS 6	CAS #	Description	Alternative Classification
293340	24526-64-5	nomifensine (INN)	
293340	1531-12-0	norlevorphanol (INN)	
293340	549-68-8	octaverine (INN)	
293340	21738-42-1	oxamniquine (INN)	
293340	485-89-2	oxycinchophen (INN)	
293340	635-05-2	pamaquine (INN)	
293340	574-77-6	papaveroline (INN)	
293340	86-78-2	pentaquine (INN)	
293340	468-07-5	phenomorphan (INN)	
293340	77472-98-1	pipequaline (INN)	
293340	90-34-6	primaquine (INN)	
293340	1698-95-9	proquinolate (INN)	
293340	548-84-5	pyrvinium chloride (INN)	
293340	86024-64-8	quinacainol (INN)	
293340	2768-90-3	quinaldine blue (INN)	
293340	85441-61-8	quinapril (INN)	
293340	85441-60-7	quinaprilat (INN)	
293340	19056-26-9	quindecamine (INN)	
293340	5714-76-1	quinetalate (INN)	
293340	86-80-6	quinisocaine (INN)	
293340	525-61-1	quinocide (INN)	
293340	13757-97-6	quinprenaline (INN)	
293340	1776-83-6	quintiofos (ISO) (INN)	
293340	510-53-2	racemethorphan (INN)	
293340	297-90-5	racemorphan (INN)	
293340	40034-42-2	rosoxacin (INN)	
293340	127779-20-8	saquinavir (INN)	
293340	61563-18-6	soquinolol (INN)	
293340	74129-03-6	tebuquine (INN)	
293340	113079-82-6	terbequinil (INN)	
293340	7175-09-9	tilbroquinol (INN)	
293340	5541-67-3	tiliquinol (INN)	
293340	53400-67-2	tiquinamide (INN)	
293340	40692-37-3	tisoquone (INN)	
293340	1748-43-2	trethinium tosilate (INN)	
293340	30418-38-3	tretoquinol (INN)	
293340	79201-80-2	veradoline (INN)	
293340	120443-16-5	vertukast (INN)	
293340	72714-74-0	viquatine (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
293351	52-43-7	allobarbital (INN)	
293351	57-43-2	amobarbital (INN)	
293351	77-02-1	aprobarbital (INN)	
293351	4388-82-3	barbexaclone (INN)	
293351	57-44-3	barbital (INN)	
293351	144-02-5	barbital sodium (INN)	
293351	744-80-9	benzobarbital (INN)	
293351	561-86-4	brallobarbital (INN)	
293351	841-73-6	bucolome (INN)	
293351	77-26-9	butalbital (INN)	
293351	960-05-4	carbubarb (INN)	
293351	52-31-3	cyclobarbital (INN)	
293351	15687-09-9	difebarbamate (INN)	
293351	27511-99-5	eterobarb (INN)	
293351	509-86-4	heptabarb (INN)	
293351	56-29-1	hexobarbital (INN)	
293351	50-11-3	metharbital (INN)	
293351	467-43-6	methitural (INN)	
293351	151-83-7	methohexital (INN)	
293351	115-38-8	methyphenobarbital (INN)	
293351	561-83-1	nealbarbital (INN)	
293351	76-74-4	pentobarbital (INN)	
293351	50-06-6	phenobarbital (INN)	
293351	57-30-7	phenobarbital sodium (INN)	
293351	357-67-5	phetharbital (INN)	
293351	2409-26-9	prazitone (INN)	
293351	143-82-8	probarbital sodium (INN)	
293351	2537-29-3	proxibarbal (INN)	
293351	125-40-6	secbutabarbital (INN)	
293351	76-73-3	secobarbital (INN)	
293351	115-44-6	talbutal (INN)	
293351	76-23-3	tetrabarbital (INN)	
293351	467-36-7	thialbarbital (INN)	
293351	71-73-8	thiopental sodium (INN)	
293351	467-38-9	thiotetrabarbital (INN)	
293351	125-42-8	vinbarbital (INN)	
293351	2430-49-1	vinylbital (INN)	
293359	55485-20-6	acaprazine (INN)	
293359	299-89-8	acetiamine (INN)	



HS 6	CAS #	Description	Alternative Classification
293359	59277-89-3	aciclovir (INN)	
293359	101197-99-3	acitemate (INN)	
293359	96914-39-5	actisomide (INN)	
293359	56066-19-4	aditeren (INN)	
293359	56066-63-8	aditoprime (INN)	
293359	56287-74-2	afloqualone (INN)	
293359	315-30-0	allopurinol (INN)	
293359	27076-46-6	alpertine (INN)	
293359	76330-71-7	altanserin (INN)	
293359	86393-37-5	amifloxacin (INN)	
293359	642-44-4	aminometradine (INN)	
293359	58602-66-7	aminopterin sodium (INN)	
293359	550-28-7	amisometradine (INN)	
293359	36590-19-9	amocarzine (INN)	
293359	75558-90-6	amperozide (INN)	
293359	121-25-5	amprolium (INN)	
293359	5587-93-9	ampyrimine (INN)	
293359	68475-42-3	anagrelide (INN)	
293359	442-03-5	anisopiról (INN)	
293359	55300-29-3	antrafenine (INN)	
293359	71576-40-4	aptazapine (INN)	
293359	86627-15-8	aronixil (INN)	
293359	55779-18-5	arprinocid (INN)	
293359	136816-75-6	atevirdine (INN)	
293359	89303-63-9	atiprosin (INN)	
293359	2856-81-7	azabuperone (INN)	
293359	62973-76-6	azanidazole (INN)	
293359	1649-18-9	azaperone (INN)	
293359	448-34-0	azaprocín (INN)	
293359	5234-86-6	azaquinazole (INN)	
293359	446-86-6	azathioprine (INN)	
293359	102280-35-3	baquiloprim (INN)	
293359	95634-82-5	batelapine (INN)	
293359	52395-99-0	belanzine (INN)	
293359	92210-43-0	bemarinone (INN)	
293359	88133-11-3	bemitradine (INN)	
293359	59752-23-7	benderizine (INN)	
293359	22457-89-2	benfotiamine (INN)	
293359	299-88-7	bentiamine (INN)	

HS 6	CAS #	Description	Alternative Classification
293359	17692-23-8	bentipimine (INN)	
293359	108210-73-7	bifeprofen (INN)	
293359	86662-54-6	binizolast (INN)	
293359	2667-89-2	bisbentiamine (INN)	
293359	55837-17-7	brindoxime (INN)	
293359	56518-41-3	brodimoprim (INN)	
293359	56741-95-8	bropirimine (INN)	
293359	51481-62-0	bucainide (INN)	
293359	86304-28-1	buciclovir (INN)	
293359	82-95-1	buclizine (INN)	
293359	62052-97-5	bumepidil (INN)	
293359	80755-51-7	bunazosin (INN)	
293359	59184-78-0	buquineran (INN)	
293359	76536-74-8	buquiterine (INN)	
293359	36505-84-7	buspironone (INN)	
293359	87051-46-5	butanserine (INN)	
293359	68741-18-4	buterizine (INN)	
293359	510-90-7	buthalital sodium (INN)	
293359	80433-71-2	calcium levofolinate (INN)	
293359	61422-45-5	carhofur (INN)	
293359	125363-87-3	carsatrin (INN)	
293359	83881-51-0	cetirizine (INN)	
293359	522-18-9	chlorbenzoxamine (INN)	
293359	82-93-9	chlorcyclizine (INN)	
293359	53131-74-1	ciapilome (INN)	
293359	37751-39-6	ciclazindol (INN)	
293359	80109-27-9	ciladopa (INN)	
293359	54063-30-8	ciltoprazine (INN)	
293359	23887-41-4	cinepazet (INN)	
293359	54063-23-9	cinepazic acid (INN)	
293359	23887-46-9	cinepazide (INN)	
293359	298-57-7	cinnarizine (INN)	
293359	60763-49-7	cinnarizine clofibrate (INN)	
293359	51493-19-7	cinprazole (INN)	
293359	23887-47-0	cinpropazide (INN)	
293359	82117-51-9	cinuperone (INN)	
293359	85721-33-1	ciprofloxacin (INN)	
293359	33453-23-5	ciproquazone (INN)	
293359	298-55-5	clocinizine (INN)	

HS 6	CAS #	Description	Alternative Classification
293359	4052-13-5	clopidone (INN)	
293359	25509-07-3	cloroqualone (INN)	
293359	5786-21-0	clozapine (INN)	
293359	82-92-8	cyclizine (INN)	
293359	112398-08-0	danofoxacin (INN)	
293359	72822-12-9	dapiprazole (INN)	
293359	3733-63-9	decloxizine (INN)	
293359	117827-81-3	delfaprazine (INN)	
293359	84408-37-7	desciclovir (INN)	
293359	24584-09-6	dexrazoxane (INN)	
293359	5355-16-8	diavendine (INN)	
293359	333-41-5	diazinon (ISO) dimpylate (INN)	
293359	86641-76-1	dibrospidium chloride (INN)	
293359	90-89-1	diethylcarbamazine (INN)	
293359	98106-17-3	difloxacin (INN)	
293359	5522-39-4	difluanazine (INN)	
293359	7008-00-6	dimetholizine (INN)	
293359	36518-02-2	diproqualone (INN)	
293359	58-32-2	dipyridamole (INN)	
293359	90808-12-1	divaplon (INN)	
293359	64019-03-0	doqualast (INN)	
293359	120770-34-5	drafiazine (INN)	
293359	17692-31-8	dropropizine (INN)	
293359	80576-83-6	edatrexate (INN)	
293359	110629-41-9	elbanizine (INN)	
293359	95520-81-3	elziverine (INN)	
293359	110690-43-2	ernitefur (INN)	
293359	107361-33-1	enazadrem (INN)	
293359	68576-86-3	enciprazine (INN)	
293359	74011-58-8	enoxacin (INN)	
293359	31729-24-5	enpiprazole (INN)	
293359	93106-60-6	enrofloxacin (INN)	
293359	18694-40-1	epirizole (INN)	
293359	73090-70-7	epiropim (INN)	
293359	10402-90-1	eprazinone (INN)	
293359	32665-36-4	eprozinol (INN)	
293359	98123-83-2	epsiprantel (INN)	
293359	64204-55-3	esaprazole (INN)	
293359	7432-25-9	etaqualone (INN)	

HS 6	CAS #	Description	Alternative Classification
293359	17692-34-1	etodroxizine (INN)	
293359	52942-31-1	etoperidone (INN)	
293359	104227-87-4	famciclovir (INN)	
293359	13246-02-1	febarbamate (INN)	
293359	7077-33-0	febuverine (INN)	
293359	54063-38-6	fenaperone (INN)	
293359	54063-39-7	fenetradil (INN)	
293359	75184-94-0	fenpropriast (INN)	
293359	3607-24-7	fenynpol (INN)	
293359	79660-72-3	fleroxacin (INN)	
293359	82190-92-9	flotrenizine (INN)	
293359	1480-19-9	fluanisone (INN)	
293359	54340-64-6	fluciprazine (INN)	
293359	2022-85-7	flucytosine (INN)	
293359	52468-60-7	flunarizine (INN)	
293359	51-21-8	fluorouracil (INN)	
293359	67121-76-0	fluperlapine (INN)	
293359	76716-60-4	fluprazine (INN)	
293359	40507-23-1	fluproquazone (INN)	
293359	37554-40-8	fluquazone (INN)	
293359	86696-88-0	frabuprofen (INN)	
293359	82410-32-0	ganciclovir (INN)	
293359	83928-76-1	gepirone (INN)	
293359	119914-60-2	grepafloxacin (INN)	
293359	55837-20-2	halofuginone (INN)	
293359	141-94-6	hexetidine (INN)	
293359	115-63-9	hexocyclium metilsulfate (INN)	
293359	21560-59-8	hoquizil (INN)	
293359	68-88-2	hydroxyzine (INN)	
293359	108674-88-0	idenast (INN)	
293359	75689-93-9	imanixil (INN)	
293359	7008-18-6	iminophenimide (INN)	
293359	41340-39-0	impacarzine (INN)	
293359	5984-97-4	iodothiouracil (INN)	
293359	69017-89-6	ipexidine (INN)	
293359	55477-19-5	iprozilamine (INN)	
293359	96478-43-2	irindalone (INN)	
293359	4214-72-6	isaxonine (INN)	
293359	74050-98-9	ketanserin (INN)	

HS 6	CAS #	Description	Alternative Classification
293359	52196-22-2	ketotrexate (INN)	
293359	143257-98-1	lerisetron (INN)	
293359	132449-46-8	lesopitron (INN)	
293359	99291-25-5	levodropropizine (INN)	
293359	3416-26-0	lidoflazine (INN)	
293359	119514-66-8	lifarizine (INN)	
293359	94192-59-3	lixazinone (INN)	
293359	-00-0	lobuprofen (INN)	
293359	86627-50-1	lodinixil (INN)	
293359	98079-51-7	lomefloxacin (INN)	
293359	101477-55-8	lomerizine (INN)	
293359	106400-81-1	lometrexol (INN)	
293359	61197-73-7	loprazolam (INN)	
293359	104719-71-3	lorcinadol (INN)	
293359	108785-69-9	lorpiprazole (INN)	
293359	72141-57-2	losulazine (INN)	
293359	80428-29-1	mafoprazine (INN)	
293359	120092-68-4	manidipine (INN)	
293359	340-57-8	mecloqualone (INN)	
293359	569-65-3	meciozine (INN)	
293359	1243-33-0	mefeclozazine (INN)	
293359	87611-28-7	mequinast (INN)	
293359	20326-12-9	mepiprazole (INN)	
293359	50-44-2	mercaptapurine (INN)	
293359	72-44-6	methaqualone (INN)	
293359	59-05-2	methotrexate (INN)	
293359	56-04-2	methylthiouracil (INN)	
293359	68902-57-8	metioprím (INN)	
293359	81043-56-3	metrenperone (INN)	
293359	50335-55-2	mezilamine (INN)	
293359	24219-97-4	miansenn (INN)	
293359	24360-55-2	milipertine (INN)	
293359	38304-91-5	minoxidil (INN)	
293359	79467-23-5	mioflazine (INN)	
293359	61337-67-5	mirtazapine (INN)	
293359	108612-45-9	mizolastine (INN)	
293359	65329-79-5	mobenzoxamine (INN)	
293359	56693-13-1	mociprazine (INN)	
293359	13665-88-8	mopidamol (INN)	

<b>HS 6</b>	<b>CAS #</b>	<b>Description</b>	<b>Alternative Classification</b>
293359	23790-08-1	moxipraquine (INN)	
293359	75438-57-2	moxonidine (INN)	
293359	5061-22-3	nafiverine (INN)	
293359	57149-07-2	naftopidil (INN)	
293359	83366-66-9	nefazodone (INN)	
293359	109713-79-3	neldazosin (INN)	
293359	27367-90-4	niaprazine (INN)	
293359	60662-19-3	nilprazole (INN)	
293359	42471-28-3	nimustine (INN)	
293359	56739-21-0	nitraquazone (INN)	
293359	5626-36-8	nonapyrimine (INN)	
293359	70458-96-7	norfloxacin (INN)	
293359	100587-52-8	norfloxacin succinil (INN)	
293359	76600-30-1	nosantine (INN)	
293359	315-72-0	opipramol (INN)	
293359	60104-30-5	orazamide (INN)	
293359	113617-63-3	orbifloxacin (INN)	
293359	6981-18-6	ormetoprim (INN)	
293359	65-86-1	orotic acid (INN)	
293359	62305-86-6	orotirelin (INN)	
293359	36531-26-7	oxantel (INN)	
293359	60607-34-3	oxatomide (INN)	
293359	2465-59-0	oxipurinol (INN)	
293359	153-87-7	oxypertine (INN)	
293359	125-53-1	oxyphencyclimine (INN)	
293359	70458-92-3	pefloxacin (INN)	
293359	2208-51-7	pelanserin (INN)	
293359	94386-65-9	pelrinone (INN)	
293359	69372-19-6	pemirolast (INN)	
293359	39809-25-1	penciclovir (INN)	
293359	-00-0	peraclopone (INN)	
293359	67254-81-3	peradoxime (INN)	
293359	72444-62-3	perafensine (INN)	
293359	35265-50-0	peraquinsin (INN)	
293359	1977-11-3	perlapine (INN)	
293359	10001-13-5	pexantel (INN)	
293359	39640-15-8	piberaline (INN)	
293359	55837-13-3	piclopastine (INN)	
293359	5636-92-0	picloxydine (INN)	

HS 6	CAS #	Description	Alternative Classification
293359	27315-91-9	pipebuzone (INN)	
293359	68399-57-5	pipecuronium bromide (INN)	
293359	51940-44-4	pipemidic acid (INN)	
293359	299-48-9	piperamide (INN)	
293359	12002-30-1	piperazine calcium edetate (INN)	
293359	54-91-1	pipobroman (INN)	
293359	2608-24-4	piposulfan (INN)	
293359	15534-05-1	pipratecol (INN)	
293359	21560-58-7	piquizil (INN)	
293359	75444-65-4	pirenperone (INN)	
293359	28797-61-7	pirenzepine (INN)	
293359	69479-26-1	pirepolol (INN)	
293359	50892-23-4	pirinixic acid (INN)	
293359	65089-17-0	pirinixil (INN)	
293359	1897-89-8	piriqualone (INN)	
293359	72732-56-0	pirtrexim (INN)	
293359	60762-57-4	pirindole (INN)	
293359	55149-05-8	pirolate (INN)	
293359	39186-49-7	pirolazamide (INN)	
293359	19562-30-2	piromidic acid (INN)	
293359	65950-99-4	pirquinozol (INN)	
293359	55268-74-1	praziquantel (INN)	
293359	67227-55-8	primidolol (INN)	
293359	111786-07-3	prinoxodan (INN)	
293359	57132-53-3	proglumetacin (INN)	
293359	51-52-5	propylthiouracil (INN)	
293359	22760-18-5	proquazone (INN)	
293359	23476-83-7	prospidium chlonde (INN)	
293359	42061-52-9	pumitepa (INN)	
293359	58-14-0	pyrimethamine (INN)	
293359	5221-49-8	pyrimitate (INN)	
293359	14222-46-9	pyritidium bromide (INN)	
293359	70018-51-8	quazinone (INN)	
293359	4015-32-1	quazodine (INN)	
293359	15793-38-1	quinazosin (INN)	
293359	97466-90-5	quinelorane (INN)	
293359	77197-48-9	quinezamide (INN)	
293359	4774-24-7	quipazine (INN)	
293359	95635-55-5	ranolazine (INN)	

HS 6	CAS #	Description	Alternative Classification
293359	21416-87-5	razoxane (INN)	
293359	85673-87-6	revenast (INN)	
293359	133718-29-3	revizinone (INN)	
293359	8063-28-3	ribaminol (INN)	
293359	79781-95-6	rilapine (INN)	
293359	28610-84-6	rimazolium metilsulfate (INN)	
293359	75859-04-0	rimcazole (INN)	
293359	37750-83-7	rimoprogin (INN)	
293359	108436-80-2	rociclovir (INN)	
293359	76696-97-4	rofelodine (INN)	
293359	1866-43-9	rolodine (INN)	
293359	3601-19-2	ropizine (INN)	
293359	62989-33-7	sapropterin (INN)	
293359	98105-99-8	sarafloxacin (INN)	
293359	87729-89-3	seganserin (INN)	
293359	115313-22-9	serazapine (INN)	
293359	131635-06-8	sifaprazine (INN)	
293359	154-82-5	simetride (INN)	
293359	98631-95-9	sobuzoxane (INN)	
293359	110871-86-8	sparfloxacin (INN)	
293359	3286-46-2	sulbutiamine (INN)	
293359	85418-85-5	sunagrel (INN)	
293359	66093-35-4	talmetoprim (INN)	
293359	128229-52-7	tamolarizine (INN)	
293359	87760-53-0	tandospirone (INN)	
293359	88579-39-9	tasuldine (INN)	
293359	80680-06-4	tefludazine (INN)	
293359	108319-06-8	temafloxacin (INN)	
293359	86181-42-2	temelastine (INN)	
293359	56693-15-3	terciprazine (INN)	
293359	14728-33-7	teroxalene (INN)	
293359	53808-87-0	tetroxoprim (INN)	
293359	91-85-0	thonzylamine (INN)	
293359	78299-53-3	tiacriast (INN)	
293359	5581-52-2	tiamiprine (INN)	
293359	154-42-7	tioguanine (INN)	
293359	52618-67-4	tiopendone (INN)	
293359	110101-66-1	tirilazad (INN)	
293359	5334-23-6	tisopurine (INN)	



HS 6	CAS #	Description	Alternative Classification
293359	41964-07-2	tolimidone (INN)	
293359	70312-00-4	tolnapersine (INN)	
293359	20326-13-0	tolpiprazole (INN)	
293359	553-08-2	tonzonium bromide (INN)	
293359	54063-58-0	toprilidine (INN)	
293359	15421-84-8	trapidil (INN)	
293359	26070-23-5	trazitiline (INN)	
293359	19794-93-5	trazodone (INN)	
293359	123205-52-7	trelnanzine (INN)	
293359	82190-93-0	trenizine (INN)	
293359	79855-88-2	trequinsin (INN)	
293359	6503-95-3	triampyzine (INN)	
293359	396-01-0	triamterene (INN)	
293359	5714-82-9	triclofenol piperazine (INN)	
293359	35795-16-5	trimazosin (INN)	
293359	5011-34-7	trimetazidine (INN)	
293359	738-70-5	trimethoprim (INN)	
293359	52128-35-5	trimetrexate (INN)	
293359	107736-98-1	umespirone (INN)	
293359	66-75-1	uramustine (INN)	
293359	34661-75-1	urapidil (INN)	
293359	124832-26-4	valaciclovir (INN)	
293359	81523-49-1	vanepirim (INN)	
293359	67469-69-6	vanoxerine (INN)	
293359	79644-90-9	vebufloxacin (INN)	
293359	66172-75-6	verofylline (INN)	
293359	26242-33-1	vintiamol (INN)	
293359	114298-18-9	zalospirone (INN)	
293359	37762-06-4	zaprnast (INN)	
293359	112733-06-9	zenarestat (INN)	
293359	34758-83-3	zipeprol (INN)	
293359	78208-13-6	zolenzepine (INN)	
293359	4004-94-8	zolertine (INN)	
293359	43200-80-2	zopiclone (INN)	
293369	27469-53-0	almitrine (INN)	
293369	645-05-6	altretamine (INN)	
293369	537-17-7	amanozine (INN)	
293369	63119-27-7	anitrazafen (INN)	
293369	500-42-5	chlorazanyl (INN)	

HS 6	CAS #	Description	Alternative Classification
293369	101831-36-1	clazunil (INN)	
293369	3378-93-6	clociguanil (INN)	
293369	609-78-9	cycloguanil embonate (INN)	
293369	66215-27-8	cyromazine (INN)	
293369	101831-37-2	diclazunil (INN)	
293369	92257-40-4	dizatrifone (INN)	
293369	57381-26-7	irsogladine (INN)	
293369	84057-84-1	lamotrigine (INN)	
293369	103337-74-2	letrazunil (INN)	
293369	13957-36-3	meladrazine (INN)	
293369	128470-15-5	melarsomine (INN)	
293369	68289-14-5	metrazifone (INN)	
293369	5580-22-3	oxonazine (INN)	
293369	98410-36-7	palatrigine (INN)	
293369	15599-44-7	spirazine (INN)	
293369	108258-89-5	sulazunil (INN)	
293369	87-90-1	symclosene (INN)	
293369	35319-70-1	tiazunil (INN)	
293369	69004-03-1	toltrazunil (INN)	
293369	51-18-3	tretamine (INN)	
293369	2244-21-5	trociosene potassium (INN)	
293379	100510-33-6	adibendan (INN)	
293379	88124-26-9	adosopine (INN)	
293379	122852-42-0	alosetron (INN)	
293379	22136-26-1	amedalin (INN)	
293379	134-37-2	amphenidone (INN)	
293379	60719-84-8	amrinone (INN)	
293379	72432-10-1	aniracetam (INN)	
293379	86541-75-5	benazepril (INN)	
293379	86541-78-8	benazeprilat (INN)	
293379	65008-93-7	bometolol (INN)	
293379	104051-20-9	brefonalol (INN)	
293379	51781-06-7	carteolol (INN)	
293379	113957-09-8	cebaracetam (INN)	
293379	29342-05-0	ciclopirox (INN)	
293379	109859-50-9	cilobradine (INN)	
293379	68550-75-4	cilostamide (INN)	
293379	73963-72-1	cilostazol (INN)	
293379	22316-47-8	ciobazam (INN)	

HS 6	CAS #	Description	Alternative Classification
293379	54063-34-2	cofisatin (INN)	
293379	120551-59-9	crivastatin (INN)	
293379	67199-66-0	daniquidone (INN)	
293379	84629-61-8	darenzepine (INN)	
293379	53086-13-8	dexindoprofen (INN)	
293379	41729-52-6	dezaguanine (INN)	
293379	126100-97-8	dimiracetam (INN)	
293379	84901-45-1	doliracetam (INN)	
293379	67793-71-9	draquinolol (INN)	
293379	59776-90-8	dupracetam (INN)	
293379	88124-27-0	etazepine (INN)	
293379	467-90-3	ethypicone (INN)	
293379	33996-58-6	etiracetam (INN)	
293379	21590-92-1	etomidoline (INN)	
293379	77862-92-1	falipamil (INN)	
293379	17692-37-4	fantridone (INN)	
293379	1980-49-0	felipyrine (INN)	
293379	98319-26-7	finasteride (INN)	
293379	2261-94-1	flucarbril (INN)	
293379	67542-41-0	imuracetam (INN)	
293379	63610-08-2	indobufen (INN)	
293379	100643-96-7	indolidan (INN)	
293379	31842-01-0	indoprofen (INN)	
293379	21766-53-0	iodidonic acid (INN)	
293379	59227-89-3	laurocapram (INN)	
293379	102767-28-2	levetiracetam (INN)	
293379	97878-35-8	libenzapril (INN)	
293379	73725-85-6	lidansenn (INN)	
293379	105431-72-9	linopirdine (INN)	
293379	128486-54-4	lurosetron (INN)	
293379	88296-61-1	medorinone (INN)	
293379	125-64-4	methyprylon (INN)	
293379	1910-68-5	metisazone (INN)	
293379	102791-47-9	nantennone (INN)	
293379	116041-13-5	nebracetam (INN)	
293379	77191-36-7	nefiracetam (INN)	
293379	128326-80-7	nicoracetam (INN)	
293379	50516-43-3	nofecainide (INN)	
293379	63958-90-7	nonathymulin (INN)	

HS 6	CAS #	Description	Alternative Classification
293379	21590-91-0	omidoline (INN)	
293379	62613-82-5	oxiracetam (INN)	
293379	125-13-3	oxyphenisatine (INN)	
293379	138506-45-3	pidobenzone (INN)	
293379	114485-92-6	pidolacetamol (INN)	
293379	98-79-3	pidolic acid (INN)	
293379	7491-74-9	piracetam (INN)	
293379	82209-39-0	piraxelate (INN)	
293379	53179-13-8	pirfenidone (INN)	
293379	50650-76-5	piroctone (INN)	
293379	108310-20-9	pirodomast (INN)	
293379	68497-62-1	pramiracetam (INN)	
293379	125-33-7	primidone (INN)	
293379	72332-33-3	procaterol (INN)	
293379	77-04-3	pyrithydione (INN)	
293379	101193-40-2	quinotolast (INN)	
293379	78466-98-5	razobazam (INN)	
293379	111911-87-6	rebamipide (INN)	
293379	2829-19-8	rolicyprine (INN)	
293379	61413-54-5	rolipram (INN)	
293379	18356-28-0	rolziracetam (INN)	
293379	91374-21-9	ropinirole (INN)	
293379	84088-42-6	roquinimex (INN)	
293379	102669-89-6	saternnone (INN)	
293379	81377-02-8	seglitide (INN)	
293379	103997-59-7	selprazine (INN)	
293379	54935-03-4	sulisatin (INN)	
293379	35115-60-7	teprotide (INN)	
293379	85136-71-6	tilisoiol (INN)	
293379	22365-40-8	triflubazam (INN)	
293379	137099-09-3	turosteride (INN)	
293379	26070-78-0	ubisindine (INN)	
293379	81840-15-5	vesnannone (INN)	
293379	85175-67-3	zatebradine (INN)	
293379	78466-70-3	zomebazam (INN)	
293390	111841-85-1	abecarnil (INN)	
293390	53164-05-9	acemetacin (INN)	
293390	3551-18-6	acetryptine (INN)	
293390	51037-30-0	acipimox (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	79152-85-5	acodazole (INN)	
293390	47487-22-9	acridorex (INN)	
293390	7527-91-5	acrisorcin (INN)	
293390	78459-19-5	adimoiol (INN)	
293390	37115-32-5	adinazolam (INN)	
293390	86696-87-9	aganodine (INN)	
293390	74258-86-9	alacepril (INN)	
293390	54965-21-8	albendazole (INN)	
293390	54029-12-8	albendazole oxide (INN)	
293390	59338-93-1	alizapride (INN)	
293390	119610-26-3	aloracetam (INN)	
293390	82626-01-5	alpidem (INN)	
293390	28981-97-7	alprazolam (INN)	
293390	93479-96-0	alteconazole (INN)	
293390	60575-32-8	amezepine (INN)	
293390	30578-37-1	amezinium metilsulfate (INN)	
293390	15180-02-6	amfonelic acid (INN)	
293390	23271-63-8	amicibone (INN)	
293390	2609-46-3	amiloride (INN)	
293390	31386-24-0	amindocate (INN)	
293390	90-45-9	aminoacridine (INN)	
293390	69635-63-8	amipizone (INN)	
293390	71675-85-9	amisulpride (INN)	
293390	24622-72-8	amixetrine (INN)	
293390	16870-37-4	amogastrin (INN)	
293390	5214-29-9	ampyzine (INN)	
293390	87344-06-7	amtolmetin guacil (INN)	
293390	132640-22-3	andolast (INN)	
293390	53716-46-4	anilopam (INN)	
293390	66635-85-6	anirolac (INN)	
293390	19281-29-9	aptocaine (INN)	
293390	37669-57-1	arfendazam (INN)	
293390	113-79-1	argipressin (INN)	
293390	113-80-4	argiprestocin (INN)	
293390	77400-65-8	asocainol (INN)	
293390	76530-44-4	azamulin (INN)	
293390	13539-59-8	azapropazone (INN)	
293390	58581-89-8	azelastine (INN)	
293390	26304-61-0	azepindole (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	64118-86-1	azimexon (INN)	
293390	1830-32-6	azintamide (INN)	
293390	58503-82-5	azipramine (INN)	
293390	87034-87-5	bamaluzole (INN)	
293390	35135-01-4	benafentrine (INN)	
293390	16506-27-7	bendamustine (INN)	
293390	20187-55-7	bendazac (INN)	
293390	621-72-7	bendazol (INN)	
293390	363-13-3	benhepazone (INN)	
293390	61864-30-0	benolizime (INN)	
293390	1050-48-2	benzilonium bromide (INN)	
293390	1980-45-6	benzodepa (INN)	
293390	13696-15-6	benzopyrrolonium bromide (INN)	
293390	39544-74-6	benzotript (INN)	
293390	63-12-7	benzquinamide (INN)	
293390	642-72-8	benzydamine (INN)	
293390	49571-04-2	bepidil (INN)	
293390	54063-27-3	biclofibrate (INN)	
293390	130641-38-2	bindarit (INN)	
293390	60662-16-0	binedaline (INN)	
293390	41510-23-0	biriperone (INN)	
293390	32195-33-8	bisbendazole (INN)	
293390	129655-21-6	bizelesin (INN)	
293390	62658-63-3	bopindolol (INN)	
293390	4774-53-2	botiacrine (INN)	
293390	10355-14-3	boxidine (INN)	
293390	84379-13-5	bretazenil (INN)	
293390	89622-90-2	brnazarone (INN)	
293390	15585-71-4	brometenamine (INN)	
293390	71119-11-4	bucindolol (INN)	
293390	316-15-4	bucricaine (INN)	
293390	36798-79-5	budralazine (INN)	
293390	55837-25-7	bufloxedil (INN)	
293390	54867-56-0	bufroliin (INN)	
293390	30103-44-7	bumecaine (INN)	
293390	3896-11-5	bumetrizole (INN)	
293390	36121-13-8	burodilone (INN)	
293390	51152-91-1	butaclamol (INN)	
293390	968-63-8	butinoline (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	62228-20-0	butopropazine (INN)	
293390	15351-05-0	buzepide metiodide (INN)	
293390	64241-34-5	cadralazine (INN)	
293390	132722-73-7	calteridol (INN)	
293390	36104-80-0	camazepam (INN)	
293390	54063-28-4	camiverine (INN)	
293390	62571-86-2	captopril (INN)	
293390	57775-29-8	carazolol (INN)	
293390	6804-07-5	carbadox (INN)	
293390	298-46-4	carbamazepine (INN)	
293390	69-81-8	carbazoChrome (INN)	
293390	51460-26-5	carbazoChrome sodium sulfonate (INN)	
293390	24279-91-2	carboquone (INN)	
293390	59009-93-7	carburazepam (INN)	
293390	33605-67-3	cargutocin (INN)	
293390	38081-67-3	carmantadine (INN)	
293390	23465-76-1	caroverine (INN)	
293390	39731-05-0	carpindolol (INN)	
293390	53716-49-7	carprofen (INN)	
293390	34966-41-1	cartazolate (INN)	
293390	72956-09-3	carvedilol (INN)	
293390	111223-26-8	ceronapril (INN)	
293390	17650-98-5	ceruletide (INN)	
293390	7007-92-3	cetohexazine (INN)	
293390	58-25-3	chlordiazepoxide (INN)	
293390	69-27-2	chlorisondamine chloride (INN)	
293390	3689-76-7	chiormidazole (INN)	
293390	65884-46-0	ciadox (INN)	
293390	66834-24-0	cianopramine (INN)	
293390	32211-97-5	ciclidole (INN)	
293390	31431-43-3	ciclobendazole (INN)	
293390	33545-56-1	ciclopramine (INN)	
293390	59865-13-3	ciclosponn (INN)	
293390	88768-40-5	cilazapril (INN)	
293390	90139-06-3	cilazaprilat (INN)	
293390	20168-99-4	cinmetacin (INN)	
293390	2056-56-6	cinnopentazone (INN)	
293390	28598-08-5	cinocframide (INN)	
293390	75696-02-5	cinolazepam (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	64557-97-7	cinoquidox (INN)	
293390	35452-73-4	ciprafamide (INN)	
293390	10171-69-4	clazolam (INN)	
293390	15686-51-8	clemastine (INN)	
293390	442-52-4	clemizole (INN)	
293390	27050-41-5	clenpirin (INN)	
293390	59467-77-5	climazolam (INN)	
293390	1159-93-9	clobenzepam (INN)	
293390	4755-59-3	clodazon (INN)	
293390	2030-63-9	clofazimine (INN)	
293390	5310-55-4	clomacran (INN)	
293390	25803-14-9	clometacin (INN)	
293390	303-49-1	clomipramine (INN)	
293390	1622-61-3	clonazepam (INN)	
293390	3861-76-5	clonitazene (INN)	
293390	42779-82-8	clopirac (INN)	
293390	5220-68-8	cloquinozine (INN)	
293390	47135-88-6	closiramine (INN)	
293390	50801-44-0	cortisuzol (INN)	
293390	1110-40-3	cortivazol (INN)	
293390	28069-65-0	cuprimyxin (INN)	
293390	15599-22-1	cyclopyrronium bromide (INN)	
293390	15687-07-7	cyprazepam (INN)	
293390	22136-27-2	daledalin (INN)	
293390	71680-63-2	dametralast (INN)	
293390	105118-14-7	datelliptium chloride (INN)	
293390	75991-50-3	dazepinil (INN)	
293390	75522-73-5	dazidamine (INN)	
293390	76002-75-0	dazoquinast (INN)	
293390	34024-41-4	deboxamet (INN)	
293390	16401-80-2	delmetacin (INN)	
293390	2894-67-9	delorazepam (INN)	
293390	963-39-3	demoxepam (INN)	
293390	42438-73-3	denpidazone (INN)	
293390	303-54-8	depramine (INN)	
293390	51987-65-6	desglugastrin (INN)	
293390	50-47-5	desipramine (INN)	
293390	103420-77-5	devazepide (INN)	
293390	52340-25-7	dexclamol (INN)	



HS 6	CAS #	Description	Alternative Classification
293390	60719-87-1	deximafen (INN)	
293390	91077-32-6	dezinamide (INN)	
293390	439-14-5	diazepam (INN)	
293390	57998-68-2	diaziquone (INN)	
293390	4498-32-2	dibenzepin (INN)	
293390	17411-19-7	dicarbine (INN)	
293390	21626-89-1	diftalone (INN)	
293390	484-23-1	dihydralazine (INN)	
293390	35898-87-4	diazep (INN)	
293390	36309-01-0	dimemorfan (INN)	
293390	4757-55-5	dimetacrine (INN)	
293390	51047-24-6	dimetipirium bromide (INN)	
293390	57109-90-7	dipotassium clorazepate (INN)	
293390	95355-10-5	domipizone (INN)	
293390	79700-61-1	dopropidil (INN)	
293390	90104-48-6	doreptide (INN)	
293390	40762-15-0	doxefazepam (INN)	
293390	76953-65-6	dramedilol (INN)	
293390	27314-77-8	drazidox (INN)	
293390	63667-16-3	dribendazole (INN)	
293390	2440-22-4	drometrizole (INN)	
293390	25771-23-7	duometacin (INN)	
293390	70977-46-7	eflumast (INN)	
293390	1232-85-5	elantrine (INN)	
293390	6196-08-3	elianzepine (INN)	
293390	69-25-0	eledoisin (INN)	
293390	52042-01-0	elfazepam (INN)	
293390	87233-61-2	emedastine (INN)	
293390	75847-73-3	enalapril (INN)	
293390	76420-72-9	enalaprilat (INN)	
293390	39715-02-1	endralazine (INN)	
293390	47206-15-5	enprazepine (INN)	
293390	80883-55-2	enviradene (INN)	
293390	72301-79-2	enviroxime (INN)	
293390	66304-03-8	epicainide (INN)	
293390	80012-43-7	epinastine (INN)	
293390	83200-08-2	eproxindine (INN)	
293390	101246-68-8	eptastigmine (INN)	
293390	72522-13-5	eptazocine (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	96645-87-3	erizepine (INN)	
293390	79286-77-4	esafloxacin (INN)	
293390	29975-16-4	estazolam (INN)	
293390	68788-56-7	etacepride (INN)	
293390	51022-77-6	etazolate (INN)	
293390	442-16-0	ethacridine (INN)	
293390	77-15-6	ethoheptazine (INN)	
293390	65400-85-3	ethyl carfiuzepate (INN)	
293390	23980-14-5	ethyl dirazepate (INN)	
293390	29177-84-2	ethyl lofazepate (INN)	
293390	84226-12-0	eticlopride (INN)	
293390	3478-15-7	etipirium iodide (INN)	
293390	911-65-9	etonitazene (INN)	
293390	54063-37-5	etopindole (INN)	
293390	2235-90-7	etryptamine (INN)	
293390	102676-47-1	fadrozole (INN)	
293390	108894-41-3	famiraprinium chloride (INN)	
293390	114432-13-2	fantofarone (INN)	
293390	49564-56-9	fazadinium bromide (INN)	
293390	5467-78-7	fenamole (INN)	
293390	43210-67-9	fenbendazole (INN)	
293390	53597-27-6	fendosai (INN)	
293390	15301-68-5	fenharmine (INN)	
293390	67227-56-9	fenoldopam (INN)	
293390	54063-41-1	fepromide (INN)	
293390	54063-46-6	fexicaine (INN)	
293390	34482-99-0	fletazepam (INN)	
293390	135381-77-0	fiez elastine (INN)	
293390	53966-34-0	floxacrine (INN)	
293390	31430-15-6	flubendazole (INN)	
293390	40594-09-0	flucindole (INN)	
293390	86386-73-4	fluconazole (INN)	
293390	3900-31-0	fludiazepam (INN)	
293390	78755-81-4	flumazenil (INN)	
293390	42835-25-6	flumequine (INN)	
293390	1622-62-4	flunitrazepam (INN)	
293390	17617-23-1	flurazepam (INN)	
293390	1841-19-6	fluspirilene (INN)	
293390	52391-89-6	flutemazepam (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	25967-29-7	flutoprazepam (INN)	
293390	70801-02-4	flutroline (INN)	
293390	93957-54-1	fluvastatin (INN)	
293390	76263-13-3	fluzinamide (INN)	
293390	35322-07-7	fosazepam (INN)	
293390	97825-24-6	fosinopril (INN)	
293390	95399-71-6	fosinoprilat (INN)	
293390	114517-02-1	fosquidone (INN)	
293390	79700-63-3	fronepidil (INN)	
293390	109623-97-4	gedocarnil (INN)	
293390	82230-53-3	ginsopam (INN)	
293390	17127-48-9	glaziovine (INN)	
293390	52443-21-7	glucametacin (INN)	
293390	596-51-0	glycopyrronium bromide (INN)	
293390	59252-59-4	guanazodine (INN)	
293390	55-65-2	guanethidine (INN)	
293390	23092-17-3	halazepam (INN)	
293390	5980-31-4	hexedine (INN)	
293390	3734-12-1	hexopyrronium bromide (INN)	
293390	493-80-1	histapyrrodine (INN)	
293390	1239-45-8	homidium bromide (INN)	
293390	848-53-3	homochlorcyclizine (INN)	
293390	35142-68-8	homopipramol (INN)	
293390	3614-47-9	hydracarbazine (INN)	
293390	86-54-4	hydralazine (INN)	
293390	7008-14-2	hydroxindasate (INN)	
293390	7008-15-3	hydroxindasol (INN)	
293390	19120-01-5	hydroxystenozole (INN)	
293390	91618-36-9	ibafloxacin (INN)	
293390	50847-11-5	ibudilast (INN)	
293390	57916-70-8	iclazepam (INN)	
293390	79449-99-3	icospiramide (INN)	
293390	116057-75-1	idoxifene (INN)	
293390	60719-86-0	imafen (INN)	
293390	59643-91-3	imexon (INN)	
293390	50-49-7	imipramine (INN)	
293390	6829-98-7	imipraminoxide (INN)	
293390	99011-02-6	imiquimod (INN)	
293390	88578-07-8	imoxiterol (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	99323-21-4	inapersone (INN)	
293390	31386-25-1	indocate (INN)	
293390	80876-01-3	indolapril (INN)	
293390	53-86-1	indometacin (INN)	
293390	69907-17-1	indopanolol (INN)	
293390	73758-06-2	indorenate (INN)	
293390	5034-76-4	indoxole (INN)	
293390	436-40-8	inproquone (INN)	
293390	125974-72-3	intopicine (INN)	
293390	15992-13-9	intrazole (INN)	
293390	7248-21-7	iprazochrome (INN)	
293390	5560-72-5	iprindole (INN)	
293390	64779-98-2	irolapride (INN)	
293390	55902-02-8	isamfazono (INN)	
293390	116861-00-8	isamoltan (INN)	
293390	86315-52-8	isomazole (INN)	
293390	34301-55-8	isometamidium chloride (INN)	
293390	56463-68-4	isoprazone (INN)	
293390	487-79-6	kainic acid (INN)	
293390	796-29-2	ketimipramine (INN)	
293390	74103-06-3	ketorolac (INN)	
293390	5633-16-9	leiopyrrole (INN)	
293390	104340-86-5	laminoprazole (INN)	
293390	36945-03-6	lergotrile (INN)	
293390	71048-87-8	levonantradol (INN)	
293390	141505-33-1	levosimendan (INN)	
293390	105102-20-3	liroidine (INN)	
293390	76547-98-3	lisinopril (INN)	
293390	6306-71-4	lobendazole (INN)	
293390	87646-83-1	lodazecar (INN)	
293390	29176-29-2	lofendazam (INN)	
293390	23047-25-8	iofepamine (INN)	
293390	50264-69-2	lonidamine (INN)	
293390	42863-81-0	lopirazepam (INN)	
293390	846-49-1	lorazepam (INN)	
293390	117857-45-1	lorelezole (INN)	
293390	848-75-9	lormetazepam (INN)	
293390	69175-77-5	iosindole (INN)	
293390	88303-60-0	losoxantrone (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	66535-86-2	lotrfen (INN)	
293390	52304-85-5	lotucaine (INN)	
293390	90509-02-7	luxabendazole (INN)	
293390	22232-71-9	mazindol (INN)	
293390	31431-39-7	mebendazole (INN)	
293390	524-81-2	mebhydroiin (INN)	
293390	15574-49-9	mecarbonate (INN)	
293390	58662-84-3	meclonazepam (INN)	
293390	2898-12-6	medazepam (INN)	
293390	300-22-1	medazomide (INN)	
293390	3735-85-1	mefeserpine (INN)	
293390	26921-72-2	melizame (INN)	
293390	28781-64-8	menitrazepam (INN)	
293390	83-89-6	mepacrine (INN)	
293390	23694-81-7	mepindolol (INN)	
293390	54340-58-8	meptazinol (INN)	
293390	16915-79-0	mequidox (INN)	
293390	65517-27-3	metaciazepam (INN)	
293390	54063-49-9	metamfazone (INN)	
293390	21730-16-5	metapramine (INN)	
293390	17692-51-2	metergoline (INN)	
293390	509-84-2	metethoheptazine (INN)	
293390	100-97-0	methenamine (INN)	
293390	469-78-3	metheptazine (INN)	
293390	15687-33-9	metindizate (INN)	
293390	54188-38-4	metralindole (INN)	
293390	1661-29-6	meturedepa (INN)	
293390	27432-00-4	mezepine (INN)	
293390	496-38-8	midamaline (INN)	
293390	59467-70-8	midazolam (INN)	
293390	3277-59-6	mimbane (INN)	
293390	55843-86-2	miroprofen (INN)	
293390	91753-07-0	mitoquidone (INN)	
293390	85622-95-3	mitozolomide (INN)	
293390	27737-38-8	mixidine (INN)	
293390	4757-49-7	monometacrine (INN)	
293390	29442-58-8	motrazepam (INN)	
293390	85856-54-8	movaltiprii (INN)	
293390	1845-11-0	nafoxidine (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	389-08-2	nalidixic acid (INN)	
293390	65511-41-3	nantradol (INN)	
293390	70696-66-1	napirimus (INN)	
293390	73865-18-6	nardeterol (INN)	
293390	55248-23-2	nebidrazine (INN)	
293390	103844-77-5	necopidem (INN)	
293390	69624-60-8	nelezaprine (INN)	
293390	93664-94-9	nemonapride (INN)	
293390	86140-10-5	neraminol (INN)	
293390	102771-12-0	nerisopam (INN)	
293390	129618-40-2	nevirapine (INN)	
293390	2011-67-8	nimetazepam (INN)	
293390	130610-93-4	niravoline (INN)	
293390	4533-39-5	nitracrine (INN)	
293390	146-22-5	nitrazepam (INN)	
293390	10448-84-7	nitromifene (INN)	
293390	24358-76-7	nivacortol (INN)	
293390	40759-33-9	nolinium bromide (INN)	
293390	15997-76-9	nonaperone (INN)	
293390	1088-11-5	nordazepam (INN)	
293390	10379-11-0	nortetrazepam (INN)	
293390	59767-12-3	octastine (INN)	
293390	3147-75-9	octrizole (INN)	
293390	23696-28-8	olaquinox (INN)	
293390	115972-78-6	olradipine (INN)	
293390	108391-88-4	orbutopri (INN)	
293390	33996-33-7	oxaceprol (INN)	
293390	56611-65-5	oxagrelate (INN)	
293390	27035-30-9	oxametacin (INN)	
293390	99258-56-7	oxamisole (INN)	
293390	35578-20-2	oxarbazole (INN)	
293390	604-75-1	oxazepam (INN)	
293390	28721-07-5	oxcarbazepine (INN)	
293390	17259-75-5	oxdralazine (INN)	
293390	53716-50-0	oxfendazole (INN)	
293390	20559-55-1	oxibendazole (INN)	
293390	64057-48-3	oxifungin (INN)	
293390	4350-09-8	oxitriptan (INN)	
293390	561-43-3	oxypyrronium bromide (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	14255-87-9	parbendazole (INN)	
293390	61484-38-6	pareptide (INN)	
293390	103238-56-8	parodiolol (INN)	
293390	65222-35-7	pazelliptine (INN)	
293390	5534-95-2	pentagastrin (INN)	
293390	54-95-5	pentetrazol (INN)	
293390	62087-72-3	pentigetide (INN)	
293390	52-62-0	pentolonium tartrate (INN)	
293390	82924-03-6	pentopril (INN)	
293390	82834-16-0	perindopril (INN)	
293390	95153-31-4	perindoprilat (INN)	
293390	84-12-8	phanquinone (INN)	
293390	82-88-2	phenindamine (INN)	
293390	62510-56-9	picilorex (INN)	
293390	64000-73-3	pildralazine (INN)	
293390	88069-67-4	pilsicainide (INN)	
293390	74150-27-9	pimobendan (INN)	
293390	54824-20-3	pinafide (INN)	
293390	52463-83-9	pinazepam (INN)	
293390	83471-41-4	pincaïnide (INN)	
293390	13523-86-9	pindolol (INN)	
293390	78541-97-6	piquindone (INN)	
293390	79672-88-1	pirprost (INN)	
293390	85691-74-3	pirmagrel (INN)	
293390	62625-18-7	pirogiliride (INN)	
293390	16378-21-5	piroheptine (INN)	
293390	91441-23-5	piroxantrone (INN)	
293390	31793-07-4	pirprofen (INN)	
293390	17243-65-1	pirralkonium bromide (INN)	
293390	55299-10-0	pivoxazepam (INN)	
293390	545-80-2	poldine metilsulfate (INN)	
293390	72702-95-5	ponalrestat (INN)	
293390	5571-84-6	potassium nitrazepate (INN)	
293390	17716-89-1	pranosal (INN)	
293390	2955-38-6	prazepam (INN)	
293390	73-07-4	prazepine (INN)	
293390	57435-86-6	premazepam (INN)	
293390	5370-41-2	pridefine (INN)	
293390	4630-95-9	prifinium bromide (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	77639-66-8	prinomide (INN)	
293390	59010-44-5	prizidilol (INN)	
293390	23249-97-0	procodazole (INN)	
293390	77-37-2	procyclidine (INN)	
293390	3734-17-6	prodiilidine (INN)	
293390	428-37-5	profadol (INN)	
293390	92-62-6	proflavine (INN)	
293390	52829-30-8	profazepam (INN)	
293390	77-14-5	proheptazine (INN)	
293390	147-85-3	proline (INN)	
293390	493-92-5	prolintane (INN)	
293390	10321-12-7	propizepine (INN)	
293390	77650-95-4	proterguride (INN)	
293390	3426-08-2	prozapine (INN)	
293390	98-96-4	pyrazinamide (INN)	
293390	7009-69-0	pyrophenidone (INN)	
293390	3563-49-3	pyrovalerone (INN)	
293390	7009-68-9	pyroxamine (INN)	
293390	2210-77-7	pyrrocaine (INN)	
293390	15686-97-2	pyrrolifene (INN)	
293390	36735-22-5	quazepam (INN)	
293390	15301-89-0	quillifoline (INN)	
293390	87056-78-8	quinagolide (INN)	
293390	130-81-4	quindonium bromide (INN)	
293390	2423-66-7	quinoxin (INN)	
293390	85760-74-3	quinpirole (INN)	
293390	84225-95-6	raclopride (INN)	
293390	87333-19-5	ramipril (INN)	
293390	87269-97-4	ramipriat (INN)	
293390	80125-14-0	remoxipride (INN)	
293390	73573-42-9	rescimetol (INN)	
293390	72238-02-9	retelliptine (INN)	
293390	83395-21-5	rdazolol (INN)	
293390	99593-25-6	rilmazafone (INN)	
293390	79282-39-6	rilozarone (INN)	
293390	26308-28-1	ripazepam (INN)	
293390	53808-86-9	nitropirronium bromide (INN)	
293390	38821-80-6	rodocaine (INN)	
293390	10078-46-3	roletamide (INN)	



HS 6	CAS #	Description	Alternative Classification
293390	66608-04-6	roligamidine (INN)	
293390	2201-39-0	rolicyclidine (INN)	
293390	53862-80-9	roxolonium metilsulfate (INN)	
293390	103884-86-6	saripidem (INN)	
293390	78771-13-8	sarmazenil (INN)	
293390	57645-05-3	semetacin (INN)	
293390	64294-95-7	setastine (INN)	
293390	57262-94-9	setiptiline (INN)	
293390	99591-83-0	siguazodan (INN)	
293390	98374-54-0	siltenzepine (INN)	
293390	131741-08-7	simendan (INN)	
293390	25126-32-3	sincalide (INN)	
293390	30033-10-4	stercuronium iodide (INN)	
293390	39862-58-3	strinoline (INN)	
293390	2898-13-7	sulazepam (INN)	
293390	73384-60-8	sulmazole (INN)	
293390	53583-79-2	sultopride (INN)	
293390	98116-53-1	sulukast (INN)	
293390	110623-33-1	sunitozole (INN)	
293390	104675-35-6	suronacrine (INN)	
293390	34061-33-1	taclamine (INN)	
293390	321-64-2	tacrine (INN)	
293390	16188-61-7	talastine (INN)	
293390	115308-98-0	tallimustine (INN)	
293390	17243-68-4	taloximine (INN)	
293390	83166-17-0	tampramine (INN)	
293390	141374-81-4	tarazepide (INN)	
293390	84812-85-1	tazadolene (INN)	
293390	87936-75-2	tazadolene (INN)	
293390	82989-25-1	tazanolast (INN)	
293390	91441-48-4	teloxantrone (INN)	
293390	846-50-4	temazepam (INN)	
293390	34499-96-2	temodox (INN)	
293390	85622-93-1	temozolomide (INN)	
293390	37686-84-3	terguride (INN)	
293390	58-46-8	tetrabenazine (INN)	
293390	10379-14-3	tetrazepam (INN)	
293390	95104-27-1	tetrazolast (INN)	
293390	17289-49-5	tetridamine (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	52-24-4	thiotepa (INN)	
293390	107489-37-2	thymoctonan (INN)	
293390	54663-47-7	tibezonium iodide (INN)	
293390	80225-28-1	tilsuprost (INN)	
293390	83275-56-3	tiracizine (INN)	
293390	27314-97-2	tirapazamine (INN)	
293390	14679-73-3	todralazine (INN)	
293390	40173-75-9	tofetridine (INN)	
293390	22345-47-7	tofisopam (INN)	
293390	26171-23-3	tolmetin (INN)	
293390	50454-68-7	tolnidamine (INN)	
293390	6187-50-4	tolquinzole (INN)	
293390	86273-92-9	tolufazepam (INN)	
293390	88107-10-2	tomelukast (INN)	
293390	76145-76-1	tomoxiprole (INN)	
293390	108138-46-1	tosufloxacin (INN)	
293390	41094-88-6	tracazolate (INN)	
293390	87679-37-6	trandolapril (INN)	
293390	87679-71-8	trandolapriat (INN)	
293390	104485-01-0	trapencaine (INN)	
293390	97110-59-3	trazium esilate (INN)	
293390	56030-50-3	trepipam (INN)	
293390	1018-34-4	trepinum iodide (INN)	
293390	55242-77-8	triafungin (INN)	
293390	68-76-8	triaziquone (INN)	
293390	28911-01-5	triazolam (INN)	
293390	96258-13-8	tnbendilol (INN)	
293390	68786-66-3	tnclabendazole (INN)	
293390	7009-76-9	tnclazate (INN)	
293390	3818-88-0	tncyclamol chloride (INN)	
293390	739-71-9	trimipramine (INN)	
293390	63619-84-1	troxifene (INN)	
293390	35710-57-7	trizoxime (INN)	
293390	14368-24-2	trocimine (INN)	
293390	97546-74-2	troxolamide (INN)	
293390	3612-98-4	troxypyrrolium tosilate (INN)	
293390	73-22-3	tryptophan (INN)	
293390	51037-88-8	tuciazepam (INN)	
293390	28546-58-9	uldazepam (INN)	

HS 6	CAS #	Description	Alternative Classification
293390	302-49-8	uredepa (INN)	
293390	137862-53-4	valsartan (INN)	
293390	112964-98-4	velnacrine (INN)	
293390	68318-20-7	verilopam (INN)	
293390	21363-18-8	viminol (INN)	
293390	70704-03-9	vinconate (INN)	
293390	106498-99-1	vintoperol (INN)	
293390	72301-78-1	viroxime (INN)	
293390	129731-10-8	vorozole (INN)	
293390	50528-97-7	xilobam (INN)	
293390	50264-78-3	xinidamine (INN)	
293390	64098-32-4	zapizolam (INN)	
293390	101975-10-4	zardaverine (INN)	
293390	62851-43-8	zidometacin (INN)	
293390	117827-79-9	zilpaterol (INN)	
293390	86111-26-4	zindoxifene (INN)	
293390	72301-78-1	zinviroxime (INN)	
293390	81872-10-8	zofenopril (INN)	
293390	75176-37-3	zofenopriat (INN)	
293390	31352-82-6	zolazepam (INN)	
293390	1222-57-7	zolimidine (INN)	
293390	82626-48-0	zolpidem (INN)	
293390	33369-31-2	zomepirac (INN)	
293410	105292-70-4	alonacic (INN)	
293410	82114-19-0	amflutizole (INN)	
293410	140-40-9	amintrozole (INN)	
293410	96-50-4	aminothiazole (INN)	
293410	490-55-1	amiphenazole (INN)	
293410	25422-75-7	antazonite (INN)	
293410	68377-92-4	arotinolol (INN)	
293410	104777-03-9	asobamast (INN)	
293410	13471-78-8	beclotiamine (INN)	
293410	61990-92-9	benpenolisin (INN)	
293410	21817-73-2	bidimazium iodide (INN)	
293410	17969-45-8	brofezil (INN)	
293410	26097-80-3	cambendazole (INN)	
293410	74772-77-3	ciglitazone (INN)	
293410	533-45-9	clornethiazole (INN)	
293410	6469-36-9	cloprothiazole (INN)	

HS 6	CAS #	Description	Alternative Classification
293410	77519-25-6	dexetozoline (INN)	
293410	109229-58-5	englitazone (INN)	
293410	74604-76-5	enoxamast (INN)	
293410	82159-09-9	epalrestat (INN)	
293410	73-09-6	etozolin (INN)	
293410	76824-35-6	famotidine (INN)	
293410	79069-94-6	fanetizole (INN)	
293410	17969-20-9	fenclozic acid (INN)	
293410	18046-21-4	fentiazac (INN)	
293410	15387-18-5	fezatione (INN)	
293410	500-08-3	forminirazole (INN)	
293410	103181-72-2	guaisteine (INN)	
293410	138511-81-6	icoduline (INN)	
293410	70529-35-0	itazigrel (INN)	
293410	53943-88-7	letosteine (INN)	
293410	27826-45-5	libecillide (INN)	
293410	71119-10-3	lotifazole (INN)	
293410	71125-38-7	meloxicam (INN)	
293410	119637-67-1	moguisteine (INN)	
293410	84233-61-4	nesosteine (INN)	
293410	54657-96-4	nifuralide (INN)	
293410	3570-75-0	nifurthiazole (INN)	
293410	61-57-4	niridazole (INN)	
293410	55981-09-4	nitazoxanide (INN)	
293410	962-02-7	nitrodan (INN)	
293410	76963-41-2	nizatidine (INN)	
293410	56784-39-5	ozolinone (INN)	
293410	68247-85-8	peplomycin (INN)	
293410	68247-85-8	peplomycin (INN)	294190
293410	29952-13-4	peratzole (INN)	
293410	121808-62-6	pidotimod (INN)	
293410	111025-46-8	pioglitazone (INN)	
293410	17243-64-0	piprozolin (INN)	
293410	13409-53-5	podifen (INN)	
293410	24840-59-3	pretamazium iodide (INN)	
293410	93738-40-0	ralitoline (INN)	
293410	80830-42-8	rentiapril (INN)	
293410	39832-48-9	tazolol (INN)	
293410	54147-28-3	tebatzole (INN)	

HS 6	CAS #	Description	Alternative Classification
293410	122946-43-4	telmestaine (INN)	
293410	3810-35-3	tenonitrozoie (INN)	
293410	148-79-8	thiabendazole (ISO) tiabendazole (INN)	
293410	473-30-3	thiazosulfone (INN)	
293410	60084-10-8	tiazofurine (INN)	
293410	30097-06-4	tidiacic (INN)	
293410	71079-19-1	timegadine (INN)	
293410	100417-09-2	timirdine (INN)	
293410	64179-54-0	timofibrate (INN)	
293410	444-27-9	timonacic (INN)	
293410	69014-14-8	tiotidine (INN)	
293410	74531-88-7	tioxamast (INN)	
293410	105523-37-3	tiprotimod (INN)	
293410	30709-69-4	tizoprollic acid (INN)	
293410	97322-87-1	trogli tazone (INN)	
293410	91257-14-6	tuvatidine (INN)	
293410	85604-00-8	zaltidine (INN)	
293410	553-13-9	zolamine (INN)	
293410	56355-17-0	zoliprofen (INN)	
293420	95-27-2	dimazole (INN)	
293420	514-73-8	dithiazanine iodide (INN)	
293420	70590-58-8	etrabamine (INN)	
293420	100035-75-4	evandamine (INN)	
293420	75889-62-2	fostedil (INN)	
293420	26130-02-9	frentizole (INN)	
293420	15599-36-7	haletazole (INN)	
293420	95847-70-4	ipsapirone (INN)	
293420	77528-67-7	manozodil (INN)	
293420	104632-26-0	pramipexole (INN)	
293420	95847-87-3	revospirone (INN)	
293420	1744-22-5	riluzole (INN)	
293420	104153-38-0	sabeluzole (INN)	
293420	49785-74-2	supidimide (INN)	
293420	79071-15-1	tazasubrate (INN)	
293420	85702-89-2	tazeprofen (INN)	
293420	32527-55-2	tiamamide (INN)	
293420	61570-90-9	tioxidazole (INN)	
293420	110703-94-1	zopolrestat (INN)	
293430	61-00-7	acepromazine (INN)	

HS 6	CAS #	Description	Alternative Classification
293430	13461-01-3	aceprometazine (INN)	
293430	2751-68-0	acetophenazine (INN)	
293430	84-96-8	alimemazine (INN)	
293430	58-37-7	aminopromazine (INN)	
293430	49864-70-2	azaciorzine (INN)	
293430	54063-26-2	azaftozine (INN)	
293430	653-03-2	butaperazine (INN)	
293430	2622-30-2	carfenazine (INN)	
293430	800-22-6	chloracyzine (INN)	
293430	84-01-5	chlorproethazine (INN)	
293430	50-53-3	chlorpromazine (INN)	
293430	17692-26-1	ciclofenazine (INN)	
293430	3546-03-0	cyamemazine (INN)	
293430	518-61-6	dacemazine (INN)	
293430	60-91-3	diethazine (INN)	
293430	15302-12-2	dimelazine (INN)	
293430	477-93-0	dimethoxanate (INN)	
293430	62030-88-0	duoperone (INN)	
293430	523-54-6	etymemazine (INN)	
293430	522-24-7	fenethazine (INN)	
293430	37561-27-6	fenovenne (INN)	
293430	30223-48-4	fluacizine (INN)	
293430	69-23-8	fluphenazine (INN)	
293430	47682-41-7	flupimazine (INN)	
293430	7220-56-6	flutiazin (INN)	
293430	33414-30-1	ftormetazine (INN)	
293430	33414-36-7	ftorpropazine (INN)	
293430	28532-90-3	furomazine (INN)	
293430	3833-99-6	homofenazine (INN)	
293430	7224-08-0	imiciopazine (INN)	
293430	60-99-1	levomepromazine (INN)	
293430	1759-09-7	levometiomeprazine (INN)	
293430	101396-42-3	mequitamium iodide (INN)	
293430	29216-28-2	mequitazine (INN)	
293430	5588-33-0	mesondazine (INN)	
293430	1982-37-2	methdilazine (INN)	
293430	7009-43-0	methiomeprazine (INN)	
293430	61-01-8	methopromazine (INN)	
293430	61-73-4	methylthioninium chloride (INN)	

HS 6	CAS #	Description	Alternative Classification
293430	13993-65-2	metiazinic acid (INN)	
293430	388-51-2	metofenazate (INN)	
293430	14008-44-7	metopimazine (INN)	
293430	31883-05-3	moracizine (INN)	
293430	16498-21-8	oxafiumazine (INN)	
293430	3689-50-7	oxomemazine (INN)	
293430	14759-04-7	oxyridazine (INN)	
293430	84-08-2	parathiazine (INN)	
293430	60-89-9	pezazine (INN)	
293430	2622-26-6	periciazine (INN)	
293430	13093-88-4	penmetazine (INN)	
293430	58-39-9	perphenazine (INN)	
293430	92-84-2	phenothiazine (INN)	
293430	84-04-8	pipamazine (INN)	
293430	3819-00-9	piperacetazine (INN)	
293430	58-38-8	prochlorperazine (INN)	
293430	522-00-9	profenamine (INN)	
293430	58-40-2	promazine (INN)	
293430	60-87-7	promethazine (INN)	
293430	17693-51-5	promethazine teoclate (INN)	
293430	362-29-8	propiomazine (INN)	
293430	145-54-0	propyromazine bromide (INN)	
293430	13799-03-6	protiznic acid (INN)	
293430	23492-69-5	sopitazine (INN)	
293430	24527-27-3	spiclomazine (INN)	
293430	14759-06-9	sulforidazine (INN)	
293430	58-34-4	thiazinamium metilsulfate (INN)	
293430	1420-55-9	thiethylperazine (INN)	
293430	84-06-0	thiopropazate (INN)	
293430	50-52-2	thionidazine (INN)	
293430	2622-37-9	trifluomeprazine (INN)	
293430	117-89-5	trifluoperazine (INN)	
293430	146-54-3	triflupromazine (INN)	
293490	2627-69-2	acadesine (INN)	
293490	10072-48-7	acefurtiamine (INN)	
293490	33665-90-6	acesulfame (INN)	
293490	42228-92-2	acivicin (INN)	
293490	39633-62-0	aciantate (INN)	
293490	748-44-7	acoxatrine (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	7008-42-6	acronine (INN)	
293490	17176-17-9	ademetonine (INN)	
293490	61-19-8	adenosine phosphate (INN)	
293490	110314-48-2	adozelesin (INN)	
293490	81403-80-7	aifuzosin (INN)	
293490	526-35-2	allomethadione (INN)	
293490	84145-89-1	almoxatone (INN)	
293490	25526-93-6	alovudine (INN)	
293490	121029-11-6	altoqualine (INN)	
293490	2207-50-3	aminorex (INN)	
293490	111393-84-1	amitvir (INN)	
293490	68302-57-8	amlexanox (INN)	
293490	22661-76-3	amoprofan (INN)	
293490	78613-35-1	amorolfine (INN)	
293490	14028-44-5	amoxapine (INN)	
293490	99464-64-9	amproxicam (INN)	
293490	95896-08-5	anaritide (INN)	
293490	77658-97-0	anaxirone (INN)	
293490	31698-14-3	ancitabine (INN)	
293490	15301-45-8	antafenite (INN)	
293490	5029-05-0	antienite (INN)	
293490	105219-56-5	apafant (INN)	
293490	92569-65-8	aprikalim (INN)	
293490	9004-04-0	aprotinin (INN)	
293490	19885-51-9	aranotin (INN)	
293490	119-96-0	arsthiol (INN)	
293490	23964-58-1	articaïne (INN)	
293490	90779-69-4	atosiban (INN)	
293490	85076-06-8	axamozide (INN)	
293490	320-67-2	azacitidine (INN)	
293490	60207-31-0	azaconazole (INN)	
293490	72822-56-1	azaloxan (INN)	
293490	37855-92-8	azanator (INN)	
293490	2169-64-4	azanbine (INN)	
293490	123040-69-7	azasetron (INN)	
293490	34959-30-3	azaspinum chlonde (INN)	
293490	13074-00-5	azastene (INN)	
293490	125-45-1	azatepa (INN)	
293490	35067-73-9	azepevole (INN)	



HS 6	CAS #	Description	Alternative Classification
293490	64748-79-4	azumolene (INN)	
293490	99156-66-8	barmastine (INN)	
293490	79784-22-8	barucaïnide (INN)	
293490	105685-11-8	batoprazine (INN)	
293490	94011-82-2	bazinaprine (INN)	
293490	15351-04-9	becantone (INN)	
293490	130782-54-6	beciparcil (INN)	
293490	112893-26-2	becliconazole (INN)	
293490	100927-14-8	befipende (INN)	
293490	134564-82-2	befioxatone (INN)	
293490	41717-30-0	befuraline (INN)	
293490	112018-01-6	bemoradan (INN)	
293490	16759-59-4	benoxafos (INN)	
293490	51234-28-7	benoxaprofen (INN)	
293490	1219-77-8	bensuldazic acid (INN)	
293490	29462-18-8	bentazepam (INN)	
293490	114776-28-2	bepafant (INN)	
293490	86434-57-3	beperidium iodide (INN)	
293490	10189-94-3	bepiastine (INN)	
293490	105567-83-7	berefriane (INN)	
293490	120410-24-4	biapenem (INN)	294190
293490	117545-11-6	bimakalim (INN)	
293490	102908-59-8	binospirone (INN)	
293490	17692-24-9	bisoxatin (INN)	
293490	69304-47-8	bnvudine (INN)	
293490	72481-99-3	brocnnat (INN)	
293490	63638-91-5	brofaromine (INN)	
293490	21440-97-1	brofoxine (INN)	
293490	5579-85-1	bromchlorenone (INN)	
293490	57801-81-7	brotizolam (INN)	
293490	76596-57-1	broxaterol (INN)	
293490	59-14-3	broxuridine (INN)	
293490	362-74-3	bucladesine (INN)	
293490	22131-35-7	butalamine (INN)	
293490	54400-59-8	butamisole (INN)	
293490	127214-23-7	camiglibose (INN)	
293490	66203-00-7	carocainide (INN)	
293490	18464-39-6	caroxazone (INN)	
293490	89213-87-6	carpentide (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	68020-77-9	carprazidil (INN)	
293490	2037-95-8	carsalam (INN)	
293490	119813-10-4	carzelesin (INN)	
293490	14176-10-4	cetiedil (INN)	
293490	494-14-4	chlordimorine (INN)	
293490	80-77-3	chlormezanone (INN)	
293490	148-65-2	chloropyrilene (INN)	
293490	113-59-7	chlorprothixene (INN)	
293490	132-89-8	chlorthenoxazine (INN)	
293490	95-25-0	chlorzoxazone (INN)	
293490	55694-98-9	ciclafrine (INN)	
293490	89943-82-8	cicletanine (INN)	
293490	66564-16-7	ciclosidomine (INN)	
293490	58765-21-2	ciclotizolam (INN)	
293490	633-90-9	cifostodine (INN)	
293490	73815-11-9	cimoxatone (INN)	
293490	62380-23-8	cinecromen (INN)	
293490	69118-25-8	cinepaxadil (INN)	
293490	477-80-5	cinnofuradione (INN)	
293490	28657-80-9	cinoxacin (INN)	
293490	88053-05-8	cinoxopazide (INN)	
293490	143631-62-3	ciprokiren (INN)	
293490	104456-79-3	cisconazole (INN)	
293490	65509-66-2	citatepine (INN)	
293490	21512-15-2	citenazone (INN)	
293490	987-78-0	citicoline (INN)	
293490	1195-16-0	citrolone (INN)	
293490	4291-63-8	cladribine (INN)	
293490	16562-98-4	clantifen (INN)	
293490	58001-44-8	clavulanic acid (INN)	
293490	96125-53-0	clentazem (INN)	
293490	33588-20-4	clidafidine (INN)	
293490	51022-75-4	cliprofen (INN)	
293490	14796-28-2	clodanolene (INN)	
293490	71923-34-7	clodoxopone (INN)	
293490	3876-10-6	clominorex (INN)	
293490	982-24-1	clopenthixol (INN)	
293490	113665-84-2	clopidogrel (INN)	
293490	60085-78-1	clopipazan (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	13448-22-1	clorotepine (INN)	
293490	2058-52-8	clotiapine (INN)	
293490	33671-46-4	clotiazepam (INN)	
293490	1856-34-4	clotioxone (INN)	
293490	4177-58-6	clotixamide (INN)	
293490	24166-13-0	cloxazolam (INN)	
293490	15311-77-0	cloxypendyl (INN)	
293490	37681-00-8	coumazoline (INN)	
293490	94470-67-4	cromakalim (INN)	
293490	53736-51-9	cromitriole (INN)	
293490	113759-50-5	cronidipine (INN)	
293490	14461-91-7	cyclazodone (INN)	
293490	15301-52-7	cyclexanone (INN)	
293490	50-18-0	cyclophosphamide (INN)	
293490	147-94-4	cytarabine (INN)	
293490	125372-33-0	dacopafant (INN)	
293490	112362-50-2	dalfopristin (INN)	
293490	1469-07-4	damotepine (INN)	
293490	7261-97-4	dantrolene (INN)	
293490	141200-24-0	darglitazone (INN)	293410
293490	72803-02-2	darodipine (INN)	
293490	61477-97-2	dazolicine (INN)	
293490	2353-33-5	decitabine (INN)	
293490	79874-76-3	delmopinol (INN)	
293490	106972-33-2	denipride (INN)	
293490	1767-88-0	desmethylnoramide (INN)	
293490	14769-74-5	dexamisole (INN)	
293490	4741-41-7	dexoxadrol (INN)	
293490	357-56-2	dextromoramide (INN)	
293490	364-98-7	diazoxide (INN)	
293490	5571-97-1	dichloromezanone (INN)	
293490	69655-05-6	didanosine (INN)	
293490	702-54-5	diethadione (INN)	
293490	86-14-6	diethylthiambutene (INN)	
293490	5617-26-5	difenclozazine (INN)	
293490	42399-41-7	diltiazem (INN)	
293490	695-53-4	dimethadione (INN)	
293490	524-84-5	dimethylthiambutene (INN)	
293490	6495-46-1	dioxadrol (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	467-86-7	dioxaphetyl butyrate (INN)	
293490	52042-24-7	diproxadol (INN)	
293490	87495-31-6	disoxaril (INN)	
293490	18471-20-0	ditazole (INN)	
293490	106707-51-1	dobupride (INN)	
293490	59831-63-9	doconazole (INN)	
293490	99248-32-5	donetidine (INN)	
293490	113-53-1	dosulepin (INN)	
293490	84625-59-2	dotarizine (INN)	
293490	26058-50-4	dotefonium bromide (INN)	
293490	309-29-5	doxapram (INN)	
293490	74191-85-8	doxazosin (INN)	
293490	3094-09-5	doxifluridine (INN)	
293490	62904-71-6	doxpicomine (INN)	
293490	35067-47-1	droxacin (INN)	
293490	90101-16-9	droxicam (INN)	
293490	116539-59-4	duloxetine (INN)	
293490	60940-34-3	ebseien (INN)	
293490	77695-52-4	ecastolol (INN)	
293490	80263-73-6	eclazolast (INN)	
293490	15176-29-1	edoxudine (INN)	
293490	89197-32-0	efaroxan (INN)	
293490	111011-63-3	efonidipine (INN)	
293490	119413-55-7	eigodipine (INN)	
293490	103946-15-2	elnadipine (INN)	
293490	72895-88-6	eltenac (INN)	
293490	98224-03-4	elitoprazine (INN)	
293490	129729-66-4	emakalim (INN)	
293490	38957-41-4	emorfazone (INN)	
293490	124378-77-4	enadoline (INN)	
293490	59798-73-1	enilospirone (INN)	
293490	55726-47-1	enocitabine (INN)	
293490	59755-82-7	enolicam (INN)	
293490	60136-25-6	epervudine (INN)	
293490	5696-17-3	epipropidine (INN)	
293490	2363-58-8	epitrostanol (INN)	
293490	87940-60-1	eprobemide (INN)	
293490	101335-99-3	eprovafen (INN)	
293490	84611-23-4	erdosteine (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	16781-39-8	etasuline (INN)	
293490	441-61-2	ethylmethylthiambutene (INN)	
293490	64420-40-2	etibendazole (INN)	
293490	21715-46-8	etifoxine (INN)	
293490	7716-60-1	etisazole (INN)	
293490	40054-69-1	etizolam (INN)	
293490	41340-25-4	etodoiac (INN)	
293490	17692-35-2	etofuradine (INN)	
293490	82140-22-5	etolotifen (INN)	
293490	28189-85-7	etoxadrol (INN)	
293490	127625-29-0	fananserine (INN)	
293490	106100-65-6	faspion (INN)	
293490	65886-71-7	fazarabine (INN)	
293490	23271-74-1	fedriate (INN)	
293490	1008-65-7	fenadiazole (INN)	
293490	4378-36-3	fenbutrazate (INN)	
293490	5588-29-4	fenmetramide (INN)	
293490	15302-16-6	fenozolone (INN)	
293490	21820-82-6	fenpipalone (INN)	
293490	5053-06-5	fenspiride (INN)	
293490	22293-47-6	feprosidine (INN)	
293490	69123-90-6	fiacitabine (INN)	
293490	69123-98-4	fialundine (INN)	
293490	78168-92-0	filenadol (INN)	
293490	34161-24-5	fipexide (INN)	
293490	15301-69-6	flavoxate (INN)	
293490	98205-89-1	flesinoxan (INN)	
293490	77590-96-6	flordipine (INN)	
293490	53731-36-5	floredil (INN)	
293490	50-91-9	floxundine (INN)	
293490	19888-56-3	fluazacort (INN)	
293490	21679-14-1	fludarabine (INN)	
293490	71923-29-0	fludoxopone (INN)	
293490	7125-73-7	flumetramide (INN)	
293490	30914-89-7	flumexadol (INN)	
293490	61325-80-2	flumezapine (INN)	
293490	720-76-3	fluminorex (INN)	
293490	60135-22-0	flumoxonide (INN)	
293490	66934-18-7	flunoxaprofen (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	105182-45-4	fluparoxan (INN)	
293490	2709-56-0	flupentixol (INN)	
293490	37717-21-8	flurocitabine (INN)	
293490	27060-91-9	flutazolam (INN)	
293490	10202-40-1	flutizenol (INN)	
293490	52867-77-3	fluzoperine (INN)	
293490	15687-22-6	folescutol (INN)	
293490	18053-31-1	fominoben (INN)	
293490	17692-39-6	fomocaine (INN)	
293490	22514-23-4	fopirtoline (INN)	
293490	37132-72-2	fotretamine (INN)	
293490	60248-23-9	fuprazole (INN)	
293490	556-12-7	furalazine (INN)	
293490	139-91-3	furaltadone (INN)	
293490	1239-29-8	furazabol (INN)	
293490	67-45-8	furazolidone (INN)	
293490	5118-17-2	furazolium chloride (INN)	
293490	85666-24-6	furegrelate (INN)	
293490	2385-81-1	furethidine (INN)	
293490	6281-26-1	furmethoxadone (INN)	
293490	138661-03-7	fumidipine (INN)	
293490	56119-96-1	furodazole (INN)	
293490	804-30-8	fursultiamine (INN)	
293490	7761-75-3	furterene (INN)	
293490	64603-91-4	gaboxadol (INN)	
293490	124012-42-6	galocitabine (INN)	
293490	95058-81-4	gemcitabine (INN)	
293490	80763-86-6	glunicate (INN)	
293490	59128-97-1	haloxazolam (INN)	
293490	7247-57-6	heteronium bromide (INN)	
293490	3105-97-3	hycanthone (INN)	
293490	611-53-0	ibacitabine (INN)	
293490	130308-48-4	icatibant (INN)	
293490	79944-58-4	idazoxan (INN)	
293490	54-42-2	idoxundine (INN)	
293490	3778-73-2	ifosfamide (INN)	
293490	119719-11-8	ilatretotide (INN)	
293490	137214-72-3	iliparici (INN)	
293490	133454-47-4	iopendone (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	81167-16-0	imiloxan (INN)	
293490	318-23-0	imolamine (INN)	
293490	60929-23-9	indeloxazine (INN)	
293490	39178-37-5	inicarone (INN)	
293490	58-63-9	inosine (INN)	
293490	13445-12-0	iobutoic acid (INN)	
293490	51934-76-0	iomonic acid (INN)	
293490	83656-38-6	ipramidil (INN)	
293490	105118-13-6	iprotiazem (INN)	
293490	97682-44-5	irinotecan (INN)	293990
293490	57067-46-6	isamoxole (INN)	
293490	59-63-2	isocarboxazid (INN)	
293490	107320-86-5	isomolpan (INN)	
293490	482-15-5	isothipendyl (INN)	
293490	75949-60-9	isoxaprolol (INN)	
293490	34552-84-6	isoxicam (INN)	
293490	75695-93-1	isrodipine (INN)	
293490	84625-61-6	itraconazole (INN)	
293490	53003-81-9	ivanmod (INN)	
293490	27223-35-4	ketazolam (INN)	
293490	65277-42-1	ketoconazole (INN)	
293490	34580-13-7	ketotifen (INN)	
293490	134678-17-4	lamivudine (INN)	
293490	101530-10-3	lanoconazole (INN)	
293490	108736-35-2	lanreotide (INN)	
293490	75706-12-6	leflunomide (INN)	
293490	26513-90-6	letimide (INN)	
293490	14769-73-4	levamisole (INN)	
293490	94535-50-9	levcromakalim (INN)	
293490	339-72-0	levcyclosetone (INN)	
293490	100986-85-4	levofloxacin (INN)	
293490	3795-88-8	levofurafadone (INN)	
293490	5666-11-5	levomoramide (INN)	
293490	4792-18-1	levoxadrol (INN)	
293490	128620-82-6	limazocic (INN)	
293490	75358-37-1	linoglrinde (INN)	
293490	33876-97-0	linsidomine (INN)	
293490	72444-63-4	lodiperone (INN)	
293490	70374-39-9	lomoxicam (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	76612-20-9	lortalamine (INN)	
293490	1977-10-2	loxapine (INN)	
293490	121288-39-9	loxoribine (INN)	
293490	479-50-5	lucanthone (INN)	
293490	76743-10-7	lucartamide (INN)	
293490	85118-42-9	lufuradom (INN)	
293490	83903-06-4	lupitidine (INN)	
293490	88859-04-5	mafosfamide (INN)	
293490	35846-53-8	maitansine (INN)	
293490	59937-28-9	malotilate (INN)	
293490	115550-35-1	marbofloxacin (INN)	
293490	65509-24-2	maroxepin (INN)	
293490	42024-98-6	mazaticol (INN)	
293490	53-31-6	medibazine (INN)	
293490	13355-00-5	melarsonyl potassium (INN)	
293490	494-79-1	melarsoprol (INN)	
293490	83784-21-8	menabitan (INN)	
293490	70-07-5	mephenoxalone (INN)	
293490	17854-59-0	mepixanox (INN)	
293490	4295-63-0	meprotixol (INN)	
293490	29053-27-8	meseclazone (INN)	
293490	34262-84-5	mesocarb (INN)	
293490	135-58-0	mesulfen (INN)	
293490	1665-48-1	metaxalone (INN)	
293490	493-78-7	methaphenilene (INN)	
293490	91-80-5	methapyriene (INN)	
293490	721-19-7	methastyndone (INN)	
293490	5800-19-1	metapine (INN)	
293490	42110-58-7	metioxate (INN)	
293490	20229-30-5	metitepine (INN)	
293490	4969-02-2	metixene (INN)	
293490	17692-22-7	metizoline (INN)	
293490	103980-45-6	metostienol (INN)	
293490	22013-23-6	metoxepin (INN)	
293490	23707-33-7	metrifudil (INN)	
293490	31868-18-5	mexazolam (INN)	
293490	94149-41-4	midesteine (INN)	
293490	37065-29-5	miloxacin (INN)	
293490	25905-77-5	minaprine (INN)	



HS 6	CAS #	Description	Alternative Classification
293490	85118-44-1	minocromil (INN)	
293490	117523-47-4	mirfentanil (INN)	
293490	7696-00-6	mitotenamine (INN)	
293490	50924-49-7	mizonibine (INN)	
293490	15518-84-0	mobecarb (INN)	
293490	71320-77-9	moclobemide (INN)	
293490	78967-07-4	mofezolac (INN)	
293490	54063-50-2	mofloverine (INN)	
293490	29936-79-6	mofoxime (INN)	
293490	5581-46-4	molinazone (INN)	
293490	7416-34-4	molindone (INN)	
293490	94746-78-8	molracetam (INN)	
293490	25717-80-0	molsidomine (INN)	
293490	132019-54-6	monatepil (INN)	
293490	90243-66-6	montirelin (INN)	
293490	75841-82-6	mopidralazine (INN)	
293490	19395-58-5	moquizone (INN)	
293490	20574-50-9	morantel (INN)	
293490	6536-18-1	morazone (INN)	
293490	31848-01-8	morclofone (INN)	
293490	41152-17-4	morforex (INN)	
293490	952-54-5	monnamide (INN)	
293490	65847-85-0	mornifumate (INN)	
293490	35843-07-3	morocromen (INN)	
293490	3731-59-7	moroxydine (INN)	
293490	469-81-8	morpheridine (INN)	
293490	3780-72-1	morsuximide (INN)	
293490	112885-41-3	mosapride (INN)	
293490	90697-57-7	motapizone (INN)	
293490	17692-56-7	moxicoumone (INN)	
293490	82239-52-9	moxirapnne (INN)	
293490	52279-59-1	moxnidazole (INN)	
293490	66203-94-9	murocamide (INN)	
293490	58019-65-1	nabazenil (INN)	
293490	66556-74-9	nabitan (INN)	
293490	53-84-9	nadide (INN)	
293490	84145-90-4	nafoxadol (INN)	
293490	28820-28-2	naftoxate (INN)	
293490	101506-83-6	namiroteno (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	22292-91-7	naranol (INN)	
293490	120819-70-7	naroparcil (INN)	
293490	88058-88-2	naxagolide (INN)	
293490	69049-73-6	nedocromil (INN)	
293490	86636-93-3	nefumozone (INN)	
293490	13669-70-0	nefopam (INN)	
293490	99453-84-6	neltexine (INN)	
293490	99803-72-2	nerbacadol (INN)	
293490	90326-85-5	nesapidil (INN)	
293490	4397-91-5	nicofurate (INN)	
293490	95058-70-1	nictiazem (INN)	
293490	555-84-0	nifuradene (INN)	
293490	4936-47-4	nifuratel (INN)	
293490	5036-03-3	nifurdazil (INN)	
293490	3363-58-4	nifurfoline (INN)	
293490	15179-96-1	nifurimide (INN)	
293490	26350-39-0	nifurizone (INN)	
293490	18857-59-5	nifurazole (INN)	
293490	57474-29-0	nifuroquine (INN)	
293490	24632-47-1	nifurpipone (INN)	
293490	13411-16-0	nifurpinnol (INN)	
293490	1614-20-6	nifurprazine (INN)	
293490	5055-20-9	nifurquinazol (INN)	
293490	23256-30-6	nifurtimox (INN)	
293490	1088-92-2	nifurtoinol (INN)	
293490	1900-13-6	nifurvidine (INN)	
293490	39978-42-2	nifurzide (INN)	
293490	50435-25-1	nimidane (INN)	
293490	6506-37-2	nimorazole (INN)	
293490	6363-02-6	nitramisole (INN)	
293490	67-20-9	nitrofurantoin (INN)	
293490	110588-56-2	noberastine (INN)	
293490	31430-18-9	nocodazole (INN)	
293490	16985-03-8	nonabine (INN)	
293490	75963-52-9	nuclomedone (INN)	
293490	36471-39-3	nuclotixene (INN)	
293490	57726-65-5	nufenoxole (INN)	
293490	129029-23-8	ocapendone (INN)	
293490	78410-57-8	ociltide (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	56391-55-0	octazamide (INN)	
293490	131796-63-9	odapipam (INN)	
293490	83380-47-6	ofloxacin (INN)	
293490	132539-06-1	olanzapine (INN)	
293490	39567-20-9	olpimedone (INN)	
293490	64224-21-1	oltipraz (INN)	
293490	60175-95-3	omonasteine (INN)	
293490	78994-24-8	ormeloxifene (INN)	
293490	16509-11-8	otimerate sodium (INN)	
293490	16485-05-5	oxadimidine (INN)	
293490	26629-87-8	oxafl ozone (INN)	
293490	56969-22-3	oxapadol (INN)	
293490	6577-41-9	oxapium iodide (INN)	
293490	21256-18-8	oxaprozin (INN)	
293490	27591-42-0	oxazidione (INN)	
293490	24143-17-7	oxazolam (INN)	
293490	25392-50-1	oxazorone (INN)	
293490	17692-63-6	oxitefonium bromide (INN)	
293490	72830-39-8	oxmetidine (INN)	
293490	90729-41-2	oxodipine (INN)	
293490	959-14-8	oxolamine (INN)	
293490	14698-29-4	oxolinic acid (INN)	
293490	5585-93-3	oxypendyl (INN)	
293490	124423-84-3	panadiplon (INN)	
293490	115-67-3	paramethadione (INN)	
293490	26513-79-1	paraxazone (INN)	
293490	61400-59-7	parconazole (INN)	
293490	61869-08-7	paroxetine (INN)	
293490	114716-16-4	pemedolac (INN)	
293490	2152-34-3	pemoline (INN)	
293490	77-12-3	pentacyinium chloride (INN)	
293490	138661-02-6	pentetreotide (INN)	
293490	81382-51-6	pentiapine (INN)	
293490	55694-83-2	pentizidone (INN)	
293490	53910-25-1	pentostatin (INN)	
293490	57083-89-3	peralopride (INN)	
293490	62435-42-1	perfosfamide (INN)	
293490	2055-44-9	perisoxal (INN)	
293490	467-84-5	phenadoxone (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	634-03-7	phendimetrazine (INN)	
293490	134-49-6	phenmetrazine (INN)	
293490	115-55-9	phenylthione (INN)	
293490	76732-75-7	picartamide (INN)	
293490	72467-44-8	piclonidine (INN)	
293490	39577-19-0	picumast (INN)	
293490	56208-01-6	pifamine (INN)	
293490	27199-40-2	pifexole (INN)	
293490	54341-02-5	piflutixol (INN)	
293490	314-03-4	pimethixene (INN)	
293490	38955-22-5	pinadoline (INN)	
293490	53251-94-8	pinaverium bromide (INN)	
293490	14008-66-3	pinoxepin (INN)	
293490	2167-85-3	pipazetate (INN)	
293490	59-39-2	piperoxan (INN)	
293490	24886-52-0	pipofezine (INN)	
293490	23744-24-3	pipoxolan (INN)	
293490	40680-87-3	piprofurol (INN)	
293490	30868-30-5	pirazofurin (INN)	
293490	1043-21-6	pirenoxine (INN)	
293490	3605-01-4	piribedil (INN)	
293490	36322-90-4	piroxicam (INN)	
293490	132722-74-8	pirsidomine (INN)	
293490	59840-71-0	pitenodil (INN)	
293490	15574-96-6	pizotifen (INN)	
293490	63394-05-8	plafibrade (INN)	
293490	140-65-8	pramocaine (INN)	
293490	103177-37-3	pranlukast (INN)	
293490	52549-17-4	pranoprofen (INN)	
293490	92623-83-1	pravadoline (INN)	
293490	19216-56-9	prazosin (INN)	
293490	47543-65-7	prenoxidiazine (INN)	
293490	30840-27-8	pretiadil (INN)	
293490	69425-13-4	prifelone (INN)	
293490	70833-07-7	prifuroline (INN)	
293490	36505-82-5	prodolic acid (INN)	
293490	34740-13-1	profexalone (INN)	
293490	3615-74-5	promolate (INN)	
293490	33743-96-3	proroxan (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	303-69-5	prothipendyl (INN)	
293490	2622-24-4	prothixene (INN)	
293490	58416-00-5	protiofate (INN)	
293490	5696-09-3	proxazole (INN)	
293490	69815-38-9	proxorphan (INN)	
293490	15686-83-6	pyrantel (INN)	
293490	7035-04-3	pyridarone (INN)	
293490	86048-40-0	quazolast (INN)	
293490	54340-59-9	quincarbate (INN)	
293490	62265-68-3	quinfamide (INN)	
293490	545-59-5	racemoramide (INN)	
293490	84449-90-1	raloxifene (INN)	
293490	84071-15-8	ramixotidine (INN)	
293490	30271-85-3	razinodil (INN)	
293490	71620-89-8	reboxetine (INN)	
293490	76053-16-2	reclazepam (INN)	
293490	73080-51-0	repirinast (INN)	
293490	36791-04-5	ribavirin (INN)	
293490	7724-76-7	riboprine (INN)	
293490	72559-06-9	rifabutin (INN)	
293490	132014-21-2	rilmakalim (INN)	
293490	54187-04-1	rilmenidine (INN)	
293490	106266-06-2	risperidone (INN)	
293490	87051-43-2	ritanserin (INN)	
293490	91833-77-1	rocastine (INN)	
293490	119302-91-9	rocuronium bromide (INN)	
293490	109543-76-2	romazart (INN)	
293490	38373-83-0	romifenone (INN)	
293490	101363-10-4	rufloxacin (INN)	
293490	126294-30-2	sagandipine (INN)	
293490	5578-73-4	sanguinarium chloride (INN)	
293490	110588-57-3	saperconazole (INN)	
293490	121617-11-6	saviprazole (INN)	
293490	79262-46-7	savoxepin (INN)	
293490	29050-11-1	seciazone (INN)	
293490	5610-40-2	securnine (INN)	
293490	116476-13-2	semotiadil (INN)	
293490	99592-32-2	sertaconazole (INN)	
293490	86487-64-1	setoperone (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	138778-28-6	siratiazem (INN)	
293490	53123-88-9	sirolimus (INN)	
293490	3064-61-7	sodium stibocaptate (INN)	
293490	4448-96-8	solyptertine (INN)	
293490	68367-52-2	sorbiniil (INN)	
293490	77181-69-2	sorivudine (INN)	
293490	95105-77-4	somidipine (INN)	
293490	90243-97-3	spiclamine (INN)	
293490	87151-85-7	spiradoline (INN)	
293490	83647-97-6	spirapril (INN)	
293490	83602-05-5	spiraprilat (INN)	
293490	41992-23-8	spirogermanium (INN)	
293490	1054-88-2	spiroxatrine (INN)	
293490	3056-17-5	stavudine (INN)	
293490	72324-18-6	stepronin (INN)	
293490	54340-66-8	subendazole (INN)	
293490	56030-54-7	sufentanil (INN)	
293490	37753-10-9	sufosfamide (INN)	
293490	58095-31-1	sulbenox (INN)	
293490	350-12-9	sulbentine (INN)	
293490	77590-92-2	suproclone (INN)	
293490	40828-46-4	suprofen (INN)	
293490	53813-83-5	suriclone (INN)	
293490	104987-11-3	tacrolimus (INN)	
293490	101626-70-4	talipexole (INN)	
293490	67489-39-8	talmetacin (INN)	
293490	66898-62-2	talnifumate (INN)	
293490	21489-20-3	talsupram (INN)	
293490	42408-80-0	tandamine (INN)	
293490	106073-01-2	taniplon (INN)	
293490	19388-87-5	taurolidine (INN)	
293490	124066-33-7	taurosteine (INN)	
293490	38668-01-8	tauruitam (INN)	
293490	79253-92-2	taziprinone (INN)	
293490	55837-23-5	teftutixol (INN)	
293490	17902-23-7	tegafur (INN)	
293490	80880-90-6	telenzepine (INN)	
293490	111902-57-9	temocapril (INN)	
293490	120210-48-2	tenidap (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	100599-27-7	tenidap (INN)	
293490	82650-83-7	tenilapine (INN)	
293490	62473-79-4	teniloxazine (INN)	
293490	86696-86-8	tenisetam (INN)	
293490	29767-20-2	teniposide (INN)	
293490	21500-98-1	tenocyclidine (INN)	
293490	95232-68-1	tenosal (INN)	
293490	129336-81-8	tenosiprol (INN)	
293490	59804-37-4	tenoxicam (INN)	
293490	893-01-6	tenylidone (INN)	
293490	63590-64-7	terazosin (INN)	
293490	67915-31-5	terconazole (INN)	
293490	86433-40-1	terflavoxate (INN)	
293490	121277-96-1	terikalant (INN)	
293490	25683-71-0	terizidone (INN)	
293490	119625-78-4	terlakiren (INN)	
293490	14636-12-5	terlipressin (INN)	
293490	59653-74-6	teroxirone (INN)	
293490	34784-64-0	tertatolol (INN)	
293490	5036-02-2	tetramisole (INN)	
293490	86-12-4	thenalidine (INN)	
293490	4304-40-9	thanium closilate (INN)	
293490	91-79-2	thenyldiamine (INN)	
293490	7219-91-2	thihexinol methylbromide (INN)	
293490	2240-21-3	thiofuradene (INN)	
293490	115103-54-3	tiagabine (INN)	
293490	31428-61-2	tiamenidine (INN)	
293490	51527-19-6	tianafac (INN)	
293490	66981-73-5	tianeptine (INN)	
293490	57010-31-8	tiapamil (INN)	
293490	14785-50-3	tiapirinol (INN)	
293490	33005-95-7	tiaprofenic acid (INN)	
293490	71116-82-0	tiaprost (INN)	
293490	5845-26-1	tiazesim (INN)	
293490	63996-84-9	tibalosin (INN)	
293490	97852-72-7	tibenelast (INN)	
293490	15686-72-3	tibrofan (INN)	
293490	70-10-0	ticlatone (INN)	
293490	55142-85-3	ticlopidine (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	144-12-7	tiemonium iodide (INN)	
293490	40180-04-9	tienilic acid (INN)	
293490	75458-65-0	tiencarbine (INN)	
293490	37967-98-9	tielopramine (INN)	
293490	90055-97-3	tiexolol (INN)	
293490	39754-64-8	tifemoxone (INN)	
293490	81656-30-6	tifluadom (INN)	
293490	89875-86-5	tiflucarbine (INN)	
293490	14176-49-9	tiletamine (INN)	
293490	58433-11-7	tilomisole (INN)	
293490	42239-60-1	tilozepine (INN)	
293490	96306-34-2	timelotem (INN)	
293490	35035-05-3	timepidium bromide (INN)	
293490	26839-75-8	timolol (INN)	
293490	50708-95-7	tinabinal (INN)	
293490	66788-41-8	tinofedrine (INN)	
293490	24237-54-5	tinoridine (INN)	
293490	22619-35-8	tiocloमारol (INN)	
293490	65899-73-2	tioconazole (INN)	
293490	66969-81-1	tiodazosin (INN)	
293490	38070-41-6	tiodonium chloride (INN)	
293490	61220-69-7	tiopinac (INN)	
293490	87691-91-6	tiospirone (INN)	
293490	34976-39-1	tioxacin (INN)	
293490	40198-53-6	tioxaprofen (INN)	
293490	4991-65-5	tioxolone (INN)	
293490	95588-08-2	tipentosin (INN)	
293490	5169-78-8	tipepidine (INN)	
293490	54376-91-9	tipetropium bromide (INN)	
293490	7489-66-9	tipindole (INN)	
293490	83153-39-3	tipinnast (INN)	
293490	71731-58-3	tiquizium bromide (INN)	
293490	35423-51-9	tisocromide (INN)	
293490	80680-05-3	tivanidazole (INN)	
293490	2949-95-3	tixadil (INN)	
293490	83573-53-9	tizabrin (INN)	
293490	51322-75-9	tizanidine (INN)	
293490	29218-27-7	toloxatone (INN)	
293490	123948-87-8	topotecan (INN)	



HS 6	CAS #	Description	Alternative Classification
293490	655-05-0	tozalinone (INN)	
293490	103624-59-5	traboxopine (INN)	
293490	4047-34-1	trantelinium bromide (INN)	
293490	58712-69-9	traxanox (INN)	
293490	35943-35-2	tricitiribine (INN)	
293490	70-00-8	trifludine (INN)	
293490	68-91-7	trimetaphan camsilate (INN)	
293490	127-48-0	trimethadione (INN)	
293490	635-41-6	trimetozine (INN)	
293490	35619-65-9	tritiozine (INN)	
293490	14504-73-5	tritoqualine (INN)	
293490	47420-28-0	trioxolane (INN)	
293490	22089-22-1	trofosfamide (INN)	
293490	27574-24-9	tropatepine (INN)	
293490	108001-60-1	troquidazole (INN)	
293490	84697-22-3	tubulozole (INN)	
293490	116289-53-3	tulopafant (INN)	
293490	118812-69-4	ularitide (INN)	350400
293490	109683-61-6	utibapril (INN)	
293490	109683-79-6	utibaprilat (INN)	
293490	64860-67-9	valperinol (INN)	
293490	17692-71-6	vanitolidide (INN)	
293490	103222-11-3	vapreotide (INN)	
293490	5536-17-4	vidarabine (INN)	
293490	46817-91-8	viloxazine (INN)	
293490	89651-00-3	voxergolide (INN)	
293490	81801-12-9	xamoterol (INN)	
293490	14008-71-0	xanthiol (INN)	
293490	52832-91-4	xinomiline (INN)	
293490	7361-61-7	xylazine (INN)	
293490	7481-89-2	zalcitabine (INN)	
293490	109826-26-8	zaldaride (INN)	
293490	89482-00-8	zaltoprofen (INN)	
293490	127308-82-1	zamifenacin (INN)	
293490	28810-23-3	zepastine (INN)	
293490	30516-87-1	zidovudine (INN)	
293490	111406-87-2	zileuton (INN)	
293490	84697-21-2	zinoconazole (INN)	
293490	52867-74-0	zoloperone (INN)	

HS 6	CAS #	Description	Alternative Classification
293490	121929-20-2	zoniclezole (INN)	
293490	26615-21-4	zotepine (INN)	
293490	61-80-3	zoxazolamine (INN)	
293490	53772-83-1	zuclopenthixol (INN)	
293500	59-66-5	acetazolamide (INN)	
293500	968-81-0	acetoexamide (INN)	
293500	3184-59-6	alipamide (INN)	
293500	81982-32-3	alpiropride (INN)	
293500	5588-16-9	altizide (INN)	
293500	3754-19-6	ambuside (INN)	
293500	1421-68-7	amidefrine mesilate (INN)	
293500	85320-68-9	amosulalol (INN)	
293500	51264-14-3	amsacrine (INN)	
293500	74863-84-6	argatroban (INN)	
293500	133267-19-3	artilide (INN)	
293500	1150-20-5	azabon (INN)	
293500	27589-33-9	azosemide (INN)	
293500	1824-52-8	bemetizide (INN)	
293500	73-48-3	bendroflumethiazide (INN)	
293500	91-33-8	benzthiazide (INN)	
293500	104-22-3	benzylsulfamide (INN)	
293500	90992-25-9	besulpamide (INN)	
293500	36148-38-6	besunide (INN)	
293500	28395-03-1	bumetanide (INN)	
293500	7007-88-7	butadiazamide (INN)	
293500	2043-38-1	butizide (INN)	
293500	339-43-5	carbutamide (INN)	
293500	42583-55-1	carmetizide (INN)	
293500	138-41-0	carzenide (INN)	
293500	58-94-6	chlorothiazide (INN)	
293500	94-20-2	chlorpropamide (INN)	
293500	77-36-1	chlortalidone (INN)	
293500	68475-40-1	cipropride (INN)	
293500	671-95-4	clofenamide (INN)	
293500	636-54-4	clopamide (INN)	
293500	2127-01-7	clorexolone (INN)	
293500	60200-06-8	clorsulon (INN)	
293500	742-20-1	cyclopenthiazide (INN)	
293500	2259-96-3	cyclothiazide (INN)	

HS 6	CAS #	Description	Alternative Classification
293500	79094-20-5	daltroban (INN)	
293500	3436-11-1	delfantrine (INN)	
293500	120-97-8	diclofenamide (INN)	
293500	22736-85-2	diflumidone (INN)	
293500	7456-24-8	dimetotiazine (INN)	
293500	96-62-8	dinsed (INN)	
293500	59032-40-5	disulergine (INN)	
293500	671-88-5	disulfamide (INN)	
293500	723-42-2	ditolamide (INN)	
293500	115256-11-6	dofetilide (INN)	
293500	120279-96-1	dorzolamide (INN)	
293500	100981-43-9	ebrotidine (INN)	
293500	1764-85-8	epitizide (INN)	
293500	1213-06-5	etebenecid (INN)	
293500	1824-58-4	ethiazide (INN)	
293500	64795-23-9	etisulergine (INN)	
293500	103745-39-7	fasudil (INN)	
293500	20287-37-0	fenquizone (INN)	
293500	80937-31-1	flosulide (INN)	
293500	56488-61-0	flubepride (INN)	
293500	148-56-1	flumethiazide (INN)	
293500	54-31-9	furosemide (INN)	
293500	52157-91-2	galosemide (INN)	
293500	51876-98-3	gliamilide (INN)	
293500	10238-21-8	glibenclamide (INN)	
293500	26944-48-9	glibornuride (INN)	
293500	36980-34-4	glicaramide (INN)	
293500	24455-58-1	glicetanile (INN)	
293500	21187-98-4	gliclazide (INN)	
293500	52994-25-9	glicondamide (INN)	
293500	3074-35-9	glidazamide (INN)	
293500	35273-88-2	gliflumide (INN)	
293500	93479-97-1	glimepiride (INN)	
293500	37598-94-0	glipalamide (INN)	
293500	32797-92-5	glipentide (INN)	
293500	29094-61-9	glipizide (INN)	
293500	33342-05-1	gliquidone (INN)	
293500	52430-65-6	glisamuride (INN)	
293500	71010-45-2	glisindamide (INN)	

HS 6	CAS #	Description	Alternative Classification
293500	24477-37-0	gliisolamide (INN)	
293500	25046-79-1	glisoxepide (INN)	
293500	7007-76-3	glucosulfamide (INN)	
293500	535-65-9	glybuthiazol (INN)	
293500	1492-02-0	glybuzole (INN)	
293500	631-27-6	glycocypramide (INN)	
293500	664-95-9	glycyclamide (INN)	
293500	451-71-8	glyhexamide (INN)	
293500	3459-20-9	glymidine sodium (INN)	
293500	1038-59-1	glyoctamide (INN)	
293500	1228-19-9	glypinamide (INN)	
293500	80-34-2	glyprothiazol (INN)	
293500	3567-08-6	glysobuzole (INN)	
293500	80-13-7	halazone (INN)	
293500	1034-82-8	heptoiamide (INN)	
293500	13957-38-5	hydrobentizide (INN)	
293500	58-93-5	hydrochlorothiazide (INN)	
293500	135-09-1	hydroflumethiazide (INN)	
293500	122647-31-8	ibutilide (INN)	
293500	26807-65-8	indapamide (INN)	
293500	42792-26-7	isosulpride (INN)	
293500	23672-07-3	levosulpiride (INN)	
293500	120824-08-0	linotroban (INN)	
293500	68677-06-5	lorapride (INN)	
293500	138-39-6	mafenide (INN)	
293500	515-57-1	maleylsulfathiazole (INN)	
293500	3568-00-1	mebutizide (INN)	
293500	7195-27-9	mefruside (INN)	
293500	122-89-4	mesulfamide (INN)	
293500	7541-30-2	mesuprine (INN)	
293500	565-33-3	metahexamide (INN)	
293500	554-57-4	methazolamide (INN)	
293500	135-07-9	methyclothiazide (INN)	
293500	77989-60-7	metibride (INN)	
293500	1084-65-7	meticrane (INN)	
293500	17560-51-9	metolazone (INN)	
293500	61477-95-0	monalazone disodium (INN)	
293500	121679-13-8	naratnptan (INN)	
293500	51803-78-2	nimesulide (INN)	

HS 6	CAS #	Description	Alternative Classification
293500	473-42-7	nitrosulfathiazole (INN)	
293500	1580-83-2	paraflutizide (INN)	
293500	21132-59-2	pazoxide (INN)	
293500	1766-91-2	penflutizide (INN)	
293500	485-24-5	phthalylsulfamethizole (INN)	
293500	85-73-4	phthalylsulfathiazole (INN)	
293500	39860-99-6	pipotiazine (INN)	
293500	55837-27-9	piretanide (INN)	
293500	346-18-9	polythiazide (INN)	
293500	57-66-9	probenecid (INN)	
293500	98-75-9	propazolamide (INN)	
293500	68556-59-2	prosulpride (INN)	
293500	73-49-4	quinethazone (INN)	
293500	64099-44-1	quisultazine (INN)	
293500	120688-08-6	risotilide (INN)	
293500	111974-60-8	ritolukast (INN)	
293500	22933-72-8	salazodine (INN)	
293500	2315-08-4	salazosulfadimidine (INN)	
293500	139-56-0	salazosulfamide (INN)	
293500	515-58-2	salazosulfathiazole (INN)	
293500	56302-13-7	satranidazole (INN)	
293500	101526-83-4	sematilide (INN)	
293500	123308-22-5	sezolamide (INN)	
293500	108894-39-9	sitalidone (INN)	
293500	3930-20-9	sotalol (INN)	
293500	13642-52-9	soterenol (INN)	
293500	498-78-2	stearyl sulfamide (INN)	
293500	116-43-8	succinylsulfathiazole (INN)	
293500	30279-49-3	suclofenide (INN)	
293500	34042-85-8	sudoxicam (INN)	
293500	2455-92-7	sulclamide (INN)	
293500	127-77-5	sulfabenz (INN)	
293500	127-71-9	sulfabenzamide (INN)	
293500	547-44-4	sulfacarbamide (INN)	
293500	21662-79-3	sulfacecole (INN)	
293500	144-80-9	sulfacetamide (INN)	
293500	80-32-0	sulfachlorpyridazine (INN)	
293500	485-41-6	sulfachrysoidine (INN)	
293500	17784-12-2	sulfacitine (INN)	

HS 6	CAS #	Description	Alternative Classification
293500	4015-18-3	sulfaciomide (INN)	
293500	54063-55-7	sulfacorazole (INN)	
293500	102-65-8	sulfaclozine (INN)	
293500	128-12-1	sulfadiazulfone sodium (INN)	
293500	68-35-9	sulfadiazine (INN)	
293500	115-68-4	sulfadicramide (INN)	
293500	122-11-2	sulfadimethoxine (INN)	
293500	57-68-1	sulfadimidine (INN)	
293500	2447-57-6	sulfadoxine (INN)	
293500	94-19-9	sulfaethidole (INN)	
293500	127-69-5	sulfafurazole (INN)	
293500	57-67-0	sulfaguanidine (INN)	
293500	27031-08-9	sulfaguanole (INN)	
293500	152-47-6	sulfalene (INN)	
293500	14376-16-0	sulfaloxic acid (INN)	
293500	65761-24-2	sulfamazone (INN)	
293500	127-79-7	sulfamerazine (INN)	
293500	127-58-2	sulfamerazine sodium (INN)	
293500	144-82-1	sulfamethizole (INN)	
293500	723-46-6	sulfamethoxazole (INN)	
293500	80-35-3	sulfamethoxy-pyridazine (INN)	
293500	3772-76-7	sulfametomidine (INN)	
293500	651-06-9	sulfametoxydiazine (INN)	
293500	32909-92-5	sulfametrole (INN)	
293500	1220-83-3	sulfamonomethoxine (INN)	
293500	729-99-7	sulfamoxole (INN)	
293500	122-16-7	sulfanitran (INN)	
293500	599-88-2	sulfaperin (INN)	
293500	526-08-9	sulfaphenazole (INN)	
293500	116-42-7	sulfaproxyline (INN)	
293500	852-19-7	sulfapyrazole (INN)	
293500	144-83-2	sulfapyridine (INN)	
293500	59-40-5	sulfaquinoxaline (INN)	
293500	599-79-1	sulfasalazine (INN)	
293500	632-00-8	sulfasomizole (INN)	
293500	3563-14-2	sulfasuccinamide (INN)	
293500	1984-94-7	sulfasymazine (INN)	
293500	72-14-0	sulfathiazole (INN)	
293500	515-49-1	sulfathiourea (INN)	

HS 6	CAS #	Description	Alternative Classification
293500	1161-88-2	sulfatolamide (INN)	
293500	23256-23-7	sulfatroxazole (INN)	
293500	13369-07-8	sulfatrozole (INN)	
293500	515-64-0	sulfisomidine (INN)	
293500	90207-12-8	sulicrinat (INN)	
293500	57479-88-6	sulimepride (INN)	
293500	121-64-2	sulocarbilate (INN)	
293500	110311-27-8	sulofenur (INN)	
293500	82666-62-4	sulosemide (INN)	
293500	72131-33-0	sulotroban (INN)	
293500	15676-16-1	sulpiride (INN)	
293500	60325-46-4	sulprostone (INN)	
293500	61-56-3	sultiame (INN)	
293500	73747-20-3	silverapride (INN)	
293500	103628-46-2	sumatriptan (INN)	
293500	32059-27-1	sumetizide (INN)	
293500	81428-04-8	taltrimide (INN)	
293500	106133-20-4	tamsulosin (INN)	
293500	85977-49-7	tauromustine (INN)	
293500	4267-05-4	teclothiazide (INN)	
293500	3692-44-2	thiohexamide (INN)	
293500	316-81-4	thiopropazine (INN)	
293500	3688-85-5	tiamizide (INN)	
293500	69387-87-7	tinisulpride (INN)	
293500	3313-26-6	tiotixene (INN)	
293500	56488-58-5	tizolemide (INN)	
293500	1156-19-0	tolazamide (INN)	
293500	64-77-7	tolbutamide (INN)	
293500	1027-87-8	tolpentamide (INN)	
293500	5588-38-5	tolpyramide (INN)	
293500	56211-40-6	torasemide (INN)	
293500	32295-18-4	tosifen (INN)	
293500	87051-13-6	tosulur (INN)	
293500	127-65-1	tosylchloramide sodium (INN)	
293500	133-67-5	trichlormethiazide (INN)	
293500	24243-89-8	triflumidate (INN)	
293500	73803-48-2	tripamide (INN)	
293500	52406-01-6	uredofos (INN)	
293500	119-85-7	vanyidisulfamide (INN)	

HS 6	CAS #	Description	Alternative Classification
293500	66644-81-3	veraipride (INN)	
293500	14293-44-8	xipamide (INN)	
293500	75820-08-5	zidapamide (INN)	
293500	37000-20-7	zinterol (INN)	
293500	68291-97-4	zonisamide (INN)	
293810	520-27-4	diosmin (INN)	
293810	30851-76-4	ethoxazonutoside (INN)	
293810	23869-24-1	monoxerutin (INN)	
293810	153-18-4	rutoside (INN)	
293810	7085-55-4	troxerutin (INN)	
293890	1111-39-3	acetyldigitoxin (INN)	
293890	36983-69-4	actodigin (INN)	
293890	17598-65-1	deslanoside (INN)	
293890	71-63-6	digitoxin (INN)	
293890	20830-75-5	digoxin (INN)	
293890	14144-06-0	disogluside (INN)	
293890	33419-42-0	etoposide (INN)	
293890	1405-76-1	gitalin, amorphous (INN)	
293890	3261-53-8	gitaloxin (INN)	
293890	10176-39-3	gitoformate (INN)	
293890	18719-76-1	keracyanin (INN)	
293890	17226-75-4	khelloside (INN)	
293890	17575-22-3	ianatoside C (INN)	
293890	33396-37-1	meproscillanin (INN)	
293890	30685-43-9	metidigoxin (INN)	
293890	131129-98-1	mipragoside (INN)	
293890	7242-04-8	pengitoxin (INN)	
293890	8063-80-7	polisaponin (INN)	
293890	466-06-8	proscillaridin (INN)	
293890	100345-64-0	siagoside (INN)	
293890	99759-19-0	tiqueside (INN)	
294000	10016-20-3	alfadex (INN)	
294000	56824-20-5	amiprilose (INN)	
294000	7585-39-9	betadex (INN)	
294000	-00-0	lactalfate (INN)	
294000	4618-18-2	lactulose (INN)	
294000	15351-13-0	nicofuranose (INN)	
294000	54182-58-0	sucralfate (INN)	
294000	57680-56-5	sucrosofate (INN)	



HS 6	CAS #	Description	Alternative Classification
294200	12182-48-8	glucalox (INN)	
294200	16037-91-5	sodium stibogluconate (INN)	
294200	12040-73-2	sucralox (INN)	
310270	156-62-7	calcium carbimide (INN)	
320300	547-17-1	xantofyl palmitate (INN)	
320412	3861-73-2	anazolene sodium (INN)	
320412	15722-48-2	olsalazine (INN)	
320413	548-62-9	methyrosanilinium chloride (INN)	
320413	92-31-9	tolonium chloride (INN)	
320419	7235-40-7	betacarotene (INN)	
320490	1461-15-0	oftasceine (INN)	
340212	8001-54-5	benzalkonium chloride (INN)	
340213	9004-95-9	cetomacrogol 1000 (INN)	
340213	9002-92-0	lauromacrogol 400 (INN)	
340213	57821-32-6	menfegol (INN)	
340213	9016-45-9	nonoxinol (INN)	
340213	9002-93-1	octoxinol (INN)	
350790	143003-46-7	algiucerase (INN)	
350790	105857-23-6	alteplase (INN)	
350790	9046-56-4	ancrod (INN)	
350790	81669-57-0	anistreplase (INN)	
350790	9039-61-6	batroxobin (INN)	
350790	9000-99-1	brinase (INN)	
350790	9001-00-7	bromelains (INN)	
350790	9001-09-6	chymopapain (INN)	
350790	9004-07-3	chymotrypsin (INN)	
350790	120608-46-0	duteplase (INN)	
350790	9004-09-5	fibrinolysin (human) (INN)	
350790	37326-33-3	hyalosidase (INN)	
350790	9001-54-1	hyaluronidase (INN)	
350790	9001-01-8	kallidinogenase (INN)	
350790	99821-44-0	nasaruplase (INN)	
350790	51899-01-5	ocrase (INN)	
350790	9016-01-7	orgotein (INN)	
350790	130167-69-0	pegaspargase (INN)	
350790	9001-74-5	penicillinase (INN)	
350790	-00-0	promelase (INN)	
350790	133652-38-7	reteplase (INN)	350400
350790	9001-62-1	rizoipase (INN)	

HS 6	CAS #	Description	Alternative Classification
350790	99149-95-8	saruplase (INN)	
350790	37312-62-2	serrapeptase (INN)	
350790	63551-77-9	sfericase (INN)	
350790	131081-40-8	silteplase (INN)	
350790	37340-82-2	streptodornase (INN)	
350790	9002-01-1	streptokinase (INN)	
350790	110294-55-8	sudismase (INN)	
350790	12211-28-8	sutilains (INN)	
350790	9002-04-4	thrombin (INN)	
350790	9031-11-2	tilactase (INN)	
350790	9039-53-6	urokinase (INN)	
380840	505-86-2	cetrimide (INN)	
382390	8063-24-9	acriflavinium chloride (INN)	
382390	87806-31-3	porfimer sodium (INN)	
382390	1338-39-2	sorbitan laurate (INN)	
382390	1338-43-8	sorbitan oleate (INN)	
382390	26266-57-9	sorbitan palmitate (INN)	
382390	8007-43-0	sorbitan sesquioleate (INN)	
382390	1338-41-6	sorbitan stearate (INN)	
382390	26658-19-5	sorbitan tristearate (INN)	
390190	25053-27-4	sodium apolate (INN)	
390290	71251-04-2	surfomer (INN)	
390461	9002-84-0	politef (INN)	
390590	9003-39-8	polyvidone (INN)	
390690	54182-57-9	carbomer (INN)	
390690	9003-97-8	polycarbophil (INN)	
390710	54531-52-1	polybenzarsol (INN)	
390720	25322-68-3	macrogol (INN)	
390720	-00-0	macrogol ester (INN)	
390720	9003-11-6	poloxalene (INN)	
390720	-00-0	polysorbate (INN)	
390720	25301-02-4	tyloxapol (INN)	
390730	9003-23-0	polyetadene (INN)	
390760	25038-59-9	pegoterate (INN)	
390799	26009-03-0	polyglycolic acid (INN)	
390810	25038-54-4	policapram (INN)	
390910	9011-05-6	polynoxylin (INN)	
390940	101418-00-2	policresulen (INN)	
391000	9006-65-9	dimeticone (INN)	

HS 6	CAS #	Description	Alternative Classification
391190	82230-03-3	carbetimer (INN)	
391190	54063-44-4	ferropolimaler (INN)	
391190	56959-18-3	glusoferron (INN)	
391190	41385-14-2	ieuciglumer (INN)	
391190	29535-27-1	maletamer (INN)	
391190	107667-60-7	polaprezinc (INN)	300390
391190	75345-27-6	polidronium chloride (INN)	
391190	90409-78-2	polifeprosan (INN)	
391190	41706-81-4	poliglecaprone (INN)	390799
391190	32289-58-0	polihexanide (INN)	
391220	9004-70-0	pyroxylin (INN)	
391231	9000-11-7	carmellose (INN)	
391239	-00-0	celucloral (INN)	
391239	8063-82-9	hypromellose (INN)	
391239	9004-67-5	methylcellulose (INN)	
391290	9004-36-8	cellaburate (INN)	
391290	9004-38-0	cellacefate (INN)	
391390	110042-95-0	acemannan (INN)	
391390	0-00-0	ardeparin sodium (INN)	
391390	64440-87-5	cideferron (INN)	
391390	9015-73-0	colextran (INN)	
391390	-00-0	dalteparin sodium (INN)	
391390	37209-31-7	detrafate (INN)	
391390	9004-54-0	dextran (INN)	
391390	56087-11-7	dextranomer (INN)	
391390	8063-26-1	dextriferron (INN)	
391390	-00-0	enoxaparin sodium (INN)	
391390	57680-55-4	gleptoferron (INN)	
391390	53973-98-1	poligeenan (INN)	
391390	9012-76-4	poligusam (INN)	
391390	9015-56-9	polygeline (INN)	
391390	9050-67-3	sizofran (INN)	
391390	57459-72-0	suleparoid sodium (INN)	
391400	50925-79-6	colestipol (INN)	
391400	11041-12-6	colestyramine (INN)	
391400	54182-62-6	polacrilin (INN)	
391400	56227-39-5	polidexide sulfate (INN)	

**ANNEX II - Prefixes and Suffixes for Salts, Esters and Hydrates of INNs**

ACETATE	CYCLOHEXYLAMMONIUM	GLUCOHEPTONATE
ACETONIDE	CYCLOHEXYLPROPIONATE	GLUCONATE
1-ACETOXYETHYL	DECANOATE	GLUCOSIDE
ACETYSALICYLATE	DIACETATE	GLYCOLATE
ADIPATE	DIAMMONIUM	GLYOXYLATE
ALLYL	DIBENZOATE	GOLD
ALLYL BROMIDE	DIBUTYRATE	HEMIHYDRATE
ALLYL IODIDE	DICHOLINE	HEMISULFATE
ALUMINIUM	DICYCLOHEXYLAMMONIUM	HEPTANOATE
AMINOSALICYLATE	DIETHYLAMINE	HEXAACETATE
AMMONIUM	DIETHYLAMMONIUM	HEXAHYDRATE
AMMONIUM FUSIDATE	DIFUROATE	HEXANOATE
ANTIPYRATE	DIHYDRATE	HIPPURATE
ARGININE	DIHYDROBROMIDE	HYDRATE
ASCORBATE	DIHYDROCHLORIDE	HYDROBROMIDE
AXETIL	DIHYDROCHLORIDE	HYDROCHLORIDE
BARBITURATE	PHOSPHATE	HYDROCHLORIDE DIHYDRATE
BENZENESULFONATE	DIHYDROGEN CITRATE	HYDROCHLORIDE
BENZOACETATE	DIHYDROGEN PHOSPHATE	HEMIHYDRATE
BENZYL	DIHYDROXYBENZOATE	HYDROCHLORIDE
BENZYL BROMIDE	DIMALATE	MONOHYDRATE
BENZYL IODIDE	DIMALEATE	HYDROCHLORIDE PHOSPHATE
BESILATE	DIMALONATE	HYDROGEN EDISILATE
BESYLATE	DIMESILATE	HYDROGEN FUMARATE
BIQUINATE	DINITRATE	HYDROGEN MALATE
BIS (HYDROGEN) MALATE	DINITROBENZOATE	HYDROGEN MALEATE
BIS (HYDROGEN) MALEATE	DIOXIDE	HYDROGEN MALONATE
BIS (HYDROGEN) MALONATE	DIPHOSPHATE	HYDROGEN OXALATE
BIS (PHOSPHATE)	DIPROPIONATE	HYDROGEN SUCCINATE
BISMUTH	DISODIUM	HYDROGEN SULFATE
BITARTRATE	DISODIUM PHOSPHATE	HYDROGEN SULFITE
BORATE	DISULFATE	HYDROGEN TARTRATE
BROMIDE	DISULFIDE	HYDROXIDE
BUTYL	DIUNDECANOATE	HYDROXYBENZOATE
t-BUTYL	EDISILATE	2-
t-BUTYL ACETATE	EMBOINATE	HYDROXYETHANESULFONATE
tert-BUTYL ACETATE	ENANTATE	HYDROXYNAPHTHOATE
tertiary BUTYL ACETATE	ENANTHATE	IODIDE
tertiary BUTYLAMINE	ESILATE	IRON CHLORIDE
t-BUTYL ESTER	ESTOLATE	ISETHIONATE
tert-BUTYL ESTER	ESYLATE	ISETIONATE
tertiary BUTYL ESTER	ETHANESULFONATE	ISOBUTYRATE
BUTYLATE	1,2-ETHANEDISULFONATE	ISONICOTINATE
BUTYLBROMIDE	ETHOBROMIDE	ISOPHTHALATE
BUTYRATE	ETHYL	ISOPROPIONATE
CALCIUM	ETHYL ESTER	ISOPROPYL
CALCIUM CHLORIDE	ETHYL IODIDE	LACTATE
CALCIUM DIHYDRATE	ETHYLAMINE	LACTOBIONATE
CAMPHOR-10-SUPHONATE	ETHYLAMMONIUM	LAURATE
CAMPHORATE	ETHYLENANTATE	LEVULINATE
CAMPHORSULFONATE	ETHYLHEXANOATE	LITHIUM
CAMSILATE	ETHYLSUCCINATE	LYSINATE
CAMSYLATE	FERROUS CITRATE	MAGNESIUM
CAPROATE	FLUORIDE	MALATE
CARBAMATE	FLUOROSULFONATE	MALATE
CARBONATE	FORMATE	MALONATE
CHLORIDE	FORMATE SODIUM	MANDELATE
8-CHLOROTHEOPHYLLINATE	FOSFATEX	MEGLUMINE
CHOLINE	FUMARATE	MESILATE
CINNAMATE	FUROATE	MESYLATE
CITRATE	GLUCARATE	METHANESULFONATE
CYCLOHEXANPROPIONATE	GLUCEPTATE	METHILSULFATE

METHYL ESTER  
METHYLBROMIDE  
4,4'-METHYLENEBIS(3-HYDROXY-2-NAPHTHOATE)  
METHYLENEDISALICYLATE  
N-METHYLGLUCAMINE  
METHYLIODIDE  
METHYLSULFATE  
METHYLSULPHATE  
MONOHYDRATE  
MONOHYDROCHLORIDE  
MONONITRATE  
N-CYCLOHEXYLSULPHAMATE  
N-OXIDE HYDROCHLORIDE  
NAFATE  
NAPADISILATE  
NAPADISYLATE  
1,5-NAPHTHALENESULFONATE  
2-NAPHTHALENESULFONATE  
NAPSILATE  
NAPSYLATE  
NICOTINATE  
NITRATE  
NITROBENZOATE  
OLEATE  
ORTHOPHOSPHATE  
OROTATE  
OXALATE  
OXIDE  
4-OXOPENTANOATE  
PALMITATE  
PALMITATE HYDROCHLORIDE  
PAMOATE  
PANTOTHENATE  
PANTOTHENATE SULFATE  
PENTAHYDRATE  
PERCHLORATE  
PHENYLPROPIONATE  
PHOSPHATE  
PHOSPHITE  
PHTHALATE  
PICRATE  
PIVALATE  
(PIVALOYLOXY)METHYL  
PIVOXIL  
PIVOXIL HYDROCHLORIDE  
POTASSIUM  
POTASSIUM SULFATE  
PROPIONATE  
PROPIONATEDODECYL  
SULPHATE  
PROPIONATE LAURYL SULFATE  
PROPYL  
PROPYL ESTER  
PYRIDYLACETATE  
QUINATE  
RESINATE  
SACCHARATE  
SALICYLATE  
SALICYLOYLACETATE  
SODIUM 3-SULPHOBENZOATE  
SODIUM HYDRATE  
SODIUMHYDROGEN  
PHOSPHATESODIUM  
METHANESULPHONATE  
SODIUM MONOHYDRATE  
SODIUM PHOSPHATE  
SODIUM SUCCINATE  
SODIUM SULFATE  
SODIUM SULFOBENZOATE  
SODIUM SULPHATE  
STEARATE  
SUCCINATE  
SUCCINIL  
SULFATE  
SULFINATE  
SULFITE  
SULFOSALICYLATE  
SULPHATE  
SULPHOSALICYLATE  
TANNATE  
TARTRATE  
TEBUTATE  
TEOCLATE  
TETRAHYDRATE  
TETRAHYDROPHTHALATE  
TETRASODIUM  
THEOCLATE  
THIOCYANATE  
P-TOLUENESULFONATE  
TOSILATE  
TOSYLATE  
TRIFLUOROACETATE  
TRIHYDRATE  
TRIIODIDE  
TRIMETHYLACETATE  
TRINITRATE  
TRIPALMITATE  
UNDEC-10-ENOATE  
UNDECANOATE  
UNDECYLENATE  
VALERATE  
ZINC

## ANNEX III.

**Salts, Esters and Hydrates of INN Active Ingredients  
Which are Not Classified in the Same HS Heading as the  
Active Ingredient.**

<u>U.S. 6</u>	<u>International Non-Proprietary Name (INN)</u>	<u>Salt, ester or hydrate of INN</u>	<u>U.S. 6</u>	<u>CAS</u>
2918.90	CARBENOXOLONE	CARBENOXOLONE DICHLORINE SALT	2923.10	742-92-2
2909.49	CHORPHENESIN	CHORPHENESIN CARBAMATE	2924.29	886-74-8
2907.29	DIENESTROL	DIENESTROL DIACETATE	2915.39	84-19-5
2907.29	DIETHYLSTILBESTROL	DIETHYLSTILBESTROL DIBUTYRATE	2915.60	74664-03-2
		DIETHYLSTILBESTROL DIFUROATE	2932.19	549-40-6
		DIETHYLSTILBESTROL DIPROPIONATE	2915.50	130-80-3
2918.90	ENOXOLONE	ENOXOLONE DIHYDROGENPHOSPHATE	2919.00	18416-35-8
2905.50	ETHCHLORVYNOL	ETHCHLORVYNOL CARBAMATE	2924.10	74263-35-3
2933.39	HALOPERIDOL	HALOPERIDOL LECITHATE	2933.90	74056-97-6
2907.29	HEXESTROL	HEXESTROL DIBUTYRATE	2915.60	36057-18-3
		HEXESTROL DIPROPIONATE	2915.50	59386-02-6
2934.90	PHENMETRAZINE	PHENMETRAZINE TEOCLATE	2939.50	13331-76-4
2934.30	PROETHAZINE	PROETHAZINE TEOCLATE	2939.50	17693-51-5

## ANNEX IV - ADDITIONAL PRODUCTS USED FOR THE MANUFACTURE OF FINISHED PHARMACEUTICAL PRODUCTS (INTERMEDIATES)

25-Mar-94

HS6	Cas No	Description
<b>2903.69</b>		
3312-04-7		1,1'-(4-Chlorobutylidene)bis(4-fluorobenzene)
620-20-2		m-Chlorobenzyl chloride
<b>2904.90</b>		
121-17-5		4-Chloro-3-nitrofluoromethylbenzene
<b>2905.22</b>		
505-32-8		Isophytol
<b>2905.50</b>		
920-66-1		Hexafluoroisopropanol
54322-20-2		Sodium 4-chloro-1-hydroxy-1-butane sulphonate
<b>2906.29</b>		
1570-95-2		2-Phenyl-1,3-propanediol
<b>2909.30</b>		
5111-65-9		2-Bromo-6-methoxynaphthalene
31264-51-4		3-Chloropropyl-2,5-xylol ether
<b>2909.50</b>		
63682-27-3		Monosodium salt of 3-Methoxy-4-hydroxy-phenyl acetone
<b>2910.90</b>		
56718-70-8		Oxirane[[4-(2-methoxyethyl)phenoxy]methyl]
<b>2911.00</b>		
94158-44-8		1,1-Dimethoxy-2-(2-methoxyethoxy) ethane

HS6	Cas No	Description
	20627-73-0	2-Nitrobenzaldehyde Dimethyl Acetal
	1132-95-2	Diisopropylcyclohexane
	2912.29	
	36649-09-1	9,10-Ethananthracene-9(10H)-acrolein
	2912.49	
	3453-33-6	6-Methoxy-2-naphthaldehyde
	2914.30	
	1210-35-1	10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-one
	2222-33-5	5-H-Dibenzo[a,d]cyclohepten-5-one
	645-13-6	Isobutyl acetophenone
	2914.49	
	85700-75-0	Pregna-1,4-diene-3,20-dione,11,17,21-trihydroxy-16-methyl-, (11 alpha, 16 beta)-
	2914.50	
	981-34-0	9.beta.11.beta-Epoxy 17.alpha.21-dihydroxy-16.beta-methylpregna-1,4-diene-3,20-dione (9,11-epoxide)
	2914.70	
	4252-78-2	2-Chloro-1-(2,4-dichlorophenyl) ethanone
	79836-44-5	4-(3,4-Dichlorophenyl)-1-Tetralone
	3874-54-2	4-Chloro-1-(4-fluorophenyl)-1-butanone
	43076-61-5	4-Chloro-1-[4-(1,1-dimethylethyl)phenyl]-1-butanone
	2915.39	
	24510-54-1	18.alpha-Methyl-1,4-pregnadiene-17.alpha.21-diol-3,20-dione 21 acetate
	131266-10-9	2-Acetoxyethyl 4-benzoyloxybutyl-1 acetate
	127047-77-2	2-Acetoxyethyl 4-iodobutyl-1 acetate



HS6	Cas No	Description
910-99-6		21-Acetoxy-17-alpha-hydroxy-16-beta-methylpregna-1,4,9,14-tetraene-3,20-dione
24510-55-2		21-Acetoxy-17-alpha-hydroxy-16-beta-methylpregna-1,4-diene-3,20-dione
10106-41-9		delta-8,11-Anhydro-16-alpha-methylprednisoloneacetate
2916.39		2-Chloro-1,5-difluorobenzoic acid
110877-64-0		alpha-(2-Bromoethyl) alpha-phenylbenzenesulfonic acid
37742-98-6		Mono-4-nitrobenzyl malonate magnesium salt dihydrate
2917.19		Monophenyl phenyl malonate
83972-01-4		Calcium lactate gluconate
2917.39		D-Mandelic Acid
21601-78-5		1,2,6,7,8-alpha-Hexahydro beta beta, delta delta beta-dihydroxy-2 beta,6 alpha-dimethyl-8 alpha-(2 beta-methyl-1-oxobutoxy)-1 beta-naphthaleneheptanoic acid, ammonium salt
2918.16 or 2918.19		8(S)-(2,2-dimethyl-1-oxobutoxy)-1,2,6,7,8,8-alpha(R), hexahydro- beta(R), delta(R)-dihydroxy-2(S),6(R)-dimethyl-1(S)-naphthaleneheptanoic acid, ammonium salt
11116-97-5		D(-)alpha-Farmyloxy-alpha-phenylacetyl chloride
2918.17		Methyl(R)-(-)-3-hydroxybutyrate
811-71-2		3-(2-Chloro-4,5-difluorophenyl)-3-oxopropionic acid ethyl ester
2918.19		Ethyl-2-oxo-4-phenylbutanoate
775(-) 37-5		(6-alpha,11-beta,16-alpha,17-alpha)-6,9-Difluoro-11,17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carboxylic acid
1396-33-43-9		
29169-64-0		
3976-69-0		
2918.30		
121873-00-5		
64920-29-2		
2918.90		
28416-82-2		

HS6	Cas No	Description
	30131-18-9	4-(Phenylbutoxy) benzoic acid
	87-13-8	Diethyl ethoxymethylene malonate
	111006-10-1	Isobutyl-3,4-epoxybutanoate
	28754-58-3	Methyl 5-glyoxy-N,2-hydroxybenzoate hydrate
	<b>2920.90 or 2919.00</b>	
	55-91-4	Phosphorofluoridic acid bis (1-methylethyl) ester
	2921.42	
	671-69-6	5-Chloroaniline-2,4-disulfonyl chloride
	2921.49	
	78617-99-5	1-Naphthalenamine 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-hydrochloride,trans (+, -)
	54388-44-0	alpha',alpha',alpha'-Trifluoro-2,3-xyldine
	103-67-3	N-Benzylmethylaniline
	3867-32-6	N-Methylpropylamine hydrochloride
	2922.19	
	38345-68-3	(1S,2R)-1-Benzyl-3-dimethylamino-2-methyl-1-phenylpropan-1-ol
	38345-68-3	(2S,3R)-(+)-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol
	23323-37-7	1-Deoxy-1-(octylamino)-D-glucitol
	120-20-7	2-(3,4-Dimethoxyphenyl)ethylaniline
	2922.30	
	2011-66-7	2-Amino-2-chloro-5-nitrobenzophenone
	2922.41	
	113403-10-4	Benzenoacetic acid, alpha-methyl-4-(2-methylpropyl)-(S)-, compound with L-lysine (1:1)
	2922.49	

HS6 Cas No	Description
82717-98-2	(S,S)-N-(1-(Carboethoxy-3-phenyl-propyl)alanine
14205-39-1	2-Butenoic acid,3-amino- methyl ester
56-12-2	4-Amino butyric acid
875-74-1	D(-)-alpha-Phenylglycine
20763-30-8	Dihydro phenyl glycine
34582-65-5	Potassium D(-)-alpha-[(3-methoxy-1-methyl-3-oxo-1-propenyl)-amino]phenyl acetate
13291-98-8	Sodium D(-)-alpha-[(3-methoxy-1-methyl-3-oxo-1-propenyl)-amino]- phenyl acetate
2922.50	
79814-47-4	(2S,3R), (+)-2-[(1S)-Hydroxyethyl-3-amino-1,5-pentane-dioic acid,5 methyl ester
24085-08-3	2-(N-Benzyl-N-tert-butylamino)-4'-hydroxy-3'-hydroxymethylacetophenone hydrochloride
90005-55-3	3-Amino-2'-hydroxyacetophenone hydrochloride
7206-70-4	4-Amino-5-chloro-2-methoxybenzoic acid
94749-03-8	4-Hydroxy-alpha-1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol
55174-61-3	Benzene-ethanamine-3,4-dimethoxy-betamelhyl
22818-40-2	D(-)-4-Hydroxyphenyl glycine
69416-61-1	d(-)-4-Hydroxyphenyl glycine-chloride hydrochloride
NA	Ethyl-2-(2-chloro-4,5-difluoro-benzoyl)-3-(2,4-difluoro phenyl-amino)-2-acrylate
24085-03-8	N-Benzyl-N-tert-butyl-2'-hydroxy-2-(3'-hydroxymethyl-4'-hydroxyphenyl)ethylamine
69416-61-1	Potassium D(-)-alpha-[(3-methoxy-1-methyl-3-oxo-1-propenyl)-amino]-4-hydroxy phenyl acetate
26787-84-8	Sodium D(-)-alpha-[(3-methoxy-1-methyl-3-oxo-1-propenyl)-amino]-4-hydroxyphenyl acetate
2923.90	
132659-89-3	3-[[Dimethylamino]methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one

HS6	Cas No	Description
2924.10		
590-63-8		1-Propaneaminium 2 [(ammoniocarbonyloxy) N,N,N-trimethyl- chloride
5794-13-8		L-Asparagine monohydrate
125496-24-4		N,O-Diformyl-(S)-isoserine
5422-34-4		N-(2-Hydroxyethyl)lactamide
2924.29		
75885-58-4		2,2-Dimethylcyclopropyl carbamate
29122-68-7		2-[4-(2-Hydroxy-3-isopropyl aminopropyl)phenyl]acetamide
1939-27-1		2-Methyl-N-[3-(trifluoromethyl)phenyl]propanamide
136450-06-1		3-[4-(phenylbutoxy) benzoylamino]-2-hydroxyacetophenone
13255-50-0		4-Formyl-N-isopropylbenzamide
30566-92-8		5-(N,N-Dibenzylglycyl)calcylamide
141862-47-7		5-Glyoxyl-2-hydroxybenzamide hydrate
4093-31-6		Methyl 3-chloro-4-acetamido-6-methoxy-benzoate
3588-83-4		N-(Benzyl oxycarbonyl)-DL-valine
121-60-8		N-Acetylsulfanilyl chloride
2925.19		
84803-46-3		2,6-Piperidinedione 4-(4-chlorophenyl)
2926.90		
14818-98-5		(1)-N-(alpha-Cyano-4-hydroxy-3-methoxy-alpha methylphenethyl) acetamide
114772-53-1		[1,1'-Biphenyl]-2-carbonitrile, 4-methyl
56326-98-8		1-(4-Fluorophenyl)-4-oxocyclohexane-carbonitrile

HS6	Cas No	Description
32852-95-2		2-(3-Phenoxyphenyl)propanonitrile
13338-63-1		3,4,5-Triethoxyphenylacetamide
NA		3-Cyano-N-(1,1-dimethylethyl)-androst-3,5-diene-17 beta-carboxamide
36622-33-0		alpha-Isopropyl-3,4,5-trimethoxybenzyl cyanide
20850-49-1		alpha-Isopropyl-3,4-dimethoxy benzylcyanide
94-05-3		Ethyl ethoxymethylene cyanoacetate
2928.00		2-(Aminoxy)-2-methylpropanoic acid monohydrochloride
89766-91-6		N,para-Chlorobenzoyl-N,para-methoxyphenyl-hydrazine
16390-07-1		
2930.90		2-Naphthylchloroformate
10506-37-3		cis-5-Fluoro-2-methyl-1-(para-methylthio-benzylidene)-indene-3-acetic acid
48627-27-2		D-(-)-3-Acetylthio-2-methyl propanoic acid
67923-49-3		D-(-)-3-acetylthio-2-methyl-propanyl chloride
76497-39-7		D-(-)-Threo-2-amino-3-(4-methylsulfonylphenyl)-1,3-propanediol
51458-28-7		D-(-)-Threo-2-amino-3-(4-methylsulfonylphenyl)-1,3-propanediol hydrochloride
NA		
10191-60-3		Dimethyl N-cyanodithioamminocarbonate
583-91-5		DL-2-hydroxy-4-(methylthio) butanoic acid
63484-12-8		Methyl-2-methoxy-5-methylsulphonyl benzoate
27366-72-9		N,N-Dimethylaminodithioacetamide hydrochloride
67305-72-0		N-(2-Mercaptoethyl)-propanamide
61832-41-5		N-Methyl-1-(methylthio)-2-nitroethanamine

HS6	Cas No	Description
2931.00	NA	[(2-Methyl-1)-oxy]propyl[propyl-(4-phenylbutyl-1)-phosphinyl] acetate
87460-09-1		[(Hydroxy-4-phenylbutyl)phosphinyl] acetic acid benzyl ester
128948-01-63		[(2-Methyl-1-(1-oxopropyl)propyl)-(4-phenylbutyl) phosphinyl] acetic acid
35000-38-5		Tertiarybutyl (triphenyl-phosphoranylidene) acetate
2932.19		S <sub>2</sub> [(2-Aminoethyl)thio]methyl-N,N-dimethyl-2-furan methanamide diamine
66356-53-4		N-[2-(5-(Dimethylamino)methyl)-2-furylmethyl]thio-ethyl-N-methyl-2-nitro-1,1-ethenediamine
66357-35-5		(3S,4S)-3-Hexyl-4-[(R)-2-hydroxytridecyl]-2-oxetanone
2932.29		8-Methoxypaoralen
104872-06-2		alpha-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol
298-81-7		D-(+)-Dihydro-3-hydroxy-4,4-dimethyl-2(3H)-furanone
24155-42-8		DL-Dihydro-3-hydroxy-4,4-dimethyl-2(3H)-furanone
599-04-2		Imperatorin
79-50-5		2,3,4,6-Tetra-O-acetyl-8-D-glucopyranosyl carbamimidate monohydrobromide
482-44-0		Calcium lactobionate dihydrate
2932.90		Calcium-bromide lactobionate
40591-65-9		Lactobionic acid
110838-68-1		N-[Dihydro-3,3-diphenyl-2(3H)-furanylidene]-N-methylmethanaminium bromide
33659-28-8		1,2-Diphenyl-4-(2-phenylthioethyl)-3,5-pyrazolidinedione
96-82-2		
37743-18-3		
2933.19		
3736-92-3		

HS6	Cas No	Description
2933.29		
99614-02-5		1,2,3,8-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazolone
133909-99-6		1H-imidazole-5-methanol 2-butyl-4-chloro-1-[(2,2-(triphénylméthyl)-2H-tétrazol-5-yl)-(1,1'-biphényl)-4-yl]-méthyl
696-23-1		2-Méthyl-4(or 5)-nitro-imidazole
NA		2-Propyl-4(5)-carbométhoxy-5(4)-pentafluoroéthyl imidazole
103094-30-0		3-Ethyl-5-méthyl-4-(2-chlorophényl)-1,4-dihydro-2-[2-(1,3-dihydro-1,3-dioxo-2H-isolindol-2-yl)]éthoxy (méthyl)-6-méthyl-3,5-pyridine dicarboxylate
822-38-6		4-Méthylimidazole
130604-35-2		N-(2,4-Difluorophényl)-N-[5-(4,5-diphényl-1H-imidazol-2-ylthio)pentyl]-N-heptylurée
2933.39		
104860-73-3		(1S,1'S,4,4'-Amino-5,5'-chloro-1,1'-(3,4'-fluorophényl)propyl)-3-méthoxy-4-piperidinyl-2-méthoxybenzamide méthanol (1,1)
83898-64-0		(-)-trans-3-Méthyl-4-phényl-4-piperidine-carboxylic acid hydrobromide
NA		(4-Fluorophényl)-(4-piperidinyl)méthanone 4-méthylbenzènesulfonate (1,1)
2147-83-3		1,3-Dihydro-1-(1,2,3,6-tetrahydro-4-pyridinyl)-2H-benzimidazol-2-one
2066-53-7		1,3-Dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one
8355-85-8		1-(3-Chloropropyl)-2,6-diméthylpiperidine hydrochloride
7597U-99-9		1-[(4-Fluorophényl)méthyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine
83857-98-9		1H-imidazole-4-carboxaldéhyde, 2-butyl-5-chloro-
82671-06-5		2,6-Dichloro-5-fluoronicotinic acid
2942-59-8		2-Chloronicotinic acid
86604-78-6		3,5-Diméthyl-2-hydroxyméthyl-4-méthoxypyridine
39512-49-7		4-(4-Chlorophényl)-4-piperidino
61380-02-7		4-(Méthoxyméthyl)-N-phényl-1-(phénylméthyl)-4-piperidamine

HS6	Gas No	Description
139781-09-2		5,5-bis(4-pyridinylmethyl)-5H-cyclopenta [2,1-b,3,4-b] dipyridine monohydrate
53786-28-0		5-Chloro-1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one
115-46-8		alpha alpha-Diphenyl-4-piperidine-methanol hydrochloride
19395-41-6		alpha-Phenyl-2-piperidine acetic acid
104860-26-6		cis-1-[3-(4-Fluorophenoxy)propyl]-3-methoxy-4-piperdinamine
NA		Dibenzocycloheptatrien-piperidine CarbinoI
53786-46-2		Ethyl 4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinecarboxylate
53786-45-1		Ethyl 4-[(2-amino-4-chlorophenyl)amino]-1-piperidinecarboxylate
84501-68-8		Ethyl 4-[(1-(4-fluorophenyl)methyl)-1H-benzimidazol-2-yl] amino-1-piperidinecarboxylate
29976-53-2		Ethyl 4-oxo-1-piperidinecarboxylate
84196-16-7		N-[4-(Methoxymethyl)-4-piperidinyl]-N-phenyl-propanamide monohydrochloride
1609-66-1		N-Phenyl-N-(4-piperidinyl)propanamide
100-76-5		Quinuclidine
43078-30-8		Terfenadone
2933.40		(3S,4a alpha,8a beta)-N-tert-Butyldecahydro-3-isoquinolinecarboxamide
138465-81-1		(S)-N-tert-Butyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide
149182-72-9		[R-(E)]-1-[[1-[3-(2-(7-Chloro-2-quinolindyl) ethenyl] phenyl)-3-(2-[1-hydroxy-1-methylethyl] propyl) thio] methyl] cyclopropanecetic acid sodium salt
142522-81-4		1,3-Dimethyl-4-amino-5-formylaminouracil
7597-60-6		1-Cyclopropyl-6,7-difluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid
93107-30-3		2-Quinolinesulfonamide,1,2,3,4-tetrahydro-6-methyl-N-(1-methylethyl)-7-nitro-monomethanesulfonate
22862-78-1		3-[1-(4-Chlorobenoyl)-3-(tert-ary-butylthio)-5-(2-quinolinylmethoxy) indol-2-yl]-2,2-dimethylpropanoic acid sodium salt
136868-42-3		



HS6	Cas No	Description
77487-87-3		3-Isouquinolinecarboxylic acid S,1,2,3,4-tetrahydro, benzyl ester, para-toluene-sulfonic acid salt
103895-01-3		6,7-Difluoro-1-[2,4-difluorophenyl]-1,4-dihydro-4-oxo-3-quinolone carboxylic acid
98105-79-4		7-Chloro-6-fluoro-1-(4-fluorophenyl)-1,4-dihydro-4-oxo-3-quinoline carboxylic acid
4865-33-7		7-Chloroquinoline
88077-28-9		Chloro-7-ethyl-1-fluoro-6-oxo-4-dihydro-1,4-quinoline-3-carboxylic acid
100501-62-0		Ethyl,1-ethyl-6,7,8-trifluoro-4-dihydro-4-oxo-3-quinoline carboxylate
136485-99-1		N-[(2-Quinolyl)carbonyloxy] succinimide
2933-59		(1S)-2-Methyl-2,5-diazabicyclo [2.2.1] heptane dihydrobromide
125224-62-6		(2Z)-3-[2-[(4-(2,4-Difluorophenyl)(hydroxymino)-methyl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one
132861-05-8		1,3-Propanediol-2-[(2-amino-6-chloro-9H-purin-9-yl)ethyl]-diacetate (ester)
97845-60-8		1-(2-Furyl)piperazine
40172-95-0		1-(3-Chlorophenyl)-4-(3-chloropropyl) piperazine hydrochloride
52605-52-4		1-(Diphenylmethyl)piperazine
841-77-0		1-[alpha,alpha-bis(4-fluorophenyl)methyl] piperazine
27469-60-9		1-Acetyl-4-(4-hydroxyphenyl) piperazine
87914-60-7		1-Amino-4-methylpiperazine
8928-85-4		1-Ethyl-6,8-Difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid
98079-51-7		2,4-Dihydro-4-[4-(4-hydroxyphenyl)-1-piperazinyl]phenyl-2-(1-methylpropyl)-3H-1,2,4-triazol-3-one
106461-41-0		2,4-Dihydroxy-6,7-dimethoxy quinazoline
28888-44-0		3-(2-Chloroethyl)-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one
41078-70-0		3-(2-Chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido [1,2-a] pyrimidin-4-one monohydrochloride
93076-03-0		

HS#	Cas No	Description
5081-87-8		3-(2-Chloroethyl)-4-(1H-3H)-quinazolinone
67914-97-0		4-[4-(1-Methyl-ethyl)-1-piperazinyl]phenol
23680-84-4		4-Amino-2-chloro-6,7-dimethoxy-quinazoline
5018-45-1		5,6-Dimethoxy-4-pyrimidinamine
94021-22-4		N-(2-pyrimidinyl)-piperazine dihydrochloride
2933.79		
76855-69-1		(1R,3S,4R)-4-Acetoxy-3'-(1-(tert-butyl dimethylsilyloxy)ethyl) azetidine-2-one
15362-40-0		1-(2,6-Dichlorophenyl)-2-indolone
61516-73-2		1-Carboethoxymethylpyrrolidin-2-one
105431-72-9		2H-Indol-2-one, 1,3-dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)
20098-03-1		3,3-Diethyl-5-(hydroxymethyl)-2,4-(1H,3H)-pyridinedione
103335-55-3		3-Oxo-4-aza-5-alpha androstene-17-beta-carboxylic acid
103335-54-2		3-Oxo-4-aza-androst-5-ene-17-beta-carboxylic acid
17630-75-0		5-Chloroindole
71107-19-2		5-Ethyl-2-pyrrolidone-3-carboxamide
103335-41-7		Methyl-3-oxo-4-aza-5-alpha-androst-1-ene-17-beta-carboxylate
2933.90		
27387-31-1		1,2,3,4-Tetrahydro-9-methyl-4H-carbazol-4-one
52089-72-6		1,3-Dihydro-1-(1-methylphenyl)-2H-benzimidazol-2-one
83783-69-1		1-[(4-Fluorophenyl)methyl]-1H-benzimidazol-2-amine
69048-98-2		1-Ethyl-1,4-dihydro-5H-tetrazol-5-one
26118-12-1		1-Ethyl-2-aminomethylpyrrolidine

HS6	Cas No	Description
124750-53-4		1H-Tetrazole 5-(4'-methyl[1,1'-biphenyl]-2-yl)-1-phenylmethyl
86388-75-6		2,4-Difluoro-2-(1H-1,2,4-triazol-1-yl)acetophenone hydrochloride
123631-92-5		2-(2,4-Difluorophenyl)-1,3-bis-(1H-1,2,4-triazol-1-yl)-2-propanol
37052-78-1		2-Mercapto-5-methoxy-benzimidazole
5521-55-1		2-Methylpyrazine-5-carboxylic acid
64838-55-7		2S-1-(3-Acetylthio-2-methyl-1-oxopropyl)-L-proline
103831-11-4		3-Aminopyrrolidine dithydrochloride
57988-58-0		4-(4-Bromophenyl)-4-piperidino]
13183-79-4		5-Mercapto-1-methyl-1,2,3,4-tetrazole
100491-29-0		7-Chloroaphthyridine ethyl ester
59468-44-9		8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo [1,5-a][1-4] benzodiazepine-3-carboxylic acid
91441-48-4		Anthra[1,9-cd]pyrazol-6(2H)-one 7,10-dihydroxy-2-(2-(2-hydroxyethyl)aminoethyl)-5-[(2-(methylaminoethyl)amino)]
55408-10-1		Ethyl tetrazole-5-carboxylate
494-19-9		Iminodibenzyl
256-96-2		Iminosilbene
13485-59-1		L-Alanyl-L-proline
1458-18-0		Methyl-3-amino-5,6-dichloro-2-pyrazinolate
103300-91-0		N-(N-(S)-1-Carboxy-3-phenyl-propyl)-N-trifluoroacetyl-L-lysyl-L-proline ethyl ester
51856-79-2		N-Methyl-2-pyrrolisacetic acid methyl ester
21732-17-2		Tetrazole-1-acetic acid
90657-55-9		trans-4-Cyclohexyl-L-proline hydrochloride

HS6	Cas No	Description
	103300-89-6	Trifluoroacetyl-L-lysine-L-proline
	105841-23-4	Trifluoroacetyl-L-lysine-L-proline lysyl salt
	2934.10	
	118154-86-8	2-(2-Aminothiazol-4-yl)-2-methoxymino acetic acid chloride hydrochloride (Z)
	65872-43-7	2-(2-Formamidothiazol-4-yl)-2-methoxymino acetic acid
	64987-08-0	2-(Formylamino)-alpha-oxo-4-thiazole acetic acid
	64987-03-7	2-(Formylamino)-thiazolyl-4-glyoxylic acid ethyl ester
	84485-82-1	Ethyl-2-(2-aminothiazole-4-yl)-2-hydroxyiminoacetate
	2934.30	
	6631-94-3	Acetyl-2-phenothiazine
	32338-15-1	Amino-2-phenothiazine
	92-39-7	Chloro-2-phenothiazine
	2934.90	
	551-18-6	(+)-6-Amino-penicillanic acid
	29707-62-8	(1-beta),6-[(Phenoxyacetyl)amino]-penicillanic acid, (4-nitrophenyl)methyl ester, 1-oxide
	14487-05-9	(2,7)[E]poxypentadeca (1,11,13) trienimino] naphtho (2,1-B) furan-1,4,8,11 (Z,H)-tetrone, 5,17,19,21-tetrahydro-23-methoxy-2,4,12,16,18,20,22-heptamethyl-21-acetate
	28092-62-8	(3aS,6aR)-1,3-Dibenzyltetrahydro-4H-imidazo[4,1-f]imidazole-2,4 (1H)-dione
	87932-78-3	(6R,7R)-3-Aceoxymethyl-7-[(R)-2-formyloxy-2-phenylacetamidol]-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid (and its salts and esters)
	38754-02-4	(6R,7R)-7-[(R)-2-Aminophenylacetamidol]-3-methyl-8-oxa-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid discolate
	53994-83-5	(6R,7R)-7-Amino-3-chloro-8-oxa-4-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid, (4-nitrophenyl) methyl ester
	30246-33-4	(7R)-7-Amino-3-[[5-methyl-1,3,4-thiadiazole-2-yl]thio]methyl]-3-oxepan-4-carboxylic acid
	53910-25-1	(R)-3-(2-Deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-imidazo-(4,5)(1,3) diazepin-8-ol

HS6	Cas No	Description
NA		[4S,5S]-4-Benzyloxy-2-oxo-5-oxazolidinyl methyl p-nitrobenzenesulfonate
114873-37-9		1,4,7,10-Tetraazacyclodecane-1,4,7,10-tetraene acid
124492-04-2		1,4-Dithia-7-azaspiro[4.4]nonane-8-(S)-carboxylic acid
28657-79-6		1-Ethyl-1,4-dihydro-4-oxo-1,3-dioxin-4(5g)-cinnoline-3-carbonitrile
5271-87-0		2-Thiophenecarbonyl Chloride
69655-05-6		2,3-Dideoxycytosine
66242-82-8		2,5-Dihydro-5-thioxo-1H-tetrazole-1-methanesulphonic acid disodium salt
84682-23-5		2-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolane-4-methanol
13062-59-4		2-(3,4-Dihydroxyphenyl)tetrahydro-1,4-oxazine
22720-75-8		2-Acetylbenzo (beta) thiophene
4295-65-2		2-Chloro-9-[3-dimethylamino)propyl]-9H-fluorene-9-ol
3158-91-6		2-Chlorobenz-(beta D)-(1,4)-oxazepin-11-(10-H)-one
39098-97-0		2-Thiophene acetyl chloride
212E-13-6		21-Hydroxy-delta-4-pregnene-3,20-dione (16 alpha, 17 alpha)-D,2'-methylloxazoline-21-acetate
246E-28-9		21-1,2-Benzothiazine-3-carboxylic acid,4-hydroxy-2-methyl-ethyl ester,1,1-dioxide
3056-17-5		3-Deoxy-2,3-didehydrothymidine
4462-55-9		3-(2,6-Dichlorophenyl)-5-methylisoxazole-4-carboxylic acid chloride
69399-79-7		3-(2-Chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylic acid chloride
25629-50-9		3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid chloride
13292-22-3		3-Formylheptamethyl esahydroxy-23-methoxy-2,7-epoxy-periladeca tleniminaphthofuran-1,2H-11-dione-21-acetate
63427-57-6		3-Methylene-7-(2-phenoxycetamidol)septam-4-carboxylic acid para-nitro-benzyl ester, 1-oxide

HS6	Cas No	Description
16883-16-2		3-Phenyl-5-methylisoxazole-4-carboxylic acid chloride
21080-92-2		3-Thiophene malonic acid
76247-39-7		4-[1is-1-azabicyclo [3 2 0] heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-iodomethyl ester, 4,4-dioxide, (2S-cis)
9585-13-5		5-Ethyl-4-(2-phenylethyl)-2H-1,2,4-triazol-3(4H)-one
29490-19-5		5-Methyl-1,3,4-thiadiazole-2-thiol
957-68-6		7-Amino cephalosporanic acid
106447-44-3		7-Amino-3-(cis-1-propenyl) ceph-3-em-carboxylic acid
24209-38-9		7-Amino-3-[(1-methyl-tetrazole-5-yl)-thiomethyl]-cephalosporanic acid
24701-69-7		7-Amino-3-methoxymethyl cephalosporanic acid
22252-43-3		7-Amino-desacetoxycephalosporanic acid
51818-85-0		7-D(-)-Mandelamidocephalosporanic acid
104146-10-3		7-Phenylacetamido-3-chloromethyl Cephem-4-carboxylate p-methoxybenzyl ester
67914-85-6		cis-2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolane-4-methanol
68377-24-2		cis-2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolane-4-methanol methanesulfonate (ester) monohydrochloride
61397-61-3		cis-2-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolane-4-methanol methanesulfonate monohydrochloride
69074-07-7		N-(2-Tetrahydrofuryl)-piperazine
84769-24-8		N-[1(S)-Ethoxycarbonyl-3-phenylpropyl]-S-Alanyl-L-carboxyanhydride
70918-74-0		Piperazine, 1-[(2,5-dihydro-1,4-benzodioxin-2-yl)carbonyl]- monohydrochloride
2935.00		
88919-22-6		3-(2-Aminoethyl)-N-methyl-1H-indole-5-methanesulphonamide
88918-84-7		4-Amino-N-methylbenzenemethanesulphonamide hydrochloride
22663-37-2		4-Chlorobenzensulphonylurea, PCBS-urea

HS6	Cas No	Description
81880-98-8		4-Hydrazine-N-methylbenzene methanesulphonamide hydrochloride
105951-35-7		5,6-Dihydro-4-oxo-4-H-thieno[2,3-beta]thopyran-2-sulfonamide-7,7-dioxide
105951-31-3		5,6-Dihydro-4-oxo-thieno[2,3-beta]thopyran-2-sulfonamide
121-30-2		5-Chloro-2,4-diaminylaniline
16673-34-0		N-(2-(4-Aminosulfonylphenyl)ethyl)-5-chloro-2-methylbenzamide
<b>2938.90</b>		
5511-98-8		Acetylcholine
8024-48-4		Casanthranol
81-27-6		Sennoside A
52730-36-6		Sennoside A, Calcium salt
128-57-4		Sennoside B
52730-37-6		Sennoside B, Calcium salt
<b>2940.00</b>		
533-67-5		2-Deoxy-D-erythro-pentose
50-69-1		D-Ribose
<b>3607.90</b>		
9003-98-9		Desoxyribonuclease
8055-80-9		Fibrinuclease Powder
9001-63-2		Mucopolide N-acetylmuramylhydrolase hydrochloride
<b>3623.90</b>		
78441-62-0		4-(2-Aminoethylthiomethyl)-1,3-thiazol-2-ylmethyl dimethylamine, in the form of a solution in toluene
NA		4-(6-Fluoro-2-methylinden-3-ylmethyl) phenyl methyl sulphide in the form of a solution in toluene

## AGREEMENT ON AGRICULTURE

### *Members,*

*Having decided* to establish a basis for initiating a process of reform of trade in agriculture in line with the objectives of the negotiations as set out in the Punta del Este Declaration;

*Recalling* that their long-term objective as agreed at the Mid-Term Review of the Uruguay Round "is to establish a fair and market-oriented agricultural trading system and that a reform process should be initiated through the negotiation of commitments on support and protection and through the establishment of strengthened and more operationally effective GATT rules and disciplines";

*Recalling* further that "the above-mentioned long-term objective is to provide for substantial progressive reductions in agricultural support and protection sustained over an agreed period of time, resulting in correcting and preventing restrictions and distortions in world agricultural markets";

*Committed* to achieving specific binding commitments in each of the following areas: market access; domestic support; export competition; and to reaching an agreement on sanitary and phytosanitary issues;

*Having agreed* that in implementing their commitments on market access, developed country Members would take fully into account the particular needs and conditions of developing country Members by providing for a greater improvement of opportunities and terms of access for agricultural products of particular interest to these Members, including the fullest liberalization of trade in tropical agricultural products as agreed at the Mid-Term Review, and for products of particular importance to the diversification of production from the growing of illicit narcotic crops;

*Noting* that commitments under the reform programme should be made in an equitable way among all Members, having regard to non-trade concerns, including food security and the need to protect the environment; having regard to the agreement that special and differential treatment for developing countries is an integral element of the negotiations, and taking into account the possible negative effects of the implementation of the reform programme on least-developed and net food-importing developing countries;

Hereby *agree* as follows:

### *Part I*

#### *Article 1*

#### *Definition of Terms*

In this Agreement, unless the context otherwise requires:

- (a) "Aggregate Measurement of Support" and "AMS" mean the annual level of support, expressed in monetary terms, provided for an agricultural product in favour of the producers of the basic agricultural product or non-product-specific support provided in favour of agricultural producers in general, other than support provided under programmes that qualify as exempt from reduction under Annex 2 to this Agreement, which is:



- (i) with respect to support provided during the base period, specified in the relevant tables of supporting material incorporated by reference in Part IV of a Member's Schedule; and
  - (ii) with respect to support provided during any year of the implementation period and thereafter, calculated in accordance with the provisions of Annex 3 of this Agreement and taking into account the constituent data and methodology used in the tables of supporting material incorporated by reference in Part IV of the Member's Schedule;
- (b) "basic agricultural product" in relation to domestic support commitments is defined as the product as close as practicable to the point of first sale as specified in a Member's Schedule and in the related supporting material;
- (c) "budgetary outlays" or "outlays" includes revenue foregone;
- (d) "Equivalent Measurement of Support" means the annual level of support, expressed in monetary terms, provided to producers of a basic agricultural product through the application of one or more measures, the calculation of which in accordance with the AMS methodology is impracticable, other than support provided under programmes that qualify as exempt from reduction under Annex 2 to this Agreement, and which is:
  - (i) with respect to support provided during the base period, specified in the relevant tables of supporting material incorporated by reference in Part IV of a Member's Schedule; and
  - (ii) with respect to support provided during any year of the implementation period and thereafter, calculated in accordance with the provisions of Annex 4 of this Agreement and taking into account the constituent data and methodology used in the tables of supporting material incorporated by reference in Part IV of the Member's Schedule;
- (e) "export subsidies" refers to subsidies contingent upon export performance, including the export subsidies listed in Article 9 of this Agreement;
- (f) "implementation period" means the six-year period commencing in the year 1995, except that, for the purposes of Article 13, it means the nine-year period commencing in 1995;
- (g) "market access concessions" includes all market access commitments undertaken pursuant to this Agreement;
- (h) "Total Aggregate Measurement of Support" and "Total AMS" mean the sum of all domestic support provided in favour of agricultural producers, calculated as the sum of all aggregate measurements of support for basic agricultural products, all non-product-specific aggregate measurements of support and all equivalent measurements of support for agricultural products, and which is:
  - (i) with respect to support provided during the base period (i.e. the "Base Total AMS") and the maximum support permitted to be provided during any year of the implementation period or thereafter (i.e. the "Annual and Final Bound Commitment Levels"), as specified in Part IV of a Member's Schedule; and

- (ii) with respect to the level of support actually provided during any year of the implementation period and thereafter (i.e. the "Current Total AMS"), calculated in accordance with the provisions of this Agreement, including Article 6, and with the constituent data and methodology used in the tables of supporting material incorporated by reference in Part IV of the Member's Schedule;
- (i) "year" in paragraph (f) above and in relation to the specific commitments of a Member refers to the calendar, financial or marketing year specified in the Schedule relating to that Member.

## *Article 2*

### *Product Coverage*

This Agreement applies to the products listed in Annex 1 to this Agreement, hereinafter referred to as agricultural products.

## *Part II*

### *Article 3*

#### *Incorporation of Concessions and Commitments*

1. The domestic support and export subsidy commitments in Part IV of each Member's Schedule constitute commitments limiting subsidization and are hereby made an integral part of GATT 1994.
2. Subject to the provisions of Article 6, a Member shall not provide support in favour of domestic producers in excess of the commitment levels specified in Section I of Part IV of its Schedule.
3. Subject to the provisions of paragraphs 2(b) and 4 of Article 9, a Member shall not provide export subsidies listed in paragraph 1 of Article 9 in respect of the agricultural products or groups of products specified in Section II of Part IV of its Schedule in excess of the budgetary outlay and quantity commitment levels specified therein and shall not provide such subsidies in respect of any agricultural product not specified in that Section of its Schedule.

## *Part III*

### *Article 4*

#### *Market Access*

1. Market access concessions contained in Schedules relate to bindings and reductions of tariffs, and to other market access commitments as specified therein.

2. Members shall not maintain, resort to, or revert to any measures of the kind which have been required to be converted into ordinary customs duties<sup>1</sup>, except as otherwise provided for in Article 5 and Annex 5.

### Article 5

#### *Special Safeguard Provisions*

1. Notwithstanding the provisions of paragraph 1(b) of Article II of GATT 1994, any Member may take recourse to the provisions of paragraphs 4 and 5 below in connection with the importation of an agricultural product, in respect of which measures referred to in paragraph 2 of Article 4 of this Agreement have been converted into an ordinary customs duty and which is designated in its Schedule with the symbol "SSG" as being the subject of a concession in respect of which the provisions of this Article may be invoked, if:

- (a) the volume of imports of that product entering the customs territory of the Member granting the concession during any year exceeds a trigger level which relates to the existing market access opportunity as set out in paragraph 4; or, but not concurrently:
- (b) the price at which imports of that product may enter the customs territory of the Member granting the concession, as determined on the basis of the c.i.f. import price of the shipment concerned expressed in terms of its domestic currency, falls below a trigger price equal to the average 1986 to 1988 reference price<sup>2</sup> for the product concerned.

2. Imports under current and minimum access commitments established as part of a concession referred to in paragraph 1 above shall be counted for the purpose of determining the volume of imports required for invoking the provisions of subparagraph 1(a) and paragraph 4, but imports under such commitments shall not be affected by any additional duty imposed under either subparagraph 1(a) and paragraph 4 or subparagraph 1(b) and paragraph 5 below.

3. Any supplies of the product in question which were *en route* on the basis of a contract settled before the additional duty is imposed under subparagraph 1(a) and paragraph 4 shall be exempted from any such additional duty, provided that they may be counted in the volume of imports of the product in question during the following year for the purposes of triggering the provisions of subparagraph 1(a) in that year.

4. Any additional duty imposed under subparagraph 1(a) shall only be maintained until the end of the year in which it has been imposed, and may only be levied at a level which shall not exceed one third of the level of the ordinary customs duty in effect in the year in which the action is taken. The trigger level shall be set according to the following schedule based on market access opportunities

---

<sup>1</sup>These measures include quantitative import restrictions, variable import levies, minimum import prices, discretionary import licensing, non-tariff measures maintained through state-trading enterprises, voluntary export restraints, and similar border measures other than ordinary customs duties, whether or not the measures are maintained under country-specific derogations from the provisions of GATT 1947, but not measures maintained under balance-of-payments provisions or under other general, non-agriculture-specific provisions of GATT 1994 or of the other Multilateral Trade Agreements in Annex 1A to the WTO Agreement.

<sup>2</sup>The reference price used to invoke the provisions of this subparagraph shall, in general, be the average c.i.f. unit value of the product concerned, or otherwise shall be an appropriate price in terms of the quality of the product and its stage of processing. It shall, following its initial use, be publicly specified and available to the extent necessary to allow other Members to assess the additional duty that may be levied.

defined as imports as a percentage of the corresponding domestic consumption<sup>3</sup> during the three preceding years for which data are available:

- (a) where such market access opportunities for a product are less than or equal to 10 per cent, the base trigger level shall equal 125 per cent;
- (b) where such market access opportunities for a product are greater than 10 per cent but less than or equal to 30 per cent, the base trigger level shall equal 110 per cent;
- (c) where such market access opportunities for a product are greater than 30 per cent, the base trigger level shall equal 105 per cent.

In all cases the additional duty may be imposed in any year where the absolute volume of imports of the product concerned entering the customs territory of the Member granting the concession exceeds the sum of (x) the base trigger level set out above multiplied by the average quantity of imports during the three preceding years for which data are available and (y) the absolute volume change in domestic consumption of the product concerned in the most recent year for which data are available compared to the preceding year, provided that the trigger level shall not be less than 105 per cent of the average quantity of imports in (x) above.

5. The additional duty imposed under subparagraph 1(b) shall be set according to the following schedule:

- (a) if the difference between the c.i.f. import price of the shipment expressed in terms of the domestic currency (hereinafter referred to as the "import price") and the trigger price as defined under that subparagraph is less than or equal to 10 per cent of the trigger price, no additional duty shall be imposed;
- (b) if the difference between the import price and the trigger price (hereinafter referred to as the "difference") is greater than 10 per cent but less than or equal to 40 per cent of the trigger price, the additional duty shall equal 30 per cent of the amount by which the difference exceeds 10 per cent;
- (c) if the difference is greater than 40 per cent but less than or equal to 60 per cent of the trigger price, the additional duty shall equal 50 per cent of the amount by which the difference exceeds 40 per cent, plus the additional duty allowed under (b);
- (d) if the difference is greater than 60 per cent but less than or equal to 75 per cent, the additional duty shall equal 70 per cent of the amount by which the difference exceeds 60 per cent of the trigger price, plus the additional duties allowed under (b) and (c);
- (e) if the difference is greater than 75 per cent of the trigger price, the additional duty shall equal 90 per cent of the amount by which the difference exceeds 75 per cent, plus the additional duties allowed under (b), (c) and (d).

6. For perishable and seasonal products, the conditions set out above shall be applied in such a manner as to take account of the specific characteristics of such products. In particular, shorter time periods under subparagraph 1(a) and paragraph 4 may be used in reference to the corresponding periods in the base period and different reference prices for different periods may be used under subparagraph 1(b).

---

<sup>3</sup>Where domestic consumption is not taken into account, the base trigger level under subparagraph 4(a) shall apply.

7. The operation of the special safeguard shall be carried out in a transparent manner. Any Member taking action under subparagraph 1(a) above shall give notice in writing, including relevant data, to the Committee on Agriculture as far in advance as may be practicable and in any event within 10 days of the implementation of such action. In cases where changes in consumption volumes must be allocated to individual tariff lines subject to action under paragraph 4, relevant data shall include the information and methods used to allocate these changes. A Member taking action under paragraph 4 shall afford any interested Members the opportunity to consult with it in respect of the conditions of application of such action. Any Member taking action under subparagraph 1(b) above shall give notice in writing, including relevant data, to the Committee on Agriculture within 10 days of the implementation of the first such action or, for perishable and seasonal products, the first action in any period. Members undertake, as far as practicable, not to take recourse to the provisions of subparagraph 1(b) where the volume of imports of the products concerned are declining. In either case a Member taking such action shall afford any interested Members the opportunity to consult with it in respect of the conditions of application of such action.

8. Where measures are taken in conformity with paragraphs 1 through 7 above, Members undertake not to have recourse, in respect of such measures, to the provisions of paragraphs 1(a) and 3 of Article XIX of GATT 1994 or paragraph 2 of Article 8 of the Agreement on Safeguards.

9. The provisions of this Article shall remain in force for the duration of the reform process as determined under Article 20.

#### *Part IV*

#### *Article 6*

#### *Domestic Support Commitments*

1. The domestic support reduction commitments of each Member contained in Part IV of its Schedule shall apply to all of its domestic support measures in favour of agricultural producers with the exception of domestic measures which are not subject to reduction in terms of the criteria set out in this Article and in Annex 2 to this Agreement. The commitments are expressed in terms of Total Aggregate Measurement of Support and "Annual and Final Bound Commitment Levels".

2. In accordance with the Mid-Term Review Agreement that government measures of assistance, whether direct or indirect, to encourage agricultural and rural development are an integral part of the development programmes of developing countries, investment subsidies which are generally available to agriculture in developing country Members and agricultural input subsidies generally available to low-income or resource-poor producers in developing country Members shall be exempt from domestic support reduction commitments that would otherwise be applicable to such measures, as shall domestic support to producers in developing country Members to encourage diversification from growing illicit narcotic crops. Domestic support meeting the criteria of this paragraph shall not be required to be included in a Member's calculation of its Current Total AMS.

3. A Member shall be considered to be in compliance with its domestic support reduction commitments in any year in which its domestic support in favour of agricultural producers expressed in terms of Current Total AMS does not exceed the corresponding annual or final bound commitment level specified in Part IV of the Member's Schedule.

4. (a) A Member shall not be required to include in the calculation of its Current Total AMS and shall not be required to reduce:

- (i) product-specific domestic support which would otherwise be required to be included in a Member's calculation of its Current AMS where such support does not exceed 5 per cent of that Member's total value of production of a basic agricultural product during the relevant year; and
    - (ii) non-product-specific domestic support which would otherwise be required to be included in a Member's calculation of its Current AMS where such support does not exceed 5 per cent of the value of that Member's total agricultural production.
  - (b) For developing country Members, the *de minimis* percentage under this paragraph shall be 10 per cent.
5. (a) Direct payments under production-limiting programmes shall not be subject to the commitment to reduce domestic support if:
- (i) such payments are based on fixed area and yields; or
  - (ii) such payments are made on 85 per cent or less of the base level of production; or
  - (iii) livestock payments are made on a fixed number of head.
- (b) The exemption from the reduction commitment for direct payments meeting the above criteria shall be reflected by the exclusion of the value of those direct payments in a Member's calculation of its Current Total AMS.

#### Article 7

##### *General Disciplines on Domestic Support*

1. Each Member shall ensure that any domestic support measures in favour of agricultural producers which are not subject to reduction commitments because they qualify under the criteria set out in Annex 2 to this Agreement are maintained in conformity therewith.
2. (a) Any domestic support measure in favour of agricultural producers, including any modification to such measure, and any measure that is subsequently introduced that cannot be shown to satisfy the criteria in Annex 2 to this Agreement or to be exempt from reduction by reason of any other provision of this Agreement shall be included in the Member's calculation of its Current Total AMS.
- (b) Where no Total AMS commitment exists in Part IV of a Member's Schedule, the Member shall not provide support to agricultural producers in excess of the relevant *de minimis* level set out in paragraph 4 of Article 6.

*Part V**Article 8**Export Competition Commitments*

Each Member undertakes not to provide export subsidies otherwise than in conformity with this Agreement and with the commitments as specified in that Member's Schedule.

*Article 9**Export Subsidy Commitments*

1. The following export subsidies are subject to reduction commitments under this Agreement:
  - (a) the provision by governments or their agencies of direct subsidies, including payments-in-kind, to a firm, to an industry, to producers of an agricultural product, to a cooperative or other association of such producers, or to a marketing board, contingent on export performance;
  - (b) the sale or disposal for export by governments or their agencies of non-commercial stocks of agricultural products at a price lower than the comparable price charged for the like product to buyers in the domestic market;
  - (c) payments on the export of an agricultural product that are financed by virtue of governmental action, whether or not a charge on the public account is involved, including payments that are financed from the proceeds of a levy imposed on the agricultural product concerned or on an agricultural product from which the exported product is derived;
  - (d) the provision of subsidies to reduce the costs of marketing exports of agricultural products (other than widely available export promotion and advisory services) including handling, upgrading and other processing costs, and the costs of international transport and freight;
  - (e) internal transport and freight charges on export shipments, provided or mandated by governments, on terms more favourable than for domestic shipments;
  - (f) subsidies on agricultural products contingent on their incorporation in exported products.
2.
  - (a) Except as provided in subparagraph (b), the export subsidy commitment levels for each year of the implementation period, as specified in a Member's Schedule, represent with respect to the export subsidies listed in paragraph 1 of this Article:
    - (i) in the case of budgetary outlay reduction commitments, the maximum level of expenditure for such subsidies that may be allocated or incurred in that year in respect of the agricultural product, or group of products, concerned; and
    - (ii) in the case of export quantity reduction commitments, the maximum quantity of an agricultural product, or group of products, in respect of which such export subsidies may be granted in that year.

- (b) In any of the second through fifth years of the implementation period, a Member may provide export subsidies listed in paragraph 1 above in a given year in excess of the corresponding annual commitment levels in respect of the products or groups of products specified in Part IV of the Member's Schedule, provided that:
- (i) the cumulative amounts of budgetary outlays for such subsidies, from the beginning of the implementation period through the year in question, does not exceed the cumulative amounts that would have resulted from full compliance with the relevant annual outlay commitment levels specified in the Member's Schedule by more than 3 per cent of the base period level of such budgetary outlays;
  - (ii) the cumulative quantities exported with the benefit of such export subsidies, from the beginning of the implementation period through the year in question, does not exceed the cumulative quantities that would have resulted from full compliance with the relevant annual quantity commitment levels specified in the Member's Schedule by more than 1.75 per cent of the base period quantities;
  - (iii) the total cumulative amounts of budgetary outlays for such export subsidies and the quantities benefiting from such export subsidies over the entire implementation period are no greater than the totals that would have resulted from full compliance with the relevant annual commitment levels specified in the Member's Schedule; and
  - (iv) the Member's budgetary outlays for export subsidies and the quantities benefiting from such subsidies, at the conclusion of the implementation period, are no greater than 64 per cent and 79 per cent of the 1986-1990 base period levels, respectively. For developing country Members these percentages shall be 76 and 86 per cent, respectively.

3. Commitments relating to limitations on the extension of the scope of export subsidization are as specified in Schedules.

4. During the implementation period, developing country Members shall not be required to undertake commitments in respect of the export subsidies listed in subparagraphs (d) and (e) of paragraph 1 above, provided that these are not applied in a manner that would circumvent reduction commitments.

#### *Article 10*

##### *Prevention of Circumvention of Export Subsidy Commitments*

1. Export subsidies not listed in paragraph 1 of Article 9 shall not be applied in a manner which results in, or which threatens to lead to, circumvention of export subsidy commitments; nor shall non-commercial transactions be used to circumvent such commitments.

2. Members undertake to work toward the development of internationally agreed disciplines to govern the provision of export credits, export credit guarantees or insurance programmes and, after agreement on such disciplines, to provide export credits, export credit guarantees or insurance programmes only in conformity therewith.

3. Any Member which claims that any quantity exported in excess of a reduction commitment level is not subsidized must establish that no export subsidy, whether listed in Article 9 or not, has been granted in respect of the quantity of exports in question.



4. Members donors of international food aid shall ensure:
- (a) that the provision of international food aid is not tied directly or indirectly to commercial exports of agricultural products to recipient countries;
  - (b) that international food aid transactions, including bilateral food aid which is monetized, shall be carried out in accordance with the FAO "Principles of Surplus Disposal and Consultative Obligations", including, where appropriate, the system of Usual Marketing Requirements (UMRs); and
  - (c) that such aid shall be provided to the extent possible in fully grant form or on terms no less concessional than those provided for in Article IV of the Food Aid Convention 1986.<sup>1</sup>

*Article 11*

*Incorporated Products*

In no case may the per-unit subsidy paid on an incorporated agricultural primary product exceed the per-unit export subsidy that would be payable on exports of the primary product as such.

*Part VI*

*Article 12*

*Disciplines on Export Prohibitions and Restrictions*

1. Where any Member institutes any new export prohibition or restriction on foodstuffs in accordance with paragraph 2(a) of Article XI of GATT 1994, the Member shall observe the following provisions:

- (a) the Member instituting the export prohibition or restriction shall give due consideration to the effects of such prohibition or restriction on importing Members' food security;
- (b) before any Member institutes an export prohibition or restriction, it shall give notice in writing, as far in advance as practicable, to the Committee on Agriculture comprising such information as the nature and the duration of such measure, and shall consult, upon request, with any other Member having a substantial interest as an importer with respect to any matter related to the measure in question. The Member instituting such export prohibition or restriction shall provide, upon request, such a Member with necessary information.

2. The provisions of this Article shall not apply to any developing country Member, unless the measure is taken by a developing country Member which is a net-food exporter of the specific foodstuff concerned.

---

<sup>1</sup>United Nations, *Treaty Series*, vol. 1429, p. 71.

*Part VII**Article 13**Due Restraint*

During the implementation period, notwithstanding the provisions of GATT 1994 and the Agreement on Subsidies and Countervailing Measures (referred to in this Article as the "Subsidies Agreement"):

- (a) domestic support measures that conform fully to the provisions of Annex 2 to this Agreement shall be:
  - (i) non-actionable subsidies for purposes of countervailing duties<sup>4</sup>;
  - (ii) exempt from actions based on Article XVI of GATT 1994 and Part III of the Subsidies Agreement; and
  - (iii) exempt from actions based on non-violation nullification or impairment of the benefits of tariff concessions accruing to another Member under Article II of GATT 1994, in the sense of paragraph 1(b) of Article XXIII of GATT 1994;
- (b) domestic support measures that conform fully to the provisions of Article 6 of this Agreement including direct payments that conform to the requirements of paragraph 5 thereof, as reflected in each Member's Schedule, as well as domestic support within *de minimis* levels and in conformity with paragraph 2 of Article 6, shall be:
  - (i) exempt from the imposition of countervailing duties unless a determination of injury or threat thereof is made in accordance with Article VI of GATT 1994 and Part V of the Subsidies Agreement, and due restraint shall be shown in initiating any countervailing duty investigations;
  - (ii) exempt from actions based on paragraph 1 of Article XVI of GATT 1994 or Articles 5 and 6 of the Subsidies Agreement, provided that such measures do not grant support to a specific commodity in excess of that decided during the 1992 marketing year; and
  - (iii) exempt from actions based on non-violation nullification or impairment of the benefits of tariff concessions accruing to another Member under Article II of GATT 1994, in the sense of paragraph 1(b) of Article XXIII of GATT 1994, provided that such measures do not grant support to a specific commodity in excess of that decided during the 1992 marketing year;
- (c) export subsidies that conform fully to the provisions of Part V of this Agreement, as reflected in each Member's Schedule, shall be:
  - (i) subject to countervailing duties only upon a determination of injury or threat thereof based on volume, effect on prices, or consequent impact in accordance with Article VI of GATT 1994 and Part V of the Subsidies Agreement, and

---

<sup>4</sup>"Countervailing duties" where referred to in this Article are those covered by Article VI of GATT 1994 and Part V of the Agreement on Subsidies and Countervailing Measures.

due restraint shall be shown in initiating any countervailing duty investigations; and

- (ii) exempt from actions based on Article XVI of GATT 1994 or Articles 3, 5 and 6 of the Subsidies Agreement.

*Part VIII*

*Article 14*

*Sanitary and Phytosanitary Measures*

Members agree to give effect to the Agreement on the Application of Sanitary and Phytosanitary Measures.

*Part IX*

*Article 15*

*Special and Differential Treatment*

1. In keeping with the recognition that differential and more favourable treatment for developing country Members is an integral part of the negotiation, special and differential treatment in respect of commitments shall be provided as set out in the relevant provisions of this Agreement and embodied in the Schedules of concessions and commitments.
2. Developing country Members shall have the flexibility to implement reduction commitments over a period of up to 10 years. Least-developed country Members shall not be required to undertake reduction commitments.

*Part X*

*Article 16*

*Least-Developed and Net Food-Importing Developing Countries*

1. Developed country Members shall take such action as is provided for within the framework of the Decision on Measures Concerning the Possible Negative Effects of the Reform Programme on Least-Developed and Net Food-Importing Developing Countries.
2. The Committee on Agriculture shall monitor, as appropriate, the follow-up to this Decision.

*Part XI*

*Article 17*

*Committee on Agriculture*

A Committee on Agriculture is hereby established.

### *Article 18*

#### *Review of the Implementation of Commitments*

1. Progress in the implementation of commitments negotiated under the Uruguay Round reform programme shall be reviewed by the Committee on Agriculture.
2. The review process shall be undertaken on the basis of notifications submitted by Members in relation to such matters and at such intervals as shall be determined, as well as on the basis of such documentation as the Secretariat may be requested to prepare in order to facilitate the review process.
3. In addition to the notifications to be submitted under paragraph 2, any new domestic support measure, or modification of an existing measure, for which exemption from reduction is claimed shall be notified promptly. This notification shall contain details of the new or modified measure and its conformity with the agreed criteria as set out either in Article 6 or in Annex 2.
4. In the review process Members shall give due consideration to the influence of excessive rates of inflation on the ability of any Member to abide by its domestic support commitments.
5. Members agree to consult annually in the Committee on Agriculture with respect to their participation in the normal growth of world trade in agricultural products within the framework of the commitments on export subsidies under this Agreement.
6. The review process shall provide an opportunity for Members to raise any matter relevant to the implementation of commitments under the reform programme as set out in this Agreement.
7. Any Member may bring to the attention of the Committee on Agriculture any measure which it considers ought to have been notified by another Member.

### *Article 19*

#### *Consultation and Dispute Settlement*

The provisions of Articles XXII and XXIII of GATT 1994, as elaborated and applied by the Dispute Settlement Understanding, shall apply to consultations and the settlement of disputes under this Agreement.

### *Part XII*

### *Article 20*

#### *Continuation of the Reform Process*

Recognizing that the long-term objective of substantial progressive reductions in support and protection resulting in fundamental reform is an ongoing process, Members agree that negotiations for continuing the process will be initiated one year before the end of the implementation period, taking into account:

- (a) the experience to that date from implementing the reduction commitments;
- (b) the effects of the reduction commitments on world trade in agriculture;

- (c) non-trade concerns, special and differential treatment to developing country Members, and the objective to establish a fair and market-oriented agricultural trading system, and the other objectives and concerns mentioned in the preamble to this Agreement; and
- (d) what further commitments are necessary to achieve the above mentioned long-term objectives.

*Part XIII*

*Article 21*

*Final Provisions*

1. The provisions of GATT 1994 and of other Multilateral Trade Agreements in Annex 1A to the WTO Agreement shall apply subject to the provisions of this Agreement.
2. The Annexes to this Agreement are hereby made an integral part of this Agreement.

## ANNEX 1

## PRODUCT COVERAGE

1. This Agreement shall cover the following products:

- (i) HS Chapters 1 to 24 less fish and fish products, plus\*
- (ii) HS Code 2905.43 (mannitol)  
 HS Code 2905.44 (sorbitol)  
 HS Heading 33.01 (essential oils)  
 HS Headings 35.01 to 35.05 (albuminoidal substances, modified starches, glues)  
 HS Code 3809.10 (finishing agents)  
 HS Code 3823.60 (sorbitol n.e.p.)  
 HS Headings 41.01 to 41.03 (hides and skins)  
 HS Heading 43.01 (raw furskins)  
 HS Headings 50.01 to 50.03 (raw silk and silk waste)  
 HS Headings 51.01 to 51.03 (wool and animal hair)  
 HS Headings 52.01 to 52.03 (raw cotton, waste and cotton carded or combed)  
 HS Heading 53.01 (raw flax)  
 HS Heading 53.02 (raw hemp)

2. The foregoing shall not limit the product coverage of the Agreement on the Application of Sanitary and Phytosanitary Measures.

\*The product descriptions in round brackets are not necessarily exhaustive.

## ANNEX 2

DOMESTIC SUPPORT: THE BASIS FOR EXEMPTION FROM  
THE REDUCTION COMMITMENTS

1. Domestic support measures for which exemption from the reduction commitments is claimed shall meet the fundamental requirement that they have no, or at most minimal, trade-distorting effects or effects on production. Accordingly, all measures for which exemption is claimed shall conform to the following basic criteria:

- (a) the support in question shall be provided through a publicly-funded government programme (including government revenue foregone) not involving transfers from consumers; and,
- (b) the support in question shall not have the effect of providing price support to producers;

plus policy-specific criteria and conditions as set out below.

*Government Service Programmes*

## 2. General services

Policies in this category involve expenditures (or revenue foregone) in relation to programmes which provide services or benefits to agriculture or the rural community. They shall not involve direct payments to producers or processors. Such programmes, which include but are not restricted to the following list, shall meet the general criteria in paragraph 1 above and policy-specific conditions where set out below:

- (a) research, including general research, research in connection with environmental programmes, and research programmes relating to particular products;
- (b) pest and disease control, including general and product-specific pest and disease control measures, such as early-warning systems, quarantine and eradication;
- (c) training services, including both general and specialist training facilities;
- (d) extension and advisory services, including the provision of means to facilitate the transfer of information and the results of research to producers and consumers;
- (e) inspection services, including general inspection services and the inspection of particular products for health, safety, grading or standardization purposes;
- (f) marketing and promotion services, including market information, advice and promotion relating to particular products but excluding expenditure for unspecified purposes that could be used by sellers to reduce their selling price or confer a direct economic benefit to purchasers; and
- (g) infrastructural services, including: electricity reticulation, roads and other means of transport, market and port facilities, water supply facilities, dams and drainage schemes, and infrastructural works associated with environmental programmes. In all cases the expenditure shall be directed to the provision or construction of capital works only, and shall exclude the subsidized provision of on-farm facilities other than for the

reticulation of generally available public utilities. It shall not include subsidies to inputs or operating costs, or preferential user charges.

3. Public stockholding for food security purposes<sup>5</sup>

Expenditures (or revenue foregone) in relation to the accumulation and holding of stocks of products which form an integral part of a food security programme identified in national legislation. This may include government aid to private storage of products as part of such a programme.

The volume and accumulation of such stocks shall correspond to predetermined targets related solely to food security. The process of stock accumulation and disposal shall be financially transparent. Food purchases by the government shall be made at current market prices and sales from food security stocks shall be made at no less than the current domestic market price for the product and quality in question.

4. Domestic food aid<sup>6</sup>

Expenditures (or revenue foregone) in relation to the provision of domestic food aid to sections of the population in need.

Eligibility to receive the food aid shall be subject to clearly-defined criteria related to nutritional objectives. Such aid shall be in the form of direct provision of food to those concerned or the provision of means to allow eligible recipients to buy food either at market or at subsidized prices. Food purchases by the government shall be made at current market prices and the financing and administration of the aid shall be transparent.

5. Direct payments to producers

Support provided through direct payments (or revenue foregone, including payments in kind) to producers for which exemption from reduction commitments is claimed shall meet the basic criteria set out in paragraph 1 above, plus specific criteria applying to individual types of direct payment as set out in paragraphs 6 through 13 below. Where exemption from reduction is claimed for any existing or new type of direct payment other than those specified in paragraphs 6 through 13, it shall conform to criteria (b) through (e) in paragraph 6, in addition to the general criteria set out in paragraph 1.

6. Decoupled income support

- (a) Eligibility for such payments shall be determined by clearly-defined criteria such as income, status as a producer or landowner, factor use or production level in a defined and fixed base period.

---

<sup>5</sup>For the purposes of paragraph 3 of this Annex, governmental stockholding programmes for food security purposes in developing countries whose operation is transparent and conducted in accordance with officially published objective criteria or guidelines shall be considered to be in conformity with the provisions of this paragraph, including programmes under which stocks of foodstuffs for food security purposes are acquired and released at administered prices, provided that the difference between the acquisition price and the external reference price is accounted for in the AMS.

<sup>5 & 6</sup>For the purposes of paragraphs 3 and 4 of this Annex, the provision of foodstuffs at subsidized prices with the objective of meeting food requirements of urban and rural poor in developing countries on a regular basis at reasonable prices shall be considered to be in conformity with the provisions of this paragraph.



- (b) The amount of such payments in any given year shall not be related to, or based on, the type or volume of production (including livestock units) undertaken by the producer in any year after the base period.
  - (c) The amount of such payments in any given year shall not be related to, or based on, the prices, domestic or international, applying to any production undertaken in any year after the base period.
  - (d) The amount of such payments in any given year shall not be related to, or based on, the factors of production employed in any year after the base period.
  - (e) No production shall be required in order to receive such payments.
7. Government financial participation in income insurance and income safety-net programmes
- (a) Eligibility for such payments shall be determined by an income loss, taking into account only income derived from agriculture, which exceeds 30 per cent of average gross income or the equivalent in net income terms (excluding any payments from the same or similar schemes) in the preceding three-year period or a three-year average based on the preceding five-year period, excluding the highest and the lowest entry. Any producer meeting this condition shall be eligible to receive the payments.
  - (b) The amount of such payments shall compensate for less than 70 per cent of the producer's income loss in the year the producer becomes eligible to receive this assistance.
  - (c) The amount of any such payments shall relate solely to income; it shall not relate to the type or volume of production (including livestock units) undertaken by the producer; or to the prices, domestic or international, applying to such production; or to the factors of production employed.
  - (d) Where a producer receives in the same year payments under this paragraph and under paragraph 8 (relief from natural disasters), the total of such payments shall be less than 100 per cent of the producer's total loss.
8. Payments (made either directly or by way of government financial participation in crop insurance schemes) for relief from natural disasters
- (a) Eligibility for such payments shall arise only following a formal recognition by government authorities that a natural or like disaster (including disease outbreaks, pest infestations, nuclear accidents, and war on the territory of the Member concerned) has occurred or is occurring; and shall be determined by a production loss which exceeds 30 per cent of the average of production in the preceding three-year period or a three-year average based on the preceding five-year period, excluding the highest and the lowest entry.
  - (b) Payments made following a disaster shall be applied only in respect of losses of income, livestock (including payments in connection with the veterinary treatment of animals), land or other production factors due to the natural disaster in question.
  - (c) Payments shall compensate for not more than the total cost of replacing such losses and shall not require or specify the type or quantity of future production.

- (d) Payments made during a disaster shall not exceed the level required to prevent or alleviate further loss as defined in criterion (b) above.
  - (e) Where a producer receives in the same year payments under this paragraph and under paragraph 7 (income insurance and income safety-net programmes), the total of such payments shall be less than 100 per cent of the producer's total loss.
9. Structural adjustment assistance provided through producer retirement programmes
- (a) Eligibility for such payments shall be determined by reference to clearly defined criteria in programmes designed to facilitate the retirement of persons engaged in marketable agricultural production, or their movement to non-agricultural activities.
  - (b) Payments shall be conditional upon the total and permanent retirement of the recipients from marketable agricultural production.
10. Structural adjustment assistance provided through resource retirement programmes
- (a) Eligibility for such payments shall be determined by reference to clearly defined criteria in programmes designed to remove land or other resources, including livestock, from marketable agricultural production.
  - (b) Payments shall be conditional upon the retirement of land from marketable agricultural production for a minimum of three years, and in the case of livestock on its slaughter or definitive permanent disposal.
  - (c) Payments shall not require or specify any alternative use for such land or other resources which involves the production of marketable agricultural products.
  - (d) Payments shall not be related to either the type or quantity of production or to the prices, domestic or international, applying to production undertaken using the land or other resources remaining in production.
11. Structural adjustment assistance provided through investment aids
- (a) Eligibility for such payments shall be determined by reference to clearly-defined criteria in government programmes designed to assist the financial or physical restructuring of a producer's operations in response to objectively demonstrated structural disadvantages. Eligibility for such programmes may also be based on a clearly-defined government programme for the reprivatization of agricultural land.
  - (b) The amount of such payments in any given year shall not be related to, or based on, the type or volume of production (including livestock units) undertaken by the producer in any year after the base period other than as provided for under criterion (e) below.
  - (c) The amount of such payments in any given year shall not be related to, or based on, the prices, domestic or international, applying to any production undertaken in any year after the base period.
  - (d) The payments shall be given only for the period of time necessary for the realization of the investment in respect of which they are provided.
  - (e) The payments shall not mandate or in any way designate the agricultural products to be produced by the recipients except to require them not to produce a particular product.

- (f) The payments shall be limited to the amount required to compensate for the structural disadvantage.

12. Payments under environmental programmes

- (a) Eligibility for such payments shall be determined as part of a clearly-defined government environmental or conservation programme and be dependent on the fulfilment of specific conditions under the government programme, including conditions related to production methods or inputs.
- (b) The amount of payment shall be limited to the extra costs or loss of income involved in complying with the government programme.

13. Payments under regional assistance programmes

- (a) Eligibility for such payments shall be limited to producers in disadvantaged regions. Each such region must be a clearly designated contiguous geographical area with a definable economic and administrative identity, considered as disadvantaged on the basis of neutral and objective criteria clearly spelt out in law or regulation and indicating that the region's difficulties arise out of more than temporary circumstances.
- (b) The amount of such payments in any given year shall not be related to, or based on, the type or volume of production (including livestock units) undertaken by the producer in any year after the base period other than to reduce that production.
- (c) The amount of such payments in any given year shall not be related to, or based on, the prices, domestic or international, applying to any production undertaken in any year after the base period.
- (d) Payments shall be available only to producers in eligible regions, but generally available to all producers within such regions.
- (e) Where related to production factors, payments shall be made at a degressive rate above a threshold level of the factor concerned.
- (f) The payments shall be limited to the extra costs or loss of income involved in undertaking agricultural production in the prescribed area.

## ANNEX 3

DOMESTIC SUPPORT:  
CALCULATION OF AGGREGATE MEASUREMENT OF SUPPORT

1. Subject to the provisions of Article 6, an Aggregate Measurement of Support (AMS) shall be calculated on a product-specific basis for each basic agricultural product receiving market price support, non-exempt direct payments, or any other subsidy not exempted from the reduction commitment ("other non-exempt policies"). Support which is non-product specific shall be totalled into one non-product-specific AMS in total monetary terms.
2. Subsidies under paragraph 1 shall include both budgetary outlays and revenue foregone by governments or their agents.
3. Support at both the national and sub-national level shall be included.
4. Specific agricultural levies or fees paid by producers shall be deducted from the AMS.
5. The AMS calculated as outlined below for the base period shall constitute the base level for the implementation of the reduction commitment on domestic support.
6. For each basic agricultural product, a specific AMS shall be established, expressed in total monetary value terms.
7. The AMS shall be calculated as close as practicable to the point of first sale of the basic agricultural product concerned. Measures directed at agricultural processors shall be included to the extent that such measures benefit the producers of the basic agricultural products.
8. Market price support: market price support shall be calculated using the gap between a fixed external reference price and the applied administered price multiplied by the quantity of production eligible to receive the applied administered price. Budgetary payments made to maintain this gap, such as buying-in or storage costs, shall not be included in the AMS.
9. The fixed external reference price shall be based on the years 1986 to 1988 and shall generally be the average f.o.b. unit value for the basic agricultural product concerned in a net exporting country and the average c.i.f. unit value for the basic agricultural product concerned in a net importing country in the base period. The fixed reference price may be adjusted for quality differences as necessary.
10. Non-exempt direct payments: non-exempt direct payments which are dependent on a price gap shall be calculated either using the gap between the fixed reference price and the applied administered price multiplied by the quantity of production eligible to receive the administered price, or using budgetary outlays.
11. The fixed reference price shall be based on the years 1986 to 1988 and shall generally be the actual price used for determining payment rates.
12. Non-exempt direct payments which are based on factors other than price shall be measured using budgetary outlays.

13. Other non-exempt measures, including input subsidies and other measures such as marketing-cost reduction measures: the value of such measures shall be measured using government budgetary outlays or, where the use of budgetary outlays does not reflect the full extent of the subsidy concerned, the basis for calculating the subsidy shall be the gap between the price of the subsidized good or service and a representative market price for a similar good or service multiplied by the quantity of the good or service.

## ANNEX 4

DOMESTIC SUPPORT:  
CALCULATION OF EQUIVALENT MEASUREMENT OF SUPPORT

1. Subject to the provisions of Article 6, equivalent measurements of support shall be calculated in respect of all basic agricultural products where market price support as defined in Annex 3 exists but for which calculation of this component of the AMS is not practicable. For such products the base level for implementation of the domestic support reduction commitments shall consist of a market price support component expressed in terms of equivalent measurements of support under paragraph 2 below, as well as any non-exempt direct payments and other non-exempt support, which shall be evaluated as provided for under paragraph 3 below. Support at both national and sub-national level shall be included.
2. The equivalent measurements of support provided for in paragraph 1 shall be calculated on a product-specific basis for all basic agricultural products as close as practicable to the point of first sale receiving market price support and for which the calculation of the market price support component of the AMS is not practicable. For those basic agricultural products, equivalent measurements of market price support shall be made using the applied administered price and the quantity of production eligible to receive that price or, where this is not practicable, on budgetary outlays used to maintain the producer price.
3. Where basic agricultural products falling under paragraph 1 are the subject of non-exempt direct payments or any other product-specific subsidy not exempted from the reduction commitment, the basis for equivalent measurements of support concerning these measures shall be calculations as for the corresponding AMS components (specified in paragraphs 10 through 13 of Annex 3).
4. Equivalent measurements of support shall be calculated on the amount of subsidy as close as practicable to the point of first sale of the basic agricultural product concerned. Measures directed at agricultural processors shall be included to the extent that such measures benefit the producers of the basic agricultural products. Specific agricultural levies or fees paid by producers shall reduce the equivalent measurements of support by a corresponding amount.

## ANNEX 5

## SPECIAL TREATMENT WITH RESPECT TO PARAGRAPH 2 OF ARTICLE 4

*Section A*

1. The provisions of paragraph 2 of Article 4 shall not apply with effect from the entry into force of the WTO Agreement to any primary agricultural product and its worked and/or prepared products ("designated products") in respect of which the following conditions are complied with (hereinafter referred to as "special treatment"):

- (a) imports of the designated products comprised less than 3 per cent of corresponding domestic consumption in the base period 1986-1988 ("the base period");
- (b) no export subsidies have been provided since the beginning of the base period for the designated products;
- (c) effective production-restricting measures are applied to the primary agricultural product;
- (d) such products are designated with the symbol "ST-Annex 5" in Section I-B of Part I of a Member's Schedule annexed to the Marrakesh Protocol, as being subject to special treatment reflecting factors of non-trade concerns, such as food security and environmental protection; and
- (e) minimum access opportunities in respect of the designated products correspond, as specified in Section I-B of Part I of the Schedule of the Member concerned, to 4 per cent of base period domestic consumption of the designated products from the beginning of the first year of the implementation period and, thereafter, are increased by 0.8 per cent of corresponding domestic consumption in the base period per year for the remainder of the implementation period.

2. At the beginning of any year of the implementation period a Member may cease to apply special treatment in respect of the designated products by complying with the provisions of paragraph 6. In such a case, the Member concerned shall maintain the minimum access opportunities already in effect at such time and increase the minimum access opportunities by 0.4 per cent of corresponding domestic consumption in the base period per year for the remainder of the implementation period. Thereafter, the level of minimum access opportunities resulting from this formula in the final year of the implementation period shall be maintained in the Schedule of the Member concerned.

3. Any negotiation on the question of whether there can be a continuation of the special treatment as set out in paragraph 1 after the end of the implementation period shall be completed within the time-frame of the implementation period itself as a part of the negotiations set out in Article 20 of this Agreement, taking into account the factors of non-trade concerns.

4. If it is agreed as a result of the negotiation referred to in paragraph 3 that a Member may continue to apply the special treatment, such Member shall confer additional and acceptable concessions as determined in that negotiation.

5. Where the special treatment is not to be continued at the end of the implementation period, the Member concerned shall implement the provisions of paragraph 6. In such a case, after the end of the implementation period the minimum access opportunities for the designated products shall be maintained at the level of 8 per cent of corresponding domestic consumption in the base period in the Schedule of the Member concerned.

6. Border measures other than ordinary customs duties maintained in respect of the designated products shall become subject to the provisions of paragraph 2 of Article 4 with effect from the beginning of the year in which the special treatment ceases to apply. Such products shall be subject to ordinary customs duties, which shall be bound in the Schedule of the Member concerned and applied, from the beginning of the year in which special treatment ceases and thereafter, at such rates as would have been applicable had a reduction of at least 15 per cent been implemented over the implementation period in equal annual instalments. These duties shall be established on the basis of tariff equivalents to be calculated in accordance with the guidelines prescribed in the attachment hereto.

#### *Section B*

7. The provisions of paragraph 2 of Article 4 shall also not apply with effect from the entry into force of the WTO Agreement to a primary agricultural product that is the predominant staple in the traditional diet of a developing country Member and in respect of which the following conditions, in addition to those specified in paragraph 1(a) through 1(d), as they apply to the products concerned, are complied with:

- (a) minimum access opportunities in respect of the products concerned, as specified in Section I-B of Part I of the Schedule of the developing country Member concerned, correspond to 1 per cent of base period domestic consumption of the products concerned from the beginning of the first year of the implementation period and are increased in equal annual instalments to 2 per cent of corresponding domestic consumption in the base period at the beginning of the fifth year of the implementation period. From the beginning of the sixth year of the implementation period, minimum access opportunities in respect of the products concerned correspond to 2 per cent of corresponding domestic consumption in the base period and are increased in equal annual instalments to 4 per cent of corresponding domestic consumption in the base period until the beginning of the 10th year. Thereafter, the level of minimum access opportunities resulting from this formula in the 10th year shall be maintained in the Schedule of the developing country Member concerned;
- (b) appropriate market access opportunities have been provided for in other products under this Agreement.

8. Any negotiation on the question of whether there can be a continuation of the special treatment as set out in paragraph 7 after the end of the 10th year following the beginning of the implementation period shall be initiated and completed within the time-frame of the 10th year itself following the beginning of the implementation period.

9. If it is agreed as a result of the negotiation referred to in paragraph 8 that a Member may continue to apply the special treatment, such Member shall confer additional and acceptable concessions as determined in that negotiation.

10. In the event that special treatment under paragraph 7 is not to be continued beyond the 10th year following the beginning of the implementation period, the products concerned shall be subject to ordinary customs duties, established on the basis of a tariff equivalent to be calculated in accordance with the guidelines prescribed in the attachment hereto, which shall be bound in the Schedule of the Member concerned. In other respects, the provisions of paragraph 6 shall apply as modified by the relevant special and differential treatment accorded to developing country Members under this Agreement.



## Attachment to Annex 5

Guidelines for the Calculation of Tariff  
Equivalents for the Specific Purpose Specified in  
Paragraphs 6 and 10 of this Annex

1. The calculation of the tariff equivalents, whether expressed as *ad valorem* or specific rates, shall be made using the actual difference between internal and external prices in a transparent manner. Data used shall be for the years 1986 to 1988. Tariff equivalents:
  - (a) shall primarily be established at the four-digit level of the HS;
  - (b) shall be established at the six-digit or a more detailed level of the HS wherever appropriate;
  - (c) shall generally be established for worked and/or prepared products by multiplying the specific tariff equivalent(s) for the primary agricultural product(s) by the proportion(s) in value terms or in physical terms as appropriate of the primary agricultural product(s) in the worked and/or prepared products, and take account, where necessary, of any additional elements currently providing protection to industry.
2. External prices shall be, in general, actual average c.i.f. unit values for the importing country. Where average c.i.f. unit values are not available or appropriate, external prices shall be either:
  - (a) appropriate average c.i.f. unit values of a near country; or
  - (b) estimated from average f.o.b. unit values of (an) appropriate major exporter(s) adjusted by adding an estimate of insurance, freight and other relevant costs to the importing country.
3. The external prices shall generally be converted to domestic currencies using the annual average market exchange rate for the same period as the price data.
4. The internal price shall generally be a representative wholesale price ruling in the domestic market or an estimate of that price where adequate data is not available.
5. The initial tariff equivalents may be adjusted, where necessary, to take account of differences in quality or variety using an appropriate coefficient.
6. Where a tariff equivalent resulting from these guidelines is negative or lower than the current bound rate, the initial tariff equivalent may be established at the current bound rate or on the basis of national offers for that product.
7. Where an adjustment is made to the level of a tariff equivalent which would have resulted from the above guidelines, the Member concerned shall afford, on request, full opportunities for consultation with a view to negotiating appropriate solutions.

## AGREEMENT ON THE APPLICATION OF SANITARY AND PHYTOSANITARY MEASURES

*Members,*

*Reaffirming* that no Member should be prevented from adopting or enforcing measures necessary to protect human, animal or plant life or health, subject to the requirement that these measures are not applied in a manner which would constitute a means of arbitrary or unjustifiable discrimination between Members where the same conditions prevail or a disguised restriction on international trade;

*Desiring* to improve the human health, animal health and phytosanitary situation in all Members;

*Noting* that sanitary and phytosanitary measures are often applied on the basis of bilateral agreements or protocols;

*Desiring* the establishment of a multilateral framework of rules and disciplines to guide the development, adoption and enforcement of sanitary and phytosanitary measures in order to minimize their negative effects on trade;

*Recognizing* the important contribution that international standards, guidelines and recommendations can make in this regard;

*Desiring* to further the use of harmonized sanitary and phytosanitary measures between Members, on the basis of international standards, guidelines and recommendations developed by the relevant international organizations, including the Codex Alimentarius Commission, the International Office of Epizootics, and the relevant international and regional organizations operating within the framework of the International Plant Protection Convention\*, without requiring Members to change their appropriate level of protection of human, animal or plant life or health;

*Recognizing* that developing country Members may encounter special difficulties in complying with the sanitary or phytosanitary measures of importing Members, and as a consequence in access to markets, and also in the formulation and application of sanitary or phytosanitary measures in their own territories, and desiring to assist them in their endeavours in this regard;

*Desiring* therefore to elaborate rules for the application of the provisions of GATT 1994 which relate to the use of sanitary or phytosanitary measures, in particular the provisions of Article XX(b);<sup>1</sup>

*Hereby agree* as follows:

\* United Nations, *Treaty Series*, vol. 150, p. 67.

<sup>1</sup> In this Agreement, reference to Article XX(b) includes also the chapeau of that Article.

### *Article 1*

#### *General Provisions*

1. This Agreement applies to all sanitary and phytosanitary measures which may, directly or indirectly, affect international trade. Such measures shall be developed and applied in accordance with the provisions of this Agreement.
2. For the purposes of this Agreement, the definitions provided in Annex A shall apply.
3. The annexes are an integral part of this Agreement.
4. Nothing in this Agreement shall affect the rights of Members under the Agreement on Technical Barriers to Trade with respect to measures not within the scope of this Agreement.

### *Article 2*

#### *Basic Rights and Obligations*

1. Members have the right to take sanitary and phytosanitary measures necessary for the protection of human, animal or plant life or health, provided that such measures are not inconsistent with the provisions of this Agreement.
2. Members shall ensure that any sanitary or phytosanitary measure is applied only to the extent necessary to protect human, animal or plant life or health, is based on scientific principles and is not maintained without sufficient scientific evidence, except as provided for in paragraph 7 of Article 5.
3. Members shall ensure that their sanitary and phytosanitary measures do not arbitrarily or unjustifiably discriminate between Members where identical or similar conditions prevail, including between their own territory and that of other Members. Sanitary and phytosanitary measures shall not be applied in a manner which would constitute a disguised restriction on international trade.
4. Sanitary or phytosanitary measures which conform to the relevant provisions of this Agreement shall be presumed to be in accordance with the obligations of the Members under the provisions of GATT 1994 which relate to the use of sanitary or phytosanitary measures, in particular the provisions of Article XX(b).

### *Article 3*

#### *Harmonization*

1. To harmonize sanitary and phytosanitary measures on as wide a basis as possible, Members shall base their sanitary or phytosanitary measures on international standards, guidelines or recommendations, where they exist, except as otherwise provided for in this Agreement, and in particular in paragraph 3.

2. Sanitary or phytosanitary measures which conform to international standards, guidelines or recommendations shall be deemed to be necessary to protect human, animal or plant life or health, and presumed to be consistent with the relevant provisions of this Agreement and of GATT 1994.
3. Members may introduce or maintain sanitary or phytosanitary measures which result in a higher level of sanitary or phytosanitary protection than would be achieved by measures based on the relevant international standards, guidelines or recommendations, if there is a scientific justification, or as a consequence of the level of sanitary or phytosanitary protection a Member determines to be appropriate in accordance with the relevant provisions of paragraphs 1 through 8 of Article 5.<sup>2</sup> Notwithstanding the above, all measures which result in a level of sanitary or phytosanitary protection different from that which would be achieved by measures based on international standards, guidelines or recommendations shall not be inconsistent with any other provision of this Agreement.
4. Members shall play a full part, within the limits of their resources, in the relevant international organizations and their subsidiary bodies, in particular the Codex Alimentarius Commission, the International Office of Epizootics, and the international and regional organizations operating within the framework of the International Plant Protection Convention, to promote within these organizations the development and periodic review of standards, guidelines and recommendations with respect to all aspects of sanitary and phytosanitary measures.
5. The Committee on Sanitary and Phytosanitary Measures provided for in paragraphs 1 and 4 of Article 12 (referred to in this Agreement as the "Committee") shall develop a procedure to monitor the process of international harmonization and coordinate efforts in this regard with the relevant international organizations.

#### *Article 4*

##### *Equivalence*

1. Members shall accept the sanitary or phytosanitary measures of other Members as equivalent, even if these measures differ from their own or from those used by other Members trading in the same product, if the exporting Member objectively demonstrates to the importing Member that its measures achieve the importing Member's appropriate level of sanitary or phytosanitary protection. For this purpose, reasonable access shall be given, upon request, to the importing Member for inspection, testing and other relevant procedures.
2. Members shall, upon request, enter into consultations with the aim of achieving bilateral and multilateral agreements on recognition of the equivalence of specified sanitary or phytosanitary measures.

---

<sup>2</sup>For the purposes of paragraph 3 of Article 3, there is a scientific justification if, on the basis of an examination and evaluation of available scientific information in conformity with the relevant provisions of this Agreement, a Member determines that the relevant international standards, guidelines or recommendations are not sufficient to achieve its appropriate level of sanitary or phytosanitary protection.

*Article 5**Assessment of Risk and Determination of the Appropriate Level of Sanitary or Phytosanitary Protection*

1. Members shall ensure that their sanitary or phytosanitary measures are based on an assessment, as appropriate to the circumstances, of the risks to human, animal or plant life or health, taking into account risk assessment techniques developed by the relevant international organizations.
2. In the assessment of risks, Members shall take into account available scientific evidence; relevant processes and production methods; relevant inspection, sampling and testing methods; prevalence of specific diseases or pests; existence of pest- or disease-free areas; relevant ecological and environmental conditions; and quarantine or other treatment.
3. In assessing the risk to animal or plant life or health and determining the measure to be applied for achieving the appropriate level of sanitary or phytosanitary protection from such risk, Members shall take into account as relevant economic factors: the potential damage in terms of loss of production or sales in the event of the entry, establishment or spread of a pest or disease; the costs of control or eradication in the territory of the importing Member; and the relative cost-effectiveness of alternative approaches to limiting risks.
4. Members should, when determining the appropriate level of sanitary or phytosanitary protection, take into account the objective of minimizing negative trade effects.
5. With the objective of achieving consistency in the application of the concept of appropriate level of sanitary or phytosanitary protection against risks to human life or health, or to animal and plant life or health, each Member shall avoid arbitrary or unjustifiable distinctions in the levels it considers to be appropriate in different situations, if such distinctions result in discrimination or a disguised restriction on international trade. Members shall cooperate in the Committee, in accordance with paragraphs 1, 2 and 3 of Article 12, to develop guidelines to further the practical implementation of this provision. In developing the guidelines, the Committee shall take into account all relevant factors, including the exceptional character of human health risks to which people voluntarily expose themselves.
6. Without prejudice to paragraph 2 of Article 3, when establishing or maintaining sanitary or phytosanitary measures to achieve the appropriate level of sanitary or phytosanitary protection, Members shall ensure that such measures are not more trade-restrictive than required to achieve their appropriate level of sanitary or phytosanitary protection, taking into account technical and economic feasibility.<sup>3</sup>
7. In cases where relevant scientific evidence is insufficient, a Member may provisionally adopt sanitary or phytosanitary measures on the basis of available pertinent information, including that from the relevant international organizations as well as from sanitary or phytosanitary measures applied by other Members. In such circumstances, Members shall seek to obtain the additional information necessary for a more objective assessment of risk and review the sanitary or phytosanitary measure accordingly within a reasonable period of time.
8. When a Member has reason to believe that a specific sanitary or phytosanitary measure introduced or maintained by another Member is constraining, or has the potential to constrain, its exports and

---

<sup>3</sup>For purposes of paragraph 6 of Article 5, a measure is not more trade-restrictive than required unless there is another measure, reasonably available taking into account technical and economic feasibility, that achieves the appropriate level of sanitary or phytosanitary protection and is significantly less restrictive to trade.

the measure is not based on the relevant international standards, guidelines or recommendations, or such standards, guidelines or recommendations do not exist, an explanation of the reasons for such sanitary or phytosanitary measure may be requested and shall be provided by the Member maintaining the measure.

#### *Article 6*

##### *Adaptation to Regional Conditions, Including Pest- or Disease-Free Areas and Areas of Low Pest or Disease Prevalence*

1. Members shall ensure that their sanitary or phytosanitary measures are adapted to the sanitary or phytosanitary characteristics of the area - whether all of a country, part of a country, or all or parts of several countries - from which the product originated and to which the product is destined. In assessing the sanitary or phytosanitary characteristics of a region, Members shall take into account, *inter alia*, the level of prevalence of specific diseases or pests, the existence of eradication or control programmes, and appropriate criteria or guidelines which may be developed by the relevant international organizations.
2. Members shall, in particular, recognize the concepts of pest- or disease-free areas and areas of low pest or disease prevalence. Determination of such areas shall be based on factors such as geography, ecosystems, epidemiological surveillance, and the effectiveness of sanitary or phytosanitary controls.
3. Exporting Members claiming that areas within their territories are pest- or disease-free areas or areas of low pest or disease prevalence shall provide the necessary evidence thereof in order to objectively demonstrate to the importing Member that such areas are, and are likely to remain, pest- or disease-free areas or areas of low pest or disease prevalence, respectively. For this purpose, reasonable access shall be given, upon request, to the importing Member for inspection, testing and other relevant procedures.

#### *Article 7*

##### *Transparency*

Members shall notify changes in their sanitary or phytosanitary measures and shall provide information on their sanitary or phytosanitary measures in accordance with the provisions of Annex B.

#### *Article 8*

##### *Control, Inspection and Approval Procedures*

Members shall observe the provisions of Annex C in the operation of control, inspection and approval procedures, including national systems for approving the use of additives or for establishing tolerances for contaminants in foods, beverages or feedstuffs, and otherwise ensure that their procedures are not inconsistent with the provisions of this Agreement.

### Article 9

#### *Technical Assistance*

1. Members agree to facilitate the provision of technical assistance to other Members, especially developing country Members, either bilaterally or through the appropriate international organizations. Such assistance may be, *inter alia*, in the areas of processing technologies, research and infrastructure, including in the establishment of national regulatory bodies, and may take the form of advice, credits, donations and grants, including for the purpose of seeking technical expertise, training and equipment to allow such countries to adjust to, and comply with, sanitary or phytosanitary measures necessary to achieve the appropriate level of sanitary or phytosanitary protection in their export markets.
2. Where substantial investments are required in order for an exporting developing country Member to fulfil the sanitary or phytosanitary requirements of an importing Member, the latter shall consider providing such technical assistance as will permit the developing country Member to maintain and expand its market access opportunities for the product involved.

### Article 10

#### *Special and Differential Treatment*

1. In the preparation and application of sanitary or phytosanitary measures, Members shall take account of the special needs of developing country Members, and in particular of the least-developed country Members.
2. Where the appropriate level of sanitary or phytosanitary protection allows scope for the phased introduction of new sanitary or phytosanitary measures, longer time-frames for compliance should be accorded on products of interest to developing country Members so as to maintain opportunities for their exports.
3. With a view to ensuring that developing country Members are able to comply with the provisions of this Agreement, the Committee is enabled to grant to such countries, upon request, specified, time-limited exceptions in whole or in part from obligations under this Agreement, taking into account their financial, trade and development needs.
4. Members should encourage and facilitate the active participation of developing country Members in the relevant international organizations.

### Article 11

#### *Consultations and Dispute Settlement*

1. The provisions of Articles XXII and XXIII of GATT 1994 as elaborated and applied by the Dispute Settlement Understanding shall apply to consultations and the settlement of disputes under this Agreement, except as otherwise specifically provided herein.
2. In a dispute under this Agreement involving scientific or technical issues, a panel should seek advice from experts chosen by the panel in consultation with the parties to the dispute. To this end, the panel may, when it deems it appropriate, establish an advisory technical experts group, or consult

the relevant international organizations, at the request of either party to the dispute or on its own initiative.

3. Nothing in this Agreement shall impair the rights of Members under other international agreements, including the right to resort to the good offices or dispute settlement mechanisms of other international organizations or established under any international agreement.

## *Article 12*

### *Administration*

1. A Committee on Sanitary and Phytosanitary Measures is hereby established to provide a regular forum for consultations. It shall carry out the functions necessary to implement the provisions of this Agreement and the furtherance of its objectives, in particular with respect to harmonization. The Committee shall reach its decisions by consensus.

2. The Committee shall encourage and facilitate ad hoc consultations or negotiations among Members on specific sanitary or phytosanitary issues. The Committee shall encourage the use of international standards, guidelines or recommendations by all Members and, in this regard, shall sponsor technical consultation and study with the objective of increasing coordination and integration between international and national systems and approaches for approving the use of food additives or for establishing tolerances for contaminants in foods, beverages or feedstuffs.

3. The Committee shall maintain close contact with the relevant international organizations in the field of sanitary and phytosanitary protection, especially with the Codex Alimentarius Commission, the International Office of Epizootics, and the Secretariat of the International Plant Protection Convention, with the objective of securing the best available scientific and technical advice for the administration of this Agreement and in order to ensure that unnecessary duplication of effort is avoided.

4. The Committee shall develop a procedure to monitor the process of international harmonization and the use of international standards, guidelines or recommendations. For this purpose, the Committee should, in conjunction with the relevant international organizations, establish a list of international standards, guidelines or recommendations relating to sanitary or phytosanitary measures which the Committee determines to have a major trade impact. The list should include an indication by Members of those international standards, guidelines or recommendations which they apply as conditions for import or on the basis of which imported products conforming to these standards can enjoy access to their markets. For those cases in which a Member does not apply an international standard, guideline or recommendation as a condition for import, the Member should provide an indication of the reason therefor, and, in particular, whether it considers that the standard is not stringent enough to provide the appropriate level of sanitary or phytosanitary protection. If a Member revises its position, following its indication of the use of a standard, guideline or recommendation as a condition for import, it should provide an explanation for its change and so inform the Secretariat as well as the relevant international organizations, unless such notification and explanation is given according to the procedures of Annex B.

5. In order to avoid unnecessary duplication, the Committee may decide, as appropriate, to use the information generated by the procedures, particularly for notification, which are in operation in the relevant international organizations.

6. The Committee may, on the basis of an initiative from one of the Members, through appropriate channels invite the relevant international organizations or their subsidiary bodies to examine specific



matters with respect to a particular standard, guideline or recommendation, including the basis of explanations for non-use given according to paragraph 4.

7. The Committee shall review the operation and implementation of this Agreement three years after the date of entry into force of the WTO Agreement, and thereafter as the need arises. Where appropriate, the Committee may submit to the Council for Trade in Goods proposals to amend the text of this Agreement having regard, *inter alia*, to the experience gained in its implementation.

### Article 13

#### *Implementation*

Members are fully responsible under this Agreement for the observance of all obligations set forth herein. Members shall formulate and implement positive measures and mechanisms in support of the observance of the provisions of this Agreement by other than central government bodies. Members shall take such reasonable measures as may be available to them to ensure that non-governmental entities within their territories, as well as regional bodies in which relevant entities within their territories are members, comply with the relevant provisions of this Agreement. In addition, Members shall not take measures which have the effect of, directly or indirectly, requiring or encouraging such regional or non-governmental entities, or local governmental bodies, to act in a manner inconsistent with the provisions of this Agreement. Members shall ensure that they rely on the services of non-governmental entities for implementing sanitary or phytosanitary measures only if these entities comply with the provisions of this Agreement.

### Article 14

#### *Final Provisions*

The least-developed country Members may delay application of the provisions of this Agreement for a period of five years following the date of entry into force of the WTO Agreement with respect to their sanitary or phytosanitary measures affecting importation or imported products. Other developing country Members may delay application of the provisions of this Agreement, other than paragraph 8 of Article 5 and Article 7, for two years following the date of entry into force of the WTO Agreement with respect to their existing sanitary or phytosanitary measures affecting importation or imported products, where such application is prevented by a lack of technical expertise, technical infrastructure or resources.

## ANNEX A

DEFINITIONS<sup>4</sup>

1. *Sanitary or phytosanitary measure* - Any measure applied:
  - (a) to protect animal or plant life or health within the territory of the Member from risks arising from the entry, establishment or spread of pests, diseases, disease-carrying organisms or disease-causing organisms;
  - (b) to protect human or animal life or health within the territory of the Member from risks arising from additives, contaminants, toxins or disease-causing organisms in foods, beverages or feedstuffs;
  - (c) to protect human life or health within the territory of the Member from risks arising from diseases carried by animals, plants or products thereof, or from the entry, establishment or spread of pests; or
  - (d) to prevent or limit other damage within the territory of the Member from the entry, establishment or spread of pests.

Sanitary or phytosanitary measures include all relevant laws, decrees, regulations, requirements and procedures including, *inter alia*, end product criteria; processes and production methods; testing, inspection, certification and approval procedures; quarantine treatments including relevant requirements associated with the transport of animals or plants, or with the materials necessary for their survival during transport; provisions on relevant statistical methods, sampling procedures and methods of risk assessment; and packaging and labelling requirements directly related to food safety.

2. *Harmonization* - The establishment, recognition and application of common sanitary and phytosanitary measures by different Members.

3. *International standards, guidelines and recommendations*

- (a) for food safety, the standards, guidelines and recommendations established by the Codex Alimentarius Commission relating to food additives, veterinary drug and pesticide residues, contaminants, methods of analysis and sampling, and codes and guidelines of hygienic practice;
- (b) for animal health and zoonoses, the standards, guidelines and recommendations developed under the auspices of the International Office of Epizootics;
- (c) for plant health, the international standards, guidelines and recommendations developed under the auspices of the Secretariat of the International Plant Protection Convention in cooperation with regional organizations operating within the framework of the International Plant Protection Convention; and

---

<sup>4</sup>For the purpose of these definitions, "animal" includes fish and wild fauna; "plant" includes forests and wild flora; "pests" include weeds; and "contaminants" include pesticide and veterinary drug residues and extraneous matter.

- (d) for matters not covered by the above organizations, appropriate standards, guidelines and recommendations promulgated by other relevant international organizations open for membership to all Members, as identified by the Committee.

4. *Risk assessment* - The evaluation of the likelihood of entry, establishment or spread of a pest or disease within the territory of an importing Member according to the sanitary or phytosanitary measures which might be applied, and of the associated potential biological and economic consequences; or the evaluation of the potential for adverse effects on human or animal health arising from the presence of additives, contaminants, toxins or disease-causing organisms in food, beverages or feedstuffs.

5. *Appropriate level of sanitary or phytosanitary protection* - The level of protection deemed appropriate by the Member establishing a sanitary or phytosanitary measure to protect human, animal or plant life or health within its territory.

NOTE: Many Members otherwise refer to this concept as the "acceptable level of risk".

6. *Pest- or disease-free area* - An area, whether all of a country, part of a country, or all or parts of several countries, as identified by the competent authorities, in which a specific pest or disease does not occur.

NOTE: A pest- or disease-free area may surround, be surrounded by, or be adjacent to an area - whether within part of a country or in a geographic region which includes parts of or all of several countries - in which a specific pest or disease is known to occur but is subject to regional control measures such as the establishment of protection, surveillance and buffer zones which will confine or eradicate the pest or disease in question.

7. *Area of low pest or disease prevalence* - An area, whether all of a country, part of a country, or all or parts of several countries, as identified by the competent authorities, in which a specific pest or disease occurs at low levels and which is subject to effective surveillance, control or eradication measures.

## ANNEX B

## TRANSPARENCY OF SANITARY AND PHYTOSANITARY REGULATIONS

*Publication of regulations*

1. Members shall ensure that all sanitary and phytosanitary regulations<sup>5</sup> which have been adopted are published promptly in such a manner as to enable interested Members to become acquainted with them.
2. Except in urgent circumstances, Members shall allow a reasonable interval between the publication of a sanitary or phytosanitary regulation and its entry into force in order to allow time for producers in exporting Members, and particularly in developing country Members, to adapt their products and methods of production to the requirements of the importing Member.

*Enquiry points*

3. Each Member shall ensure that one enquiry point exists which is responsible for the provision of answers to all reasonable questions from interested Members as well as for the provision of relevant documents regarding:
  - (a) any sanitary or phytosanitary regulations adopted or proposed within its territory;
  - (b) any control and inspection procedures, production and quarantine treatment, pesticide tolerance and food additive approval procedures, which are operated within its territory;
  - (c) risk assessment procedures, factors taken into consideration, as well as the determination of the appropriate level of sanitary or phytosanitary protection;
  - (d) the membership and participation of the Member, or of relevant bodies within its territory, in international and regional sanitary and phytosanitary organizations and systems, as well as in bilateral and multilateral agreements and arrangements within the scope of this Agreement, and the texts of such agreements and arrangements.
4. Members shall ensure that where copies of documents are requested by interested Members, they are supplied at the same price (if any), apart from the cost of delivery, as to the nationals<sup>6</sup> of the Member concerned.

*Notification procedures*

5. Whenever an international standard, guideline or recommendation does not exist or the content of a proposed sanitary or phytosanitary regulation is not substantially the same as the content of an international standard, guideline or recommendation, and if the regulation may have a significant effect on trade of other Members, Members shall:

---

<sup>5</sup>Sanitary and phytosanitary measures such as laws, decrees or ordinances which are applicable generally

<sup>6</sup>When "nationals" are referred to in this Agreement, the term shall be deemed, in the case of a separate customs territory Member of the WTO, to mean persons, natural or legal, who are domiciled or who have a real and effective industrial or commercial establishment in that customs territory.

- (a) publish a notice at an early stage in such a manner as to enable interested Members to become acquainted with the proposal to introduce a particular regulation;
- (b) notify other Members, through the Secretariat, of the products to be covered by the regulation together with a brief indication of the objective and rationale of the proposed regulation. Such notifications shall take place at an early stage, when amendments can still be introduced and comments taken into account;
- (c) provide upon request to other Members copies of the proposed regulation and, whenever possible, identify the parts which in substance deviate from international standards, guidelines or recommendations;
- (d) without discrimination, allow reasonable time for other Members to make comments in writing, discuss these comments upon request, and take the comments and the results of the discussions into account.

6. However, where urgent problems of health protection arise or threaten to arise for a Member, that Member may omit such of the steps enumerated in paragraph 5 of this Annex as it finds necessary, provided that the Member:

- (a) immediately notifies other Members, through the Secretariat, of the particular regulation and the products covered, with a brief indication of the objective and the rationale of the regulation, including the nature of the urgent problem(s);
- (b) provides, upon request, copies of the regulation to other Members;
- (c) allows other Members to make comments in writing, discusses these comments upon request, and takes the comments and the results of the discussions into account.

7. Notifications to the Secretariat shall be in English, French or Spanish.

8. Developed country Members shall, if requested by other Members, provide copies of the documents or, in case of voluminous documents, summaries of the documents covered by a specific notification in English, French or Spanish.

9. The Secretariat shall promptly circulate copies of the notification to all Members and interested international organizations and draw the attention of developing country Members to any notifications relating to products of particular interest to them.

10. Members shall designate a single central government authority as responsible for the implementation, on the national level, of the provisions concerning notification procedures according to paragraphs 5, 6, 7 and 8 of this Annex.

#### *General reservations*

11. Nothing in this Agreement shall be construed as requiring:

- (a) the provision of particulars or copies of drafts or the publication of texts other than in the language of the Member except as stated in paragraph 8 of this Annex; or

- (b) Members to disclose confidential information which would impede enforcement of sanitary or phytosanitary legislation or which would prejudice the legitimate commercial interests of particular enterprises.

## ANNEX C

CONTROL, INSPECTION AND APPROVAL PROCEDURES<sup>7</sup>

1. Members shall ensure, with respect to any procedure to check and ensure the fulfilment of sanitary or phytosanitary measures, that:

- (a) such procedures are undertaken and completed without undue delay and in no less favourable manner for imported products than for like domestic products;
- (b) the standard processing period of each procedure is published or that the anticipated processing period is communicated to the applicant upon request; when receiving an application, the competent body promptly examines the completeness of the documentation and informs the applicant in a precise and complete manner of all deficiencies; the competent body transmits as soon as possible the results of the procedure in a precise and complete manner to the applicant so that corrective action may be taken if necessary; even when the application has deficiencies, the competent body proceeds as far as practicable with the procedure if the applicant so requests; and that upon request, the applicant is informed of the stage of the procedure, with any delay being explained;
- (c) information requirements are limited to what is necessary for appropriate control, inspection and approval procedures, including for approval of the use of additives or for the establishment of tolerances for contaminants in food, beverages or feedstuffs;
- (d) the confidentiality of information about imported products arising from or supplied in connection with control, inspection and approval is respected in a way no less favourable than for domestic products and in such a manner that legitimate commercial interests are protected;
- (e) any requirements for control, inspection and approval of individual specimens of a product are limited to what is reasonable and necessary;
- (f) any fees imposed for the procedures on imported products are equitable in relation to any fees charged on like domestic products or products originating in any other Member and should be no higher than the actual cost of the service;
- (g) the same criteria should be used in the siting of facilities used in the procedures and the selection of samples of imported products as for domestic products so as to minimize the inconvenience to applicants, importers, exporters or their agents;
- (h) whenever specifications of a product are changed subsequent to its control and inspection in light of the applicable regulations, the procedure for the modified product is limited to what is necessary to determine whether adequate confidence exists that the product still meets the regulations concerned; and

---

<sup>7</sup>Control, inspection and approval procedures include, *inter alia*, procedures for sampling, testing and certification.

- (i) a procedure exists to review complaints concerning the operation of such procedures and to take corrective action when a complaint is justified.

Where an importing Member operates a system for the approval of the use of food additives or for the establishment of tolerances for contaminants in food, beverages or feedstuffs which prohibits or restricts access to its domestic markets for products based on the absence of an approval, the importing Member shall consider the use of a relevant international standard as the basis for access until a final determination is made.

2. Where a sanitary or phytosanitary measure specifies control at the level of production, the Member in whose territory the production takes place shall provide the necessary assistance to facilitate such control and the work of the controlling authorities.

3. Nothing in this Agreement shall prevent Members from carrying out reasonable inspection within their own territories.